[
  {
    "id": 10,
    "user_query": "Name synonym of Acrokeratosis paraneoplastica.",
    "llama-2-7b-chat-hf_response": "Acrokeratosis paraneoplastica is a rare skin condition that is characterized by the growth of thick, scaly patches on the skin. There are several synonyms for this condition, including:\n1. Acrokeratosis paraneoplastica verrucosa: This term is used to describe the specific type of acrokeratosis paraneoplastica that is characterized by the growth of thick, scaly patches on the skin, often with a verrucous appearance.\n2. Keratosis paraneoplastica: This term is used to describe the general category of skin conditions that are associated with the development of keratinous lesions, including acrokeratosis paraneoplastica.\n3. Paraneoplastic keratosis: This term is used to describe a group of skin conditions that are associated with the development of keratinous lesions, including acrokeratosis paraneoplastica.\n4. Acrokeratosis: This term is used to describe a group of skin conditions that are characterized by the growth of thick, scaly patches on the skin. While acrokeratosis paraneoplastica is a specific type of acrokeratosis, the term \"acrokeratosis\" can also be used more broadly to describe any condition that involves the growth of thick, scaly patches on the skin.\n5. Paraneoplastic skin lesions: This term is used to describe a group of skin conditions that are associated with the development of keratinous lesions, including acrokeratosis paraneoplastica.\nIt's important to note that these terms are not interchangeable, and each term refers to a specific type of skin condition. If you have any further questions or concerns, please don't hesitate to ask.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrokeratosis paraneoplastica verrucosa is characterized by the growth of thick, scaly patches on the skin with a verrucous appearance.\n2. Keratosis paraneoplastica is a general category of skin conditions associated with the development of keratinous lesions.\n3. Paraneoplastic keratosis is a group of skin conditions associated with the development of keratinous lesions.\n4. Acrokeratosis is a group of skin conditions characterized by the growth of thick, scaly patches on the skin.\n5. Paraneoplastic skin lesions are a group of skin conditions associated with the development of keratinous lesions.",
    "llama-2-7b-chat-hf_fact": [
      "Acrokeratosis paraneoplastica verrucosa is characterized by the growth of thick, scaly patches on the skin with a verrucous appearance.",
      "Keratosis paraneoplastica is a general category of skin conditions associated with the development of keratinous lesions.",
      "Paraneoplastic keratosis is a group of skin conditions associated with the development of keratinous lesions.",
      "Acrokeratosis is a group of skin conditions characterized by the growth of thick, scaly patches on the skin.",
      "Paraneoplastic skin lesions are a group of skin conditions associated with the development of keratinous lesions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Paraneoplastic keratosis is not a recognized term; it should be keratosis paraneoplastica.\n4. FALSE [correction]: Acrokeratosis is not a group but rather specific types of skin conditions, such as Acrokeratosis verruciformis.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 47,
    "user_query": "Is Weaver syndrome similar to Sotos?",
    "llama-2-7b-chat-hf_response": "Weaver syndrome and Sotos syndrome are both rare genetic disorders that can have some similar symptoms and characteristics. However, they are distinct conditions with different causes and genetic mutations. Here's a detailed comparison of the two syndromes:\n1. Causes:\nWeaver syndrome is caused by a mutation in the FGD1 gene, which codes for a protein involved in the development and maintenance of the nervous system. Sotos syndrome, on the other hand, is caused by a mutation in the NSD1 gene, which codes for a protein involved in the regulation of gene expression.\n2. Symptoms:\nBoth Weaver syndrome and Sotos syndrome can cause a range of symptoms, including:\n* Delayed cognitive and motor development\n* Intellectual disability\n* Distinctive facial features, such as a long, narrow face and small eyes\n* Short stature\n* Coordination and balance problems\n* Vision and hearing problems\n* Heart defects\n* Respiratory problems\n3. Age of onset:\nWeaver syndrome typically becomes apparent in the first year of life, usually before the age of 6 months. Sotos syndrome can be diagnosed at any age, but it is usually apparent by the age of 2-3 years.\n4. Prevalence:\nWeaver syndrome is a rare disorder, with an estimated prevalence of 1 in 100,000 to 1 in 50,000 births. Sotos syndrome is also rare, with an estimated prevalence of 1 in 100,000 to 1 in 50,000 births.\n5. Genetic inheritance:\nWeaver syndrome is inherited in an autosomal dominant pattern, which means that a single copy of the mutated gene is enough to cause the condition. Sotos syndrome is inherited in an autosomal mutation, which means that the mutation can occur on any chromosome.\n6. Prognosis:\nBoth Weaver syndrome and Sotos syndrome can have a significant impact on an individual's quality of life, particularly in terms of cognitive and intellectual disability. However, with appropriate support and interventions, many individuals with these conditions can lead",
    "llama-2-7b-chat-hf_fact_raw": "1. Weaver syndrome is caused by a mutation in the FGD1 gene.\n2. Sotos syndrome is caused by a mutation in the NSD1 gene.\n3. Symptoms of Weaver syndrome and Sotos syndrome include delayed cognitive and motor development, intellectual disability, and distinctive facial features.\n4. Weaver syndrome typically becomes apparent in the first year of life, usually before the age of 6 months.\n5. Sotos syndrome is usually apparent by the age of 2-3 years.",
    "llama-2-7b-chat-hf_fact": [
      "Weaver syndrome is caused by a mutation in the FGD1 gene.",
      "Sotos syndrome is caused by a mutation in the NSD1 gene.",
      "Symptoms of Weaver syndrome and Sotos syndrome include delayed cognitive and motor development, intellectual disability, and distinctive facial features.",
      "Weaver syndrome typically becomes apparent in the first year of life, usually before the age of 6 months.",
      "Sotos syndrome is usually apparent by the age of 2-3 years."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Weaver syndrome is caused by a mutation in the EZH2 gene.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 81,
    "user_query": "List the releases of JASPAR database",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! The JASPAR database is a widely used tool for predicting DNA-binding proteins and their binding affinity to specific DNA sequences. Here are the releases of the JASPAR database:\n1. JASPAR1: The first release of the JASPAR database was published in 1996 and contained 167 protein-DNA binding sites from 14 different organisms.\n2. JASPAR2: Released in 2000, JASPAR2 added 277 new binding sites and improved the accuracy of the predictions for the original 167 sites.\n3. JASPAR3: Published in 2003, JASPAR3 included 447 new binding sites and improved the methodology for predicting protein-DNA interactions.\n4. JASPAR4: Released in 2007, JASPAR4 added 577 new binding sites and improved the accuracy of the predictions for all sites in the database.\n5. JASPAR5: Published in 2010, JASPAR5 included 700 new binding sites and improved the methodology for predicting protein-DNA interactions.\n6. JASPAR6: Released in 2014, JASPAR6 added 847 new binding sites and improved the accuracy of the predictions for all sites in the database.\n7. JASPAR7: Published in 2018, JASPAR7 included 1,000 new binding sites and improved the methodology for predicting protein-DNA interactions.\n8. JASPAR8: Released in 2020, JASPAR8 added 1,200 new binding sites and improved the accuracy of the predictions for all sites in the database.\nEach release of the JASPAR database has improved upon the previous one in terms of the number of binding sites, the accuracy of the predictions, and the methodology used to generate the predictions. The latest releases of the JASPAR database are considered to be the most accurate and comprehensive tools for predicting protein-DNA interactions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The first release of the JASPAR database was in 1996 with 167 protein-DNA binding sites.\n2. JASPAR2 was released in 2000 and added 277 new binding sites.\n3. JASPAR3, published in 2003, included 447 new binding sites.\n4. JASPAR4 was released in 2007 and added 577 new binding sites.\n5. JASPAR7, published in 2018, included 1,000 new binding sites.",
    "llama-2-7b-chat-hf_fact": [
      "The first release of the JASPAR database was in 1996 with 167 protein-DNA binding sites.",
      "JASPAR2 was released in 2000 and added 277 new binding sites.",
      "JASPAR3, published in 2003, included 447 new binding sites.",
      "JASPAR4 was released in 2007 and added 577 new binding sites.",
      "JASPAR7, published in 2018, included 1,000 new binding sites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The first release of the JASPAR database was in 2004 with 123 protein-DNA binding sites.\n2. FALSE [correction]: JASPAR2 was released in 2004 and added 135 new binding sites.\n3. FALSE [correction]: JASPAR3, published in 2006, included 180 new binding sites.\n4. FALSE [correction]: JASPAR4 was released in 2008 and added 240 new binding sites.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 99,
    "user_query": "What is the function of the viral KP4 protein?",
    "llama-2-7b-chat-hf_response": "The KP4 protein, also known as the keratin-associated protein 4, is a protein that is found in the cytoplasm of cells and is involved in various cellular processes. The KP4 protein is a type of keratin-associated protein, which means that it is bound to the protein keratin and plays a role in maintaining the structure and function of epithelial tissues.\nThe primary function of the KP4 protein is to regulate the cytoskeleton, which is the network of filaments and molecules that give cells their shape and help them move and divide. The KP4 protein helps to organize the actin cytoskeleton, which is made up of actin filaments and other proteins, and is involved in cellular processes such as cell migration, cell division, and cell signaling.\nStudies have shown that the KP4 protein is involved in a variety of cellular processes, including:\n1. Cell migration: The KP4 protein helps to regulate the movement of cells during tissue development and wound healing.\n2. Cell division: The KP4 protein is involved in the regulation of cell division, particularly during the process of cytokinesis, where the cell divides into two daughter cells.\n3. Cell signaling: The KP4 protein can act as a signaling molecule, transmitting signals from one part of the cell to another and helping to coordinate cellular responses.\n4. Cell adhesion: The KP4 protein is involved in the formation and maintenance of adhesion junctions, which are specialized structures that help cells stick together and form tissues.\n5. Cancer: The KP4 protein has been implicated in cancer, particularly in the development of pancreatic cancer.\n6. Neurodegenerative diseases: The KP4 protein has been found to be involved in the development of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.\n7. Muscle function: The KP4 protein is involved in the regulation of muscle contraction and relaxation.\n8. Immune response: The KP4 protein has been found to be involved in the immune response, particularly in the activation of immune cells and the regulation of inflammation.\n9. Vasc",
    "llama-2-7b-chat-hf_fact_raw": "1. The KP4 protein is involved in maintaining the structure and function of epithelial tissues.\n2. The KP4 protein helps to organize the actin cytoskeleton involved in cell migration, division, and signaling.\n3. The KP4 protein is implicated in the development of pancreatic cancer.\n4. The KP4 protein has been found to be involved in neurodegenerative diseases such as Alzheimer's and Parkinson's disease.\n5. The KP4 protein is involved in the regulation of muscle contraction and relaxation.",
    "llama-2-7b-chat-hf_fact": [
      "The KP4 protein is involved in maintaining the structure and function of epithelial tissues.",
      "The KP4 protein helps to organize the actin cytoskeleton involved in cell migration, division, and signaling.",
      "The KP4 protein is implicated in the development of pancreatic cancer.",
      "The KP4 protein has been found to be involved in neurodegenerative diseases such as Alzheimer's and Parkinson's disease.",
      "The KP4 protein is involved in the regulation of muscle contraction and relaxation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\nWithout specific context or source material to verify these statements, it is impossible to determine their accuracy.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 124,
    "user_query": "Is DITPA a thyroid hormone analog utilized in experimental and clinical studies",
    "llama-2-7b-chat-hf_response": "Yes, DITPA (3,5-dinitro-2-hydroxyphenyl-glycine) is a thyroid hormone analog that has been utilized in both experimental and clinical studies. It is a synthetic compound that mimics the action of thyroid hormones in the body, and has been used to investigate the mechanisms of thyroid hormone action, as well as to study the effects of thyroid hormone deficiency or excess in various diseases.\nDITPA works by binding to thyroid hormone receptors in the nucleus of cells, where it activates genes involved in metabolism, growth, and development. It has been shown to have a wide range of effects on various physiological processes, including:\n1. Metabolism: DITPA increases the activity of enzymes involved in glucose and lipid metabolism, leading to increased glucose uptake and fatty acid oxidation in adipose tissue.\n2. Growth and development: DITPA promotes the growth and differentiation of cells in the embryo and fetus, and has been shown to increase the birth weight of offspring in animal models.\n3. Cardiovascular system: DITPA has been shown to improve cardiac function and reduce cardiac hypertrophy in animal models of heart failure.\n4. Neurological system: DITPA has been shown to improve cognitive function and reduce neuroinflammation in animal models of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.\n5. Immune system: DITPA has been shown to modulate the immune response, reducing inflammation and immune activation in animal models of autoimmune diseases such as multiple sclerosis and type 1 diabetes.\nClinical studies have also been conducted to investigate the potential therapeutic use of DITPA in various diseases, including:\n1. Hypothyroidism: DITPA has been shown to improve cognitive function and reduce muscle weakness in patients with hypothyroidism.\n2. Hyperthyroidism: DITPA has been shown to reduce the symptoms of hyperthyroidism, including tremors, tachycardia, and",
    "llama-2-7b-chat-hf_fact_raw": "1. DITPA (3,5-dinitro-2-hydroxyphenyl-glycine) is a thyroid hormone analog used in experimental and clinical studies.\n2. DITPA mimics the action of thyroid hormones in the body.\n3. DITPA works by binding to thyroid hormone receptors in the nucleus of cells.\n4. DITPA has been shown to improve cardiac function and reduce cardiac hypertrophy in animal models of heart failure.\n5. Clinical studies have indicated that DITPA can improve cognitive function and reduce muscle weakness in patients with hypothyroidism.",
    "llama-2-7b-chat-hf_fact": [
      "DITPA (3,5-dinitro-2-hydroxyphenyl-glycine) is a thyroid hormone analog used in experimental and clinical studies.",
      "DITPA mimics the action of thyroid hormones in the body.",
      "DITPA works by binding to thyroid hormone receptors in the nucleus of cells.",
      "DITPA has been shown to improve cardiac function and reduce cardiac hypertrophy in animal models of heart failure.",
      "Clinical studies have indicated that DITPA can improve cognitive function and reduce muscle weakness in patients with hypothyroidism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 144,
    "user_query": "What is the COUGER tool?",
    "llama-2-7b-chat-hf_response": "The COUGER tool is a software tool designed to help clinicians and researchers analyze and interpret complex clinical data, particularly those related to cardiovascular disease. The acronym COUGER stands for \"Clinical Outcomes Using Glycometabolomics and Epigenomics Research,\" and it represents a multidisciplinary approach to understanding the complex interplay between genetic and environmental factors that influence human health and disease.\nThe COUGER tool is a web-based platform that provides a range of analytical and visualization tools for working with large-scale clinical datasets. These datasets may include clinical, genomic, transcriptomic, and metabolomic data, as well as other types of omics data. The tool allows users to integrate and analyze these different types of data to identify patterns and relationships that may not be apparent through single-modality analysis.\nSome of the key features of the COUGER tool include:\n1. Data integration: COUGER allows users to bring together data from different sources and integrate them into a single, queryable dataset. This enables researchers to identify patterns and relationships that may not be apparent through single-modality analysis.\n2. Data visualization: The tool provides a range of visualization tools to help users explore and understand their data. These tools include interactive heat maps, scatter plots, and network graphs, among others.\n3. Machine learning: COUGER includes a range of machine learning algorithms that users can apply to their data to identify patterns and make predictions. These algorithms can be used for tasks such as predicting patient outcomes, identifying biomarkers for disease diagnosis, and identifying potential drug targets.\n4. Clinical decision support: COUGER provides clinical decision support tools that allow users to identify potential treatment options for patients based on their clinical and genomic data. These tools can help clinicians make more informed decisions about patient care.\n5. Collaboration: COUGER is designed to facilitate collaboration among researchers and clinicians. The tool provides features such as real-time collaboration and data sharing, which can help teams work together more effectively.\nOverall, the COUGER tool is a powerful platform for analyzing and interpreting complex clinical data. Its ability to integrate and analyze large-scale datasets, provide visualization tools, and support machine learning and clinical decision support make it a valuable resource",
    "llama-2-7b-chat-hf_fact_raw": "1. The COUGER tool is designed to help clinicians and researchers analyze and interpret complex clinical data.\n2. COUGER stands for \"Clinical Outcomes Using Glycometabolomics and Epigenomics Research.\"\n3. The tool is web-based and provides analytical and visualization tools for large-scale clinical datasets.\n4. COUGER includes machine learning algorithms for tasks such as predicting patient outcomes and identifying biomarkers.\n5. The tool supports clinical decision-making and facilitates collaboration among researchers and clinicians.",
    "llama-2-7b-chat-hf_fact": [
      "The COUGER tool is designed to help clinicians and researchers analyze and interpret complex clinical data.",
      "COUGER stands for \"Clinical Outcomes Using Glycometabolomics and Epigenomics Research.\"",
      "The tool is web-based and provides analytical and visualization tools for large-scale clinical datasets.",
      "COUGER includes machine learning algorithms for tasks such as predicting patient outcomes and identifying biomarkers.",
      "The tool supports clinical decision-making and facilitates collaboration among researchers and clinicians."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: COUGER stands for \"Computational Genomics Utilizing Electronic Health Record and Genomics.\"\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 145,
    "user_query": "Are there drugs for Tick-borne Encephalitis?",
    "llama-2-7b-chat-hf_response": "Yes, there are drugs available to treat Tick-borne Encephalitis (TBE), also known as tick-borne meningitis or tick fever. TBE is caused by the bite of an infected tick, typically the blacklegged tick (Ixodes scapularis) in the northeastern United States or the wood tick (Dermacentor reticulatus) in the western United States.\nThe most common treatment for TBE is antiviral medication, which can help reduce the severity and duration of symptoms. The most commonly used antiviral medications for TBE are:\n1. Ribavirin: This is the most commonly used antiviral medication for TBE. It works by reducing the amount of viral replication in the body and can help alleviate symptoms such as headache, fever, and muscle weakness. Ribavirin is usually given orally for 7-10 days, and it can help reduce the risk of long-term neurological problems.\n2. Aztreonam: This antibiotic is sometimes used to treat TBE, particularly in cases where the infection is severe or there are signs of bacterial superinfection. Aztreonam works by killing bacteria and can help reduce inflammation in the brain.\n3. Cidofovir: This antiviral medication is sometimes used to treat TBE, particularly in cases where the infection is severe or there are signs of bacterial superinfection. Cidofovir works by reducing the amount of viral replication in the body and can help alleviate symptoms such as headache, fever, and muscle weakness.\nIt's important to note that these medications may not completely eliminate the symptoms of TBE, and they may not prevent long-term neurological problems in all cases. Additionally, these medications may have side effects, so it's important to discuss the potential benefits and risks with a healthcare provider before starting treatment.\nIn addition to antiviral medication, other treatments for TBE may include:\n1. Pain relief medication: Over-the-counter pain relief medication, such as acetaminophen or ibuprofen, can help alleviate headache and muscle aches",
    "llama-2-7b-chat-hf_fact_raw": "1. Tick-borne Encephalitis (TBE) is caused by the bite of an infected tick.\n2. The blacklegged tick (Ixodes scapularis) is a carrier of TBE in the northeastern United States.\n3. The wood tick (Dermacentor reticulatus) is a carrier of TBE in the western United States.\n4. Ribavirin is an antiviral medication commonly used to treat TBE.\n5. Aztreonam is an antibiotic used to treat TBE, particularly in severe cases or when there is bacterial superinfection.",
    "llama-2-7b-chat-hf_fact": [
      "Tick-borne Encephalitis (TBE) is caused by the bite of an infected tick.",
      "The blacklegged tick (Ixodes scapularis) is a carrier of TBE in the northeastern United States.",
      "The wood tick (Dermacentor reticulatus) is a carrier of TBE in the western United States.",
      "Ribavirin is an antiviral medication commonly used to treat TBE.",
      "Aztreonam is an antibiotic used to treat TBE, particularly in severe cases or when there is bacterial superinfection."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The blacklegged tick (Ixodes scapularis) is not a carrier of TBE. It is a carrier of Lyme disease.\n3. FALSE [correction]: The wood tick (Dermacentor andersoni) is a carrier of Rocky Mountain spotted fever, not TBE.\n4. FALSE [correction]: There is no specific antiviral treatment for TBE. Ribavirin is used to treat other viral infections such as Hepatitis C.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 151,
    "user_query": "Which genome browser database for DNA shape annotations is available?",
    "llama-2-7b-chat-hf_response": "There are several genome browsers available that provide DNA shape annotations, each with its own strengths and limitations. Here are some of the most popular ones:\n1. UCSC Genome Browser: The University of California, Santa Cruz (UCSC) Genome Browser is a widely used tool for exploring genomic sequences. It provides a variety of features, including DNA shape annotations, using the Ensembl API. The browser offers a variety of display options, including a 3D view of the genome, and allows users to filter and search the data based on various criteria.\n2. Ensembl: Ensembl is a comprehensive and widely used genome browser that provides DNA shape annotations, along with a wealth of other genomic data. It offers a variety of features, including a 3D view of the genome, and allows users to filter and search the data based on various criteria. Ensembl also provides a variety of tools for analyzing and interpreting genomic data.\n3. Genome Atlas: Genome Atlas is a genome browser that provides DNA shape annotations, along with a variety of other genomic data. It offers a 3D view of the genome and allows users to filter and search the data based on various criteria. Genome Atlas also provides a variety of tools for analyzing and interpreting genomic data.\n4. Open3D: Open3D is an open-source genome browser that provides DNA shape annotations, along with a variety of other genomic data. It offers a 3D view of the genome and allows users to filter and search the data based on various criteria. Open3D also provides a variety of tools for analyzing and interpreting genomic data.\n5. Cytoscape: Cytoscape is a cytochrome oxidase 4 (COX4) protein-based genome browser that provides DNA shape annotations, along with a variety of other genomic data. It offers a 3D view of the genome and allows users to filter and search the data based on various criteria. Cytoscape also provides a variety of tools for analyzing and interpreting genomic data.\n6. Genome3D: Genome3D is a genome browser that provides DNA shape annotations, along with a variety of other genomic data. It offers a 3D view of the genome and allows users to filter and search the data based on various criteria. Genome3",
    "llama-2-7b-chat-hf_fact_raw": "1. UCSC Genome Browser provides DNA shape annotations using the Ensembl API.\n2. Ensembl is a genome browser that offers DNA shape annotations and a 3D view of the genome.\n3. Genome Atlas is a genome browser that offers DNA shape annotations and a variety of other genomic data.\n4. Open3D is an open-source genome browser that provides DNA shape annotations and a 3D view of the genome.\n5. Cytoscape is a COX4 protein-based genome browser that provides DNA shape annotations and a variety of other genomic data.",
    "llama-2-7b-chat-hf_fact": [
      "UCSC Genome Browser provides DNA shape annotations using the Ensembl API.",
      "Ensembl is a genome browser that offers DNA shape annotations and a 3D view of the genome.",
      "Genome Atlas is a genome browser that offers DNA shape annotations and a variety of other genomic data.",
      "Open3D is an open-source genome browser that provides DNA shape annotations and a 3D view of the genome.",
      "Cytoscape is a COX4 protein-based genome browser that provides DNA shape annotations and a variety of other genomic data."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: Cytoscape is not a genome browser but a software platform for visualizing molecular interaction networks and biological pathways and for integrating these networks with annotations, gene expression profiles, and other state data.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 174,
    "user_query": "Which syndromes are associated with mutations in the EZH2 gene?",
    "llama-2-7b-chat-hf_response": "The EZH2 gene encodes for the enzyme enzyme polycomb repressive complex 2 (PRC2), which plays a crucial role in regulating gene expression by modifying histones through the addition of 20-carbon atoms, known as methyl groups. Mutations in the EZH2 gene have been associated with several syndromes, including:\n1. Gorlin Syndrome: Gorlin syndrome is a rare genetic disorder that affects the development of bones, teeth, and skin. Mutations in the EZH2 gene are associated with this syndrome, which can lead to the formation of benign tumors, particularly in the skin and face.\n2. Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, and mutations in the EZH2 gene have been linked to an increased risk of developing BCC.\n3. Medullary Thyroid Cancer: Medullary thyroid cancer is a rare type of thyroid cancer that affects the thyroid gland. Mutations in the EZH2 gene have been found in some cases of medullary thyroid cancer.\n4. Clear Cell Sarcoma: Clear cell sarcoma is a rare type of cancer that affects the soft tissue of the body, particularly in the legs and pelvis. Mutations in the EZH2 gene have been linked to an increased risk of developing clear cell sarcoma.\n5. Wilms' Tumor: Wilms' tumor is a rare and aggressive type of cancer that affects the small intestine in children. Mutations in the EZH2 gene have been found in some cases of Wilms' tumor.\n6. Lymphoma: Mutations in the EZH2 gene have been linked to an increased risk of developing certain types of lymphoma, including follicular lymphoma and diffuse large B-cell lymphoma.\n7. Hodgkin's Lymphoma: Hodgkin's lymphoma is a type of cancer that affects the immune system. Mutations in the EZH2 gene have been found in some cases of Hodgkin's lymphoma.\n8. Myxoid Liver Tumors: Myxoid liver",
    "llama-2-7b-chat-hf_fact_raw": "1. Gorlin Syndrome is associated with mutations in the EZH2 gene.\n2. Mutations in the EZH2 gene increase the risk of developing Basal Cell Carcinoma.\n3. Some cases of Medullary Thyroid Cancer have been linked to mutations in the EZH2 gene.\n4. Mutations in the EZH2 gene increase the risk of Clear Cell Sarcoma.\n5. Mutations in the EZH2 gene have been found in some cases of Wilms' Tumor.",
    "llama-2-7b-chat-hf_fact": [
      "Gorlin Syndrome is associated with mutations in the EZH2 gene.",
      "Mutations in the EZH2 gene increase the risk of developing Basal Cell Carcinoma.",
      "Some cases of Medullary Thyroid Cancer have been linked to mutations in the EZH2 gene.",
      "Mutations in the EZH2 gene increase the risk of Clear Cell Sarcoma.",
      "Mutations in the EZH2 gene have been found in some cases of Wilms' Tumor."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gorlin Syndrome is associated with mutations in the PTCH1 gene.\n2. UNKNOWN\n3. FALSE [correction]: Some cases of Medullary Thyroid Cancer have been linked to mutations in the RET gene.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 193,
    "user_query": "List human proteins that are subject to a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_response": "Certainly! There are several human proteins that are known to undergo a dimer-to-tetramer transition, which is a common structural transition in proteins. Here are some examples:\n1. Hemoglobin: Hemoglobin is a critical protein in red blood cells that facilitates the transport of oxygen from the lungs to the body's tissues. It is a tetrameric protein, consisting of four subunits (two alpha and two beta subunits). However, under certain conditions, such as high temperatures or pH, hemoglobin can undergo a dimer-to-tetramer transition, which can affect its function and stability.\n2. Myoglobin: Myoglobin is a protein found in muscle cells that stores oxygen for quick release during muscle contractions. It is also a tetrameric protein, consisting of four subunits. Like hemoglobin, myoglobin can undergo a dimer-to-tetramer transition, which can affect its function and stability.\n3. Carbonic anhydrase: Carbonic anhydrase is an enzyme that plays a critical role in the regulation of pH in the body. It is a tetrameric protein, consisting of four subunits. However, under certain conditions, such as high temperatures or pH, carbonic anhydrase can undergo a dimer-to-tetramer transition, which can affect its function and stability.\n4. Chloride channel: Chloride channels are proteins that regulate the flow of chloride ions across cell membranes. They are tetrameric proteins, consisting of four subunits. However, under certain conditions, such as high temperatures or pH, chloride channels can undergo a dimer-to-tetramer transition, which can affect their function and stability.\n5. K-complexes: K-complexes are protein structures that are formed when the protein undergoes a dimer-to-tetramer transition. They are found in various proteins, including hemoglobin, myoglobin, and carbonic anhydrase. K-complexes are thought to play a role in protein folding and stability",
    "llama-2-7b-chat-hf_fact_raw": "1. Hemoglobin is a tetrameric protein consisting of two alpha and two beta subunits.\n2. Myoglobin is a tetrameric protein consisting of four subunits.\n3. Carbonic anhydrase is a tetrameric protein consisting of four subunits.\n4. Chloride channels are tetrameric proteins consisting of four subunits.\n5. K-complexes are protein structures formed during a dimer-to-tetramer transition.",
    "llama-2-7b-chat-hf_fact": [
      "Hemoglobin is a tetrameric protein consisting of two alpha and two beta subunits.",
      "Myoglobin is a tetrameric protein consisting of four subunits.",
      "Carbonic anhydrase is a tetrameric protein consisting of four subunits.",
      "Chloride channels are tetrameric proteins consisting of four subunits.",
      "K-complexes are protein structures formed during a dimer-to-tetramer transition."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Myoglobin is a monomeric protein consisting of a single subunit.\n3. FALSE [correction]: Carbonic anhydrase is not a tetrameric protein; it can exist as a monomer or dimer depending on the isoform.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 210,
    "user_query": "Which protein has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! After conducting research, I have found that the protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is Bcl-2.\nBcl-2 (B-cell CLL/lymphoma 2) is a family of proteins that play a crucial role in regulating programmed cell death (apoptosis) in various cell types, including cancer cells. Phospholamban (PLN) is a protein that inhibits the activity of the enzyme ATPase subunit of the Na+/K+-ATPase pump, which is involved in maintaining the concentration gradients of sodium and potassium ions across the cell membrane.\nStudies have shown that Bcl-2 can interact with PLN and inhibit its activity, thereby preventing the induction of apoptosis. This suggests that Bcl-2 may play a role in protecting cells from undergoing programmed cell death, which could be beneficial in certain contexts, such as during development or in response to stress.\nHowever, it is important to note that Bcl-2 can also promote the survival of cancer cells, and its overexpression is often associated with cancer. Therefore, while Bcl-2 may interact with PLN and be an anti-apoptotic protein, its role in cancer is complex and multifaceted.\nIn summary, the protein that has been found to interact with phospholamban (PLN) and is also an anti-apoptotic protein is Bcl-2. Further research is needed to fully understand the mechanisms underlying this interaction and its implications for cancer development and treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Bcl-2 is a protein that interacts with phospholamban (PLN).\n2. Bcl-2 is an anti-apoptotic protein.\n3. Phospholamban (PLN) inhibits the activity of the enzyme ATPase subunit of the Na+/K+-ATPase pump.\n4. Bcl-2 can inhibit the activity of PLN and prevent the induction of apoptosis.\n5. Overexpression of Bcl-2 is often associated with cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Bcl-2 is a protein that interacts with phospholamban (PLN).",
      "Bcl-2 is an anti-apoptotic protein.",
      "Phospholamban (PLN) inhibits the activity of the enzyme ATPase subunit of the Na+/K+-ATPase pump.",
      "Bcl-2 can inhibit the activity of PLN and prevent the induction of apoptosis.",
      "Overexpression of Bcl-2 is often associated with cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: Phospholamban (PLN) inhibits the activity of the enzyme SERCA (sarco/endoplasmic reticulum Ca2+-ATPase), not the Na+/K+-ATPase pump.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 218,
    "user_query": "Has vitamin D has been shown to reduce incidence of falls in older people in clinical trials?",
    "llama-2-7b-chat-hf_response": "Yes, there is evidence to suggest that vitamin D supplementation can reduce the incidence of falls in older people. Here are some clinical trials that have investigated the relationship between vitamin D and falls in older adults:\n1. The Vitamin D and Falls Study (2010): This randomized controlled trial included 1,654 community-dwelling older adults (ages 70-89) who were randomized to receive either vitamin D3 supplements (2,000 IU/day) or a placebo. The study found that the incidence of falls was significantly lower in the vitamin D group compared to the placebo group over a 12-month period.\n2. The Fracture Prevention and Treatment Research (FRACTAL) Study (2013): This randomized controlled trial included 240 community-dwelling older adults (ages 70-85) who were randomized to receive either vitamin D3 supplements (1,000 IU/day) or a placebo. The study found that the incidence of falls was significantly lower in the vitamin D group compared to the placebo group over a 12-month period.\n3. The Vitamin D and Falls in Older Adults (VDFO) Study (2016): This randomized controlled trial included 300 community-dwelling older adults (ages 65-84) who were randomized to receive either vitamin D3 supplements (1,500 IU/day) or a placebo. The study found that the incidence of falls was significantly lower in the vitamin D group compared to the placebo group over a 12-month period.\n4. The Vitamin D and Injury Prevention in the Elderly (VDIPE) Study (2018): This randomized controlled trial included 200 community-dwelling older adults (ages 70-84) who were randomized to receive either vitamin D3 supplements (1,500 IU/day) or a placebo. The study found that the incidence of falls was significantly lower in the vitamin D group compared to the placebo group over a 12-month period.\nOver",
    "llama-2-7b-chat-hf_fact_raw": "1. The Vitamin D and Falls Study (2010) included 1,654 older adults aged 70-89 and found a lower incidence of falls in the group receiving vitamin D3 supplements compared to a placebo group.\n2. The Fracture Prevention and Treatment Research (FRACTAL) Study (2013) included 240 older adults aged 70-85 and found a lower incidence of falls in the group receiving vitamin D3 supplements compared to a placebo group.\n3. The Vitamin D and Falls in Older Adults (VDFO) Study (2016) included 300 older adults aged 65-84 and found a lower incidence of falls in the group receiving vitamin D3 supplements compared to a placebo group.\n4. The Vitamin D and Injury Prevention in the Elderly (VDIPE) Study (2018) included 200 older adults aged 70-84 and found a lower incidence of falls in the group receiving vitamin D3 supplements compared to a placebo group.",
    "llama-2-7b-chat-hf_fact": [
      "The Vitamin D and Falls Study (2010) included 1,654 older adults aged 70-89 and found a lower incidence of falls in the group receiving vitamin D3 supplements compared to a placebo group.",
      "The Fracture Prevention and Treatment Research (FRACTAL) Study (2013) included 240 older adults aged 70-85 and found a lower incidence of falls in the group receiving vitamin D3 supplements compared to a placebo group.",
      "The Vitamin D and Falls in Older Adults (VDFO) Study (2016) included 300 older adults aged 65-84 and found a lower incidence of falls in the group receiving vitamin D3 supplements compared to a placebo group.",
      "The Vitamin D and Injury Prevention in the Elderly (VDIPE) Study (2018) included 200 older adults aged 70-84 and found a lower incidence of falls in the group receiving vitamin D3 supplements compared to a placebo group."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 222,
    "user_query": "Is there any association between Jarid2 and miR-155 in Th17 cells?",
    "llama-2-7b-chat-hf_response": "Yes, there is an association between Jarid2 and miR-155 in Th17 cells.\nJarid2 is a histone methyltransferase that is specifically expressed in T cells, including Th17 cells. It plays a crucial role in regulating the epigenetic landscape of T cells by methylating histone H3 on lysine 4 (H3K4) and histone H3 on lysine 27 (H3K27), leading to the activation of T cell-specific genes.\nmiR-155 is a microRNA that is highly expressed in Th17 cells and plays a critical role in regulating the differentiation and function of these cells. miR-155 targets and negatively regulates the expression of genes involved in T cell activation and differentiation, including the transcription factor retinoblastoma gene (Rb).\nStudies have shown that Jarid2 and miR-155 interact in Th17 cells. For example, one study found that Jarid2 and miR-155 colocalize in the nuclei of Th17 cells, suggesting a direct association between these two molecules. Another study found that Jarid2 is required for the maintenance of miR-155 expression in Th17 cells, as depletion of Jarid2 leads to a decrease in miR-155 levels.\nFurthermore, miR-155 has been shown to regulate the expression of Jarid2 itself. One study found that miR-155 binds to the 3'UTR of Jarid2 and inhibits its translation, suggesting a negative feedback loop between these two molecules.\nIn summary, there is an association between Jarid2 and miR-155 in Th17 cells, with Jarid2 playing a role in maintaining miR-155 expression, and miR-155 regulating the expression of Jarid2 itself. This interaction may play a critical role in regulating the differentiation and function of Th17 cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. Jarid2 is a histone methyltransferase that is specifically expressed in T cells, including Th17 cells.\n2. Jarid2 methylates histone H3 on lysine 4 (H3K4) and histone H3 on lysine 27 (H3K27), leading to the activation of T cell-specific genes.\n3. miR-155 is highly expressed in Th17 cells and regulates the differentiation and function of these cells.\n4. Studies have shown that Jarid2 and miR-155 colocalize in the nuclei of Th17 cells.\n5. Depletion of Jarid2 leads to a decrease in miR-155 levels in Th17 cells.",
    "llama-2-7b-chat-hf_fact": [
      "Jarid2 is a histone methyltransferase that is specifically expressed in T cells, including Th17 cells.",
      "Jarid2 methylates histone H3 on lysine 4 (H3K4) and histone H3 on lysine 27 (H3K27), leading to the activation of T cell-specific genes.",
      "miR-155 is highly expressed in Th17 cells and regulates the differentiation and function of these cells.",
      "Studies have shown that Jarid2 and miR-155 colocalize in the nuclei of Th17 cells.",
      "Depletion of Jarid2 leads to a decrease in miR-155 levels in Th17 cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Jarid2 is not a histone methyltransferase, but rather a protein that associates with the Polycomb repressive complex 2 (PRC2), which has histone methyltransferase activity.\n2. FALSE [correction]: Jarid2 does not directly methylate histones; instead, it is a part of the PRC2 complex that catalyzes the di- and tri-methylation of histone H3 at lysine 27 (H3K27me2/3). It is not known to methylate H3K4.\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 224,
    "user_query": "How many genes does the human hoxD cluster contain?",
    "llama-2-7b-chat-hf_response": "The human hoxD cluster contains a total of 16 genes. These genes are located on chromosome 2 and are involved in the development and patterning of the embryo. The hoxD genes are part of the homeobox gene family, which are characterized by a conserved DNA sequence that encodes a protein with a homeobox domain.\nThe 16 genes in the human hoxD cluster are:\n1. HOXD1\n2. HOXD2\n3. HOXD3\n4. HOXD4\n5. HOXD5\n6. HOXD6\n7. HOXD7\n8. HOXD8\n9. HOXD9\n10. HOXD10\n11. HOXD11\n12. HOXD12\n13. HOXD13\n14. HOXD14\n15. HOXD15\n16. HOXD16\nEach of these genes plays a specific role in the development of the embryo, and they work together to establish the proper pattern of gene expression during embryonic development. The hoxD genes are particularly important for the development of the anterior-posterior axis, which is the main axis of body organization in the embryo. They also play a role in the development of the limbs, the nervous system, and other tissues.\nMutations in the hoxD genes can lead to a variety of developmental disorders, including limb abnormalities and neural tube defects. For example, mutations in the HOXD12 gene can cause a condition called clubfoot, while mutations in the HOXD13 gene can cause a condition called polydactyly, which is characterized by extra fingers or toes.\nOverall, the human hoxD cluster is a critical set of genes that play a central role in the development and patterning of the embryo. Their proper function is essential for the formation of the proper body plan and the proper development of tissues and organs.",
    "llama-2-7b-chat-hf_fact_raw": "1. The human hoxD cluster contains a total of 16 genes.\n2. These genes are located on chromosome 2.\n3. The hoxD genes are part of the homeobox gene family.\n4. Mutations in the HOXD12 gene can cause a condition called clubfoot.\n5. Mutations in the HOXD13 gene can cause a condition called polydactyly.",
    "llama-2-7b-chat-hf_fact": [
      "The human hoxD cluster contains a total of 16 genes.",
      "These genes are located on chromosome 2.",
      "The hoxD genes are part of the homeobox gene family.",
      "Mutations in the HOXD12 gene can cause a condition called clubfoot.",
      "Mutations in the HOXD13 gene can cause a condition called polydactyly."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The human hoxD cluster contains a total of 9 genes.\n2. FALSE [correction]: These genes are located on chromosome 2q31.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 268,
    "user_query": "List phosphorylation consensus motifs for Casein Kinase 1 (CK1)?",
    "llama-2-7b-chat-hf_response": "Casein Kinase 1 (CK1) is a serine/threonine protein kinase that plays a crucial role in various cellular processes, including cell signaling, metabolism, and gene expression. Phosphorylation of CK1 by other kinases can activate or inhibit its activity, leading to a wide range of cellular responses. Here are some common phosphorylation consensus motifs for CK1:\n1. Autophosphorylation site: CK1 can autophosphorylate at specific sites, including Tyr-223, Tyr-225, and Tyr-230 in the catalytic domain. These sites are important for regulating CK1 activity and are often phosphorylated in response to various signals.\n2. Sites phosphorylated by other kinases: CK1 can be phosphorylated by other kinases, such as MAPK, CDK, and ATM. These phosphorylation sites are typically located in the N-terminal domain of CK1 and include Ser-216, Ser-221, and Ser-227.\n3. Phosphorylation sites in the regulatory domain: The regulatory domain of CK1 contains several phosphorylation sites that are important for regulating CK1 activity. These sites include Ser-181, Ser-193, and Ser-202, which are phosphorylated by various kinases, including CK1 itself.\n4. Phosphorylation sites in the substrate binding domain: The substrate binding domain of CK1 contains several phosphorylation sites that are important for substrate binding and catalysis. These sites include Ser-166, Ser-170, and Ser-176, which are phosphorylated by CK1 and other kinases.\n5. Phosphorylation sites in the C-terminal domain: The C-terminal domain of CK1 contains several phosphorylation sites that are important for regulating CK1 activity. These sites include Ser-303, Ser-307, and Ser-311, which are phosphorylated by various kinases, including CK1 itself.\n6. Phosphorylation sites in the",
    "llama-2-7b-chat-hf_fact_raw": "1. Casein Kinase 1 (CK1) can autophosphorylate at Tyr-223, Tyr-225, and Tyr-230 in the catalytic domain.\n2. CK1 can be phosphorylated by kinases such as MAPK, CDK, and ATM at sites including Ser-216, Ser-221, and Ser-227 in the N-terminal domain.\n3. The regulatory domain of CK1 has phosphorylation sites Ser-181, Ser-193, and Ser-202.\n4. The substrate binding domain of CK1 has phosphorylation sites Ser-166, Ser-170, and Ser-176.\n5. The C-terminal domain of CK1 has phosphorylation sites Ser-303, Ser-307, and Ser-311.",
    "llama-2-7b-chat-hf_fact": [
      "Casein Kinase 1 (CK1) can autophosphorylate at Tyr-223, Tyr-225, and Tyr-230 in the catalytic domain.",
      "CK1 can be phosphorylated by kinases such as MAPK, CDK, and ATM at sites including Ser-216, Ser-221, and Ser-227 in the N-terminal domain.",
      "The regulatory domain of CK1 has phosphorylation sites Ser-181, Ser-193, and Ser-202.",
      "The substrate binding domain of CK1 has phosphorylation sites Ser-166, Ser-170, and Ser-176.",
      "The C-terminal domain of CK1 has phosphorylation sites Ser-303, Ser-307, and Ser-311."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: These statements pertain to highly specific biochemical information that requires domain knowledge or access to scientific literature to verify.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 305,
    "user_query": "Which are the different proteins/isoforms encoded but the ASPH (aspartate beta-hydroxylase) gene in humans?",
    "llama-2-7b-chat-hf_response": "The ASPH (aspartate beta-hydroxylase) gene in humans encodes for multiple proteins and isoforms, including:\n1. Aspartate beta-hydroxylase (ABH): This is the primary protein product of the ASPH gene, which is a key enzyme in the production of the neurotransmitter serotonin. ABH catalyzes the conversion of L-aspartate and L-β-hydroxyaspartate to L-serotonin and 4-hydroxyphenylpyruvate.\n2. Tissue-specific isoforms: The ASPH gene can produce different isoforms that are specifically expressed in certain tissues, such as the brain, liver, and kidneys. These tissue-specific isoforms may have different functions or activities compared to the full-length ABH protein.\n3. Carboxyl-terminal domain-deleted isoforms: Deletion of the carboxyl-terminal domain of the ASPH protein can result in the formation of isoforms that are missing this domain. The carboxyl-terminal domain is involved in the regulation of protein-protein interactions and subcellular localization, so the loss of this domain may affect the function of the protein.\n4. N-terminal domain-deleted isoforms: Deletion of the N-terminal domain of the ASPH protein can also result in the formation of isoforms that are missing this domain. The N-terminal domain is involved in the regulation of protein-protein interactions and subcellular localization, so the loss of this domain may affect the function of the protein.\n5. Glycosylated isoforms: The ASPH protein can be glycosylated, which can result in the formation of isoforms with additional carbohydrate chains attached to the protein. These glycosylated isoforms may have different functions or activities compared to the non-glycosylated isoforms.\n6. Phosphorylated isoforms: The ASPH protein can be phosphorylated, which can result in the formation of isoforms with phosphate groups added to specific residues. Phosphorylation can affect the activity or function of the protein, and different phosphorylation sites",
    "llama-2-7b-chat-hf_fact_raw": "1. The ASPH gene encodes for the primary protein product, Aspartate beta-hydroxylase (ABH).\n2. ABH is an enzyme involved in the production of the neurotransmitter serotonin.\n3. The ASPH gene can produce tissue-specific isoforms expressed in the brain, liver, and kidneys.\n4. Isoforms of the ASPH protein can be formed with the deletion of the carboxyl-terminal or N-terminal domain.\n5. The ASPH protein can undergo glycosylation and phosphorylation, resulting in the formation of glycosylated and phosphorylated isoforms.",
    "llama-2-7b-chat-hf_fact": [
      "The ASPH gene encodes for the primary protein product, Aspartate beta-hydroxylase (ABH).",
      "ABH is an enzyme involved in the production of the neurotransmitter serotonin.",
      "The ASPH gene can produce tissue-specific isoforms expressed in the brain, liver, and kidneys.",
      "Isoforms of the ASPH protein can be formed with the deletion of the carboxyl-terminal or N-terminal domain.",
      "The ASPH protein can undergo glycosylation and phosphorylation, resulting in the formation of glycosylated and phosphorylated isoforms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: ABH is an enzyme involved in the post-translational modification of proteins by adding hydroxyl groups to aspartate and asparagine residues, not in the production of serotonin.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 330,
    "user_query": "When was empagliflozin FDA approved?",
    "llama-2-7b-chat-hf_response": "Empagliflozin, also known as Jardiance, is a medication used to treat type 2 diabetes. It was approved by the US Food and Drug Administration (FDA) in 2014.\nEmpagliflozin was approved on August 18, 2014, based on the results of a clinical trial called EMPA-REG OUTCOME. This trial showed that empagliflozin could help reduce the risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke in people with type 2 diabetes and established cardiovascular disease.\nThe FDA approved empagliflozin for the treatment of type 2 diabetes in adults, and it has since become a widely used medication for this condition. It is important to note that empagliflozin is not approved for the treatment of type 1 diabetes or for people with diabetes who do not have established cardiovascular disease.\nI hope this information helps! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Empagliflozin, also known as Jardiance, is a medication used to treat type 2 diabetes.\n2. Empagliflozin was approved by the US Food and Drug Administration in 2014.\n3. The FDA approved empagliflozin on August 18, 2014.\n4. Empagliflozin's approval was based on the results of the EMPA-REG OUTCOME clinical trial.\n5. Empagliflozin is not approved for the treatment of type 1 diabetes or for people with diabetes who do not have established cardiovascular disease.",
    "llama-2-7b-chat-hf_fact": [
      "Empagliflozin, also known as Jardiance, is a medication used to treat type 2 diabetes.",
      "Empagliflozin was approved by the US Food and Drug Administration in 2014.",
      "The FDA approved empagliflozin on August 18, 2014.",
      "Empagliflozin's approval was based on the results of the EMPA-REG OUTCOME clinical trial.",
      "Empagliflozin is not approved for the treatment of type 1 diabetes or for people with diabetes who do not have established cardiovascular disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Empagliflozin is not approved for the treatment of type 1 diabetes, but it is approved for people with type 2 diabetes who have established cardiovascular disease as indicated by the results of the EMPA-REG OUTCOME clinical trial.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 350,
    "user_query": "What are the results of loss of the protein Lon1 in the plant Arabidopsis?",
    "llama-2-7b-chat-hf_response": "Loss of the protein Lon1 in the plant Arabidopsis has been shown to have several interesting consequences. Lon1 is a key regulator of the longevity protein network in Arabidopsis, and its loss can lead to a range of phenotypes. Here are some of the results of loss of Lon1 in Arabidopsis:\n1. Increased sensitivity to oxidative stress: Lon1 plays a critical role in protecting against oxidative damage in plants. The loss of Lon1 in Arabidopsis leads to increased sensitivity to oxidative stress, as demonstrated by increased levels of reactive oxygen species (ROS) and lipid peroxidation in lon1 mutants.\n2. Enhanced cell death: Lon1 regulates programmed cell death (PCD) in Arabidopsis, and its loss can lead to increased levels of PCD. This can result in the formation of aberrant tissues and organs, such as the accumulation of dead cells in leaves and stems.\n3. Altered hormone regulation: Lon1 has been shown to interact with plant hormone signaling pathways, including the brassinosteroid and abscisic acid pathways. The loss of Lon1 can lead to altered hormone regulation, which can impact plant growth and development. For example, lon1 mutants have been shown to have altered responses to drought and salt stress.\n4. Changes in metabolism: Lon1 regulates a range of metabolic pathways in Arabidopsis, including the biosynthesis of amino acids and sugars. The loss of Lon1 can lead to changes in these pathways, which can impact plant growth and development. For example, lon1 mutants have been shown to have altered levels of sugars and amino acids.\n5. Impacts on flowering time: Lon1 regulates the timing of flowering in Arabidopsis, and its loss can lead to earlier flowering times. This can have implications for plant breeding and agriculture, as well as for our understanding of the genetic regulation of flowering time.\n6. Changes in root architecture: Lon1 regulates root architecture in Arabidopsis, and its loss can lead to changes in root length and branching patterns. This can impact plant",
    "llama-2-7b-chat-hf_fact_raw": "1. Lon1 loss in Arabidopsis leads to increased sensitivity to oxidative stress, causing higher levels of reactive oxygen species and lipid peroxidation.\n2. The absence of Lon1 results in enhanced programmed cell death in the plant.\n3. Loss of Lon1 affects hormone regulation, impacting plant growth and responses to stress like drought and salt.\n4. Changes in metabolism, specifically in the biosynthesis of amino acids and sugars, occur due to Lon1 loss.\n5. Lon1 loss can cause earlier flowering times in Arabidopsis.",
    "llama-2-7b-chat-hf_fact": [
      "Lon1 loss in Arabidopsis leads to increased sensitivity to oxidative stress, causing higher levels of reactive oxygen species and lipid peroxidation.",
      "The absence of Lon1 results in enhanced programmed cell death in the plant.",
      "Loss of Lon1 affects hormone regulation, impacting plant growth and responses to stress like drought and salt.",
      "Changes in metabolism, specifically in the biosynthesis of amino acids and sugars, occur due to Lon1 loss.",
      "Lon1 loss can cause earlier flowering times in Arabidopsis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 409,
    "user_query": "Does a linker histone exist in the yeast genome?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! I'm happy to help you with that.\nA linker histone is a type of histone protein that is involved in the regulation of chromatin structure and gene expression. While histones are found in the genomes of many organisms, including yeast, the specific type of histone you are referring to, linker histone, is not present in the yeast genome.\nHistones are the chief components of chromatin, the complex of DNA and proteins that make up the chromosome. There are five main types of histones found in eukaryotic cells, including histones H2A, H2B, H3, and H4. These histones are highly modified with a variety of post-translational modifications (PTMs), such as acetylation, methylation, and phosphorylation, which can alter their interaction with DNA and other proteins, leading to changes in chromatin structure and gene expression.\nLinker histones, on the other hand, are a distinct type of histone that is specifically involved in the formation of higher-order chromatin structures, such as chromatin loops and domain structures. These structures are thought to play important roles in regulating gene expression, chromatin stability, and cellular differentiation.\nWhile linker histones have been identified in some organisms, including humans and mice, they are not present in the yeast genome. Instead, yeast cells use a different type of histone, called histone H3, to form the nucleosome, the basic unit of chromatin.\nIn summary, linker histones are not found in the yeast genome, and yeast cells use histone H3 to form the nucleosome. However, the study of histones and chromatin structure in yeast has contributed significantly to our understanding of the mechanisms that regulate gene expression and chromatin dynamics in eukaryotic cells.",
    "llama-2-7b-chat-hf_fact_raw": "1. A linker histone is involved in the regulation of chromatin structure and gene expression.\n2. The specific type of histone referred to as linker histone is not present in the yeast genome.\n3. Yeast cells use a different type of histone, called histone H3, to form the nucleosome.\n4. There are five main types of histones found in eukaryotic cells: H2A, H2B, H3, and H4.\n5. Chromatin is composed of DNA and proteins that make up the chromosome.",
    "llama-2-7b-chat-hf_fact": [
      "A linker histone is involved in the regulation of chromatin structure and gene expression.",
      "The specific type of histone referred to as linker histone is not present in the yeast genome.",
      "Yeast cells use a different type of histone, called histone H3, to form the nucleosome.",
      "There are five main types of histones found in eukaryotic cells: H2A, H2B, H3, and H4.",
      "Chromatin is composed of DNA and proteins that make up the chromosome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: While some species of yeast may lack linker histones, others do have variants of linker histones.\n3. FALSE [correction]: Yeast cells use histone H3 along with other histones to form the nucleosome; H3 is not a different type specific to yeast.\n4. FALSE [correction]: There are five main types of histones found in eukaryotic cells: H1 (linker histone), H2A, H2B, H3, and H4.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 418,
    "user_query": "Is there evidence that tomato juice lowers cholesterol levels?",
    "llama-2-7b-chat-hf_response": "Yes, there is evidence to suggest that tomato juice can help lower cholesterol levels. Here are some studies and findings that support this claim:\n1. A 2013 study published in the Journal of Nutrition found that drinking tomato juice for 12 weeks reduced total cholesterol and LDL (\"bad\") cholesterol in healthy adults. The study involved 40 participants who were randomly assigned to drink either tomato juice or a placebo.\n2. A 2011 study published in the European Journal of Nutrition found that drinking tomato juice for 8 weeks reduced LDL cholesterol in healthy adults. The study involved 30 participants who were divided into two groups: one group drank tomato juice, and the other group drank a placebo.\n3. A 2009 study published in the Journal of Agricultural and Food Chemistry found that tomato juice contains a compound called lycopene, which has been shown to reduce cholesterol levels in animal studies. The study found that lycopene inhibited the production of cholesterol in the liver and intestines.\n4. A 2018 review published in the journal Nutrients found that tomato juice may help lower cholesterol levels due to its high content of lycopene and other antioxidants. The review analyzed 17 studies on the effects of tomato juice on cholesterol levels and found that tomato juice consistently lowered cholesterol levels in both healthy individuals and those with high cholesterol.\nWhile these studies suggest that tomato juice may help lower cholesterol levels, it's important to note that more research is needed to confirm these findings and to determine the optimal amount and duration of tomato juice consumption for cholesterol reduction. Additionally, tomato juice should be consumed as part of a balanced diet and lifestyle, rather than relying solely on it for cholesterol reduction.\nIn summary, while there is some evidence to suggest that tomato juice may help lower cholesterol levels, more research is needed to fully understand its effects. As with any dietary change, it's important to consult with",
    "llama-2-7b-chat-hf_fact_raw": "1. A 2013 study in the Journal of Nutrition reported that drinking tomato juice for 12 weeks reduced total cholesterol and LDL cholesterol in healthy adults.\n2. A 2011 study in the European Journal of Nutrition found that drinking tomato juice for 8 weeks lowered LDL cholesterol in healthy adults.\n3. A 2009 study in the Journal of Agricultural and Food Chemistry discovered that tomato juice contains lycopene, which inhibited cholesterol production in the liver and intestines in animal studies.\n4. A 2018 review in the journal Nutrients analyzed 17 studies and concluded that tomato juice consistently lowered cholesterol levels in both healthy individuals and those with high cholesterol.",
    "llama-2-7b-chat-hf_fact": [
      "A 2013 study in the Journal of Nutrition reported that drinking tomato juice for 12 weeks reduced total cholesterol and LDL cholesterol in healthy adults.",
      "A 2011 study in the European Journal of Nutrition found that drinking tomato juice for 8 weeks lowered LDL cholesterol in healthy adults.",
      "A 2009 study in the Journal of Agricultural and Food Chemistry discovered that tomato juice contains lycopene, which inhibited cholesterol production in the liver and intestines in animal studies.",
      "A 2018 review in the journal Nutrients analyzed 17 studies and concluded that tomato juice consistently lowered cholesterol levels in both healthy individuals and those with high cholesterol."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 472,
    "user_query": "How do Hsp70 and Hsp110 affect mRNA stability?",
    "llama-2-7b-chat-hf_response": "Hsp70 and Hsp110 are two heat shock proteins that play important roles in regulating mRNA stability. These proteins are involved in various cellular processes, including protein folding, degradation, and transport. In addition to their chaperone functions, Hsp70 and Hsp110 have been shown to influence mRNA stability by modulating the activity of RNA-binding proteins and microRNAs (miRNAs). Here's a detailed explanation of how these proteins affect mRNA stability:\n1. Hsp70: Hsp70 is a ubiquitous protein that is involved in protein folding, transport, and degradation. It has been shown to interact with several RNA-binding proteins, including the RNA-binding protein AUF1. AUF1 is a key regulator of mRNA stability, and its activity is modulated by Hsp70. Studies have shown that Hsp70 can bind to the 3' untranslated region (UTR) of target mRNAs and inhibit the activity of AUF1, leading to increased mRNA stability.\n2. Hsp110: Hsp110 is a heat shock protein that is highly expressed in the brain and is involved in protein folding and degradation. It has been shown to interact with miRNAs, which are small non-coding RNAs that play important roles in post-transcriptional regulation of gene expression. Hsp110 can bind to miRNAs and inhibit their activity, leading to increased mRNA stability.\n3. Hsp70 and Hsp110 interaction: Hsp70 and Hsp110 have been shown to interact with each other, and their combination has been shown to have a synergistic effect on mRNA stability. Studies have shown that Hsp70 can enhance the activity of Hsp110, leading to increased mRNA stability. Conversely, Hsp110 can also enhance the activity of Hsp70, leading to further increased mRNA stability.\n4. mRNA stability regulation: Hsp70 and Hsp110 have been shown to regulate mRNA stability by modulating the activity of RNA-binding",
    "llama-2-7b-chat-hf_fact_raw": "1. Hsp70 interacts with RNA-binding proteins, including AUF1, which is a key regulator of mRNA stability.\n2. Hsp70 can bind to the 3' untranslated region of target mRNAs and inhibit the activity of AUF1.\n3. Hsp110 is highly expressed in the brain and involved in protein folding and degradation.\n4. Hsp110 can bind to microRNAs and inhibit their activity, resulting in increased mRNA stability.\n5. Studies have demonstrated that Hsp70 and Hsp110 can have a synergistic effect on mRNA stability when interacting with each other.",
    "llama-2-7b-chat-hf_fact": [
      "Hsp70 interacts with RNA-binding proteins, including AUF1, which is a key regulator of mRNA stability.",
      "Hsp70 can bind to the 3' untranslated region of target mRNAs and inhibit the activity of AUF1.",
      "Hsp110 is highly expressed in the brain and involved in protein folding and degradation.",
      "Hsp110 can bind to microRNAs and inhibit their activity, resulting in increased mRNA stability.",
      "Studies have demonstrated that Hsp70 and Hsp110 can have a synergistic effect on mRNA stability when interacting with each other."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 481,
    "user_query": "Which deiodinases are present in skeletal  muscle?",
    "llama-2-7b-chat-hf_response": "Deiodinases are enzymes that play a crucial role in regulating the activity of thyroid hormones in various tissues throughout the body, including skeletal muscle. There are three main types of deiodinases:\n1. Type I deiodinase (Dio1): This is the main deiodinase present in skeletal muscle, and it is responsible for converting T4 (tetraiodothyronine) into T3 (triiodothyronine) in the muscle tissue. T3 is the most active form of thyroid hormone, and it plays a critical role in regulating muscle contraction and metabolism.\n2. Type II deiodinase (Dio2): This deiodinase is less abundant in skeletal muscle compared to Dio1, but it still plays a role in converting T4 into T3. Dio2 is also involved in the regulation of genes involved in glucose and lipid metabolism.\n3. Type III deiodinase (Dio3): This deiodinase is present in low levels in skeletal muscle and is primarily involved in the inactivation of T3. Dio3 is also involved in the regulation of genes involved in immune response and inflammation.\nThe balance between these different deiodinases can have significant effects on muscle function and metabolism. For example, an imbalance in favor of Dio1 can lead to increased muscle contraction and metabolism, which can be beneficial for athletes and bodybuilders looking to increase muscle mass and strength. On the other hand, an imbalance in favor of Dio2 can lead to decreased muscle contraction and metabolism, which can be detrimental for muscle function and overall health.\nIn addition to these three main deiodinases, there are also other deiodinases present in skeletal muscle, such as Dio4 and Dio5, which have more specialized functions. For example, Dio4 is involved in the regulation of muscle-specific genes, while Dio5 is involved in the regulation of immune response genes.\nOverall, the balance of different deiodinases in skeletal muscle is critical for maintaining proper muscle function and met",
    "llama-2-7b-chat-hf_fact_raw": "1. Type I deiodinase (Dio1) is the main deiodinase present in skeletal muscle, responsible for converting T4 into T3.\n2. Type II deiodinase (Dio2) is less abundant in skeletal muscle but still contributes to converting T4 into T3 and regulating glucose and lipid metabolism genes.\n3. Type III deiodinase (Dio3) is present in low levels in skeletal muscle and primarily inactivates T3 while also regulating immune response and inflammation genes.\n4. An imbalance favoring Dio1 can lead to increased muscle contraction and metabolism.\n5. There are additional deiodinases in skeletal muscle, such as Dio4 and Dio5, with specialized functions in regulating muscle-specific and immune response genes.",
    "llama-2-7b-chat-hf_fact": [
      "Type I deiodinase (Dio1) is the main deiodinase present in skeletal muscle, responsible for converting T4 into T3.",
      "Type II deiodinase (Dio2) is less abundant in skeletal muscle but still contributes to converting T4 into T3 and regulating glucose and lipid metabolism genes.",
      "Type III deiodinase (Dio3) is present in low levels in skeletal muscle and primarily inactivates T3 while also regulating immune response and inflammation genes.",
      "An imbalance favoring Dio1 can lead to increased muscle contraction and metabolism.",
      "There are additional deiodinases in skeletal muscle, such as Dio4 and Dio5, with specialized functions in regulating muscle-specific and immune response genes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: There are no known deiodinases such as Dio4 and Dio5 in skeletal muscle; there are only three types of deiodinases (Dio1, Dio2, and Dio3).",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 534,
    "user_query": "List inflammatory caspase proteins?",
    "llama-2-7b-chat-hf_response": "Certainly! Inflammatory caspase proteins are a family of enzymes that play a crucial role in the regulation of inflammation and immune responses. Here are some of the most well-known inflammatory caspase proteins:\n1. Caspase-1 (also known as C1 or NEDD1L): This caspase is involved in the activation of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α), two potent pro-inflammatory cytokines. Caspase-1 also activates the inflammatory transcription factor NF-κB.\n2. Caspase-2 (also known as C2 or LRCH1): This caspase is involved in the activation of IL-1β and TNF-α, as well as the processing of the cell surface receptor TNF-R1.\n3. Caspase-3 (also known as C3 or APO1): This caspase is involved in the activation of the pro-inflammatory cytokines IL-1β, TNF-α, and IL-6. Caspase-3 also plays a role in the regulation of apoptosis, or programmed cell death.\n4. Caspase-4 (also known as C4 or LRCH2): This caspase is involved in the activation of the pro-inflammatory cytokines IL-1β and TNF-α.\n5. Caspase-5 (also known as C5 or LRCH3): This caspase is involved in the activation of the pro-inflammatory cytokine IL-6.\n6. Caspase-6 (also known as C6 or LRCH4): This caspase is involved in the activation of the pro-inflammatory cytokine TNF-α.\n7. Caspase-7 (also known as C7 or LRCH5): This caspase is involved in the activation of the pro-inflammatory cytokine IL-1β.\n8. Caspase-8 (also known as C8 or LRCH6): This caspase is involved in the activation of the pro-inflammatory cy",
    "llama-2-7b-chat-hf_fact_raw": "1. Caspase-1 is involved in the activation of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α).\n2. Caspase-2 is involved in the activation of IL-1β and TNF-α, as well as the processing of the cell surface receptor TNF-R1.\n3. Caspase-3 is involved in the activation of the pro-inflammatory cytokines IL-1β, TNF-α, and IL-6.\n4. Caspase-4 is involved in the activation of the pro-inflammatory cytokines IL-1β and TNF-α.\n5. Caspase-5 is involved in the activation of the pro-inflammatory cytokine IL-6.",
    "llama-2-7b-chat-hf_fact": [
      "Caspase-1 is involved in the activation of interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α).",
      "Caspase-2 is involved in the activation of IL-1β and TNF-α, as well as the processing of the cell surface receptor TNF-R1.",
      "Caspase-3 is involved in the activation of the pro-inflammatory cytokines IL-1β, TNF-α, and IL-6.",
      "Caspase-4 is involved in the activation of the pro-inflammatory cytokines IL-1β and TNF-α.",
      "Caspase-5 is involved in the activation of the pro-inflammatory cytokine IL-6."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Caspase-2 is known for its involvement in the intrinsic apoptosis pathway and not directly in the activation of IL-1β and TNF-α or processing of TNF-R1.\n3. FALSE [correction]: Caspase-3 is primarily involved in the execution phase of cell apoptosis and not directly in the activation of cytokines.\n4. FALSE [correction]: Caspase-4 is involved in the activation of IL-1β through the non-canonical inflammasome pathway, but not directly in the activation of TNF-α.\n5. FALSE [correction]: Caspase-5 is involved in the activation of IL-1β as part of the inflammasome complex, not mentioned for IL-6.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 579,
    "user_query": "Is there any link between the aurora B kinase and the polycomb protein ring1B?",
    "llama-2-7b-chat-hf_response": "Yes, there is a link between the aurora B kinase and the polycomb protein Ring1B. Both proteins have been implicated in various cellular processes, including cell cycle regulation, DNA repair, and epigenetic modification. While they have different functions, there is evidence to suggest that they interact and coordinate their actions in certain contexts.\nAurora B kinase is a serine/threonine kinase that plays a critical role in the regulation of the cell cycle, particularly during mitosis. It is activated at the G2/M checkpoint and phosphorylates various substrates to promote the progression of the cell cycle. Aurora B kinase has also been shown to interact with other proteins, including the polycomb protein Ring1B.\nRing1B is a polycomb group protein that is involved in the regulation of gene expression, particularly during cellular differentiation and development. It is a histone methyltransferase that catalyzes the mono- and di-methylation of histone H3 at lysine 27, leading to the repression of gene expression. Ring1B has also been implicated in the maintenance of stem cell self-renewal and the regulation of cellular differentiation.\nStudies have shown that Aurora B kinase and Ring1B interact in various contexts. For example, Aurora B kinase has been shown to phosphorylate Ring1B, leading to its activation and the regulation of polycomb-mediated gene silencing. Conversely, Ring1B has been shown to interact with Aurora B kinase and regulate its activity, particularly during the G2/M checkpoint.\nOne study published in the journal Nature Communications in 2018 found that Aurora B kinase and Ring1B interact in the regulation of DNA damage response and repair. The study showed that Aurora B kinase phosphorylates Ring1B, leading to its activation and the recruitment of polycomb complexes to sites of DNA damage. This recruitment facilitates the repair of DNA damage by promoting the expression of genes involved in the repair process.\nAnother study published in the journal Cell Reports in 2019 found that Ring1B regulates the activity of Aurora B kinase during mitosis. The study showed that",
    "llama-2-7b-chat-hf_fact_raw": "1. Aurora B kinase is a serine/threonine kinase involved in cell cycle regulation during mitosis.\n2. Aurora B kinase is activated at the G2/M checkpoint of the cell cycle.\n3. Ring1B is a polycomb group protein that acts as a histone methyltransferase for histone H3 at lysine 27.\n4. Aurora B kinase can phosphorylate Ring1B, leading to its activation.\n5. A study in Nature Communications in 2018 found that Aurora B kinase and Ring1B interact in the regulation of DNA damage response and repair.",
    "llama-2-7b-chat-hf_fact": [
      "Aurora B kinase is a serine/threonine kinase involved in cell cycle regulation during mitosis.",
      "Aurora B kinase is activated at the G2/M checkpoint of the cell cycle.",
      "Ring1B is a polycomb group protein that acts as a histone methyltransferase for histone H3 at lysine 27.",
      "Aurora B kinase can phosphorylate Ring1B, leading to its activation.",
      "A study in Nature Communications in 2018 found that Aurora B kinase and Ring1B interact in the regulation of DNA damage response and repair."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 597,
    "user_query": "What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! Non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are specific sequences that are not part of the canonical splice sites, but can still be recognized by the splicing machinery. These motifs can affect splicing efficiency, alternative splicing, and gene regulation. Here are some of the most frequent non-canonical sequence motifs found at the donor and acceptor splice sites in vertebrates:\nDonor Splice Sites:\n1. GG(A/C)AG: This motif is found in the 3' untranslated region (3' UTR) of many mRNAs and can act as a weak donor splice site. The GG(A/C)AG motif is recognized by the splicing machinery, but the splicing efficiency is lower than that of the canonical donor site.\n2. GT(A/C)AG: Similar to the GG(A/C)AG motif, the GT(A/C)AG motif is also found in the 3' UTR of some mRNAs and can act as a weak donor splice site.\n3. G(A/C)AT: This motif is found in the 5' UTR of some mRNAs and can act as a weak donor splice site.\nAcceptor Splice Sites:\n1. U(A/C)G: This motif is found in the 5' UTR of many mRNAs and can act as a weak acceptor splice site. The U(A/C)G motif is recognized by the splicing machinery, but the splicing efficiency is lower than that of the canonical acceptor site.\n2. U(A/C)U: Similar to the U(A/C)G motif, the U(A/C)U motif is found in the 5' UTR of some mRNAs and can act as a weak acceptor splice site.\n3. U(A/C)GU: This motif is found in the 5' UTR of some mRNAs and can act as a weak acceptor splice site.\nIt's worth noting that the frequency",
    "llama-2-7b-chat-hf_fact_raw": "1. The GG(A/C)AG motif is found in the 3' untranslated region of many mRNAs.\n2. The GT(A/C)AG motif can act as a weak donor splice site.\n3. G(A/C)AT is a motif found in the 5' UTR of some mRNAs.\n4. The U(A/C)G motif can act as a weak acceptor splice site and is found in the 5' UTR of many mRNAs.\n5. U(A/C)GU is a motif found in the 5' UTR of some mRNAs and can act as a weak acceptor splice site.",
    "llama-2-7b-chat-hf_fact": [
      "The GG(A/C)AG motif is found in the 3' untranslated region of many mRNAs.",
      "The GT(A/C)AG motif can act as a weak donor splice site.",
      "G(A/C)AT is a motif found in the 5' UTR of some mRNAs.",
      "The U(A/C)G motif can act as a weak acceptor splice site and is found in the 5' UTR of many mRNAs.",
      "U(A/C)GU is a motif found in the 5' UTR of some mRNAs and can act as a weak acceptor splice site."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: The U(A/C)G motif can act as a weak acceptor splice site, but it is found in the 3' untranslated region of many mRNAs, not the 5' UTR.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 629,
    "user_query": "Which event results in the acetylation of S6K1?",
    "llama-2-7b-chat-hf_response": "The acetylation of S6K1 (S6 kinase 1) is a complex process that involves multiple signaling pathways and molecular mechanisms. Here's a detailed answer to your question:\nS6K1 is a key regulator of protein synthesis and cell growth, and it is acetylated in response to various signals, including:\n1. Insulin/IGF-1 signaling pathway: Insulin and IGF-1 (insulin-like growth factor 1) are important regulators of cell growth and metabolism. When insulin binds to its receptor on the surface of cells, it activates the insulin receptor kinase (IRK), which in turn phosphorylates and activates the serine/threonine kinase IRS1 (insulin receptor substrate 1). IRS1 then activates the PI3K (phosphatidylinositol 3-kinase) pathway, which generates PIP3 (phosphatidylinositol 3,4,5-trisphosphate), a lipid second messenger that activates S6K1.\n2. mTOR signaling pathway: The mTOR (mechanistic target of rapamycin) pathway is a central regulator of cell growth and metabolism. When mTOR senses changes in nutrient availability, it activates or inhibits various downstream signaling pathways, including the PI3K/AKT and S6K1 pathways.\n3. Nutrient availability: The availability of nutrients, particularly glucose and amino acids, can also regulate S6K1 activity. When nutrients are abundant, S6K1 is activated, leading to increased protein synthesis and cell growth. Conversely, when nutrients are limiting, S6K1 activity is reduced, leading to decreased protein synthesis and cell growth.\n4. Hormonal signaling: Hormones, such as corticosteroids and growth factors, can also regulate S6K1 activity. For example, corticosteroids can activate the PI3K/AKT pathway, leading to increased S6K1 activity and",
    "llama-2-7b-chat-hf_fact_raw": "1. S6K1 is acetylated in response to the Insulin/IGF-1 signaling pathway.\n2. The Insulin/IGF-1 signaling pathway involves the activation of the insulin receptor kinase (IRK), phosphorylation of IRS1, and activation of the PI3K pathway.\n3. The mTOR signaling pathway acts as a central regulator of cell growth and metabolism and can activate the S6K1 pathway.\n4. Nutrient availability, particularly glucose and amino acids, can regulate S6K1 activity.\n5. Hormonal signaling, including corticosteroids and growth factors, can affect S6K1 activity.",
    "llama-2-7b-chat-hf_fact": [
      "S6K1 is acetylated in response to the Insulin/IGF-1 signaling pathway.",
      "The Insulin/IGF-1 signaling pathway involves the activation of the insulin receptor kinase (IRK), phosphorylation of IRS1, and activation of the PI3K pathway.",
      "The mTOR signaling pathway acts as a central regulator of cell growth and metabolism and can activate the S6K1 pathway.",
      "Nutrient availability, particularly glucose and amino acids, can regulate S6K1 activity.",
      "Hormonal signaling, including corticosteroids and growth factors, can affect S6K1 activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 632,
    "user_query": "What is the cause of episodic ataxia type 6?",
    "llama-2-7b-chat-hf_response": "Episodic ataxia type 6 (EA6) is a rare genetic disorder that affects the brain and spinal cord, leading to episodes of ataxia (loss of coordination and balance), seizures, and other neurological symptoms. The cause of EA6 is a mutation in the CACNA1C gene, which codes for a subunit of the calcium channel complex in nerve cells.\nThe CACNA1C gene is located on chromosome 17 and is one of the most well-known genetic causes of episodic ataxia. The mutation leads to an abnormal calcium channel that allows excessive amounts of calcium ions to enter the nerve cells, leading to disruptions in the normal functioning of the nervous system.\nThe symptoms of EA6 typically begin in childhood or adolescence and can vary in severity and frequency. Episodes of ataxia, seizures, and other neurological symptoms can occur spontaneously or can be triggered by certain activities, such as exercise or stress. The episodes can last from hours to days and can be accompanied by other symptoms such as confusion, disorientation, and difficulty with speech and language.\nThere is currently no cure for EA6, but various treatments can help manage the symptoms. These may include anticonvulsant medications to reduce the frequency and severity of seizures, physical therapy to improve coordination and balance, and speech therapy to improve communication skills. In some cases, surgery may be recommended to relieve pressure on the brain or to remove a tumor that may be causing the symptoms.\nResearch into the genetic basis of EA6 is ongoing, and several other genes have been identified as potential causes of the disorder. Understanding the genetic basis of EA6 can help identify new targets for treatment and may lead to the development of more effective therapies in the future.\nIn summary, the cause of episodic ataxia type 6 is a mutation in the CACNA1C gene, which leads to an abnormal calcium channel in nerve cells and disruptions in the normal functioning of the nervous system. While there is currently no cure for EA6, various treatments can help manage the symptoms and improve",
    "llama-2-7b-chat-hf_fact_raw": "1. Episodic ataxia type 6 is caused by a mutation in the CACNA1C gene.\n2. The CACNA1C gene is located on chromosome 17.\n3. The mutation in the CACNA1C gene leads to an abnormal calcium channel that allows excessive amounts of calcium ions to enter nerve cells.\n4. Symptoms of episodic ataxia type 6 typically begin in childhood or adolescence.\n5. There is currently no cure for episodic ataxia type 6, but treatments are available to help manage symptoms.",
    "llama-2-7b-chat-hf_fact": [
      "Episodic ataxia type 6 is caused by a mutation in the CACNA1C gene.",
      "The CACNA1C gene is located on chromosome 17.",
      "The mutation in the CACNA1C gene leads to an abnormal calcium channel that allows excessive amounts of calcium ions to enter nerve cells.",
      "Symptoms of episodic ataxia type 6 typically begin in childhood or adolescence.",
      "There is currently no cure for episodic ataxia type 6, but treatments are available to help manage symptoms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Episodic ataxia type 6 is caused by a mutation in the SLC1A3 gene.\n2. TRUE\n3. FALSE [correction]: The mutation in the CACNA1C gene leads to an abnormal calcium channel that does not function properly, affecting the regulation of calcium ions in nerve cells.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 646,
    "user_query": "Are chromomethylases present in animal genomes?",
    "llama-2-7b-chat-hf_response": "Yes, chromomethylases are present in animal genomes. Chromomethylases are enzymes that modify DNA by adding a methyl group to the cytosine residue of CpG dinucleotides, which are found in the DNA of many organisms, including animals.\nIn animals, chromomethylases are involved in a variety of processes, including:\n1. Epigenetic regulation of gene expression: Chromomethylases can add a methyl group to the cytosine residue of CpG dinucleotides, which can result in the repression of gene expression. This process is known as epigenetic regulation.\n2. Cell fate determination: Chromomethylases have been shown to play a role in the determination of cell fate, particularly in the development of the immune system.\n3. Cancer: Chromomethylases have been implicated in the development and progression of cancer. For example, the enzyme DNA methyltransferase (Dnmt3a) has been shown to be overexpressed in various types of cancer, including breast, lung, and colon cancer.\n4. X chromosome inactivation: Chromomethylases are involved in the inactivation of one of the two X chromosomes in female mammals. This process, known as X chromosome inactivation, is necessary to avoid a doubling of gene expression due to the presence of two X chromosomes in female cells.\n5. Sperm methylation: Chromomethylases have been shown to be involved in the methylation of sperm DNA, which is important for sperm fertility and viability.\n6. Embryonic development: Chromomethylases have been implicated in the regulation of gene expression during embryonic development, particularly in the formation of the nervous system.\n7. Immune system: Chromomethylases have been shown to be involved in the regulation of immune cell function, particularly in the activation and differentiation of T cells.\n8. Neurodegenerative diseases: Chromomethylases have been implicated in the development of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. Chromomethylases are enzymes that modify DNA by adding a methyl group to the cytosine residue of CpG dinucleotides.\n2. Chromomethylases are found in the DNA of many organisms, including animals.\n3. The enzyme DNA methyltransferase (Dnmt3a) is overexpressed in various types of cancer, including breast, lung, and colon cancer.\n4. Chromomethylases are involved in the inactivation of one of the two X chromosomes in female mammals, a process known as X chromosome inactivation.\n5. Chromomethylases are involved in the methylation of sperm DNA, which is important for sperm fertility and viability.",
    "llama-2-7b-chat-hf_fact": [
      "Chromomethylases are enzymes that modify DNA by adding a methyl group to the cytosine residue of CpG dinucleotides.",
      "Chromomethylases are found in the DNA of many organisms, including animals.",
      "The enzyme DNA methyltransferase (Dnmt3a) is overexpressed in various types of cancer, including breast, lung, and colon cancer.",
      "Chromomethylases are involved in the inactivation of one of the two X chromosomes in female mammals, a process known as X chromosome inactivation.",
      "Chromomethylases are involved in the methylation of sperm DNA, which is important for sperm fertility and viability."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Chromomethylases are found primarily in plants, not in many organisms including animals.\n3. TRUE\n4. FALSE [correction]: Chromomethylases do not directly involve in X chromosome inactivation. It is the DNA methyltransferase enzymes that are responsible for the methylation during X chromosome inactivation.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 650,
    "user_query": "List packages for transcription factor binding sites' (TFBS) analysis available in R/Bioconductor",
    "llama-2-7b-chat-hf_response": "Certainly! There are several packages available in R/Bioconductor for the analysis of transcription factor binding sites (TFBS). Here are some of the most popular ones:\n1. HISAT2: HISAT2 is a widely used package for ChIP-seq analysis, including the detection of TFBS. It uses a probabilistic model to predict the binding sites of transcription factors and can also be used for the analysis of other types of chromatin immunoprecipitation (ChIP) data.\n2. DREAM: DREAM is a package for the analysis of TFBS in ChIP-seq data. It uses a Bayesian approach to predict the binding sites of transcription factors and can also be used for the analysis of other types of ChIP data.\n3. ChIPseek: ChIPseek is a package for the analysis of TFBS in ChIP-seq data. It uses a probabilistic model to predict the binding sites of transcription factors and can also be used for the analysis of other types of ChIP data.\n4. DeepTools: DeepTools is a package for the analysis of ChIP-seq data, including the detection of TFBS. It uses a combination of machine learning algorithms and statistical methods to predict the binding sites of transcription factors.\n5. ChIPster: ChIPster is a package for the analysis of ChIP-seq data, including the detection of TFBS. It uses a Bayesian approach to predict the binding sites of transcription factors and can also be used for the analysis of other types of ChIP data.\n6. ChIPpeakAnno: ChIPpeakAnno is a package for the analysis of ChIP-seq data, including the detection of TFBS. It uses a combination of machine learning algorithms and statistical methods to predict the binding sites of transcription factors and can also be used for the analysis of other types of ChIP data.\n7. ChIPseeker: ChIPseeker is a package for the analysis of ChIP-seq data, including the detection of TFBS. It uses a probabilistic model to predict the binding sites of transcription factors and can also be used for the analysis of other types of ChIP data.\n8. ChromHMM: ChromHMM is a package for the analysis of ChIP-seq data, including the detection of T",
    "llama-2-7b-chat-hf_fact_raw": "1. HISAT2 is a package in R/Bioconductor for ChIP-seq analysis and detection of TFBS.\n2. DREAM is a package in R/Bioconductor that uses a Bayesian approach for analyzing TFBS in ChIP-seq data.\n3. ChIPseek is a package in R/Bioconductor that uses a probabilistic model for TFBS analysis in ChIP-seq data.\n4. DeepTools is a package in R/Bioconductor that combines machine learning algorithms and statistical methods for ChIP-seq data analysis, including TFBS detection.\n5. ChIPster is a package in R/Bioconductor that uses a Bayesian approach for TFBS detection in ChIP-seq data analysis.",
    "llama-2-7b-chat-hf_fact": [
      "HISAT2 is a package in R/Bioconductor for ChIP-seq analysis and detection of TFBS.",
      "DREAM is a package in R/Bioconductor that uses a Bayesian approach for analyzing TFBS in ChIP-seq data.",
      "ChIPseek is a package in R/Bioconductor that uses a probabilistic model for TFBS analysis in ChIP-seq data.",
      "DeepTools is a package in R/Bioconductor that combines machine learning algorithms and statistical methods for ChIP-seq data analysis, including TFBS detection.",
      "ChIPster is a package in R/Bioconductor that uses a Bayesian approach for TFBS detection in ChIP-seq data analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: HISAT2 is not a package in R/Bioconductor, it is a fast and sensitive alignment program for mapping next-generation sequencing reads to a population of genomes.\n2. FALSE [correction]: DREAM is not a package in R/Bioconductor for analyzing TFBS in ChIP-seq data, it is designed for regulatory element analysis in genomics applications.\n3. UNKNOWN\n4. FALSE [correction]: DeepTools is not a package in R/Bioconductor, it is a suite of python tools particularly developed for the efficient analysis of high-throughput sequencing data, such as ChIP-seq.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 721,
    "user_query": "List clinical trials for prevention of sarcopenia",
    "llama-2-7b-chat-hf_response": "Certainly! Here are some ongoing and completed clinical trials related to the prevention of sarcopenia:\n1. A Randomized Controlled Trial of Resistance Training Versus Aerobic Training Versus Both Combined in Older Adults (R01 AG056864): This study, conducted by researchers at the University of California, San Francisco, is examining the effects of resistance training, aerobic training, and a combination of both on muscle mass and function in older adults.\n2. The Fitness and Nutrition for Independent Living (FINI) Study (R01 AG049194): This study, conducted by researchers at the University of California, Los Angeles, is evaluating the effects of a comprehensive exercise and nutrition program on cognitive function, mobility, and quality of life in older adults.\n3. The Hormone-Optimized Strength Training (HOST) Trial (R01 AG049194): This study, conducted by researchers at the University of California, Los Angeles, is examining the effects of a strength training program on hormone levels and muscle mass in older adults.\n4. The Effects of Resistance Training on Muscle Mass and Function in Older Adults (R01 AG049194): This study, conducted by researchers at the University of California, San Francisco, is evaluating the effects of resistance training on muscle mass and function in older adults.\n5. The Impact of Exercise on Cognitive Function in Older Adults (R01 AG049194): This study, conducted by researchers at the University of California, Los Angeles, is examining the effects of exercise on cognitive function in older adults.\n6. The Effects of a Multicomponent Exercise Program on Functional Capacity and Quality of Life in Older Adults (R01 AG049194): This study, conducted by researchers at the University of California, San Francisco, is evaluating the effects of a multicomponent exercise program on functional capacity and quality of life in older adults.\n7. The Role of Exercise in the Prevention of Disability in Older Adults (",
    "llama-2-7b-chat-hf_fact_raw": "1. The University of California, San Francisco is conducting a study (R01 AG056864) on the effects of resistance training, aerobic training, and both combined on muscle mass and function in older adults.\n2. The University of California, Los Angeles is conducting the Fitness and Nutrition for Independent Living (FINI) Study (R01 AG049194) to evaluate the effects of exercise and nutrition on cognitive function, mobility, and quality of life in older adults.\n3. The Hormone-Optimized Strength Training (HOST) Trial (R01 AG049194) is being conducted by researchers at the University of California, Los Angeles to examine the effects of strength training on hormone levels and muscle mass in older adults.\n4. The University of California, San Francisco is conducting a study (R01 AG049194) to evaluate the effects of resistance training on muscle mass and function in older adults.\n5. Researchers at the University of California, Los Angeles are examining the effects of exercise on cognitive function in older adults in a study (R01 AG049194).",
    "llama-2-7b-chat-hf_fact": [
      "The University of California, San Francisco is conducting a study (R01 AG056864) on the effects of resistance training, aerobic training, and both combined on muscle mass and function in older adults.",
      "The University of California, Los Angeles is conducting the Fitness and Nutrition for Independent Living (FINI) Study (R01 AG049194) to evaluate the effects of exercise and nutrition on cognitive function, mobility, and quality of life in older adults.",
      "The Hormone-Optimized Strength Training (HOST) Trial (R01 AG049194) is being conducted by researchers at the University of California, Los Angeles to examine the effects of strength training on hormone levels and muscle mass in older adults.",
      "The University of California, San Francisco is conducting a study (R01 AG049194) to evaluate the effects of resistance training on muscle mass and function in older adults.",
      "Researchers at the University of California, Los Angeles are examining the effects of exercise on cognitive function in older adults in a study (R01 AG049194)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: The University of California, San Francisco is conducting a study (R01 AG056864) on the effects of resistance training on muscle mass and function in older adults, as mentioned in statement 1.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 722,
    "user_query": "Which is the database of molecular recognition features in membrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several databases that contain molecular recognition features in membrane proteins. Here are some of the most well-known and widely used databases in this field:\n1. The Membrane Protein Database (MPD): This database contains a comprehensive collection of structural and functional information on membrane proteins, including their three-dimensional structures, binding sites, and recognition features. MPD also provides a tool for searching and analyzing the sequences and structures of membrane proteins.\n2. The Protein Data Bank (PDB): This is a comprehensive database of the three-dimensional structures of proteins, including membrane proteins. The PDB contains over 170,000 structures of proteins from all domains of life, including membrane proteins.\n3. The Membrane Protein Structural Database (MPSD): This database contains a collection of structural data on membrane proteins, including their three-dimensional structures, binding sites, and recognition features. MPSD also provides a tool for searching and analyzing the sequences and structures of membrane proteins.\n4. The Membrane Protein Interaction Database (MPID): This database contains information on the interactions between membrane proteins and other molecules, including ligands, drugs, and other proteins. MPID provides a tool for searching and analyzing the interactions between membrane proteins and their binding partners.\n5. The Membrane Protein Functional Database (MPFD): This database contains information on the functional properties of membrane proteins, including their transport, signaling, and enzymatic activities. MPFD provides a tool for searching and analyzing the functional properties of membrane proteins.\n6. The Membrane Protein Topology Database (MPTD): This database contains information on the topological structure of membrane proteins, including their lipid-anchoring sites, transmembrane helices, and intracellular domains. MPTD provides a tool for searching and analyzing the topological structure of membrane proteins.\n7. The Membrane Protein-Ligand Interaction Database (MPLID): This database contains information on the interactions between membrane proteins and their ligands, including drugs, toxins, and other signaling molecules. MPLID provides a tool for searching and analyzing the interactions between membrane proteins and their ligands.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Membrane Protein Database (MPD) contains structural and functional information on membrane proteins.\n2. The Protein Data Bank (PDB) has over 170,000 structures of proteins, including membrane proteins.\n3. The Membrane Protein Structural Database (MPSD) includes three-dimensional structures and recognition features of membrane proteins.\n4. The Membrane Protein Interaction Database (MPID) has information on interactions between membrane proteins and other molecules.\n5. The Membrane Protein Functional Database (MPFD) provides information on the functional properties of membrane proteins.",
    "llama-2-7b-chat-hf_fact": [
      "The Membrane Protein Database (MPD) contains structural and functional information on membrane proteins.",
      "The Protein Data Bank (PDB) has over 170,000 structures of proteins, including membrane proteins.",
      "The Membrane Protein Structural Database (MPSD) includes three-dimensional structures and recognition features of membrane proteins.",
      "The Membrane Protein Interaction Database (MPID) has information on interactions between membrane proteins and other molecules.",
      "The Membrane Protein Functional Database (MPFD) provides information on the functional properties of membrane proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 745,
    "user_query": "Is rivaroxaban metabolized in kidneys?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! Rivaroxaban, also known as Xarelto, is a blood thinner that is used to prevent blood clots in patients with various conditions, such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism.\nYes, rivaroxaban is metabolized in the kidneys. The drug is primarily metabolized by the liver enzyme CYP2C9, but a small amount is also metabolized by the kidneys through the CYP2A6 enzyme. The kidneys play a minor role in the metabolism of rivaroxaban, but they can still have an impact on the drug's efficacy and side effects.\nStudies have shown that patients with impaired kidney function may have increased levels of rivaroxaban in their system, which can increase the risk of bleeding. In these patients, the kidneys may not be able to metabolize the drug as efficiently, leading to higher concentrations of the drug in the bloodstream.\nAdditionally, the kidneys can also affect the elimination of rivaroxaban from the body. Patients with impaired kidney function may have longer half-lives for the drug, meaning it stays in their system for longer periods of time. This can increase the risk of side effects, such as bruising or bleeding, and may also affect the drug's efficacy.\nIt's important for patients taking rivaroxaban to have regular monitoring of their kidney function, especially if they have pre-existing kidney disease or are at risk for kidney problems. This can help healthcare providers adjust the drug's dosage and frequency of administration to ensure the best possible outcome.\nIn summary, while the kidneys play a minor role in the metabolism of rivaroxaban, they can still have an impact on the drug's efficacy and side effects. Patients taking this medication should be monitored closely for any changes in kidney function to ensure safe and effective treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. Rivaroxaban is metabolized by the liver enzyme CYP2C9.\n2. A small amount of rivaroxaban is metabolized by the kidneys through the CYP2A6 enzyme.\n3. Patients with impaired kidney function may have increased levels of rivaroxaban in their system.\n4. Impaired kidney function can lead to longer half-lives for rivaroxaban in the body.\n5. Regular monitoring of kidney function is important for patients taking rivaroxaban.",
    "llama-2-7b-chat-hf_fact": [
      "Rivaroxaban is metabolized by the liver enzyme CYP2C9.",
      "A small amount of rivaroxaban is metabolized by the kidneys through the CYP2A6 enzyme.",
      "Patients with impaired kidney function may have increased levels of rivaroxaban in their system.",
      "Impaired kidney function can lead to longer half-lives for rivaroxaban in the body.",
      "Regular monitoring of kidney function is important for patients taking rivaroxaban."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Rivaroxaban is metabolized by liver enzymes CYP3A4 and CYP2J2, and is also a substrate of P-glycoprotein.\n2. FALSE [correction]: Rivaroxaban is not metabolized by the kidneys through the CYP2A6 enzyme; kidney excretion of unchanged rivaroxaban accounts for about one-third of the elimination of the drug.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 763,
    "user_query": "Which genes are regulated by TRalpha2  in the heart?",
    "llama-2-7b-chat-hf_response": "TRalpha2 is a G-protein coupled receptor (GPCR) that is primarily expressed in the heart, where it plays a crucial role in regulating cardiac function and development. The activation of TRalpha2 leads to the activation of downstream signaling pathways that regulate various cellular processes, including gene expression.\nSeveral studies have identified genes that are regulated by TRalpha2 in the heart. Here are some of the key findings:\n1. Cardiac hypertrophy genes: TRalpha2 has been shown to regulate genes involved in cardiac hypertrophy, a process that occurs in response to increased workload on the heart. For example, TRalpha2 has been shown to activate the expression of genes such as atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and cardiac myosin-binding protein C (MBC) (1,2).\n2. Contractility genes: TRalpha2 has also been shown to regulate genes involved in cardiac contractility, such as troponin I (TnI) and tropomyosin (Tpm) (3,4).\n3. Electrophysiology genes: TRalpha2 has been implicated in the regulation of genes involved in cardiac electrophysiology, such as the ion channels and pumps (5,6).\n4. Fibrosis genes: TRalpha2 has been shown to regulate genes involved in cardiac fibrosis, a process that can lead to heart failure (7,8).\n5. Growth and differentiation genes: TRalpha2 has been implicated in the regulation of genes involved in cardiac growth and differentiation, such as the growth factor receptors (9,10).\n6. Inflammation genes: TRalpha2 has been shown to regulate genes involved in cardiac inflammation, such as the inflammatory cytokines (11,12).\n7. Metabolism genes: TRalpha2 has been implicated in the regulation of genes involved in cardiac metabolism, such as the glucose and lipid metabolism genes (13,14).\n8. Stress response genes: TR",
    "llama-2-7b-chat-hf_fact_raw": "1. TRalpha2 is a G-protein coupled receptor primarily expressed in the heart.\n2. TRalpha2 activation regulates genes involved in cardiac hypertrophy, such as ANP, BNP, and MBC.\n3. TRalpha2 regulates genes involved in cardiac contractility, like TnI and Tpm.\n4. TRalpha2 has a role in regulating genes involved in cardiac electrophysiology, including ion channels and pumps.\n5. TRalpha2 regulates genes involved in cardiac fibrosis, which can lead to heart failure.",
    "llama-2-7b-chat-hf_fact": [
      "TRalpha2 is a G-protein coupled receptor primarily expressed in the heart.",
      "TRalpha2 activation regulates genes involved in cardiac hypertrophy, such as ANP, BNP, and MBC.",
      "TRalpha2 regulates genes involved in cardiac contractility, like TnI and Tpm.",
      "TRalpha2 has a role in regulating genes involved in cardiac electrophysiology, including ion channels and pumps.",
      "TRalpha2 regulates genes involved in cardiac fibrosis, which can lead to heart failure."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: These statements are specific to a scientific context and without the relevant passage or scientific knowledge, it is difficult to determine their accuracy.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 786,
    "user_query": "List available biomedical question answering systems.",
    "llama-2-7b-chat-hf_response": "Certainly! There are several biomedical question answering systems available, each with their own strengths and weaknesses. Here are some of the most notable ones:\n1. PubMed Central's \"Ask a Biologist\": PubMed Central is a free database of biomedical literature, and its \"Ask a Biologist\" feature allows users to ask questions on a wide range of biomedical topics. The system uses a combination of natural language processing and expert answerers to provide detailed and accurate responses.\n2. Google's \"Bioinformatics\": Google's bioinformatics tool provides a range of resources for biomedical researchers, including a question answering system. Users can ask questions on a variety of topics, including gene expression, protein structure, and genomics.\n3. IBM's \"Watson for Genomics\": IBM's Watson for Genomics is a question answering system specifically designed for genomics research. It uses natural language processing and machine learning to provide accurate and relevant answers to questions on topics such as gene expression, genetic variation, and genomic analysis.\n4. The Biomedical Informatics Research Network's (BIRN) \"BioQA\": BIRN's BioQA is a question answering system that provides detailed and accurate answers to biomedical questions. It uses a combination of natural language processing and expert answerers to provide answers on a wide range of topics, including gene expression, protein structure, and genomics.\n5. The National Center for Biotechnology Information's (NCBI) \"Bookshelf\": NCBI's Bookshelf is a comprehensive database of biomedical literature, and its question answering system provides answers to a wide range of biomedical questions. It uses natural language processing and expert answerers to provide accurate and relevant answers to questions on topics such as gene expression, genetic variation, and genomic analysis.\n6. The University of California, San Diego's \"Bioinformatics and Biological Computing\": This program provides a range of resources for biomedical researchers, including a question answering system. Users can ask questions on a variety of topics, including gene expression, protein structure, and genomics.\n7. The University of Texas Southwestern Medical Center's \"Biomedical Informatics\": This program provides a range of resources for biomedical researchers, including",
    "llama-2-7b-chat-hf_fact_raw": "1. PubMed Central's \"Ask a Biologist\" is a biomedical question answering system that uses natural language processing and expert answerers.\n2. Google's bioinformatics tool includes a question answering system for biomedical researchers.\n3. IBM's \"Watson for Genomics\" is a question answering system designed for genomics research, utilizing natural language processing and machine learning.\n4. The Biomedical Informatics Research Network's \"BioQA\" is a biomedical question answering system that provides detailed answers using natural language processing and expert answerers.\n5. The National Center for Biotechnology Information's \"Bookshelf\" has a question answering system within its database of biomedical literature.",
    "llama-2-7b-chat-hf_fact": [
      "PubMed Central's \"Ask a Biologist\" is a biomedical question answering system that uses natural language processing and expert answerers.",
      "Google's bioinformatics tool includes a question answering system for biomedical researchers.",
      "IBM's \"Watson for Genomics\" is a question answering system designed for genomics research, utilizing natural language processing and machine learning.",
      "The Biomedical Informatics Research Network's \"BioQA\" is a biomedical question answering system that provides detailed answers using natural language processing and expert answerers.",
      "The National Center for Biotechnology Information's \"Bookshelf\" has a question answering system within its database of biomedical literature."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: PubMed Central's \"Ask a Biologist\" is an educational resource, not a biomedical question answering system.\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: The National Center for Biotechnology Information's \"Bookshelf\" does not have a question answering system; it provides free access to books and documents in life science and healthcare.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 794,
    "user_query": "Which trancription factor activates the betalain pathway?",
    "llama-2-7b-chat-hf_response": "The betalain pathway is a complex network of enzymes and regulatory proteins involved in the biosynthesis of betalains, a class of natural pigments that are important for plant defense and stress responses. There are several transcription factors that have been identified as playing a key role in activating the betalain pathway in response to various stimuli. Here are some of the most well-studied trancription factors involved in the regulation of the betalain pathway:\n1. WRKY70: WRKY70 is a transcription factor that belongs to the WRKY family of proteins, which are involved in the regulation of plant defense and stress responses. Studies have shown that WRKY70 plays a key role in activating the betalain pathway in response to abiotic stressors such as drought, high temperature, and salt stress.\n2. MYB76: MYB76 is a transcription factor that belongs to the MYB family of proteins, which are involved in the regulation of plant defense and stress responses. MYB76 has been shown to be involved in the regulation of the betalain pathway, particularly in the response to biotic stressors such as bacterial infection.\n3. NAC1: NAC1 is a transcription factor that belongs to the NAC family of proteins, which are involved in the regulation of plant defense and stress responses. NAC1 has been shown to be involved in the regulation of the betalain pathway, particularly in the response to abiotic stressors such as drought and high temperature.\n4. DREB2A: DREB2A is a transcription factor that belongs to the DREB family of proteins, which are involved in the regulation of plant defense and stress responses. DREB2A has been shown to be involved in the regulation of the betalain pathway, particularly in the response to abiotic stressors such as drought and high temperature.\n5. HY5: HY5 is a transcription factor that belongs to the HY5 family of proteins, which are involved in the regulation of plant defense and stress responses. HY5 has been shown to be involved in the regulation of the betalain pathway, particularly in the response to biotic",
    "llama-2-7b-chat-hf_fact_raw": "1. WRKY70 is a transcription factor that activates the betalain pathway in response to abiotic stressors.\n2. MYB76 is a transcription factor that regulates the betalain pathway in response to biotic stressors such as bacterial infection.\n3. NAC1 is a transcription factor that regulates the betalain pathway, particularly in response to drought and high temperature.\n4. DREB2A is a transcription factor involved in the regulation of the betalain pathway in response to drought and high temperature.\n5. HY5 is a transcription factor that regulates the betalain pathway in response to biotic stressors.",
    "llama-2-7b-chat-hf_fact": [
      "WRKY70 is a transcription factor that activates the betalain pathway in response to abiotic stressors.",
      "MYB76 is a transcription factor that regulates the betalain pathway in response to biotic stressors such as bacterial infection.",
      "NAC1 is a transcription factor that regulates the betalain pathway, particularly in response to drought and high temperature.",
      "DREB2A is a transcription factor involved in the regulation of the betalain pathway in response to drought and high temperature.",
      "HY5 is a transcription factor that regulates the betalain pathway in response to biotic stressors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: These statements are highly specific and require expertise in plant biology and the function of transcription factors within the betalain pathway. Without additional context or reference, it is not possible to accurately determine the truthfulness of these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 883,
    "user_query": "Global quantitative phosphoproteomic analyses are emerging. List the preferred technologies for the enrichment for phosphorylated peptides?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! Global quantitative phosphoproteomic analyses are indeed emerging as a powerful tool for understanding the complexities of cellular signaling pathways and protein function. When it comes to enriching phosphorylated peptides for downstream analysis, there are several preferred technologies that are commonly used. Here are some of the most popular ones:\n1. Hydrophobic interaction chromatography (HIC): HIC is a widely used technique for separating phosphorylated peptides based on their hydrophobicity. Phosphorylated peptides are more hydrophobic than their non-phosphorylated counterparts, so they tend to bind more strongly to hydrophobic resins like reversed-phase HIC columns. By applying a high-pressure buffer solution, these peptides can be separated from non-phosphorylated peptides and analyzed further.\n2. Cation exchange chromatography (CEC): CEC is another popular technique for separating phosphorylated peptides based on their charge repulsion. Phosphorylated peptides have a higher charge-to-mass ratio than non-phosphorylated peptides, which makes them more prone to exchanging ions with the stationary phase. By using a cation exchange resin, these peptides can be separated from non-phosphorylated peptides and analyzed further.\n3. Gel electrophoresis: Gel electrophoresis is a widely used technique for separating phosphorylated peptides based on their size and charge. Phosphorylated peptides tend to be larger and more charged than non-phosphorylated peptides, which makes them easier to separate using gel electrophoresis. By applying an electric field, these peptides can be separated from non-phosphorylated peptides and analyzed further.\n4. Ion exchange chromatography (IEX): IEX is a technique that separates phosphorylated peptides based on their charge. Phosphorylated peptides have a higher charge-to-mass ratio than non-phosphorylated peptides, which makes them more prone to exchanging ions with the stationary phase. By using an",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrophobic interaction chromatography is a technique used for separating phosphorylated peptides based on their hydrophobicity.\n2. Cation exchange chromatography is used for separating phosphorylated peptides based on their charge repulsion.\n3. Gel electrophoresis is a technique used for separating phosphorylated peptides based on their size and charge.\n4. Ion exchange chromatography separates phosphorylated peptides based on their charge.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrophobic interaction chromatography is a technique used for separating phosphorylated peptides based on their hydrophobicity.",
      "Cation exchange chromatography is used for separating phosphorylated peptides based on their charge repulsion.",
      "Gel electrophoresis is a technique used for separating phosphorylated peptides based on their size and charge.",
      "Ion exchange chromatography separates phosphorylated peptides based on their charge."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Hydrophobic interaction chromatography is a technique used for separating proteins based on their hydrophobicity, not specifically for phosphorylated peptides.\n2. TRUE\n3. TRUE\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 901,
    "user_query": "Which disorder is rated by Palmini classification?",
    "llama-2-7b-chat-hf_response": "The Palmini classification is a system used to classify and categorize mental disorders based on their underlying psychopathology. The Palmini classification system is not a widely recognized or accepted classification system in the field of psychiatry, and it is not used in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), which is the standard reference guide for psychiatric diagnoses.\nThe Palmini classification system was developed by Dr. John Palmini and is based on his belief that mental disorders can be grouped into three main categories:\n1. Disorders of thought and perception: These disorders are characterized by disturbances in thinking, perception, and cognition. Examples of disorders in this category include schizophrenia, schizoaffective disorder, and brief psychotic disorder.\n2. Disorders of mood and emotional dysregulation: These disorders are characterized by difficulties in regulating and managing emotions, including depression, bipolar disorder, and cyclothymic disorder.\n3. Disorders of personality and impulse control: These disorders are characterized by difficulties in regulating impulses, behaviors, and emotions, including borderline personality disorder, narcissistic personality disorder, and antisocial personality disorder.\nIt is important to note that the Palmini classification system is not widely accepted or used in the field of psychiatry, and it is not a substitute for a thorough clinical evaluation and diagnosis by a qualified mental health professional. If you or someone you know is experiencing symptoms of a mental disorder, it is important to seek professional help from a licensed psychiatrist or psychologist.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Palmini classification system is used to classify and categorize mental disorders.\n2. Palmini classification system is not used in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).\n3. The Palmini classification system was developed by Dr. John Palmini.\n4. The Palmini classification system groups mental disorders into three main categories: disorders of thought and perception, disorders of mood and emotional dysregulation, and disorders of personality and impulse control.\n5. The Palmini classification system is not a widely recognized or accepted classification system in the field of psychiatry.",
    "llama-2-7b-chat-hf_fact": [
      "The Palmini classification system is used to classify and categorize mental disorders.",
      "Palmini classification system is not used in the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).",
      "The Palmini classification system was developed by Dr. John Palmini.",
      "The Palmini classification system groups mental disorders into three main categories: disorders of thought and perception, disorders of mood and emotional dysregulation, and disorders of personality and impulse control.",
      "The Palmini classification system is not a widely recognized or accepted classification system in the field of psychiatry."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The DSM-5 (Diagnostic and Statistical Manual of Mental Disorders) is used to classify and categorize mental disorders, not the Palmini classification system.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 905,
    "user_query": "Are viruses involved in the etiology of human subacute thyroiditis?",
    "llama-2-7b-chat-hf_response": "Subacute thyroiditis is a rare inflammatory condition that affects the thyroid gland, and while the exact cause of this condition is still not fully understood, there is evidence to suggest that viruses may play a role in its etiology.\nOne study published in the Journal of Clinical Endocrinology and Metabolism in 2013 found that 75% of patients with subacute thyroiditis had evidence of a viral infection in their thyroid tissue. The study used polymerase chain reaction (PCR) to detect the presence of viral DNA in thyroid tissue samples from 30 patients with subacute thyroiditis. The researchers found that 23 of the 30 patients (76%) had detectable viral DNA in their thyroid tissue, with the most common viruses detected being influenza virus, adenovirus, and enterovirus.\nAnother study published in the Journal of Thyroid Research in 2018 found that subacute thyroiditis was more common in patients who had a history of viral infections, particularly respiratory viruses. The study analyzed data from 1,000 patients with thyroiditis and found that 31% of patients with subacute thyroiditis had a history of respiratory viral infections, compared to 16% of patients with chronic thyroiditis and 10% of healthy controls.\nWhile these studies suggest that viruses may play a role in the etiology of subacute thyroiditis, it's important to note that the exact mechanisms by which viruses contribute to the development of this condition are not yet fully understood. It's possible that viruses may trigger an immune response that leads to inflammation in the thyroid gland, or that they may directly infect the thyroid cells and disrupt their function.\nIt's also worth noting that subacute thyroiditis is a relatively rare condition, and the majority of patients with thyroid problems do not have a viral infection. Other factors, such as genetics, hormonal imbalances, and environmental toxins, may also play a role in the development of thyroid problems.\nIn summary, while there is evidence to suggest that viruses may be involved in the",
    "llama-2-7b-chat-hf_fact_raw": "1. Subacute thyroiditis is a rare inflammatory condition that affects the thyroid gland.\n2. A 2013 study in the Journal of Clinical Endocrinology and Metabolism found 75% of patients with subacute thyroiditis had evidence of a viral infection in their thyroid tissue.\n3. The most common viruses detected in the study were influenza virus, adenovirus, and enterovirus.\n4. A 2018 study in the Journal of Thyroid Research found that 31% of patients with subacute thyroiditis had a history of respiratory viral infections.\n5. Subacute thyroiditis is more common in patients with a history of viral infections than in patients with chronic thyroiditis or healthy controls.",
    "llama-2-7b-chat-hf_fact": [
      "Subacute thyroiditis is a rare inflammatory condition that affects the thyroid gland.",
      "A 2013 study in the Journal of Clinical Endocrinology and Metabolism found 75% of patients with subacute thyroiditis had evidence of a viral infection in their thyroid tissue.",
      "The most common viruses detected in the study were influenza virus, adenovirus, and enterovirus.",
      "A 2018 study in the Journal of Thyroid Research found that 31% of patients with subacute thyroiditis had a history of respiratory viral infections.",
      "Subacute thyroiditis is more common in patients with a history of viral infections than in patients with chronic thyroiditis or healthy controls."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: A 2013 study in the Journal of Clinical Endocrinology and Metabolism found that a significant portion of patients with subacute thyroiditis had evidence of a viral infection in their thyroid tissue, but the exact percentage is not specified in this statement.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 963,
    "user_query": "Is STAT3 involved in EIF2AK2-dependent suppression of autophagy?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! I'm here to help you understand the relationship between STAT3 and EIF2AK2 in the context of autophagy.\nFirstly, let's define the terms:\n* STAT3 (Signal Transducer and Activator of Transcription 3) is a transcription factor that plays a crucial role in regulating cellular processes such as inflammation, immune response, and cell survival.\n* EIF2AK2 (Eukaryotic Translation Initiation Factor 2-Associated Kinase 2) is an enzyme that regulates protein synthesis by phosphorylating the alpha subunit of the translation initiation factor eIF2.\nNow, to answer your question, there is evidence to suggest that STAT3 is involved in EIF2AK2-dependent suppression of autophagy. Autophagy is a catabolic process that involves the degradation of cellular components, such as proteins and organelles, to maintain cellular homeostasis and survival.\nStudies have shown that STAT3 can inhibit autophagy by interacting with and phosphorylating EIF2AK2. This interaction can lead to the suppression of autophagy by inhibiting the translation initiation process, thereby reducing the amount of proteins available for autophagy.\nAdditionally, STAT3 has been shown to regulate the expression of genes involved in autophagy, such as ATG5 and LC3B, which are essential for the initiation and execution of autophagy. By modulating the expression of these genes, STAT3 can indirectly regulate autophagy.\nFurthermore, STAT3 has been shown to interact with other autophagy-related proteins, such as mTOR and AMPK, which are involved in the regulation of autophagy. These interactions can also contribute to the suppression of autophagy by STAT3.\nIn summary, STAT3 is involved in EIF2AK2-dependent suppression of autophagy by interacting with and phosphorylating EIF2AK2, regulating the expression of autophagy-related genes, and interacting with other autophagy-related proteins.\nI hope this helps clarify the relationship between STAT3 and",
    "llama-2-7b-chat-hf_fact_raw": "1. STAT3 is a transcription factor that regulates cellular processes such as inflammation, immune response, and cell survival.\n2. EIF2AK2 is an enzyme that regulates protein synthesis by phosphorylating the alpha subunit of the translation initiation factor eIF2.\n3. There is evidence that STAT3 is involved in EIF2AK2-dependent suppression of autophagy.\n4. STAT3 can inhibit autophagy by interacting with and phosphorylating EIF2AK2.\n5. STAT3 regulates the expression of autophagy-related genes, such as ATG5 and LC3B.",
    "llama-2-7b-chat-hf_fact": [
      "STAT3 is a transcription factor that regulates cellular processes such as inflammation, immune response, and cell survival.",
      "EIF2AK2 is an enzyme that regulates protein synthesis by phosphorylating the alpha subunit of the translation initiation factor eIF2.",
      "There is evidence that STAT3 is involved in EIF2AK2-dependent suppression of autophagy.",
      "STAT3 can inhibit autophagy by interacting with and phosphorylating EIF2AK2.",
      "STAT3 regulates the expression of autophagy-related genes, such as ATG5 and LC3B."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: There is no evidence that STAT3 directly interacts with and phosphorylates EIF2AK2 to inhibit autophagy.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 973,
    "user_query": "Describe what is the usage of the Theatre software tool for genomic analysis.",
    "llama-2-7b-chat-hf_response": "Theatre is a software tool designed for genomic analysis, specifically for the analysis of next-generation sequencing (NGS) data. It is a powerful and flexible tool that can be used for a wide range of genomic analysis tasks, including:\n1. Read mapping: Theatre can map reads from NGS datasets to a reference genome, allowing researchers to identify the locations of the reads on the genome.\n2. Variant calling: Theatre can identify genetic variants, such as single nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations, in the NGS data.\n3. Genome assembly: Theatre can assemble the genomic DNA sequence from the NGS data, allowing researchers to reconstruct the original DNA sequence of an organism.\n4. Transcriptome analysis: Theatre can analyze the RNA-seq data to identify differentially expressed genes, alternative splicing events, and other features of the transcriptome.\n5. Functional genomics: Theatre can be used to identify functional elements in the genome, such as gene regulatory regions, and to study their function in the context of the genome.\n6. Epigenomics: Theatre can be used to study the epigenetic marks in the genome, such as DNA methylation and histone modifications, and how they relate to gene expression and other genomic features.\n7. Genome-wide association studies (GWAS): Theatre can be used to identify genetic variants associated with specific traits or diseases by analyzing large-scale genomic data sets.\n8. Population genomics: Theatre can be used to study the genetic diversity and structure of different populations, and to identify genetic variants that are specific to particular populations.\n9. Evolutionary genomics: Theatre can be used to study the evolutionary history of organisms by analyzing genomic data from different species and genera.\n10. Systems biology: Theatre can be used to study the interactions between different genes, proteins, and other molecular components in a systematic way, allowing researchers to gain insights into the complex networks that underlie biological processes.\nIn summary, Theatre is a powerful tool for genomic analysis that can be used for a wide range of tasks, from read mapping and variant calling to genome assembly and functional genomics. Its flexibility and scalability make it",
    "llama-2-7b-chat-hf_fact_raw": "1. Theatre is designed for the analysis of next-generation sequencing (NGS) data.\n2. Theatre can map reads from NGS datasets to a reference genome.\n3. Theatre identifies genetic variants such as SNPs, insertions, deletions, and copy number variations in NGS data.\n4. Theatre can assemble genomic DNA sequences from NGS data.\n5. Theatre can be used for transcriptome analysis, functional genomics, epigenomics, genome-wide association studies, population genomics, evolutionary genomics, and systems biology.",
    "llama-2-7b-chat-hf_fact": [
      "Theatre is designed for the analysis of next-generation sequencing (NGS) data.",
      "Theatre can map reads from NGS datasets to a reference genome.",
      "Theatre identifies genetic variants such as SNPs, insertions, deletions, and copy number variations in NGS data.",
      "Theatre can assemble genomic DNA sequences from NGS data.",
      "Theatre can be used for transcriptome analysis, functional genomics, epigenomics, genome-wide association studies, population genomics, evolutionary genomics, and systems biology."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The statement is vague as \"Theatre\" could refer to a software or a concept in genomics but without a specific name or context, it's difficult to determine the truth of the statement.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 997,
    "user_query": "Which  is the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences",
    "llama-2-7b-chat-hf_response": "The execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on the size of the sequences and the type of comparison being made.\nFor the basic Smith-Waterman algorithm, the time complexity is O(n^2), where n is the length of the shorter sequence. This is because the algorithm needs to compare each element in the shorter sequence with every element in the longer sequence, which results in a total of n^2 comparisons.\nHowever, there are several optimizations that can be made to the Smith-Waterman algorithm to reduce the time complexity:\n1. Using a sliding window approach: Instead of comparing the entire shorter sequence with the entire longer sequence, the algorithm can use a sliding window approach, where it compares a fixed-size window of the shorter sequence with the longer sequence. This reduces the time complexity to O(n + m), where n is the length of the shorter sequence and m is the length of the longer sequence.\n2. Using a dynamic programming approach: The Smith-Waterman algorithm can also be implemented using dynamic programming, which involves storing the results of the comparisons in a two-dimensional table. This reduces the time complexity to O(n + m \\* m), where n is the length of the shorter sequence and m is the length of the longer sequence.\n3. Using a parallel or distributed computing approach: The Smith-Waterman algorithm can be parallelized or distributed across multiple processors or computers, which can further reduce the time complexity.\nIt's worth noting that the time complexity of the Smith-Waterman algorithm can be improved by using more advanced algorithms, such as the Needleman-Wunsch algorithm or the global alignment algorithm. These algorithms have lower time complexities than the Smith-Waterman algorithm, but they may require more memory and computational resources to implement.\nIn summary, the execution time (complexity) of the Smith-Waterman algorithm for the alignment of two sequences depends on the size of the sequences and the type of comparison being made. The time complexity can be improved by using optimizations such as a sliding window approach, dynamic programming, or parallel or distributed computing.",
    "llama-2-7b-chat-hf_fact_raw": "1. The basic time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.\n2. Using a sliding window approach can reduce the time complexity of the Smith-Waterman algorithm to O(n + m).\n3. Implementing the Smith-Waterman algorithm with dynamic programming can reduce the time complexity to O(n + m * m).\n4. Parallelizing or distributing the Smith-Waterman algorithm can further reduce its time complexity.",
    "llama-2-7b-chat-hf_fact": [
      "The basic time complexity of the Smith-Waterman algorithm is O(n^2), where n is the length of the shorter sequence.",
      "Using a sliding window approach can reduce the time complexity of the Smith-Waterman algorithm to O(n + m).",
      "Implementing the Smith-Waterman algorithm with dynamic programming can reduce the time complexity to O(n + m * m).",
      "Parallelizing or distributing the Smith-Waterman algorithm can further reduce its time complexity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Using a sliding window approach doesn't generally change the overall time complexity of the Smith-Waterman algorithm, which remains O(n^2).\n3. FALSE [correction]: Implementing the Smith-Waterman algorithm with dynamic programming does not alter the time complexity, which remains O(n^2).\n4. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1004,
    "user_query": "Which SLC family is FLVCR1 a member of?",
    "llama-2-7b-chat-hf_response": "FLVCR1 (Flotilin-like 1) is a member of the VCL (Vesicular Trafficking and Cytoskeleton) family of proteins. The VCL family is a group of proteins that are involved in the regulation of intracellular transport and the cytoskeleton.\nFLVCR1 is specifically a member of the FLVCR (Flotilin-like 1, Vesicular Trafficking and Cytoskeleton Regulator) subfamily of the VCL family. This subfamily is composed of proteins that are involved in the regulation of vesicle trafficking and cytoskeleton organization, particularly in the endosomal system.\nFLVCR1 is expressed in many tissues, including the brain, heart, and muscle, and it has been implicated in a variety of biological processes, including cell adhesion, migration, and signaling. Mutations in the FLVCR1 gene have been associated with a number of human diseases, including cardiomyopathy and neurodegenerative disorders.\nIn summary, FLVCR1 is a member of the VCL family, specifically the FLVCR subfamily, and plays a role in regulating intracellular transport and cytoskeleton organization in various tissues and cell types.",
    "llama-2-7b-chat-hf_fact_raw": "1. FLVCR1 is a member of the VCL family of proteins.\n2. The VCL family is involved in the regulation of intracellular transport and the cytoskeleton.\n3. FLVCR1 belongs to the FLVCR subfamily within the VCL family.\n4. FLVCR1 is expressed in the brain, heart, and muscle tissues.\n5. Mutations in the FLVCR1 gene have been linked to human diseases such as cardiomyopathy and neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact": [
      "FLVCR1 is a member of the VCL family of proteins.",
      "The VCL family is involved in the regulation of intracellular transport and the cytoskeleton.",
      "FLVCR1 belongs to the FLVCR subfamily within the VCL family.",
      "FLVCR1 is expressed in the brain, heart, and muscle tissues.",
      "Mutations in the FLVCR1 gene have been linked to human diseases such as cardiomyopathy and neurodegenerative disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: FLVCR1 is a member of the major facilitator superfamily (MFS) of transporter proteins, not the VCL family.\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1047,
    "user_query": "List GATA-1 interacting partners as discovered with the help of the biotinylation tagging approach.",
    "llama-2-7b-chat-hf_response": "Certainly! GATA-1 is a transcription factor that plays a crucial role in regulating gene expression during erythropoiesis, the process of red blood cell production. The biotinylation tagging approach involves using a biotinylation tag, such as BirA, to label specific proteins of interest and study their interacting partners. Here are some of the interacting partners of GATA-1 that have been identified through biotinylation tagging studies:\n1. Runx1 (RUNX1): GATA-1 has been shown to interact with the transcription factor Runx1, which is a key regulator of erythropoiesis. The interaction between GATA-1 and Runx1 is important for the proper regulation of red blood cell production.\n2. HIF-1α (HIF-1A): GATA-1 has been shown to interact with HIF-1α, a transcription factor that regulates the expression of genes involved in response to hypoxia. The interaction between GATA-1 and HIF-1α is important for the regulation of red blood cell production in response to hypoxia.\n3. BCL-XL (BCL-XL): GATA-1 has been shown to interact with BCL-XL, a pro-survival protein that is important for the survival of red blood cells. The interaction between GATA-1 and BCL-XL is important for the regulation of red blood cell survival and function.\n4. PU.1 (PU.1): GATA-1 has been shown to interact with PU.1, a transcription factor that regulates the expression of genes involved in the immune response. The interaction between GATA-1 and PU.1 is important for the regulation of the immune response during erythropoiesis.\n5. TFAP2S (TFAP2S): GATA-1 has been shown to interact with TFAP2S, a transcription factor that regulates the expression of genes involved in the development and function of red blood cells. The interaction between GATA-1 and TFAP2S is important for the regulation of red blood cell development and function.\n6. KLF1 (KLF1): GATA-1 has been",
    "llama-2-7b-chat-hf_fact_raw": "1. GATA-1 interacts with the transcription factor Runx1, which regulates erythropoiesis.\n2. GATA-1 interacts with HIF-1α, a transcription factor involved in the response to hypoxia.\n3. GATA-1 interacts with BCL-XL, a pro-survival protein important for red blood cell survival.\n4. GATA-1 interacts with PU.1, a transcription factor involved in the immune response.\n5. GATA-1 interacts with TFAP2S, a transcription factor involved in red blood cell development and function.",
    "llama-2-7b-chat-hf_fact": [
      "GATA-1 interacts with the transcription factor Runx1, which regulates erythropoiesis.",
      "GATA-1 interacts with HIF-1α, a transcription factor involved in the response to hypoxia.",
      "GATA-1 interacts with BCL-XL, a pro-survival protein important for red blood cell survival.",
      "GATA-1 interacts with PU.1, a transcription factor involved in the immune response.",
      "GATA-1 interacts with TFAP2S, a transcription factor involved in red blood cell development and function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: GATA-1 interacts with TFAP2C, a transcription factor involved in red blood cell development and function, not TFAP2S.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1072,
    "user_query": "What is the outcome of TAF10 interacting with the GATA1 transcription factor?",
    "llama-2-7b-chat-hf_response": "TAF10 (Tricothecin A-like Factor 10) is a protein that plays a crucial role in the regulation of gene expression, particularly in the context of hematopoiesis (the production of blood cells). GATA1 (GATA-binding Protein 1) is a transcription factor that is essential for the development and function of hematopoietic cells, including red blood cells, granulocytes, and platelets.\nWhen TAF10 interacts with GATA1, it can have both positive and negative effects on gene expression, depending on the context.\nPositive effects:\n1. Enhanced GATA1 activity: TAF10 can potentiate the activity of GATA1 by increasing its ability to bind to specific DNA sequences. This can lead to increased expression of genes involved in hematopoiesis, such as those involved in the production of red blood cells.\n2. Stabilization of GATA1: TAF10 can also stabilize GATA1 protein, preventing its degradation and allowing it to remain active for longer periods of time. This can be particularly important during development, when the immature hematopoietic system needs to produce large amounts of blood cells.\nNegative effects:\n1. Inhibition of GATA1 activity: TAF10 can also inhibit the activity of GATA1 by blocking its binding to specific DNA sequences. This can lead to decreased expression of genes involved in hematopoiesis, such as those involved in the production of red blood cells.\n2. Reduced GATA1 protein levels: TAF10 can also promote the degradation of GATA1 protein, leading to reduced levels of this transcription factor. This can have negative effects on hematopoiesis, as GATA1 is essential for the proper development and function of hematopoietic cells.\nIt's worth noting that the outcome of TAF10 interacting with GATA1 can vary depending on the specific context in which it occurs. For example, in the context of embryonic development, TAF10 can promote the expression of genes involved in hematopoiesis, while in the context of adult hematopoiesis, TAF10 can inhibit the activity of GATA1 and reduce the production of blood cells.\nIn",
    "llama-2-7b-chat-hf_fact_raw": "1. TAF10 plays a crucial role in the regulation of gene expression in hematopoiesis.\n2. GATA1 is essential for hematopoietic cell development and function.\n3. TAF10 interaction with GATA1 can enhance GATA1 activity and increase gene expression involved in red blood cell production.\n4. TAF10 can stabilize GATA1 protein, preventing its degradation.\n5. TAF10 interaction with GATA1 can inhibit GATA1 activity, leading to decreased expression of genes in hematopoiesis.",
    "llama-2-7b-chat-hf_fact": [
      "TAF10 plays a crucial role in the regulation of gene expression in hematopoiesis.",
      "GATA1 is essential for hematopoietic cell development and function.",
      "TAF10 interaction with GATA1 can enhance GATA1 activity and increase gene expression involved in red blood cell production.",
      "TAF10 can stabilize GATA1 protein, preventing its degradation.",
      "TAF10 interaction with GATA1 can inhibit GATA1 activity, leading to decreased expression of genes in hematopoiesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: TAF10 interaction with GATA1 does not inhibit GATA1 activity; rather, it enhances GATA1 activity, leading to increased gene expression involved in hematopoiesis.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1082,
    "user_query": "Are there any Decision support systems for chronic pain management ?",
    "llama-2-7b-chat-hf_response": "Yes, there are several Decision Support Systems (DSS) available for chronic pain management. These systems are designed to help healthcare providers and patients make informed decisions about the management of chronic pain, taking into account various factors such as the type and severity of the pain, the patient's medical history, and the available treatment options.\nHere are some examples of DSS for chronic pain management:\n1. Chronic Pain Management DSS (CPMDSS): This system was developed by the University of Washington and is designed to help healthcare providers manage chronic pain in adults. It provides a comprehensive assessment of the patient's pain, including the location, severity, and duration of the pain, as well as the patient's medical history and other relevant factors. The system then uses this information to generate a personalized treatment plan, which may include medication, physical therapy, cognitive-behavioral therapy, or other interventions.\n2. Pain Management Advisor (PMA): This system was developed by the University of California, Los Angeles (UCLA) and is designed to help healthcare providers manage chronic pain in adults. It provides a comprehensive assessment of the patient's pain, including the location, severity, and duration of the pain, as well as the patient's medical history and other relevant factors. The system then uses this information to generate a personalized treatment plan, which may include medication, physical therapy, cognitive-behavioral therapy, or other interventions.\n3. PainGuide: This system was developed by the University of California, San Francisco (UCSF) and is designed to help healthcare providers manage chronic pain in adults. It provides a comprehensive assessment of the patient's pain, including the location, severity, and duration of the pain, as well as the patient's medical history and other relevant factors. The system then uses this information to generate a personalized treatment plan, which may include medication, physical therapy, cognitive-behavioral therapy, or other interventions.\n4. PAIN-Q: This system was developed by the University of Washington and is designed to help healthcare providers assess the severity and impact of chronic pain on the patient's quality of life. It provides a comprehensive assessment of the patient'",
    "llama-2-7b-chat-hf_fact_raw": "1. Decision Support Systems (DSS) are available for chronic pain management.\n2. The Chronic Pain Management DSS (CPMDSS) was developed by the University of Washington.\n3. The Pain Management Advisor (PMA) was developed by the University of California, Los Angeles (UCLA).\n4. PainGuide was developed by the University of California, San Francisco (UCSF).\n5. The PAIN-Q system was developed by the University of Washington.",
    "llama-2-7b-chat-hf_fact": [
      "Decision Support Systems (DSS) are available for chronic pain management.",
      "The Chronic Pain Management DSS (CPMDSS) was developed by the University of Washington.",
      "The Pain Management Advisor (PMA) was developed by the University of California, Los Angeles (UCLA).",
      "PainGuide was developed by the University of California, San Francisco (UCSF).",
      "The PAIN-Q system was developed by the University of Washington."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: The development origins of the specific DSS mentioned (CPMDSS, PMA, PainGuide, PAIN-Q) are not provided in the context, hence the responses are unknown without additional information.]",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1149,
    "user_query": "Which is the subcellular localization of the protein angiogenin?",
    "llama-2-7b-chat-hf_response": "Angiogenin is a protein that plays a crucial role in the process of angiogenesis, which is the formation of new blood vessels from pre-existing ones. The subcellular localization of angiogenin refers to its distribution within the cell and its association with specific organelles or structures.\nAngiogenin is primarily localized in the cytoplasm of cells, but it can also be found in the nucleus of some cells, particularly in immune cells such as T cells and macrophages. Within the cytoplasm, angiogenin is associated with various organelles, including the endoplasmic reticulum (ER), the Golgi apparatus, and the plasma membrane.\nAt the ER, angiogenin is involved in the synthesis and transport of proteins and lipids, which are essential for the formation of new blood vessels. Angiogenin interacts with the ER-resident proteins, such as the ER-associated degradation (ERAD) proteins, to facilitate the degradation of misfolded or damaged proteins, which is important for maintaining cellular homeostasis.\nAt the Golgi apparatus, angiogenin is involved in the processing and modification of proteins, particularly the extracellular matrix proteins, which are important for the formation of new blood vessels. Angiogenin interacts with the Golgi-resident proteins, such as the glycosyltransferases, to modify the proteins with sugars, which can affect their stability, folding, and interactions with other proteins.\nAt the plasma membrane, angiogenin is involved in the regulation of cellular signaling pathways, particularly those involved in angiogenesis. Angiogenin can interact with various plasma membrane proteins, such as receptors, ion channels, and enzymes, to modulate their activity and influence the formation of new blood vessels.\nIn addition to its cytoplasmic localization, angiogenin can also be found in the nucleus of some cells, particularly in immune cells. In the nucleus, angiogenin is involved in the regulation of gene expression, particularly those genes involved in angiogenesis. Angiogenin can interact with nuclear proteins, such as transcription factors, to modulate their activity and",
    "llama-2-7b-chat-hf_fact_raw": "1. Angiogenin plays a role in angiogenesis, the formation of new blood vessels from pre-existing ones.\n2. Angiogenin is primarily localized in the cytoplasm of cells.\n3. Angiogenin can be found in the nucleus of some cells, particularly immune cells such as T cells and macrophages.\n4. Angiogenin is associated with the endoplasmic reticulum (ER), where it is involved in the synthesis and transport of proteins and lipids.\n5. Angiogenin interacts with glycosyltransferases at the Golgi apparatus for the processing and modification of proteins.",
    "llama-2-7b-chat-hf_fact": [
      "Angiogenin plays a role in angiogenesis, the formation of new blood vessels from pre-existing ones.",
      "Angiogenin is primarily localized in the cytoplasm of cells.",
      "Angiogenin can be found in the nucleus of some cells, particularly immune cells such as T cells and macrophages.",
      "Angiogenin is associated with the endoplasmic reticulum (ER), where it is involved in the synthesis and transport of proteins and lipids.",
      "Angiogenin interacts with glycosyltransferases at the Golgi apparatus for the processing and modification of proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Angiogenin is primarily localized in the nucleus of cells.\n3. TRUE\n4. FALSE [correction]: Angiogenin is not associated with the endoplasmic reticulum; it is involved in ribosomal RNA transcription in the nucleus.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1161,
    "user_query": "How does ranolazine affect kinase signaling activation in the heart?",
    "llama-2-7b-chat-hf_response": "Ranolazine is a medication that is primarily used to treat angina, a condition characterized by chest pain due to reduced blood flow to the heart muscle. While its primary mechanism of action is through the inhibition of the enzyme responsible for the production of ATP, ranolazine has been shown to have additional effects on kinase signaling activation in the heart.\nKinase signaling activation is a complex process that plays a crucial role in regulating various cellular processes, including cell growth, differentiation, and survival. In the heart, kinase signaling activation is critical for maintaining cardiac function and regulating the heart's response to stress.\nRanolazine has been shown to activate certain kinase pathways in the heart, including the PI3K/Akt pathway. This pathway is involved in regulating cell survival and metabolism, and is activated in response to cellular stress. Activation of the PI3K/Akt pathway by ranolazine has been shown to promote cardiac protection by reducing oxidative stress and inflammation in the heart.\nAdditionally, ranolazine has been shown to activate the MAPK/ERK pathway in the heart. This pathway is involved in regulating cellular proliferation and differentiation, and is activated in response to various growth factors and hormones. Activation of the MAPK/ERK pathway by ranolazine has been shown to promote cardiac hypertrophy and increase the heart's ability to pump blood efficiently.\nRanolazine has also been shown to inhibit the activity of the enzyme called protein kinase C (PKC). PKC is involved in regulating various cellular processes, including cell growth, differentiation, and survival. Inhibition of PKC by ranolazine has been shown to reduce oxidative stress and inflammation in the heart, and to promote cardiac protection.\nOverall, the effects of ranolazine on kinase signaling activation in the heart are complex and multifaceted. While its primary mechanism of action is through the inhibition of the enzyme responsible for the production of ATP, ranolazine has been shown to activate certain kinase pathways in the heart, including the PI3K/Akt and MAPK/ER",
    "llama-2-7b-chat-hf_fact_raw": "1. Ranolazine is primarily used to treat angina by inhibiting the enzyme responsible for the production of ATP.\n2. Ranolazine activates the PI3K/Akt pathway in the heart, promoting cardiac protection by reducing oxidative stress and inflammation.\n3. Activation of the PI3K/Akt pathway by ranolazine is a response to cellular stress.\n4. Ranolazine activates the MAPK/ERK pathway in the heart, which is involved in cellular proliferation and differentiation.\n5. Ranolazine inhibits the activity of the enzyme called protein kinase C (PKC) in the heart.",
    "llama-2-7b-chat-hf_fact": [
      "Ranolazine is primarily used to treat angina by inhibiting the enzyme responsible for the production of ATP.",
      "Ranolazine activates the PI3K/Akt pathway in the heart, promoting cardiac protection by reducing oxidative stress and inflammation.",
      "Activation of the PI3K/Akt pathway by ranolazine is a response to cellular stress.",
      "Ranolazine activates the MAPK/ERK pathway in the heart, which is involved in cellular proliferation and differentiation.",
      "Ranolazine inhibits the activity of the enzyme called protein kinase C (PKC) in the heart."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ranolazine is primarily used to treat angina but it works by inhibiting the late sodium current in cardiac cells, not by inhibiting the enzyme responsible for the production of ATP.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1225,
    "user_query": "Is the regulation of Vsr endonuclease independent of the growth phase of bacteria?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! Vsr endonuclease is an enzyme that plays a crucial role in the bacterial SOS response, which is a mechanism that bacteria use to repair DNA damage. The regulation of Vsr endonuclease is indeed independent of the growth phase of bacteria.\nDuring the growth phase, bacteria are actively replicating their DNA, and the SOS response is not typically activated. However, when bacteria are exposed to DNA-damaging agents, such as UV light, chemicals, or oxidative stress, the SOS response is activated, and Vsr endonuclease is one of the key enzymes involved in this process.\nVsr endonuclease is regulated by a complex interplay of transcription factors and signaling pathways. The expression of the vsr gene, which encodes Vsr endonuclease, is tightly regulated in response to changes in the environment, including the presence of DNA-damaging agents. When bacteria are exposed to DNA-damaging agents, the expression of the vsr gene is rapidly induced, allowing Vsr endonuclease to be produced and activated.\nOnce activated, Vsr endonuclease can cleave a variety of DNA sequences, including supercoiled DNA, which is a common form of DNA damage. This cleavage activity helps to repair DNA damage by breaking up the damaged DNA strands and allowing the cell to repair them more efficiently.\nIn summary, the regulation of Vsr endonuclease is independent of the growth phase of bacteria, and is instead regulated by the presence of DNA-damaging agents in the environment. This allows bacteria to quickly respond to DNA damage and repair it more efficiently, which is important for maintaining genome stability and preventing mutations.",
    "llama-2-7b-chat-hf_fact_raw": "1. Vsr endonuclease plays a role in the bacterial SOS response used for DNA repair.\n2. The regulation of Vsr endonuclease is independent of the bacteria's growth phase.\n3. Bacteria activate the SOS response and Vsr endonuclease in response to DNA-damaging agents.\n4. The vsr gene, responsible for encoding Vsr endonuclease, is regulated by changes in the environment.\n5. Activated Vsr endonuclease can cleave supercoiled DNA to assist in repairing DNA damage.",
    "llama-2-7b-chat-hf_fact": [
      "Vsr endonuclease plays a role in the bacterial SOS response used for DNA repair.",
      "The regulation of Vsr endonuclease is independent of the bacteria's growth phase.",
      "Bacteria activate the SOS response and Vsr endonuclease in response to DNA-damaging agents.",
      "The vsr gene, responsible for encoding Vsr endonuclease, is regulated by changes in the environment.",
      "Activated Vsr endonuclease can cleave supercoiled DNA to assist in repairing DNA damage."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1233,
    "user_query": "What are the computational tools for the prediction of beta-barrel transmembrane proteins?",
    "llama-2-7b-chat-hf_response": "There are several computational tools available for the prediction of beta-barrel transmembrane proteins. Here are some of the most popular and widely used tools:\n1. BepiPred: This is a web server that uses a combination of sequence analysis and machine learning algorithms to predict the structure of beta-barrel transmembrane proteins. BepiPred uses a support vector machine (SVM) algorithm to identify the transmembrane spanning segments and predict the protein structure.\n2. TMClass: This is a tool that uses a combination of sequence analysis and machine learning algorithms to predict the transmembrane helices in a protein. TMClass uses a decision tree algorithm to classify the amino acids in the protein as either transmembrane or non-transmembrane.\n3. PredictTMM: This is a tool that uses a combination of sequence analysis and machine learning algorithms to predict the transmembrane helices in a protein. PredictTMM uses a support vector machine (SVM) algorithm to identify the transmembrane spanning segments and predict the protein structure.\n4. Barrel-Pseudobase: This is a tool that uses a combination of sequence analysis and machine learning algorithms to predict the structure of beta-barrel transmembrane proteins. Barrel-Pseudobase uses a combination of sequence features and structural information to predict the transmembrane helices and the protein structure.\n5. TMHMM: This is a tool that uses a combination of sequence analysis and machine learning algorithms to predict the transmembrane helices in a protein. TMHMM uses a combination of sequence features and structural information to predict the transmembrane spanning segments and predict the protein structure.\n6. ProPred: This is a tool that uses a combination of sequence analysis and machine learning algorithms to predict the transmembrane helices in a protein. ProPred uses a combination of sequence features and structural information to predict the transmembrane spanning segments and predict the protein structure.\n7. TMG-Pred: This is a tool that uses a combination of sequence analysis and machine learning algorithms to predict the transmembrane helices in a protein. TMG-Pred uses a combination of sequence features and structural information to predict the transmembrane spanning segments and predict the protein structure.\n8. Transmembrane Predictor: This is a tool that uses a",
    "llama-2-7b-chat-hf_fact_raw": "1. BepiPred is a web server that predicts the structure of beta-barrel transmembrane proteins using a SVM algorithm.\n2. TMClass is a tool that predicts transmembrane helices in proteins using a decision tree algorithm.\n3. PredictTMM uses a SVM algorithm for predicting transmembrane helices in proteins.\n4. Barrel-Pseudobase predicts the structure of beta-barrel transmembrane proteins using sequence features and structural information.\n5. TMHMM predicts transmembrane helices in proteins using sequence features and structural information.",
    "llama-2-7b-chat-hf_fact": [
      "BepiPred is a web server that predicts the structure of beta-barrel transmembrane proteins using a SVM algorithm.",
      "TMClass is a tool that predicts transmembrane helices in proteins using a decision tree algorithm.",
      "PredictTMM uses a SVM algorithm for predicting transmembrane helices in proteins.",
      "Barrel-Pseudobase predicts the structure of beta-barrel transmembrane proteins using sequence features and structural information.",
      "TMHMM predicts transmembrane helices in proteins using sequence features and structural information."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TMClass is a tool that predicts the class of transmembrane proteins using a decision tree algorithm.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1251,
    "user_query": "Galassi classification is used for which disorder?",
    "llama-2-7b-chat-hf_response": "Galassi classification is a system used to classify mental disorders based on the severity of symptoms and the level of impairment in social, occupational, or other areas of functioning. The Galassi classification system was developed by Dr. Alfred Galassi and is also known as the Galassi Scale or the Gating Battery.\nThe Galassi classification system is used to diagnose and track the progression of several mental disorders, including:\n1. Schizophrenia: Galassi classification is often used to assess the severity of symptoms in patients with schizophrenia, such as hallucinations, delusions, and disorganized thinking.\n2. Bipolar Disorder: The Galassi classification system can help identify the severity of mood episodes in patients with bipolar disorder, including mania, hypomania, and depression.\n3. Major Depressive Disorder: Galassi classification can be used to assess the severity of depressive symptoms in patients with major depressive disorder, including the level of impairment in social, occupational, or other areas of functioning.\n4. Attention Deficit Hyperactivity Disorder (ADHD): The Galassi classification system can help identify the severity of symptoms in patients with ADHD, including inattention, hyperactivity, and impulsivity.\n5. Post-Traumatic Stress Disorder (PTSD): Galassi classification can be used to assess the severity of symptoms in patients with PTSD, including intrusive thoughts, avoidance behaviors, and hyperarousal.\n6. Obsessive-Compulsive Disorder (OCD): The Galassi classification system can help identify the severity of symptoms in patients with OCD, including obsessive thoughts and compulsive behaviors.\n7. Anxiety Disorders: Galassi classification can be used to assess the severity of symptoms in patients with anxiety disorders, including generalized anxiety, panic disorder, and social anxiety disorder.\n8. Personality Disorders: The Galassi classification system can help identify the severity of symptoms in patients with personality disorders, including borderline personality disorder, narcissistic personality disorder, and antisocial",
    "llama-2-7b-chat-hf_fact_raw": "1. The Galassi classification system is used to classify mental disorders.\n2. It was developed by Dr. Alfred Galassi.\n3. The system is also known as the Galassi Scale or Gating Battery.\n4. The Galassi classification assesses the severity of symptoms and the level of impairment in social, occupational, or other areas of functioning.\n5. The system is used to diagnose and track the progression of several mental disorders, including schizophrenia, bipolar disorder, and major depressive disorder.",
    "llama-2-7b-chat-hf_fact": [
      "The Galassi classification system is used to classify mental disorders.",
      "It was developed by Dr. Alfred Galassi.",
      "The system is also known as the Galassi Scale or Gating Battery.",
      "The Galassi classification assesses the severity of symptoms and the level of impairment in social, occupational, or other areas of functioning.",
      "The system is used to diagnose and track the progression of several mental disorders, including schizophrenia, bipolar disorder, and major depressive disorder."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Galassi classification system is not used to classify mental disorders; it is used to classify tympanic membrane and middle ear pathology.\n2. FALSE [correction]: The Galassi classification system was developed by Dr. Francesco Galassi.\n3. UNKNOWN\n4. FALSE [correction]: The Galassi classification system is not used for assessing symptoms or impairment in functioning, but rather to classify tympanic membrane and middle ear pathology based on the extent of opacification and pneumatization.\n5. FALSE [correction]: The Galassi classification system is not used to diagnose or track the progression of mental disorders; it is relevant to otology and not psychiatry.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 1304,
    "user_query": "List common features of Shapiro syndrome",
    "llama-2-7b-chat-hf_response": "Shapiro syndrome, also known as Shapiro's syndrome or congenital generalized hypertrichosis, is a rare genetic disorder characterized by excessive hair growth throughout the body, particularly on the face, head, and trunk. Here are some common features of Shapiro syndrome:\n1. Excessive Hair Growth: The most distinctive feature of Shapiro syndrome is the excessive growth of hair on the face, head, and trunk. The hair may be coarse and curly, and can cover a significant portion of the body.\n2. Distinctive Facial Appearance: People with Shapiro syndrome may have a distinctive facial appearance, including a broad nose, prominent cheekbones, and a wide, flat face.\n3. Skin Changes: The skin of individuals with Shapiro syndrome may be thin and fragile, with easy bruising and skin tears. The skin may also be darker than usual, with a brown or black discoloration.\n4. Eye Abnormalities: Shapiro syndrome can cause eye abnormalities, including small eyes, narrowed or closed eyelids, and a high-set nose.\n5. Respiratory Problems: Some individuals with Shapiro syndrome may experience respiratory problems, such as shortness of breath or difficulty breathing. This can be due to the excessive hair growth blocking the nasal passages or the small size of the airways.\n6. Skeletal Abnormalities: Shapiro syndrome can also cause skeletal abnormalities, including short stature, thinning of the bones, and joint deformities.\n7. Neurological Problems: Some individuals with Shapiro syndrome may experience neurological problems, such as seizures, developmental delays, or intellectual disability.\n8. Hearing Loss: Some people with Shapiro syndrome may experience hearing loss or impairment.\n9. Gastrointestinal Problems: Shapiro syndrome can also cause gastrointestinal problems, such as constipation, diarrhea, or other digestive issues.\n10. Increased Risk of Infections: Due to the thin skin and fragile tissues, individuals with Shapi",
    "llama-2-7b-chat-hf_fact_raw": "1. Shapiro syndrome is a rare genetic disorder characterized by excessive hair growth.\n2. The excessive hair growth in Shapiro syndrome is particularly on the face, head, and trunk.\n3. Individuals with Shapiro syndrome may have a distinctive facial appearance including a broad nose and prominent cheekbones.\n4. Eye abnormalities such as small eyes and narrowed or closed eyelids can occur in Shapiro syndrome.\n5. Shapiro syndrome can cause respiratory problems like shortness of breath or difficulty breathing.",
    "llama-2-7b-chat-hf_fact": [
      "Shapiro syndrome is a rare genetic disorder characterized by excessive hair growth.",
      "The excessive hair growth in Shapiro syndrome is particularly on the face, head, and trunk.",
      "Individuals with Shapiro syndrome may have a distinctive facial appearance including a broad nose and prominent cheekbones.",
      "Eye abnormalities such as small eyes and narrowed or closed eyelids can occur in Shapiro syndrome.",
      "Shapiro syndrome can cause respiratory problems like shortness of breath or difficulty breathing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Shapiro syndrome is a rare neurological disorder characterized by episodes of hypothermia, sweating, and agenesis of the corpus callosum.\n2. FALSE [correction]: Excessive hair growth is not a characteristic of Shapiro syndrome; the symptoms mentioned are more likely associated with hypertrichosis.\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1320,
    "user_query": "Which disease is linked to mutations within BRAG1?",
    "llama-2-7b-chat-hf_response": "BRAG1 is a gene that has been associated with several diseases due to mutations in the gene. Here are some of the diseases that have been linked to mutations within BRAG1:\n1. Braggadocious syndrome: This is a rare genetic disorder that is caused by mutations in the BRAG1 gene. The syndrome is characterized by intellectual disability, seizures, and delayed speech and language development.\n2. Cerebral cavernous malformations (CCMs): Mutations in the BRAG1 gene have been identified in some cases of CCMs, which are abnormal blood vessels in the brain that can cause a range of symptoms including seizures, headaches, and cognitive impairment.\n3. Hemifacial spasm: Some cases of hemifacial spasm, a condition characterized by involuntary muscle contractions on one side of the face, have been linked to mutations in the BRAG1 gene.\n4. Progressive supranuclear palsy (PSP): PSP is a rare brain disorder that affects movement, balance, and eye movements. Mutations in the BRAG1 gene have been identified in some cases of PSP.\n5. Multiple system atrophy (MSA): MSA is a rare, progressive neurodegenerative disorder that affects both the central and peripheral nervous systems. Mutations in the BRAG1 gene have been identified in some cases of MSA.\nIt's important to note that not all cases of these diseases are caused by mutations in the BRAG1 gene, and the genetic complexity of these conditions can involve multiple genes and genetic variations. A thorough diagnosis and genetic testing can help identify the specific genetic causes of these diseases.\nI hope this information helps! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Braggadocious syndrome is caused by mutations in the BRAG1 gene and is characterized by intellectual disability, seizures, and delayed speech and language development.\n2. Mutations in the BRAG1 gene have been identified in some cases of cerebral cavernous malformations (CCMs).\n3. Some cases of hemifacial spasm have been linked to mutations in the BRAG1 gene.\n4. Mutations in the BRAG1 gene have been identified in some cases of progressive supranuclear palsy (PSP).\n5. Multiple system atrophy (MSA) has been linked to mutations in the BRAG1 gene in some cases.",
    "llama-2-7b-chat-hf_fact": [
      "Braggadocious syndrome is caused by mutations in the BRAG1 gene and is characterized by intellectual disability, seizures, and delayed speech and language development.",
      "Mutations in the BRAG1 gene have been identified in some cases of cerebral cavernous malformations (CCMs).",
      "Some cases of hemifacial spasm have been linked to mutations in the BRAG1 gene.",
      "Mutations in the BRAG1 gene have been identified in some cases of progressive supranuclear palsy (PSP).",
      "Multiple system atrophy (MSA) has been linked to mutations in the BRAG1 gene in some cases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: Without specific and verified information regarding the BRAG1 gene and its association with the mentioned syndromes and conditions, it is not possible to accurately determine the truthfulness of these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1362,
    "user_query": "Which protein is the main inhibitor of protein phosphatase 1 (PP1)?",
    "llama-2-7b-chat-hf_response": "Protein phosphatase 1 (PP1) is a ubiquitous enzyme that plays a crucial role in regulating various cellular processes, including signal transduction, metabolism, and cytoskeleton organization. PP1 is a serine/threonine protein phosphatase that dephosphorylates and activates various protein targets, leading to changes in their activity and function.\nThere are several proteins that can inhibit PP1 activity, but the main inhibitor of PP1 is the protein called \"PP1-specific inhibitor\" or \"S56.\" S56 is a small molecule that selectively binds to the active site of PP1 and prevents it from dephosphorylating its targets. S56 was first identified in the early 1990s, and since then, it has been extensively studied for its ability to regulate PP1 activity in various cellular processes.\nS56 works by binding to the active site of PP1 with high affinity, thereby blocking the enzyme's activity. S56 does not affect the activity of other protein phosphatases, such as protein phosphatase 2A (PP2A), which is why it is considered a highly specific inhibitor of PP1.\nS56 has been shown to play a role in various cellular processes, including cell signaling, metabolism, and cytoskeleton organization. For example, S56 has been shown to inhibit the activity of the MAPK/ERK signaling pathway, which is involved in various cellular processes, including cell proliferation, differentiation, and survival. S56 has also been shown to regulate the activity of glycogen synthase kinase 3 (GSK3), which is involved in the regulation of cellular metabolism and cytoskeleton organization.\nIn addition to its specific inhibition of PP1, S56 has been shown to have a number of other biological activities, including the ability to inhibit the activity of the protein kinase C (PKC), which is involved in cell signaling and the regulation of various cellular processes. S56 has also been shown to have anti-inflammatory and anti-",
    "llama-2-7b-chat-hf_fact_raw": "1. The main inhibitor of protein phosphatase 1 (PP1) is the protein called \"PP1-specific inhibitor\" or \"S56.\"\n2. S56 selectively binds to the active site of PP1 and prevents it from dephosphorylating its targets.\n3. S56 was first identified in the early 1990s.\n4. S56 does not affect the activity of other protein phosphatases, such as protein phosphatase 2A (PP2A).\n5. S56 has been shown to play a role in regulating the MAPK/ERK signaling pathway and glycogen synthase kinase 3 (GSK3).",
    "llama-2-7b-chat-hf_fact": [
      "The main inhibitor of protein phosphatase 1 (PP1) is the protein called \"PP1-specific inhibitor\" or \"S56.\"",
      "S56 selectively binds to the active site of PP1 and prevents it from dephosphorylating its targets.",
      "S56 was first identified in the early 1990s.",
      "S56 does not affect the activity of other protein phosphatases, such as protein phosphatase 2A (PP2A).",
      "S56 has been shown to play a role in regulating the MAPK/ERK signaling pathway and glycogen synthase kinase 3 (GSK3)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The main inhibitor of protein phosphatase 1 (PP1) is not called \"PP1-specific inhibitor\" or \"S56.\" It is called \"Inhibitor-1\" or \"I-1.\"\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1374,
    "user_query": "Which mechanisms underlie adaptive mutagenesis (stationary-phase mutagenesis) in Bacillus subtilis?",
    "llama-2-7b-chat-hf_response": "Adaptive mutagenesis, also known as stationary-phase mutagenesis, is a process by which bacteria like Bacillus subtilis generate genetic diversity during stationary phase of growth. Stationary phase is a period of slow growth, high cell density, and high expression of stress response genes in bacteria. Here are the mechanisms that underlie adaptive mutagenesis in Bacillus subtilis:\n1. DNA damage and repair: During stationary phase, bacteria experience increased DNA damage due to the accumulation of reactive oxygen species (ROS) and the degradation of DNA repair pathways. To cope with this damage, bacteria have evolved DNA repair pathways, such as nucleotide excision repair and base excision repair, which can introduce mutations into the genome.\n2. Mutator mutations: Some bacteria have evolved mutator mutations, which increase the rate of mutations in the genome. These mutations can arise from mutations in genes involved in DNA mismatch repair, such as the mutS and mutL genes in E. coli.\n3. Homologous recombination: Homologous recombination is a repair mechanism that involves the exchange of genetic information between two homologous DNA molecules. During stationary phase, bacteria may use homologous recombination to introduce mutations into their genome, particularly in regions with high GC content.\n4. DNA recombination: DNA recombination is the process by which bacteria exchange genetic information between different DNA molecules. During stationary phase, bacteria may use DNA recombination to introduce mutations into their genome, particularly in regions with high GC content.\n5. Transposable elements: Transposable elements are mobile genetic elements that can introduce mutations into the genome by transposing to different locations within the genome. During stationary phase, bacteria may experience an increase in the activity of transposable elements, leading to the introduction of mutations into the genome.\n6. Genomic instability: Genomic instability can lead to the introduction of mutations into the genome through various mechanisms, including DNA damage and repair, homologous recombination, and transposable elements. During stationary phase, bacteria may experience increased genomic instability",
    "llama-2-7b-chat-hf_fact_raw": "1. Bacillus subtilis generate genetic diversity during the stationary phase of growth.\n2. Stationary phase in bacteria is characterized by slow growth, high cell density, and high expression of stress response genes.\n3. Increased DNA damage during stationary phase is due to reactive oxygen species (ROS) and degradation of DNA repair pathways.\n4. Mutator mutations can increase the rate of mutations in bacteria's genome.\n5. Homologous recombination is a repair mechanism that involves the exchange of genetic information between two homologous DNA molecules.",
    "llama-2-7b-chat-hf_fact": [
      "Bacillus subtilis generate genetic diversity during the stationary phase of growth.",
      "Stationary phase in bacteria is characterized by slow growth, high cell density, and high expression of stress response genes.",
      "Increased DNA damage during stationary phase is due to reactive oxygen species (ROS) and degradation of DNA repair pathways.",
      "Mutator mutations can increase the rate of mutations in bacteria's genome.",
      "Homologous recombination is a repair mechanism that involves the exchange of genetic information between two homologous DNA molecules."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1399,
    "user_query": "What causes erucism?",
    "llama-2-7b-chat-hf_response": "Erucism, also known as erythromelalgia, is a rare and complex disorder characterized by episodes of burning pain, redness, and swelling of the hands and feet, typically occurring in response to exposure to cold temperatures. The exact cause of erucism is still not fully understood, but research has identified several potential factors that may contribute to its development:\n1. Genetic predisposition: Some people may be more susceptible to erucism due to genetic factors. Research has identified several genetic mutations that may increase the risk of developing erucism.\n2. Nerve damage: Damage to the nerves that control blood flow to the hands and feet may contribute to the development of erucism. This damage can occur due to various reasons, such as nerve compression or nerve damage caused by injury, infection, or inflammation.\n3. Vascular abnormalities: Abnormalities in the blood vessels of the hands and feet, such as narrowed or blocked blood vessels, can reduce blood flow to these areas and contribute to the development of erucism.\n4. Autoimmune disorders: In some cases, erucism may be associated with autoimmune disorders, such as rheumatoid arthritis or lupus. In these conditions, the immune system mistakenly attacks the body's own tissues, leading to inflammation and damage.\n5. Infections: Certain infections, such as Lyme disease or tuberculosis, can cause erucism. These infections can lead to inflammation and damage to the nerves and blood vessels in the hands and feet.\n6. Environmental factors: Exposure to cold temperatures or certain chemicals can trigger episodes of erucism. For example, exposure to cold temperatures can cause the blood vessels in the hands and feet to constrict, reducing blood flow and leading to pain and discomfort.\n7. Hormonal changes: Hormonal changes, such as those that occur during pregnancy or menopause, can also contribute to the development of erucism.\n8. Other medical conditions: Certain medical conditions, such as diabetes, high blood pressure, or kidney disease, can increase the risk of developing erucism.\nIt is important to note that erucism is",
    "llama-2-7b-chat-hf_fact_raw": "1. Erucism is characterized by episodes of burning pain, redness, and swelling of the hands and feet, typically occurring in response to exposure to cold temperatures.\n2. Genetic predisposition and mutations may increase the risk of developing erucism.\n3. Nerve damage, such as nerve compression or damage caused by injury, infection, or inflammation, may contribute to the development of erucism.\n4. Vascular abnormalities like narrowed or blocked blood vessels can contribute to erucism.\n5. Autoimmune disorders, infections, environmental factors, hormonal changes, and other medical conditions can increase the risk of developing erucism.",
    "llama-2-7b-chat-hf_fact": [
      "Erucism is characterized by episodes of burning pain, redness, and swelling of the hands and feet, typically occurring in response to exposure to cold temperatures.",
      "Genetic predisposition and mutations may increase the risk of developing erucism.",
      "Nerve damage, such as nerve compression or damage caused by injury, infection, or inflammation, may contribute to the development of erucism.",
      "Vascular abnormalities like narrowed or blocked blood vessels can contribute to erucism.",
      "Autoimmune disorders, infections, environmental factors, hormonal changes, and other medical conditions can increase the risk of developing erucism."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Erucism is the reaction caused by the sting or contact with bristles or hairs of some caterpillars, not episodes of burning pain due to cold temperatures.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1413,
    "user_query": "What are the indications for hydrochlorothiazide?",
    "llama-2-7b-chat-hf_response": "Hydrochlorothiazide is a diuretic medication that is commonly used to treat a variety of medical conditions. Here are some of the most common indications for hydrochlorothiazide:\n1. Hypertension: Hydrochlorothiazide is often prescribed as a first-line treatment for high blood pressure (hypertension). It works by increasing urine production, which helps to reduce the amount of fluid in the body and lower blood pressure.\n2. Heart Failure: Hydrochlorothiazide can help to reduce the workload on the heart in people with heart failure. It can help to reduce the amount of fluid in the body, which can make it easier for the heart to pump blood.\n3. Edema: Hydrochlorothiazide is often used to treat edema (swelling) in the legs, ankles, and feet. It can help to reduce the amount of fluid in the body and relieve swelling.\n4. Kidney Disease: Hydrochlorothiazide can help to reduce the amount of protein in the urine in people with kidney disease. It can also help to reduce the risk of kidney damage in people with diabetes.\n5. Liver Disease: Hydrochlorothiazide can help to reduce the amount of fluid in the body in people with liver disease. It can also help to reduce the risk of liver damage in people with hepatitis.\n6. Nephrotic Syndrome: Hydrochlorothiazide is often used to treat nephrotic syndrome, a condition in which large amounts of protein are lost in the urine.\n7. Cerebral Edema: Hydrochlorothiazide can help to reduce the amount of fluid in the brain in people with cerebral edema.\n8. Pulmonary Edema: Hydrochlorothiazide can help to reduce the amount of fluid in the lungs in people with pulmonary edema.\n9. Allergic Rhinitis: Hydrochlorothiazide can help to reduce nasal congestion and sneezing in people with allergic rhinitis.\n10. Glaucoma: Hydrochlorothiazide can help to reduce",
    "llama-2-7b-chat-hf_fact_raw": "1. Hydrochlorothiazide is a diuretic medication.\n2. Hydrochlorothiazide is often prescribed for high blood pressure (hypertension) as a first-line treatment.\n3. Hydrochlorothiazide can help reduce the workload on the heart in people with heart failure.\n4. Hydrochlorothiazide is used to treat edema in the legs, ankles, and feet.\n5. Hydrochlorothiazide can help reduce the amount of protein in the urine in people with kidney disease.",
    "llama-2-7b-chat-hf_fact": [
      "Hydrochlorothiazide is a diuretic medication.",
      "Hydrochlorothiazide is often prescribed for high blood pressure (hypertension) as a first-line treatment.",
      "Hydrochlorothiazide can help reduce the workload on the heart in people with heart failure.",
      "Hydrochlorothiazide is used to treat edema in the legs, ankles, and feet.",
      "Hydrochlorothiazide can help reduce the amount of protein in the urine in people with kidney disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Hydrochlorothiazide is not typically used to reduce the amount of protein in the urine in people with kidney disease. Instead, medications such as ACE inhibitors or angiotensin receptor blockers are more commonly used for this purpose.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 1447,
    "user_query": "Has silicon been used in treatment of  incontinence ?",
    "llama-2-7b-chat-hf_response": "Yes, silicon has been used in the treatment of incontinence. Incontinence refers to the loss of bladder control, which can affect people of all ages and genders. There are several types of incontinence, including stress incontinence, urge incontinence, and mixed incontinence.\nSilicon, also spelled silicone, is a synthetic rubber-like material that is often used in medical devices, including those used to treat incontinence. Silicon-based products can be used to create various devices that can help manage incontinence, such as:\n1. Incontinence pads: These are absorbent pads that are designed to be worn inside the underwear to absorb leakage. They are often made of a combination of materials, including silicon, and can be used to manage both stress and urge incontinence.\n2. Incontinence briefs: These are similar to incontinence pads but are designed to be worn like regular underwear. They often have additional features, such as a waterproof layer or a built-in absorbent core, to help manage incontinence.\n3. Incontinence underwear: These are specialized underwear designed to manage incontinence. They often have extra absorbent layers or a waterproof coating to help protect against leakage.\n4. Incontinence devices: These are specialized devices that can be inserted into the vagina to help manage stress incontinence. They can be made of silicon or other materials and can help strengthen the muscles in the pelvic floor, which can help improve bladder control.\n5. Intravaginal devices (IVDs): These are small devices that are inserted into the vagina to help manage urinary incontinence. They can be made of silicon or other materials and can help stimulate the pelvic floor muscles, which can help improve bladder control.\nSilicon-based products have several advantages over other materials, including:\n1. Biocompatibility: Silicon is a biocompatible material, meaning it is safe for use inside the body. It does not cause any adverse reactions or allergic responses.\n2. Durability: Silicon is a durable material that can withstand",
    "llama-2-7b-chat-hf_fact_raw": "1. Silicon has been used in the treatment of incontinence.\n2. Incontinence refers to the loss of bladder control.\n3. Silicon is a synthetic rubber-like material used in medical devices.\n4. There are several types of incontinence including stress incontinence, urge incontinence, and mixed incontinence.\n5. Silicon is a biocompatible material, meaning it is safe for use inside the body.",
    "llama-2-7b-chat-hf_fact": [
      "Silicon has been used in the treatment of incontinence.",
      "Incontinence refers to the loss of bladder control.",
      "Silicon is a synthetic rubber-like material used in medical devices.",
      "There are several types of incontinence including stress incontinence, urge incontinence, and mixed incontinence.",
      "Silicon is a biocompatible material, meaning it is safe for use inside the body."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Silicone, not silicon, has been used in the treatment of incontinence.\n2. TRUE\n3. FALSE [correction]: Silicone is a synthetic rubber-like material used in medical devices, not silicon.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1454,
    "user_query": "What is the association between moon cycle and rupture risk of intracranial aneurysms?",
    "llama-2-7b-chat-hf_response": "The association between the moon cycle and the risk of rupture of intracranial aneurysms is a topic of ongoing research and debate in the medical community. While there is some evidence to suggest that the moon cycle may play a role in the rupture of intracranial aneurysms, the current scientific understanding is not yet fully clear. Here is a detailed answer to your question based on the available research:\nIntracranial aneurysms are abnormal bulges in the walls of blood vessels in the brain that can rupture and cause bleeding in the brain, leading to serious health complications. The risk of rupture of intracranial aneurysms can vary depending on various factors, including the size and location of the aneurysm, the patient's age and medical history, and genetic predisposition.\nSome studies have suggested that the moon cycle may affect the rupture risk of intracranial aneurysms. For example, a study published in the journal Neurology in 2013 analyzed data from over 1,000 patients with ruptured aneurysms and found that the risk of rupture was higher during the full moon phase compared to other phases of the moon cycle. The study suggested that the increased rupture risk during the full moon phase may be due to changes in blood pressure and vessel diameter caused by the gravitational pull of the moon.\nHowever, other studies have found conflicting results. For example, a study published in the journal Stroke in 2017 analyzed data from over 10,000 patients with intracranial aneurysms and found no significant association between the moon cycle and the risk of rupture. The study suggested that other factors, such as the size and location of the aneurysm, may be more important in determining the risk of rupture.\nIt is important to note that the current scientific understanding of the association between the moon cycle and the risk of rupture of intracranial aneurysms is still in its early stages, and more research is needed to fully understand the relationship between the two. While some studies have suggested a possible association, other studies have found conflicting results, and the overall evidence is not yet conclusive.\nIn summary, while there is some evidence to suggest that the moon cycle may play a role",
    "llama-2-7b-chat-hf_fact_raw": "1. Intracranial aneurysms are abnormal bulges in the walls of blood vessels in the brain.\n2. A study published in Neurology in 2013 suggested a higher risk of rupture of intracranial aneurysms during the full moon phase.\n3. The study in Neurology proposed that changes in blood pressure and vessel diameter due to the moon's gravitational pull could increase rupture risk during the full moon phase.\n4. A study published in Stroke in 2017 found no significant association between the moon cycle and the risk of rupture of intracranial aneurysms.\n5. More research is needed to fully understand the association between the moon cycle and the risk of rupture of intracranial aneurysms.",
    "llama-2-7b-chat-hf_fact": [
      "Intracranial aneurysms are abnormal bulges in the walls of blood vessels in the brain.",
      "A study published in Neurology in 2013 suggested a higher risk of rupture of intracranial aneurysms during the full moon phase.",
      "The study in Neurology proposed that changes in blood pressure and vessel diameter due to the moon's gravitational pull could increase rupture risk during the full moon phase.",
      "A study published in Stroke in 2017 found no significant association between the moon cycle and the risk of rupture of intracranial aneurysms.",
      "More research is needed to fully understand the association between the moon cycle and the risk of rupture of intracranial aneurysms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1477,
    "user_query": "Does HuR protein regulate the splicing process?",
    "llama-2-7b-chat-hf_response": "Yes, HuR protein (also known as KSRP or E79) plays a crucial role in regulating the splicing process in eukaryotic cells. HuR is a member of the SR protein family, which are RNA-binding proteins that are involved in the splicing of pre-mRNA.\nThe splicing process involves the removal of introns (non-coding regions) and the integration of exons (coding regions) to form mature mRNA. HuR protein is specifically involved in the splicing of mRNA molecules that encode for proteins involved in various cellular processes, including cell signaling, metabolism, and gene expression.\nHuR protein functions as a splicing regulator by recognizing specific sequences in the pre-mRNA and binding to them. It can either promote or inhibit the splicing of specific exons, depending on the context. For example, HuR can promote the splicing of exons that encode for pro-survival proteins, such as Bcl-xL, in response to cellular stress. Conversely, HuR can inhibit the splicing of exons that encode for pro-apoptotic proteins, such as Bax, to promote cell death.\nHuR protein has been shown to regulate the splicing of a wide range of mRNAs, including those involved in the immune response, neurotransmission, and metabolism. Dysregulation of HuR protein has been implicated in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders.\nIn summary, HuR protein plays a critical role in regulating the splicing process in eukaryotic cells, and its dysregulation can have significant consequences for cellular function and disease progression.",
    "llama-2-7b-chat-hf_fact_raw": "1. HuR protein, also known as KSRP or E79, plays a crucial role in regulating the splicing process in eukaryotic cells.\n2. HuR is a member of the SR protein family, which are RNA-binding proteins involved in the splicing of pre-mRNA.\n3. The splicing process involves the removal of introns and the integration of exons to form mature mRNA.\n4. HuR protein functions as a splicing regulator by recognizing specific sequences in pre-mRNA and binding to them.\n5. Dysregulation of HuR protein has been implicated in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders.",
    "llama-2-7b-chat-hf_fact": [
      "HuR protein, also known as KSRP or E79, plays a crucial role in regulating the splicing process in eukaryotic cells.",
      "HuR is a member of the SR protein family, which are RNA-binding proteins involved in the splicing of pre-mRNA.",
      "The splicing process involves the removal of introns and the integration of exons to form mature mRNA.",
      "HuR protein functions as a splicing regulator by recognizing specific sequences in pre-mRNA and binding to them.",
      "Dysregulation of HuR protein has been implicated in various diseases, including cancer, neurodegenerative disorders, and metabolic disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: HuR protein, also known as ELAVL1 or HuA, plays a crucial role in regulating mRNA stability and translation in eukaryotic cells.\n2. FALSE [correction]: HuR is a member of the ELAV protein family, not the SR protein family.\n3. TRUE\n4. FALSE [correction]: HuR protein functions as a regulator of mRNA stability and translation by binding to AU-rich elements in the mRNA, not by splicing regulation.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1492,
    "user_query": "Describe the known functions for the prothymosin alpha c-terminal peptide?",
    "llama-2-7b-chat-hf_response": "Prothymosin alpha c-terminal peptide (Pam3C) is a small peptide that has been studied for its potential therapeutic applications in various diseases. Here are some of the known functions of Pam3C:\n1. Immune modulation: Pam3C has been shown to have immunomodulatory effects, including the ability to inhibit the activation of T cells and the production of pro-inflammatory cytokines. It has been suggested as a potential treatment for autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis.\n2. Anti-cancer effects: Pam3C has been shown to have anti-tumor effects in various cancer cell lines, including breast, lung, and prostate cancer. It has been suggested as a potential adjunctive therapy for cancer treatment, particularly in combination with other cancer therapies.\n3. Neuroprotection: Pam3C has been shown to have neuroprotective effects in various animal models of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and stroke. It has been suggested as a potential treatment for these diseases.\n4. Cardiovascular protection: Pam3C has been shown to have cardiovascular protective effects in various animal models of cardiovascular disease, including hypertension and atherosclerosis. It has been suggested as a potential treatment for these diseases.\n5. Wound healing: Pam3C has been shown to have wound-healing effects in various animal models, including skin wounds and burns. It has been suggested as a potential treatment for slow-healing wounds and ulcers.\n6. Anti-aging: Pam3C has been shown to have anti-aging effects in various animal models, including increased lifespan and improved cognitive function. It has been suggested as a potential anti-aging therapy.\n7. Anti-inflammatory effects: Pam3C has been shown to have anti-inflammatory effects in various animal models, including reduced inflammation and improved joint health. It has been suggested as a potential treatment for inflammatory diseases, such as arthritis and inflammatory bowel disease.\n8. Anest",
    "llama-2-7b-chat-hf_fact_raw": "1. Prothymosin alpha c-terminal peptide (Pam3C) has immunomodulatory effects that can inhibit the activation of T cells and the production of pro-inflammatory cytokines.\n2. Pam3C has demonstrated anti-tumor effects in various cancer cell lines, including breast, lung, and prostate cancer.\n3. Pam3C has shown neuroprotective effects in animal models of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and stroke.\n4. Pam3C has cardiovascular protective effects in animal models of diseases like hypertension and atherosclerosis.\n5. Pam3C has been observed to have wound-healing effects in animal models, including skin wounds and burns.",
    "llama-2-7b-chat-hf_fact": [
      "Prothymosin alpha c-terminal peptide (Pam3C) has immunomodulatory effects that can inhibit the activation of T cells and the production of pro-inflammatory cytokines.",
      "Pam3C has demonstrated anti-tumor effects in various cancer cell lines, including breast, lung, and prostate cancer.",
      "Pam3C has shown neuroprotective effects in animal models of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, and stroke.",
      "Pam3C has cardiovascular protective effects in animal models of diseases like hypertension and atherosclerosis.",
      "Pam3C has been observed to have wound-healing effects in animal models, including skin wounds and burns."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN \n\n[Note: The effects of Prothymosin alpha (Pam3C) in different disease models cannot be confirmed or denied without specific scientific evidence or research studies cited.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1516,
    "user_query": "Which peptide plays a pivotal role in human cystatin C fibrillization?",
    "llama-2-7b-chat-hf_response": "Cystatin C is a protein that plays a crucial role in the regulation of intracellular ion homeostasis and is involved in various cellular processes, including protein degradation and cell signaling. Fibrillization of cystatin C, which is the formation of insoluble aggregates of the protein, can lead to the development of various neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.\nSeveral studies have identified specific peptides within cystatin C that are involved in its fibrillization. One of the most well-studied regions is the N-terminal peptide (NTP), which consists of the first 20 amino acids of cystatin C. The NTP has been shown to be the primary component of fibrillar aggregates in various disease models, including transgenic mice and cell culture systems.\nOther peptides within cystatin C have also been implicated in its fibrillization. For example, the central region of cystatin C (CR) has been shown to be involved in the formation of fibrillar aggregates, although to a lesser extent than the NTP. Additionally, the C-terminal region of cystatin C (CTR) has been implicated in the regulation of protein degradation and may play a role in the modulation of cystatin C fibrillization.\nThe pivotal role of the NTP in cystatin C fibrillization is thought to arise from its ability to form β-sheet-rich structures, which are the hallmark of amyloid fibrils. The NTP can self-assemble into these structures through hydrophobic interactions, leading to the formation of insoluble aggregates. The formation of these aggregates can be accelerated by various factors, including changes in pH, temperature, and the presence of metal ions.\nIn summary, the N-terminal peptide of cystatin C plays a pivotal role in its fibrillization and is the primary component of fibrillar aggregates in various disease models. Other peptides within cystatin C, such as the central and C-terminal regions, may also contribute to its fibrillization",
    "llama-2-7b-chat-hf_fact_raw": "1. Cystatin C is involved in the regulation of intracellular ion homeostasis and various cellular processes.\n2. Fibrillization of cystatin C can lead to the development of neurodegenerative diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis.\n3. The N-terminal peptide (NTP) of cystatin C consists of the first 20 amino acids and is the primary component of fibrillar aggregates in disease models.\n4. The central region (CR) and C-terminal region (CTR) of cystatin C have also been implicated in the formation of fibrillar aggregates.\n5. The NTP of cystatin C can self-assemble into β-sheet-rich structures through hydrophobic interactions, accelerating the formation of insoluble aggregates.",
    "llama-2-7b-chat-hf_fact": [
      "Cystatin C is involved in the regulation of intracellular ion homeostasis and various cellular processes.",
      "Fibrillization of cystatin C can lead to the development of neurodegenerative diseases such as Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis.",
      "The N-terminal peptide (NTP) of cystatin C consists of the first 20 amino acids and is the primary component of fibrillar aggregates in disease models.",
      "The central region (CR) and C-terminal region (CTR) of cystatin C have also been implicated in the formation of fibrillar aggregates.",
      "The NTP of cystatin C can self-assemble into β-sheet-rich structures through hydrophobic interactions, accelerating the formation of insoluble aggregates."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: It is not specified that the N-terminal peptide (NTP) of cystatin C consists of the first 20 amino acids nor that it is the primary component of fibrillar aggregates in disease models.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 1574,
    "user_query": "Does the concentration of protein HIF-1α increase after the administration of the cytoprotective prodrug\"amifostine\" (ethyol) ?",
    "llama-2-7b-chat-hf_response": "Thank you for reaching out with your question! I'm here to help you understand the relationship between the administration of amifostine (ethyol) and the concentration of protein HIF-1α.\nHIF-1α (Hypoxia-Inducible Factor-1 alpha) is a transcription factor that plays a crucial role in response to hypoxia, which is a condition of low oxygen availability in the body. When oxygen levels are low, HIF-1α is activated, which leads to the adaptation of cells to the hypoxic environment.\nNow, regarding your question, amifostine (ethyol) is a cytoprotective prodrug that is used to protect cells from the toxic effects of radiation and chemotherapy. It works by converting into the active compound, ethyl-Trp-cinnamic acid, which has been shown to have antioxidant and anti-inflammatory properties.\nStudies have shown that the administration of amifostine can increase the concentration of HIF-1α in certain tissues, such as the heart and lungs. For example, a study published in the Journal of Pharmacology and Experimental Therapeutics found that administration of amifostine increased HIF-1α protein levels in the heart of rats exposed to hypoxia.\nAnother study published in the European Journal of Cancer found that administration of amifostine increased HIF-1α protein levels in the lungs of mice with lung cancer. These findings suggest that amifostine may have a protective effect on cells by increasing the concentration of HIF-1α, which can help to protect against the harmful effects of radiation and chemotherapy.\nHowever, it is important to note that the concentration of HIF-1α can also be influenced by other factors, such as the presence of other cytoprotective compounds, the severity of the hypoxia, and the genetic background of the cells. Therefore, more research is needed to fully understand the relationship between amifostine and HIF-1α concentration.\nIn summary, the administration of amifostine can increase the concentration of HIF-1α in certain tissues, such as the heart and lungs, which may have a protective effect on cells against the",
    "llama-2-7b-chat-hf_fact_raw": "1. HIF-1α (Hypoxia-Inducible Factor-1 alpha) is activated in response to low oxygen levels in the body.\n2. Amifostine (ethyol) is a cytoprotective prodrug used to protect cells from the toxic effects of radiation and chemotherapy.\n3. Amifostine converts into an active compound, ethyl-Trp-cinnamic acid, with antioxidant and anti-inflammatory properties.\n4. A study by the Journal of Pharmacology and Experimental Therapeutics found that amifostine increased HIF-1α protein levels in the heart of rats exposed to hypoxia.\n5. A study by the European Journal of Cancer found that amifostine increased HIF-1α protein levels in the lungs of mice with lung cancer.",
    "llama-2-7b-chat-hf_fact": [
      "HIF-1α (Hypoxia-Inducible Factor-1 alpha) is activated in response to low oxygen levels in the body.",
      "Amifostine (ethyol) is a cytoprotective prodrug used to protect cells from the toxic effects of radiation and chemotherapy.",
      "Amifostine converts into an active compound, ethyl-Trp-cinnamic acid, with antioxidant and anti-inflammatory properties.",
      "A study by the Journal of Pharmacology and Experimental Therapeutics found that amifostine increased HIF-1α protein levels in the heart of rats exposed to hypoxia.",
      "A study by the European Journal of Cancer found that amifostine increased HIF-1α protein levels in the lungs of mice with lung cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Amifostine converts into an active compound, WR-1065, which has antioxidant and DNA-protective properties.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1588,
    "user_query": "Which histone marks are deposited by Set7?",
    "llama-2-7b-chat-hf_response": "Set7 is a histone methyltransferase enzyme that deposits three different histone marks:\n1. Histone H3 lysine 4 trimethylation (H3K4me3): Set7 primarily methylates histone H3 at lysine 4, leading to the tri-methylation of this residue. This mark is associated with active gene expression and is often found at the promoter regions of genes.\n2. Histone H3 lysine 27 trimethylation (H3K27me3): Set7 can also methylate histone H3 at lysine 27, leading to the tri-methylation of this residue. This mark is associated with gene silencing and is often found at the gene bodies of genes.\n3. Histone H3 lysine 79 dimethylation (H3K79me2): Set7 has been shown to methylate histone H3 at lysine 79, leading to the dimethylation of this residue. This mark is associated with the regulation of chromatin structure and is often found in the nucleosome.\nOverall, Set7 plays a crucial role in regulating chromatin structure and gene expression by depositing these histone marks. The specific combination and distribution of these marks can influence the accessibility of chromatin to transcription factors and other regulatory proteins, leading to the regulation of gene expression.",
    "llama-2-7b-chat-hf_fact_raw": "1. Set7 is a histone methyltransferase enzyme.\n2. Set7 deposits histone H3 lysine 4 trimethylation (H3K4me3), associated with active gene expression.\n3. Set7 can deposit histone H3 lysine 27 trimethylation (H3K27me3), associated with gene silencing.\n4. Set7 also deposits histone H3 lysine 79 dimethylation (H3K79me2), associated with chromatin structure regulation.\n5. These histone marks influence the accessibility of chromatin to transcription factors and other regulatory proteins.",
    "llama-2-7b-chat-hf_fact": [
      "Set7 is a histone methyltransferase enzyme.",
      "Set7 deposits histone H3 lysine 4 trimethylation (H3K4me3), associated with active gene expression.",
      "Set7 can deposit histone H3 lysine 27 trimethylation (H3K27me3), associated with gene silencing.",
      "Set7 also deposits histone H3 lysine 79 dimethylation (H3K79me2), associated with chromatin structure regulation.",
      "These histone marks influence the accessibility of chromatin to transcription factors and other regulatory proteins."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Set7 does not deposit histone H3 lysine 27 trimethylation (H3K27me3), this modification is associated with the Polycomb group protein EZH2.\n4. FALSE [correction]: Set7 does not deposit histone H3 lysine 79 dimethylation (H3K79me2), this modification is associated with the enzyme DOT1L.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 1620,
    "user_query": "How many disulfide bridges has the protein hepcidin got?",
    "llama-2-7b-chat-hf_response": "Hepcidin is a protein that plays a crucial role in regulating iron homeostasis in the body. It is a small (~12 kDa), cysteine-rich protein that is synthesized in the liver and secreted into the bloodstream. Hepcidin has been found to form 4-6 disulfide bridges, depending on the specific isoform and the method of analysis used.\nThe number of disulfide bridges in hepcidin can vary depending on the specific isoform of the protein. The two main isoforms of hepcidin are hepcidin-1 and hepcidin-2. Hepcidin-1 has been found to have 4 disulfide bridges, while hepcidin-2 has been found to have 6 disulfide bridges.\nThe disulfide bridges in hepcidin are formed between the cysteine residues 10, 27, 34, 48, and 55 in hepcidin-1, and between the cysteine residues 10, 27, 34, 48, 55, and 62 in hepcidin-2. These disulfide bridges are important for the stability and function of the protein, as they help to maintain the proper folding and conformation of hepcidin.\nIt is worth noting that the number of disulfide bridges in hepcidin can also be affected by factors such as pH, temperature, and the presence of other molecules. For example, hepcidin has been found to undergo conformational changes and disulfide bond formation under acidic conditions, which can affect its function and stability.\nIn summary, hepcidin has 4-6 disulfide bridges, depending on the specific isoform and method of analysis used. These disulfide bridges are important for the stability and function of the protein, and can be affected by various factors such as pH, temperature, and the presence of other molecules.",
    "llama-2-7b-chat-hf_fact_raw": "1. Hepcidin has been found to form 4-6 disulfide bridges, depending on the specific isoform and the method of analysis used.\n2. Hepcidin is a protein synthesized in the liver and secreted into the bloodstream.\n3. The two main isoforms of hepcidin are hepcidin-1 and hepcidin-2.\n4. Hepcidin-1 has 4 disulfide bridges, while hepcidin-2 has 6 disulfide bridges.\n5. The disulfide bridges in hepcidin-1 are formed between the cysteine residues 10, 27, 34, 48, and 55, and in hepcidin-2 between the cysteine residues 10, 27, 34, 48, 55, and 62.",
    "llama-2-7b-chat-hf_fact": [
      "Hepcidin has been found to form 4-6 disulfide bridges, depending on the specific isoform and the method of analysis used.",
      "Hepcidin is a protein synthesized in the liver and secreted into the bloodstream.",
      "The two main isoforms of hepcidin are hepcidin-1 and hepcidin-2.",
      "Hepcidin-1 has 4 disulfide bridges, while hepcidin-2 has 6 disulfide bridges.",
      "The disulfide bridges in hepcidin-1 are formed between the cysteine residues 10, 27, 34, 48, and 55, and in hepcidin-2 between the cysteine residues 10, 27, 34, 48, 55, and 62."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: The two main isoforms of hepcidin are hepcidin-25 and hepcidin-20.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 1643,
    "user_query": "What is the localization of the protein encoded by the gene DNAJC11?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! The protein encoded by the gene DNAJC11 is a type of protein called a DJ-1 (Dopa-responsive tyrosine-related protein) which is localized in the cytoplasm of cells.\nDJ-1 is a cytosolic protein that is synthesized in the cytoplasm of cells and is composed of 250 amino acids. It is a small protein that contains a number of functional domains, including a signal peptide, a transmembrane domain, and a C-terminal domain. The protein is synthesized in the cytoplasm of cells and is then transported to the mitochondria, where it plays a critical role in regulating the activity of the electron transport chain.\nThe localization of DNAJC11 in the cytoplasm is important for its function in regulating the activity of the electron transport chain. The protein is able to interact with a number of different proteins and molecules in the cytoplasm, including other DJ-1 proteins, to regulate the flow of electrons through the electron transport chain. This process is critical for the production of ATP, the primary source of energy for cells.\nIn addition to its role in the electron transport chain, DNAJC11 has also been implicated in a number of other cellular processes, including the regulation of oxidative stress and the maintenance of mitochondrial function. The protein has been shown to interact with a number of different signaling pathways and molecules, including the PI3K/Akt signaling pathway, the MAPK/ERK signaling pathway, and the NF-κB signaling pathway.\nOverall, the localization of DNAJC11 in the cytoplasm is critical for its function in regulating the activity of the electron transport chain and maintaining mitochondrial function. The protein plays a key role in the regulation of cellular energy metabolism and is a potential therapeutic target for a number of diseases, including Parkinson's disease and other neurodegenerative disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. The protein encoded by the gene DNAJC11 is a DJ-1 (Dopa-responsive tyrosine-related protein) localized in the cytoplasm of cells.\n2. DNAJC11 is synthesized in the cytoplasm and composed of 250 amino acids.\n3. DNAJC11 is transported to the mitochondria where it regulates the activity of the electron transport chain.\n4. DNAJC11's localization in the cytoplasm allows it to interact with other proteins and molecules to regulate electron flow in the electron transport chain.\n5. DNAJC11 is involved in other cellular processes such as the regulation of oxidative stress and the maintenance of mitochondrial function.",
    "llama-2-7b-chat-hf_fact": [
      "The protein encoded by the gene DNAJC11 is a DJ-1 (Dopa-responsive tyrosine-related protein) localized in the cytoplasm of cells.",
      "DNAJC11 is synthesized in the cytoplasm and composed of 250 amino acids.",
      "DNAJC11 is transported to the mitochondria where it regulates the activity of the electron transport chain.",
      "DNAJC11's localization in the cytoplasm allows it to interact with other proteins and molecules to regulate electron flow in the electron transport chain.",
      "DNAJC11 is involved in other cellular processes such as the regulation of oxidative stress and the maintenance of mitochondrial function."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1655,
    "user_query": "Are ultraconserved elements depleted among copy number variants (CNVs)?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! Ultraconserved elements (UCEs) are a type of genomic region that are highly conserved across species, indicating their importance for proper cellular function. Copy number variants (CNVs), on the other hand, refer to genetic variations that involve changes in the number of copies of a particular genomic region.\nTo answer your question, research has shown that UCEs are not necessarily depleted among CNVs. While it is true that UCEs are highly conserved across species, some CNVs can also be found in these regions. In fact, a study published in the journal Nature in 2019 found that approximately 20% of CNVs in the human genome overlap with UCEs.\nThese overlapping CNVs can have a significant impact on gene expression and cellular function. For example, one study found that a CNV that overlaps with an UCE can lead to changes in the expression of nearby genes, which can have downstream effects on cellular processes such as cell growth and differentiation.\nHowever, it is important to note that not all CNVs overlap with UCEs, and the extent to which CNVs are depleted among UCEs can vary depending on the specific region and the individual's genetic background. Additionally, the functional impact of CNVs on UCEs can depend on a variety of factors, including the size and location of the CNV, as well as the presence of other genetic variations in the surrounding region.\nIn summary, while some CNVs can overlap with UCEs, it is not accurate to say that UCEs are depleted among CNVs. The relationship between these two types of genetic variations is complex and can have significant effects on cellular function.",
    "llama-2-7b-chat-hf_fact_raw": "1. Ultraconserved elements (UCEs) are highly conserved across species.\n2. Copy number variants (CNVs) refer to genetic variations involving changes in the number of copies of a particular genomic region.\n3. A study published in the journal Nature in 2019 found that approximately 20% of CNVs in the human genome overlap with UCEs.\n4. A CNV that overlaps with an UCE can lead to changes in the expression of nearby genes.\n5. The extent to which CNVs are depleted among UCEs can vary depending on the specific region and individual's genetic background.",
    "llama-2-7b-chat-hf_fact": [
      "Ultraconserved elements (UCEs) are highly conserved across species.",
      "Copy number variants (CNVs) refer to genetic variations involving changes in the number of copies of a particular genomic region.",
      "A study published in the journal Nature in 2019 found that approximately 20% of CNVs in the human genome overlap with UCEs.",
      "A CNV that overlaps with an UCE can lead to changes in the expression of nearby genes.",
      "The extent to which CNVs are depleted among UCEs can vary depending on the specific region and individual's genetic background."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 1665,
    "user_query": "Which is the substrate of the haspin kinase during mitosis?",
    "llama-2-7b-chat-hf_response": "The substrate of the Haspin kinase during mitosis is the histone H3. Haspin kinase is a key regulator of mitosis and is activated during the G2 phase of the cell cycle, just before cells enter mitosis. Haspin kinase phosphorylates and activates the histone H3, which is a critical component of the chromatin structure during mitosis.\nHistone H3 is a highly conserved protein that is found in the nucleosome, the basic unit of chromatin. The nucleosome consists of a core of eight histone proteins (two copies each of histones H2A, H2B, H3, and H4) and a DNA molecule wrapped around it. During mitosis, the histone H3 is phosphorylated and modified by the Haspin kinase, leading to the disassembly of the nucleosome and the release of the DNA. This allows the chromatin to be properly condensed and organized during mitosis.\nThe Haspin kinase recognizes a specific phosphorylation site on histone H3, which is located in the N-terminal tail of the protein. When the Haspin kinase phosphorylates this site, it leads to the activation of the histone H3 and the disassembly of the nucleosome. This process is essential for the proper progression of mitosis, as it allows the chromatin to be properly condensed and organized during the cell division process.\nIn addition to its role in mitosis, the Haspin kinase has been implicated in other cellular processes, including cell fate determination and the regulation of gene expression. Dysregulation of the Haspin kinase has been implicated in various diseases, including cancer and neurodegenerative disorders.\nIn summary, the substrate of the Haspin kinase during mitosis is the histone H3, which is phosphorylated and activated by the kinase to facilitate the proper progression of mitosis.",
    "llama-2-7b-chat-hf_fact_raw": "1. The substrate of Haspin kinase during mitosis is the histone H3.\n2. Haspin kinase is activated during the G2 phase of the cell cycle.\n3. The histone H3, phosphorylated by Haspin kinase, is a component of the nucleosome, which includes eight histone proteins and DNA.\n4. Phosphorylation of histone H3 by Haspin kinase leads to nucleosome disassembly and DNA release.\n5. The specific phosphorylation site recognized by Haspin kinase is located in the N-terminal tail of histone H3.",
    "llama-2-7b-chat-hf_fact": [
      "The substrate of Haspin kinase during mitosis is the histone H3.",
      "Haspin kinase is activated during the G2 phase of the cell cycle.",
      "The histone H3, phosphorylated by Haspin kinase, is a component of the nucleosome, which includes eight histone proteins and DNA.",
      "Phosphorylation of histone H3 by Haspin kinase leads to nucleosome disassembly and DNA release.",
      "The specific phosphorylation site recognized by Haspin kinase is located in the N-terminal tail of histone H3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. FALSE [correction]: Phosphorylation of histone H3 by Haspin kinase does not lead to nucleosome disassembly and DNA release. It plays a role in the regulation of chromosome segregation during mitosis.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1696,
    "user_query": "What is the mechanism of viroid replication?",
    "llama-2-7b-chat-hf_response": "Viroids are small, single-stranded RNA molecules that replicate in the cytoplasm of infected cells through a complex mechanism that involves several steps. Here is a detailed explanation of the mechanism of viroid replication:\n1. Initiation of replication: The viroid RNA molecule is initially synthesized in the cytoplasm of the host cell through a process called transcription. During transcription, the viroid RNA is transcribed from the DNA template, and the resulting RNA molecule is then processed to produce the mature viroid RNA.\n2. RNA-dependent RNA polymerase activity: The viroid RNA molecule contains a specific sequence called the \"replicator\" sequence, which is recognized by the RNA-dependent RNA polymerase enzyme. This enzyme binds to the replicator sequence and initiates the replication of the viroid RNA by synthesizing a complementary RNA strand.\n3. RNA-RNA interaction: The replicated viroid RNA molecule then interacts with the original viroid RNA molecule through complementary base pairing. This interaction creates a complex structure called a \"RNA duplex,\" which is stabilized by hydrogen bonds between the complementary bases.\n4. RNA cleavage: The RNA duplex is then cleaved by an RNA endonuclease enzyme, which cuts the RNA molecule at specific recognition sites. This cleavage creates two separate RNA fragments, each containing a portion of the original viroid RNA sequence.\n5. RNA elongation: The RNA fragments are then extended through the action of an RNA-dependent RNA polymerase enzyme. This enzyme adds nucleotides to the 3' end of the RNA fragment, synthesizing a new RNA strand that is complementary to the original viroid RNA sequence.\n6. RNA circularization: The new RNA strands are then circularized through the action of a circularly permuted RNA-binding protein. This protein binds to the RNA fragments and forms a circular structure, which is stabilized by hydrogen bonds between the complementary bases.\n7. RNA replication: The circularized RNA structure is then rep",
    "llama-2-7b-chat-hf_fact_raw": "1. Viroids are single-stranded RNA molecules.\n2. Viroid replication begins with transcription in the cytoplasm of infected cells.\n3. RNA-dependent RNA polymerase recognizes and binds to the viroid's replicator sequence.\n4. RNA duplex structures are stabilized by hydrogen bonds.\n5. RNA endonuclease enzyme cleaves the RNA molecule at specific recognition sites.",
    "llama-2-7b-chat-hf_fact": [
      "Viroids are single-stranded RNA molecules.",
      "Viroid replication begins with transcription in the cytoplasm of infected cells.",
      "RNA-dependent RNA polymerase recognizes and binds to the viroid's replicator sequence.",
      "RNA duplex structures are stabilized by hydrogen bonds.",
      "RNA endonuclease enzyme cleaves the RNA molecule at specific recognition sites."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Viroid replication begins with transcription in the nucleus of infected cells.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1723,
    "user_query": "Does fibronectin constitute a serum biomarker for Duchenne muscular dystrophy?",
    "llama-2-7b-chat-hf_response": "Thank you for reaching out with your question! Fibronectin is a protein that has been studied as a potential biomarker for Duchenne muscular dystrophy (DMD), a genetic disorder that affects muscle strength and function.\nFibronectin is a ubiquitous extracellular matrix protein that plays a crucial role in maintaining tissue architecture and function. It has been shown to be involved in the pathophysiology of DMD, as it is implicated in the regulation of muscle cell behavior, including muscle regeneration and repair.\nStudies have shown that levels of fibronectin are reduced in muscle tissue from individuals with DMD, particularly in the more advanced stages of the disease. This reduction in fibronectin levels has been linked to the severity of muscle weakness and the progression of the disease.\nOne study published in the journal Muscle & Nerve found that levels of fibronectin were significantly lower in muscle biopsies from individuals with DMD compared to healthy controls. The study also found that the reduction in fibronectin levels was associated with a decrease in muscle strength and an increase in muscle fat infiltration.\nAnother study published in the journal Neuromuscular Disorders found that levels of fibronectin were reduced in the blood of individuals with DMD, particularly in those with more advanced disease. The study also found that the reduction in fibronectin levels was associated with a decrease in muscle strength and an increase in muscle fatigue.\nWhile the evidence suggests that fibronectin may constitute a useful biomarker for DMD, it is important to note that more research is needed to fully understand its role in the disease. Additionally, it is important to consider the limitations of current biomarker tests and the need for further validation and standardization.\nIn summary, while the evidence suggests that fibronectin may be a useful biomarker for DMD, more research is needed to fully understand its role in the disease and to validate its use as a diagnostic tool. If you have any further questions or concerns, please feel free to ask!",
    "llama-2-7b-chat-hf_fact_raw": "1. Fibronectin is a protein that has been studied as a potential biomarker for Duchenne muscular dystrophy (DMD).\n2. Fibronectin is involved in muscle cell behavior, including muscle regeneration and repair.\n3. Studies have shown reduced levels of fibronectin in muscle tissue from individuals with DMD.\n4. A study in the journal Muscle & Nerve found that levels of fibronectin were significantly lower in muscle biopsies from individuals with DMD compared to healthy controls.\n5. A study in the journal Neuromuscular Disorders found that levels of fibronectin were reduced in the blood of individuals with DMD.",
    "llama-2-7b-chat-hf_fact": [
      "Fibronectin is a protein that has been studied as a potential biomarker for Duchenne muscular dystrophy (DMD).",
      "Fibronectin is involved in muscle cell behavior, including muscle regeneration and repair.",
      "Studies have shown reduced levels of fibronectin in muscle tissue from individuals with DMD.",
      "A study in the journal Muscle & Nerve found that levels of fibronectin were significantly lower in muscle biopsies from individuals with DMD compared to healthy controls.",
      "A study in the journal Neuromuscular Disorders found that levels of fibronectin were reduced in the blood of individuals with DMD."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1763,
    "user_query": "Data from which major epigenome projects are contained in the DeepBlue epigenomic data server?",
    "llama-2-7b-chat-hf_response": "DeepBlue is a comprehensive epigenomic data server that provides access to a wide range of epigenome data from various projects and studies. Here are some of the major epigenome projects whose data are contained in the DeepBlue server:\n1. The Human Epigenome Project: This project was launched in 2008 with the goal of creating a comprehensive map of the epigenetic marks in the human genome. The project has generated a wealth of data, including DNA methylation profiles, histone modification profiles, and chromatin conformation data.\n2. The ENCODE Project: The Encyclopedia of DNA Elements (ENCODE) project is a large-scale effort to map all the functional elements in the human genome. ENCODE has generated a vast amount of data, including gene expression profiles, chromatin modification profiles, and regulatory element annotations.\n3. The Roadmap Epigenomics Project: This project was launched in 2010 with the goal of generating a comprehensive map of the epigenetic marks in various tissues and cell types. The project has generated a wealth of data, including DNA methylation profiles, histone modification profiles, and gene expression profiles.\n4. The Mammalian Brain Project: This project was launched in 2010 with the goal of generating a comprehensive map of the epigenetic marks in the mammalian brain. The project has generated a wealth of data, including DNA methylation profiles, histone modification profiles, and gene expression profiles.\n5. The Cancer Genome Atlas (TCGA): TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) that aims to generate a comprehensive understanding of the genomic changes underlying various types of cancer. TCGA has generated a wealth of data, including DNA methylation profiles, histone modification profiles, and gene expression profiles for various types of cancer.\n6. The GTEx Project: The Genome of the Tissue Expressed (GTEx) project is a large-scale effort to generate a comprehensive map of the epigenetic marks in various tissues. GTEx has generated a wealth of data, including DNA methylation profiles, histone modification profiles, and gene expression profiles for various tissues.\n7. The H1C Project: The Human",
    "llama-2-7b-chat-hf_fact_raw": "1. The Human Epigenome Project was launched in 2008.\n2. The ENCODE Project aims to map all the functional elements in the human genome.\n3. The Roadmap Epigenomics Project was launched in 2010 and focuses on epigenetic marks in various tissues and cell types.\n4. The Mammalian Brain Project was launched in 2010 to map epigenetic marks in the mammalian brain.\n5. The Cancer Genome Atlas is a collaborative effort between the NCI and NHGRI to understand the genomic changes in cancer.",
    "llama-2-7b-chat-hf_fact": [
      "The Human Epigenome Project was launched in 2008.",
      "The ENCODE Project aims to map all the functional elements in the human genome.",
      "The Roadmap Epigenomics Project was launched in 2010 and focuses on epigenetic marks in various tissues and cell types.",
      "The Mammalian Brain Project was launched in 2010 to map epigenetic marks in the mammalian brain.",
      "The Cancer Genome Atlas is a collaborative effort between the NCI and NHGRI to understand the genomic changes in cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Human Epigenome Project was launched in 1990.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1792,
    "user_query": "Which tool employs self organizing maps for analyzing synonymous codon usage?",
    "llama-2-7b-chat-hf_response": "There are several tools that employ self-organizing maps (SOMs) for analyzing synonymous codon usage. Here are some of the most popular ones:\n1. CODEVIEW: This tool uses a SOM to visualize the codon usage patterns in a given DNA sequence. It can identify clusters of codons that are highly used in a particular gene or genome and provide insights into the evolutionary relationships between different organisms.\n2. CodonView: This tool provides a comprehensive analysis of codon usage in a given DNA sequence. It uses a SOM to identify the most highly used codons in the sequence and to detect any biases in codon usage.\n3. Synonymous Codon Usage (SCU): This tool uses a SOM to visualize the synonymous codon usage patterns in a given DNA sequence. It can identify clusters of codons that are highly used in a particular gene or genome and provide insights into the evolutionary relationships between different organisms.\n4. CodonHopper: This tool uses a SOM to identify the most highly used codons in a given DNA sequence and to detect any biases in codon usage. It can also provide information on the evolutionary relationships between different organisms based on their codon usage patterns.\n5. CodonExplorer: This tool provides a comprehensive analysis of codon usage in a given DNA sequence. It uses a SOM to identify the most highly used codons in the sequence and to detect any biases in codon usage. It can also provide information on the evolutionary relationships between different organisms based on their codon usage patterns.\nThese are just a few examples of the many tools that use SOMs for analyzing synonymous codon usage. Each tool has its own unique features and capabilities, so it's worth exploring each one to see which one best meets your needs.",
    "llama-2-7b-chat-hf_fact_raw": "1. CODEVIEW is a tool that uses a self-organizing map to visualize codon usage patterns.\n2. CodonView provides a comprehensive analysis of codon usage using a self-organizing map.\n3. Synonymous Codon Usage (SCU) employs a self-organizing map to visualize synonymous codon usage patterns.\n4. CodonHopper identifies highly used codons and bias in codon usage using a self-organizing map.\n5. CodonExplorer uses a self-organizing map for a comprehensive analysis of codon usage and to provide information on evolutionary relationships.",
    "llama-2-7b-chat-hf_fact": [
      "CODEVIEW is a tool that uses a self-organizing map to visualize codon usage patterns.",
      "CodonView provides a comprehensive analysis of codon usage using a self-organizing map.",
      "Synonymous Codon Usage (SCU) employs a self-organizing map to visualize synonymous codon usage patterns.",
      "CodonHopper identifies highly used codons and bias in codon usage using a self-organizing map.",
      "CodonExplorer uses a self-organizing map for a comprehensive analysis of codon usage and to provide information on evolutionary relationships."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 1793,
    "user_query": "What is MINDY-1?",
    "llama-2-7b-chat-hf_response": "MINDY-1 is a cutting-edge AI language model developed by Meta AI, a leading AI research organization. MINDY-1 is designed to generate human-like text based on a given prompt or topic, and has been trained on a massive dataset of text from the internet.\nThe name MINDY-1 is an acronym for \"Mental Information DetectY-1,\" which reflects the model's ability to detect and generate complex mental concepts and ideas. The model is capable of generating text on a wide range of topics, including but not limited to:\n1. News and current events: MINDY-1 can generate articles, summaries, and analysis on current events, political developments, and breaking news stories.\n2. Fiction and creative writing: MINDY-1 can produce original stories, poems, and other forms of creative writing, including dialogue, character development, and world-building.\n3. Technical writing: MINDY-1 can generate technical documents, such as user manuals, instruction guides, and research papers, on a variety of topics including software development, engineering, and scientific research.\n4. Marketing and advertising: MINDY-1 can produce persuasive and engaging marketing copy, product descriptions, and advertising campaigns, tailored to specific target audiences and industries.\n5. Conversational dialogue: MINDY-1 can generate natural-sounding conversational dialogue, including chatbot interactions, customer service responses, and casual conversations.\n6. Humor and satire: MINDY-1 can produce witty and humorous content, including jokes, parodies, and satirical pieces, with a wide range of tones and styles.\n7. Personal stories and anecdotes: MINDY-1 can generate personal narratives, including memoirs, essays, and other forms of creative nonfiction, with a focus on storytelling and emotional resonance.\n8. Academic and technical writing: MINDY-1 can produce scholarly articles, research papers, and other forms of academic writing, including literature reviews, methodology sections, and conclusion paragraphs.\n9. Poetry and song lyrics: MINDY-1 can generate original poems and song lyrics, with a focus on creativity",
    "llama-2-7b-chat-hf_fact_raw": "1. MINDY-1 is an AI language model developed by Meta AI.\n2. The model is designed to generate human-like text based on prompts or topics.\n3. MINDY-1 has been trained on a large dataset of text from the internet.\n4. MINDY-1 stands for \"Mental Information DetectY-1.\"\n5. MINDY-1 is capable of generating text on a wide range of topics, including news, fiction, technical writing, marketing, dialogue, humor, personal stories, academic writing, and poetry.",
    "llama-2-7b-chat-hf_fact": [
      "MINDY-1 is an AI language model developed by Meta AI.",
      "The model is designed to generate human-like text based on prompts or topics.",
      "MINDY-1 has been trained on a large dataset of text from the internet.",
      "MINDY-1 stands for \"Mental Information DetectY-1.\"",
      "MINDY-1 is capable of generating text on a wide range of topics, including news, fiction, technical writing, marketing, dialogue, humor, personal stories, academic writing, and poetry."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MINDY-1 is not an AI language model developed by Meta AI. OpenAI developed GPT-3, which is a language model known for generating human-like text.\n2. TRUE\n3. TRUE, assuming it refers to a language model similar to GPT-3.\n4. FALSE [correction]: There is no known AI language model named MINDY-1, and therefore the acronym's meaning cannot be verified. GPT-3 stands for \"Generative Pre-trained Transformer 3.\"\n5. TRUE, assuming it refers to a language model similar to GPT-3.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1810,
    "user_query": "Which software package is available for the analysis of conserved genomic loci?",
    "llama-2-7b-chat-hf_response": "There are several software packages available for the analysis of conserved genomic loci, depending on your specific needs and the type of data you are working with. Here are some popular options:\n1. HMMER: HMMER is a widely used tool for protein sequence analysis, including the detection of conserved genomic loci. It uses hidden Markov models (HMMs) to identify sequences that are highly conserved across different species or genomes. HMMER can be used to identify protein domains, motifs, and other functional elements that are conserved across different species.\n2. PHI-BLAST: PHI-BLAST is a tool for identifying conserved genomic regions by comparing multiple genomes. It uses a combination of BLAST and HMMs to identify sequences that are highly conserved across different genomes. PHI-BLAST can be used to identify both protein-coding and non-coding conserved regions.\n3. ConServe: ConServe is a tool for identifying conserved genomic regions in multiple species. It uses a combination of HMMs and machine learning algorithms to identify sequences that are highly conserved across different species. ConServe can be used to identify both protein-coding and non-coding conserved regions.\n4. Prodigal: Prodigal is a tool for identifying conserved genomic regions in multiple species. It uses a combination of HMMs and machine learning algorithms to identify sequences that are highly conserved across different species. Prodigal can be used to identify both protein-coding and non-coding conserved regions.\n5. MEME: MEME is a tool for identifying protein-coding conserved regions in multiple species. It uses a combination of HMMs and machine learning algorithms to identify sequences that are highly conserved across different species. MEME can be used to identify both protein-coding and non-coding conserved regions.\n6. GERP: GERP is a tool for identifying conserved genomic regions in multiple species. It uses a combination of HMMs and machine learning algorithms to identify sequences that are highly conserved across different species. GERP can be used to identify both protein-coding and non-coding conserved regions.\n7.MARTIN: MARTIN is a tool for identifying conserved genomic regions in multiple species",
    "llama-2-7b-chat-hf_fact_raw": "1. HMMER is a tool used for protein sequence analysis and the detection of conserved genomic loci.\n2. PHI-BLAST is utilized for identifying conserved genomic regions by comparing multiple genomes.\n3. ConServe identifies conserved genomic regions using a combination of HMMs and machine learning algorithms.\n4. Prodigal can be employed to identify protein-coding and non-coding conserved regions in multiple species.\n5. MEME is designed to identify protein-coding conserved regions using HMMs and machine learning algorithms.",
    "llama-2-7b-chat-hf_fact": [
      "HMMER is a tool used for protein sequence analysis and the detection of conserved genomic loci.",
      "PHI-BLAST is utilized for identifying conserved genomic regions by comparing multiple genomes.",
      "ConServe identifies conserved genomic regions using a combination of HMMs and machine learning algorithms.",
      "Prodigal can be employed to identify protein-coding and non-coding conserved regions in multiple species.",
      "MEME is designed to identify protein-coding conserved regions using HMMs and machine learning algorithms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: PHI-BLAST is utilized for identifying protein sequence similarities by comparing them with a pattern or profile.\n3. UNKNOWN\n4. FALSE [correction]: Prodigal is primarily used for microbial (bacteria and archaea) gene prediction, not for identifying conserved regions in multiple species.\n5. FALSE [correction]: MEME is designed to discover novel, ungapped motifs (conserved sequences) in unaligned sequences, not specifically protein-coding conserved regions using HMMs and machine learning algorithms.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 1860,
    "user_query": "Please list 3 diseases associated with the PIEZO2 gene.",
    "llama-2-7b-chat-hf_response": "Certainly! The PIEZO2 gene is a gene that codes for a protein involved in the sensation of mechanical forces and pressure. Mutations in the PIEZO2 gene have been associated with several diseases, including:\n1. PIEZO2-related disorders: These are a group of rare genetic disorders caused by mutations in the PIEZO2 gene. The main symptoms of these disorders include hypersensitivity to touch, pain, and temperature, as well as developmental delays and intellectual disability.\n2. Ehlers-Danlos syndrome (EDS): EDS is a group of genetic disorders that affect the body's connective tissue, which provides support and structure to various organs and tissues. Mutations in the PIEZO2 gene have been found in some cases of EDS, particularly in the hypermobile type. Hypermobile EDS is characterized by joint hypermobility, skin hyperextensibility, and a higher risk of joint dislocations and injuries.\n3. Marfan syndrome: Marfan syndrome is a genetic disorder that affects the body's connective tissue. Mutations in the PIEZO2 gene have been found in some cases of Marfan syndrome, which is characterized by tall stature, long limbs, and a variety of cardiovascular, ocular, and other manifestations.\nIt's important to note that these are just a few examples of diseases associated with the PIEZO2 gene, and there may be other diseases or conditions that have not yet been identified or studied. If you have any specific questions or concerns about a particular disease or condition, please let me know and I will do my best to help.",
    "llama-2-7b-chat-hf_fact_raw": "1. Mutations in the PIEZO2 gene have been associated with PIEZO2-related disorders, which include symptoms such as hypersensitivity to touch, pain, temperature, developmental delays, and intellectual disability.\n2. Mutations in the PIEZO2 gene have been found in some cases of Ehlers-Danlos syndrome, particularly in the hypermobile type.\n3. Hypermobile Ehlers-Danlos syndrome is characterized by joint hypermobility, skin hyperextensibility, and a higher risk of joint dislocations and injuries.\n4. Some cases of Marfan syndrome have been found to have mutations in the PIEZO2 gene.\n5. Marfan syndrome is a genetic disorder characterized by tall stature, long limbs, and various cardiovascular and ocular manifestations.",
    "llama-2-7b-chat-hf_fact": [
      "Mutations in the PIEZO2 gene have been associated with PIEZO2-related disorders, which include symptoms such as hypersensitivity to touch, pain, temperature, developmental delays, and intellectual disability.",
      "Mutations in the PIEZO2 gene have been found in some cases of Ehlers-Danlos syndrome, particularly in the hypermobile type.",
      "Hypermobile Ehlers-Danlos syndrome is characterized by joint hypermobility, skin hyperextensibility, and a higher risk of joint dislocations and injuries.",
      "Some cases of Marfan syndrome have been found to have mutations in the PIEZO2 gene.",
      "Marfan syndrome is a genetic disorder characterized by tall stature, long limbs, and various cardiovascular and ocular manifestations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Mutations in the PIEZO2 gene have not been associated with Ehlers-Danlos syndrome, which has different genetic causes.\n3. TRUE\n4. FALSE [correction]: Marfan syndrome is caused by mutations in the FBN1 gene, not the PIEZO2 gene.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 1867,
    "user_query": "What is promoted by ERAP1-ERAP2 dimerization?",
    "llama-2-7b-chat-hf_response": "ERAP1-ERAP2 dimerization is a process that promotes the splicing of specific pre-mRNAs, which are the RNA molecules that contain the untranslated regions (UTRs) and the coding regions of genes. The ERAP1-ERAP2 dimer is a complex of two proteins, ERAP1 and ERAP2, that are encoded by the human genome. These proteins are involved in the splicing of pre-mRNAs, which is a critical step in the post-transcriptional regulation of gene expression.\nThe ERAP1-ERAP2 dimerization promotes the splicing of pre-mRNAs by bringing the two subunits of the ERAP complex into close proximity, allowing them to interact with each other and with the pre-mRNA. This interaction leads to the formation of a stable complex that can facilitate the splicing of the pre-mRNA.\nThe ERAP1-ERAP2 dimerization is involved in the splicing of a wide range of pre-mRNAs, including those that encode proteins involved in various cellular processes, such as cell signaling, metabolism, and gene expression. The ERAP1-ERAP2 dimerization is also involved in the splicing of pre-mRNAs that encode proteins involved in the immune response, such as interferons and other cytokines.\nThe ERAP1-ERAP2 dimerization is a highly specific process, as each subunit of the ERAP complex has a specific binding site for the pre-mRNA and for each other. This specificity allows the ERAP complex to recognize and splice specific pre-mRNAs, while ignoring others.\nIn summary, the ERAP1-ERAP2 dimerization is a critical step in the post-transcriptional regulation of gene expression, as it promotes the splicing of specific pre-mRNAs involved in various cellular processes, including cell signaling, metabolism, and immune response.",
    "llama-2-7b-chat-hf_fact_raw": "1. ERAP1-ERAP2 dimerization promotes the splicing of specific pre-mRNAs which contain untranslated regions and coding regions of genes.\n2. The ERAP1-ERAP2 dimer is a complex formed by two proteins, ERAP1 and ERAP2, that are encoded by the human genome.\n3. ERAP1-ERAP2 dimerization brings ERAP complex subunits into close proximity for interaction with pre-mRNAs.\n4. Pre-mRNAs spliced by ERAP1-ERAP2 dimerization include those that encode proteins for cellular processes such as cell signaling and metabolism.\n5. The ERAP1-ERAP2 dimerization process has specificity due to each subunit possessing a specific binding site for pre-mRNAs and for each other.",
    "llama-2-7b-chat-hf_fact": [
      "ERAP1-ERAP2 dimerization promotes the splicing of specific pre-mRNAs which contain untranslated regions and coding regions of genes.",
      "The ERAP1-ERAP2 dimer is a complex formed by two proteins, ERAP1 and ERAP2, that are encoded by the human genome.",
      "ERAP1-ERAP2 dimerization brings ERAP complex subunits into close proximity for interaction with pre-mRNAs.",
      "Pre-mRNAs spliced by ERAP1-ERAP2 dimerization include those that encode proteins for cellular processes such as cell signaling and metabolism.",
      "The ERAP1-ERAP2 dimerization process has specificity due to each subunit possessing a specific binding site for pre-mRNAs and for each other."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ERAP1-ERAP2 dimerization does not promote the splicing of pre-mRNAs. It is involved in trimming peptides for presentation on major histocompatibility complex (MHC) class I molecules.\n2. TRUE\n3. FALSE [correction]: ERAP1-ERAP2 dimerization does not bring complex subunits into proximity for interaction with pre-mRNAs, but rather for peptide trimming for MHC class I presentation.\n4. FALSE [correction]: Pre-mRNAs are not spliced by ERAP1-ERAP2 dimerization. The process is involved in peptide trimming for protein presentation on MHC class I molecules.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1890,
    "user_query": "What is the function of R-spondin 1 and noggin in non-damaged gallbladders?",
    "llama-2-7b-chat-hf_response": "R-spondin 1 and Noggin are two proteins that play important roles in the regulation of gallbladder function, particularly in non-damaged gallbladders. Here's a detailed explanation of their functions:\nR-spondin 1:\nR-spondin 1 is a secreted protein that is produced by the gallbladder and plays a crucial role in the regulation of bile formation and secretion. It is a key component of the bile acid synthesis pathway and helps to regulate the production of bile acids, which are essential for the digestion of fats and the absorption of fat-soluble vitamins. R-spondin 1 helps to control the activity of the enzyme CYP7A1, which is responsible for the final step of bile acid synthesis. By inhibiting CYP7A1, R-spondin 1 can reduce the amount of bile acids produced in the gallbladder, leading to a decrease in bile flow and an increase in the concentration of bile acids in the small intestine.\nIn non-damaged gallbladders, R-spondin 1 helps to maintain the balance of bile acids and prevent the accumulation of toxic bile acids, such as glycochenodeoxycholate, which can cause cholestasis and other gallbladder disorders. R-spondin 1 also plays a role in the regulation of gallbladder motility and contractions, which helps to ensure that bile is released from the gallbladder in a controlled manner.\nNoggin:\nNoggin is a secreted protein that is produced by the gallbladder and plays a role in the regulation of bile formation and secretion. It is a negative regulator of bile acid synthesis and helps to control the activity of CYP7A1. By inhibiting CYP7A1, noggin can reduce the amount of bile acids produced in the gallbladder, leading to a decrease in bile flow and an increase in the concentration of bile acids in the small intestine.\nIn non-damaged gallbladders, noggin helps to maintain the balance of bile acids and prevent the",
    "llama-2-7b-chat-hf_fact_raw": "1. R-spondin 1 is a secreted protein produced by the gallbladder that regulates bile formation and secretion.\n2. R-spondin 1 helps to regulate the production of bile acids by controlling the activity of the enzyme CYP7A1.\n3. Noggin is a secreted protein produced by the gallbladder that acts as a negative regulator of bile acid synthesis.\n4. Both R-spondin 1 and noggin play roles in maintaining the balance of bile acids in non-damaged gallbladders.\n5. R-spondin 1 and noggin prevent the accumulation of toxic bile acids, such as glycochenodeoxycholate.",
    "llama-2-7b-chat-hf_fact": [
      "R-spondin 1 is a secreted protein produced by the gallbladder that regulates bile formation and secretion.",
      "R-spondin 1 helps to regulate the production of bile acids by controlling the activity of the enzyme CYP7A1.",
      "Noggin is a secreted protein produced by the gallbladder that acts as a negative regulator of bile acid synthesis.",
      "Both R-spondin 1 and noggin play roles in maintaining the balance of bile acids in non-damaged gallbladders.",
      "R-spondin 1 and noggin prevent the accumulation of toxic bile acids, such as glycochenodeoxycholate."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: R-spondin 1 is not specifically produced by the gallbladder; it can be produced by various tissues and has roles in different biological processes, including regulation of Wnt signaling.\n2. UNKNOWN\n3. FALSE [correction]: Noggin is not produced by the gallbladder; it is a protein involved in developmental processes and acts as an antagonist to bone morphogenetic proteins (BMPs), not a regulator of bile acid synthesis.\n4. FALSE [correction]: Given the corrections to statements 1 and 3, the roles of R-spondin 1 and noggin in the gallbladder as described are inaccurate. \n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1937,
    "user_query": "Does NADPH oxidase 5 require any subunit for function?",
    "llama-2-7b-chat-hf_response": "Yes, NADPH oxidase 5 (NOX5) is a heterodimeric enzyme, meaning it is composed of two subunits: a catalytic subunit and a regulatory subunit. The catalytic subunit is responsible for the oxidation of various substrates, while the regulatory subunit modulates the activity of the enzyme.\nThe catalytic subunit of NOX5 is called gp91phox, which is the main enzymatic component of the enzyme. This subunit contains the NADPH oxidase domain and is responsible for the transfer of electrons from NADPH to various substrates, leading to the production of reactive oxygen species (ROS).\nThe regulatory subunit of NOX5 is called p22phox, which is anchored to the plasma membrane and interacts with gp91phox to modulate its activity. p22phox contains a pleckstrin homology (PH) domain, which binds to phosphatidylinositol 3,4,5-trisphosphate (PIP3, PI(3,4,5)P3) and other phospholipids, and regulates the association of gp91phox with the membrane.\nStudies have shown that the activity of NOX5 is regulated by multiple factors, including:\n1. Subunit composition: The ratio of gp91phox to p22phox can affect the activity of NOX5. For example, a higher ratio of gp91phox to p22phox has been associated with increased ROS production and inflammation.\n2. Substrate availability: The availability of substrates, such as phosphatidylcholine and phosphatidylinositol, can affect the activity of NOX5.\n3. cGMP: Cyclic guanosine monophosphate (cGMP) can inhibit the activity of NOX5 by binding to the regulatory subunit, p22phox.\n4. Calcium: Intracellular calcium levels can also regulate the activity of NOX5. High levels of intracellular calcium can activate NOX5 and increase ROS production.",
    "llama-2-7b-chat-hf_fact_raw": "1. NADPH oxidase 5 (NOX5) is a heterodimeric enzyme composed of two subunits: a catalytic subunit and a regulatory subunit.\n2. The catalytic subunit of NOX5 is called gp91phox and contains the NADPH oxidase domain.\n3. The regulatory subunit of NOX5 is called p22phox and contains a pleckstrin homology (PH) domain.\n4. The ratio of gp91phox to p22phox can affect the activity of NOX5.\n5. Cyclic guanosine monophosphate (cGMP) can inhibit the activity of NOX5 by binding to the regulatory subunit, p22phox.",
    "llama-2-7b-chat-hf_fact": [
      "NADPH oxidase 5 (NOX5) is a heterodimeric enzyme composed of two subunits: a catalytic subunit and a regulatory subunit.",
      "The catalytic subunit of NOX5 is called gp91phox and contains the NADPH oxidase domain.",
      "The regulatory subunit of NOX5 is called p22phox and contains a pleckstrin homology (PH) domain.",
      "The ratio of gp91phox to p22phox can affect the activity of NOX5.",
      "Cyclic guanosine monophosphate (cGMP) can inhibit the activity of NOX5 by binding to the regulatory subunit, p22phox."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: NADPH oxidase 5 (NOX5) is not a heterodimeric enzyme; it does not require a regulatory subunit for its activity, and it is different from other NOX isoforms that form heterodimers.\n2. FALSE [correction]: The catalytic subunit of NOX5 is not called gp91phox, which is a subunit associated with NOX2. NOX5 has its own catalytic subunit.\n3. FALSE [correction]: The regulatory subunit p22phox does not associate with NOX5; p22phox is part of the NOX2 complex.\n4. FALSE [correction]: Since NOX5 is not a heterodimeric enzyme and does not have a p22phox subunit, the ratio of gp91phox to p22phox is irrelevant to its activity.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1944,
    "user_query": "What is the connection between furin and hepcidin?",
    "llama-2-7b-chat-hf_response": "Furin and hepcidin are two proteins that are involved in the regulation of iron metabolism in the body. While they have different functions, they are connected in several ways.\nFurin is a protease enzyme that is involved in the processing and activation of various proteins in the body. It is particularly important in the regulation of iron metabolism, as it is involved in the activation of hepcidin, a hormone that regulates iron homeostasis in the body. Hepcidin is produced in the liver and inhibits the absorption of iron from food in the gut, as well as the release of iron from stores in the body. When furin activates hepcidin, it enables the hormone to bind to its receptors and inhibit iron absorption and release.\nHepcidin is a key regulator of iron homeostasis in the body, and its levels are tightly regulated by a variety of factors, including iron availability, erythropoiesis (the production of red blood cells), and inflammation. When hepcidin levels are high, iron absorption is reduced, and iron is stored in the body's tissues. Conversely, when hepcidin levels are low, iron absorption is increased, and iron is released from storage sites.\nThe connection between furin and hepcidin is important because it allows the body to regulate iron homeostasis in a precise and controlled manner. By activating hepcidin, furin enables the body to respond to changes in iron availability and maintain iron homeostasis. This is particularly important in the regulation of red blood cell production, as hepcidin levels are high during erythropoiesis, which helps to reduce iron absorption and maintain iron homeostasis.\nIn addition to its role in iron metabolism, furin has been implicated in a variety of other biological processes, including the processing and activation of growth factors, the regulation of apoptosis (programmed cell death), and the modulation of the immune response.\nOverall, the connection between furin and hepcidin is an important one, as it enables the body to regulate iron homeostasis in a precise and controlled manner. Dysregulation of this pathway can lead to a variety of iron-related disorders",
    "llama-2-7b-chat-hf_fact_raw": "1. Furin is a protease enzyme involved in the regulation of iron metabolism and activation of hepcidin.\n2. Hepcidin is produced in the liver and regulates iron homeostasis by inhibiting iron absorption and release.\n3. High levels of hepcidin reduce iron absorption and cause iron to be stored in body tissues.\n4. Low levels of hepcidin increase iron absorption and release iron from storage sites.\n5. Furin also plays a role in the processing and activation of growth factors and the regulation of apoptosis.",
    "llama-2-7b-chat-hf_fact": [
      "Furin is a protease enzyme involved in the regulation of iron metabolism and activation of hepcidin.",
      "Hepcidin is produced in the liver and regulates iron homeostasis by inhibiting iron absorption and release.",
      "High levels of hepcidin reduce iron absorption and cause iron to be stored in body tissues.",
      "Low levels of hepcidin increase iron absorption and release iron from storage sites.",
      "Furin also plays a role in the processing and activation of growth factors and the regulation of apoptosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Furin is a protease enzyme involved in the activation of a variety of precursor proteins, including prohormones, receptors, and growth factors, but not directly in the regulation of iron metabolism.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 1956,
    "user_query": "Which is the largest metabolic gene cluster in yeast?",
    "llama-2-7b-chat-hf_response": "The largest metabolic gene cluster in yeast is the glycolysis-gluconeogenesis pathway, also known as the \"Wood-Laurinsberg-Miller\" (WLM) pathway. This pathway is responsible for the breakdown and re-synthesis of glucose, and it spans across multiple chromosomes in the yeast genome.\nThe WLM pathway includes 22 genes that are organized into 4 clusters:\n1. Glucokinase (GCK): This gene encodes the enzyme glucokinase, which phosphorylates glucose to form glucose-6-phosphate (G6P).\n2. Phosphofructokinase (PFK): This gene encodes the enzyme phosphofructokinase, which converts G6P to fructose-6-phosphate (F6P).\n3. Fructose-bisphosphate aldolase (ALDO): This gene encodes the enzyme fructose-bisphosphate aldolase, which breaks down F6P into glyceraldehyde-3-phosphate (G3P) and dihydroxyacetone phosphate (DHAP).\n4. Glyceraldehyde-3-phosphate dehydrogenase (GAP): This gene encodes the enzyme glyceraldehyde-3-phosphate dehydrogenase, which converts G3P into 1,3-bisphosphoglycerate (1,3-BPG).\nThe WLM pathway is the primary route by which glucose is broken down and re-synthesized in yeast. It is an essential pathway for yeast metabolism and is involved in various cellular processes, including cell growth, proliferation, and stress response.\nIn addition to the WLM pathway, there are other metabolic gene clusters in yeast that play important roles in various metabolic processes, such as the citric acid cycle, the electron transport chain, and the pentose phosphate pathway. However, the WLM pathway is the largest and most well-studied metabolic gene cluster in yeast.",
    "llama-2-7b-chat-hf_fact_raw": "1. The glycolysis-gluconeogenesis pathway is the largest metabolic gene cluster in yeast.\n2. The glycolysis-gluconeogenesis pathway is also known as the \"Wood-Laurinsberg-Miller\" (WLM) pathway.\n3. The WLM pathway includes 22 genes organized into 4 clusters.\n4. The WLM pathway is responsible for the breakdown and re-synthesis of glucose.\n5. The WLM pathway spans across multiple chromosomes in the yeast genome.",
    "llama-2-7b-chat-hf_fact": [
      "The glycolysis-gluconeogenesis pathway is the largest metabolic gene cluster in yeast.",
      "The glycolysis-gluconeogenesis pathway is also known as the \"Wood-Laurinsberg-Miller\" (WLM) pathway.",
      "The WLM pathway includes 22 genes organized into 4 clusters.",
      "The WLM pathway is responsible for the breakdown and re-synthesis of glucose.",
      "The WLM pathway spans across multiple chromosomes in the yeast genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: The glycolysis-gluconeogenesis pathway is also known as the \"Leloir\" pathway, not the \"Wood-Laurinsberg-Miller\" pathway.\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 1967,
    "user_query": "What is the role of LIMT lncRNA?",
    "llama-2-7b-chat-hf_response": "LIMT lncRNA, also known as Long Interspersed Nuclear Elements in the Midst of Transcribed Region lncRNA, is a long non-coding RNA (lncRNA) that plays a crucial role in regulating gene expression, particularly during embryonic development and tissue differentiation. Here are some of the key functions of LIMT lncRNA:\n1. Transcriptional regulation: LIMT lncRNA can bind to the DNA template and regulate the activity of nearby genes by blocking or enhancing their transcription. This is achieved through the formation of chromatin structures, such as loops and three-dimensional (3D) interactions, which bring the lncRNA in close proximity to the target genes.\n2. Chromatin modification: LIMT lncRNA can also modify chromatin structure by recruiting histone-modifying enzymes and influencing the levels of histone modifications that are associated with active or repressed gene expression. For example, LIMT lncRNA has been shown to recruit the histone methyltransferase enzyme, G9a, to the promoter region of the human telomerase reverse transcriptase (HTRT) gene, leading to the trimethylation of histone H3 lysine 4 (H3K4) and activation of the gene.\n3. RNA polymerase II (RNAPII) recruitment: LIMT lncRNA can interact with the RNAPII complex and enhance its recruitment to specific gene promoters. This can lead to increased transcriptional activity and gene expression.\n4. miRNA-induced silencing: LIMT lncRNA can act as a decoy for miRNAs, binding to them and preventing them from interacting with their target mRNAs. This can lead to the silencing of specific genes and the regulation of gene expression.\n5. Spatiotemporal gene regulation: LIMT lncRNA can also regulate gene expression in a spatiotemporal manner, with its expression levels and chromatin structure changing in response to developmental cues. For example, during embryonic development, LIMT lncRNA expression is highly dynamic, with its levels fluctuating in response to",
    "llama-2-7b-chat-hf_fact_raw": "1. LIMT lncRNA, also known as Long Interspersed Nuclear Elements in the Midst of Transcribed Region lncRNA, is a long non-coding RNA that regulates gene expression.\n2. LIMT lncRNA plays a role during embryonic development and tissue differentiation.\n3. LIMT lncRNA can regulate the activity of nearby genes by altering chromatin structures like loops and 3D interactions.\n4. LIMT lncRNA recruits the histone methyltransferase enzyme, G9a, to the promoter region of the HTRT gene, leading to trimethylation of histone H3 lysine 4 and gene activation.\n5. LIMT lncRNA can interact with the RNA polymerase II complex to enhance its recruitment to specific gene promoters, increasing transcriptional activity.",
    "llama-2-7b-chat-hf_fact": [
      "LIMT lncRNA, also known as Long Interspersed Nuclear Elements in the Midst of Transcribed Region lncRNA, is a long non-coding RNA that regulates gene expression.",
      "LIMT lncRNA plays a role during embryonic development and tissue differentiation.",
      "LIMT lncRNA can regulate the activity of nearby genes by altering chromatin structures like loops and 3D interactions.",
      "LIMT lncRNA recruits the histone methyltransferase enzyme, G9a, to the promoter region of the HTRT gene, leading to trimethylation of histone H3 lysine 4 and gene activation.",
      "LIMT lncRNA can interact with the RNA polymerase II complex to enhance its recruitment to specific gene promoters, increasing transcriptional activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: LIMT lncRNA recruits the histone methyltransferase enzyme, G9a, to the promoter region of the TERT gene, leading to trimethylation of histone H3 lysine 9 and gene repression.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 1984,
    "user_query": "Which R / bioconductor package is used for performing SNP enrichment analysis?",
    "llama-2-7b-chat-hf_response": "There are several R packages that can be used for performing SNP enrichment analysis, but some of the most popular and widely used packages are:\n1. \"SNP-Enricher\" package: This package uses a Bayesian approach to identify genetic variants that are enriched in functional categories, such as gene-body, gene-promoter, or gene-regulatory elements. It can also be used to identify variants that are associated with specific biological processes or diseases.\n2. \"GSEA\" (Gene Set Enrichment Analysis) package: This package uses a modified hypergeometric test to identify gene sets that are overrepresented among the top-ranked variants. It can be used to identify gene sets associated with specific biological processes or diseases, and to identify genetic variants that are enriched in functional categories.\n3. \"Pathway Studio\" package: This package uses a combination of statistical and machine learning methods to identify genetic variants that are enriched in specific biological pathways or networks. It can be used to identify genetic variants that are associated with specific diseases or biological processes, and to identify genetic variants that are enriched in functional categories.\n4. \"MAS5\" package: This package uses a modified version of the hypergeometric test to identify genetic variants that are enriched in specific functional categories, such as gene-body or gene-promoter regions. It can also be used to identify variants that are associated with specific biological processes or diseases.\n5. \"Genome-Wide Association Study\" (GWAS) package: This package is specifically designed for identifying genetic variants associated with specific diseases or traits. It can be used to perform GWAS and identify genetic variants that are associated with specific biological processes or diseases.\n6. \"BioConductor\" package: This package is a collection of R packages for bioinformatics analysis, including those related to genetics, genomics, and proteomics. It can be used to perform a wide range of bioinformatics analyses, including SNP enrichment analysis.\n7. \"GenomicRules\" package: This package uses a machine learning approach to identify genetic variants that are enriched in specific functional categories, such as gene-body or gene-promoter regions. It can also be used",
    "llama-2-7b-chat-hf_fact_raw": "1. The \"SNP-Enricher\" package in R uses a Bayesian approach for SNP enrichment analysis.\n2. The \"GSEA\" package in R uses a modified hypergeometric test for Gene Set Enrichment Analysis.\n3. The \"Pathway Studio\" package in R combines statistical and machine learning methods for identifying enriched genetic variants.\n4. The \"MAS5\" package in R uses a modified hypergeometric test to identify enriched genetic variants.\n5. The \"BioConductor\" package in R is a collection of bioinformatics analysis packages, including those for SNP enrichment analysis.",
    "llama-2-7b-chat-hf_fact": [
      "The \"SNP-Enricher\" package in R uses a Bayesian approach for SNP enrichment analysis.",
      "The \"GSEA\" package in R uses a modified hypergeometric test for Gene Set Enrichment Analysis.",
      "The \"Pathway Studio\" package in R combines statistical and machine learning methods for identifying enriched genetic variants.",
      "The \"MAS5\" package in R uses a modified hypergeometric test to identify enriched genetic variants.",
      "The \"BioConductor\" package in R is a collection of bioinformatics analysis packages, including those for SNP enrichment analysis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. FALSE [correction]: The \"MAS5\" algorithm in R is actually used for Affymetrix microarray data normalization, not for identifying enriched genetic variants.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "false",
      "true"
    ]
  },
  {
    "id": 2015,
    "user_query": "Which are the key players on radial glial specification to ependymal cells?",
    "llama-2-7b-chat-hf_response": "Radial glial cells are a type of glial cell that are found in the developing brain and play a crucial role in the specification of ependymal cells. Ependymal cells are a type of glial cell that line the ventricles of the brain and are involved in the production and circulation of cerebrospinal fluid (CSF). Here are some of the key players involved in radial glial specification to ependymal cells:\n1. Radial glial cells: These are the cells that are directly involved in the specification of ependymal cells. Radial glial cells are characterized by their radially arranged processes and are found in the developing brain, particularly in the ventricular zone.\n2. Notch signaling pathway: The Notch signaling pathway is a crucial regulator of radial glial cell fate. Notch signaling regulates the expression of genes involved in the specification of ependymal cells, such as the transcription factor NeuroD.\n3. NeuroD: This transcription factor is a key regulator of ependymal cell fate. NeuroD is expressed in radial glial cells and promotes their differentiation into ependymal cells.\n4. Shh signaling pathway: The Shh signaling pathway is also involved in the specification of ependymal cells. Shh signaling regulates the expression of NeuroD and other genes involved in ependymal cell fate.\n5. Pax6: This transcription factor is involved in the specification of ependymal cells and is required for the proper formation of the ventricular system.\n6. Rho GTPase: This small GTPase regulates the cytoskeleton of radial glial cells and is involved in their migration and differentiation into ependymal cells.\n7. Caveolin-1: This protein is involved in the regulation of cell signaling and is expressed in radial glial cells. Caveolin-1 regulates the activity of the Notch and Shh signaling pathways and is required for the proper specification of ependymal cells.\n8. GABA: This neurotransmitter is involved in the regulation of ependymal cell activity and is produced by ependymal cells. GABA regulates the activity of radial glial cells and promotes",
    "llama-2-7b-chat-hf_fact_raw": "1. Radial glial cells play a crucial role in the specification of ependymal cells in the developing brain.\n2. The Notch signaling pathway is a crucial regulator of radial glial cell fate and ependymal cell specification.\n3. NeuroD is a transcription factor that promotes the differentiation of radial glial cells into ependymal cells.\n4. The Shh signaling pathway regulates the expression of genes involved in ependymal cell fate, including NeuroD.\n5. Pax6 is a transcription factor required for the proper formation of the ventricular system and the specification of ependymal cells.",
    "llama-2-7b-chat-hf_fact": [
      "Radial glial cells play a crucial role in the specification of ependymal cells in the developing brain.",
      "The Notch signaling pathway is a crucial regulator of radial glial cell fate and ependymal cell specification.",
      "NeuroD is a transcription factor that promotes the differentiation of radial glial cells into ependymal cells.",
      "The Shh signaling pathway regulates the expression of genes involved in ependymal cell fate, including NeuroD.",
      "Pax6 is a transcription factor required for the proper formation of the ventricular system and the specification of ependymal cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2065,
    "user_query": "How are triple negative gliomas characterized?",
    "llama-2-7b-chat-hf_response": "Triple negative gliomas, also known as TNGs, are a type of brain tumor that lacks the characteristic molecular markers used to diagnose other types of gliomas, such as astrocytomas or oligodendrogliomas. These markers include EGFR, ERBB2 (Her2), and EGFRvIII. As a result, TNGs are difficult to diagnose and treat, and their prognosis is generally poorer than that of other types of gliomas.\nThe following are some of the key characteristics of triple negative gliomas:\n1. Lack of Molecular Markers: As mentioned earlier, TNGs lack the characteristic molecular markers used to diagnose other types of gliomas. This makes it challenging to identify and diagnose TNGs, especially in the early stages.\n2. Diffuse or Multifocal Distribution: TNGs can grow in a diffuse or multifocal pattern, meaning they can affect multiple areas of the brain simultaneously or in different areas at different times. This can make it difficult to determine the extent of the tumor and its potential impact on brain function.\n3. High Proliferation Rate: TNGs have a high proliferation rate, meaning they grow and divide quickly. This can lead to rapid expansion of the tumor and increased pressure within the skull, which can cause a range of symptoms including headaches, seizures, and cognitive decline.\n4. Aggressive Behavior: TNGs are known to be highly aggressive and tend to infiltrate surrounding brain tissue, leading to a higher risk of recurrence after surgery or treatment.\n5. Poor Response to Chemotherapy: TNGs are often resistant to chemotherapy, which can limit treatment options for patients with this type of glioma.\n6. Genetic Instability: TNGs are characterized by genetic instability, which can lead to the development of new mutations and the evolution of the tumor over time.\n7. Tumor Heterogeneity: TNGs are composed of a heterogeneous population of cells, which can make it difficult to identify the most effective treatment approach.\n8. Limited Treatment Options: Due to their lack of molecular markers and aggressive behavior, TNGs have limited treatment options. Surgery, radiation ther",
    "llama-2-7b-chat-hf_fact_raw": "1. Triple negative gliomas lack the molecular markers EGFR, ERBB2 (Her2), and EGFRvIII.\n2. They can exhibit a diffuse or multifocal pattern of growth.\n3. Triple negative gliomas have a high proliferation rate.\n4. They tend to infiltrate surrounding brain tissue and have a high risk of recurrence after treatment.\n5. These types of gliomas often show poor response to chemotherapy.",
    "llama-2-7b-chat-hf_fact": [
      "Triple negative gliomas lack the molecular markers EGFR, ERBB2 (Her2), and EGFRvIII.",
      "They can exhibit a diffuse or multifocal pattern of growth.",
      "Triple negative gliomas have a high proliferation rate.",
      "They tend to infiltrate surrounding brain tissue and have a high risk of recurrence after treatment.",
      "These types of gliomas often show poor response to chemotherapy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Triple negative gliomas lack the molecular markers IDH, ATRX, and TP53. \n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2069,
    "user_query": "What is TOPAZ1?",
    "llama-2-7b-chat-hf_response": "TOPAZ1 is a software tool used in computational biology and bioinformatics for the analysis of next-generation sequencing (NGS) data, particularly for transcriptome analysis. It is a widely used tool in the field and has been cited in numerous research papers.\nTOPAZ1 was developed by the laboratory of Dr. Michael S. H. H. R. Koster, a computational biologist at the University of California, San Diego. The tool was designed to process and analyze large-scale RNA sequencing (RNA-seq) data, which is a powerful tool for understanding gene expression and regulation.\nTOPAZ1 performs a variety of functions, including:\n1. Read trimming and quality control: TOPAZ1 can trim adapters and low-quality bases from the raw sequencing reads, and perform quality control to remove reads with poor quality scores.\n2. Mapping: TOPAZ1 can map the cleaned reads to a reference genome or to a transcriptome assembly, allowing researchers to identify which genes are expressed and at what level.\n3. Counting: TOPAZ1 can calculate the number of reads that map to each gene, allowing researchers to quantify gene expression levels.\n4. Normalization: TOPAZ1 can perform normalization to account for library size biases and other technical variability, which helps to make the data more comparable across different samples.\n5. Pathway analysis: TOPAZ1 can perform pathway analysis to identify which biological pathways are enriched with highly expressed genes.\n6. Differential expression analysis: TOPAZ1 can perform differential expression analysis to identify genes that are differentially expressed between different samples, such as between healthy and diseased tissues.\n7. Interaction network analysis: TOPAZ1 can perform interaction network analysis to identify which genes are highly connected in the network and which genes are central to the network.\nTOPAZ1 is a powerful tool for analyzing NGS data, and it has been used in a wide range of applications, including cancer research, developmental biology, and immunology. It is available for free download on the TOPAZ1 website.",
    "llama-2-7b-chat-hf_fact_raw": "1. TOPAZ1 is a software tool used for the analysis of next-generation sequencing data.\n2. It was developed by the laboratory of Dr. Michael S. H. H. R. Koster at the University of California, San Diego.\n3. TOPAZ1 is designed to process and analyze large-scale RNA sequencing data.\n4. The tool performs functions such as read trimming, quality control, mapping, counting, normalization, pathway analysis, and differential expression analysis.\n5. TOPAZ1 has been used in various research fields, including cancer research, developmental biology, and immunology.",
    "llama-2-7b-chat-hf_fact": [
      "TOPAZ1 is a software tool used for the analysis of next-generation sequencing data.",
      "It was developed by the laboratory of Dr. Michael S. H. H. R. Koster at the University of California, San Diego.",
      "TOPAZ1 is designed to process and analyze large-scale RNA sequencing data.",
      "The tool performs functions such as read trimming, quality control, mapping, counting, normalization, pathway analysis, and differential expression analysis.",
      "TOPAZ1 has been used in various research fields, including cancer research, developmental biology, and immunology."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. FALSE [correction]: It was developed by the laboratory of Dr. Michael S. H. Koster at the University of California, Davis.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2075,
    "user_query": "Which gene controls the expression of GATA-1 isoforms?",
    "llama-2-7b-chat-hf_response": "The expression of GATA-1 isoforms is controlled by multiple genetic and epigenetic factors. GATA-1 is a transcription factor that plays a crucial role in regulating the expression of genes involved in hematopoiesis, particularly in the production of red blood cells. There are several isoforms of GATA-1, including GATA-1a, GATA-1b, and GATA-1c, each with distinct functions and tissue-specific expressions.\nThe gene that controls the expression of GATA-1 isoforms is the GATA1 gene, which is located on chromosome 7q31.2. The GATA1 gene contains multiple exons that encode the GATA-1 protein, and the expression of these exons is tightly regulated by a complex interplay of transcription factors, enhancers, and promoters.\nSeveral transcription factors have been identified that play a critical role in regulating the expression of GATA-1 isoforms. These include:\n1. GATA-1 itself: GATA-1 is a transcriptional activator that binds to the GATA-1 response element (GRE) in the promoter region of the GATA1 gene and activates its transcription.\n2. Runx1: Runx1 is a transcription factor that is essential for the regulation of hematopoiesis. It binds to the GATA-1-binding site in the GATA1 gene and enhances the transcription of GATA-1.\n3. GATA-2: GATA-2 is another transcription factor that regulates the expression of GATA-1 isoforms. It binds to the GATA-1-binding site in the GATA1 gene and antagonizes the activity of GATA-1.\n4. NF-κB: NF-κB is a transcription factor that regulates the expression of GATA-1 isoforms in response to cytokines and growth factors. It binds to the GATA-1-binding site in the GATA1 gene and enhances the transcription of GATA-1.\n5. HIF-1α: HIF-1α is a transcription factor that regulates the expression of GATA-1 isoforms in response to hypoxia. It binds",
    "llama-2-7b-chat-hf_fact_raw": "1. The GATA1 gene, located on chromosome 7q31.2, controls the expression of GATA-1 isoforms.\n2. GATA-1 is a transcription factor that regulates genes involved in hematopoiesis, particularly in the production of red blood cells.\n3. The GATA1 gene has multiple exons that encode the GATA-1 protein.\n4. Runx1 is a transcription factor essential for the regulation of hematopoiesis and enhances the transcription of GATA-1.\n5. NF-κB regulates the expression of GATA-1 isoforms in response to cytokines and growth factors.",
    "llama-2-7b-chat-hf_fact": [
      "The GATA1 gene, located on chromosome 7q31.2, controls the expression of GATA-1 isoforms.",
      "GATA-1 is a transcription factor that regulates genes involved in hematopoiesis, particularly in the production of red blood cells.",
      "The GATA1 gene has multiple exons that encode the GATA-1 protein.",
      "Runx1 is a transcription factor essential for the regulation of hematopoiesis and enhances the transcription of GATA-1.",
      "NF-κB regulates the expression of GATA-1 isoforms in response to cytokines and growth factors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The GATA1 gene is located on chromosome Xp11.23, not 7q31.2.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Runx1 is a transcription factor essential for hematopoiesis, but it is not specifically known to enhance the transcription of GATA-1.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2076,
    "user_query": "What is MIRA-seq?",
    "llama-2-7b-chat-hf_response": "MIRA-seq is a powerful tool in the field of single-cell transcriptomics that allows for the simultaneous measurement of gene expression and epigenetic marks at the single-cell level. Here's a detailed explanation of what MIRA-seq is and how it works:\nWhat is MIRA-seq?\nMIRA-seq is a method for profiling the transcriptome and epigenome of individual cells. The term \"MIRA-seq\" is short for \"Methylation-based In situ RNA sequencing.\" It is a combination of two techniques: in situ hybridization and RNA sequencing.\nIn situ hybridization is a method for detecting specific RNA molecules within cells. It involves using a probe that is complementary to the RNA molecule of interest, which is then hybridized to the RNA molecule within the cell. This allows researchers to visualize the location of the RNA molecule within the cell.\nRNA sequencing, on the other hand, is a method for measuring the expression levels of genes within a cell. It involves isolating RNA from the cell, converting it into cDNA (complementary DNA), and then sequencing the cDNA using next-generation sequencing technologies.\nMIRA-seq combines these two techniques by using in situ hybridization to detect specific RNA molecules within cells, and then sequencing the cDNA generated from these RNA molecules. This allows researchers to simultaneously measure the expression levels of genes and the epigenetic marks (such as DNA methylation) within individual cells.\nHow does MIRA-seq work?\nThe process of MIRA-seq involves several steps:\n1. Cell isolation: The first step is to isolate the cells of interest. This can be done using various techniques, such as flow cytometry or microdissection.\n2. Probe design: Next, probes are designed that are complementary to the RNA molecules of interest. These probes are used in the in situ hybridization step.\n3. In situ hybridization: The isolated cells are then hybridized with the probes. This involves adding the probes to the cells and allowing them to bind to the RNA molecules within the cells.\n4. CDNA generation:",
    "llama-2-7b-chat-hf_fact_raw": "1. MIRA-seq stands for \"Methylation-based In situ RNA sequencing.\"\n2. MIRA-seq is a technique used in single-cell transcriptomics to measure gene expression and epigenetic marks at the single-cell level.\n3. In situ hybridization, used in MIRA-seq, is a method that detects specific RNA molecules within cells using a complementary probe.\n4. RNA sequencing measures the expression levels of genes within a cell and involves converting RNA into cDNA for sequencing.\n5. The process of MIRA-seq includes cell isolation, probe design, in situ hybridization, and cDNA generation.",
    "llama-2-7b-chat-hf_fact": [
      "MIRA-seq stands for \"Methylation-based In situ RNA sequencing.\"",
      "MIRA-seq is a technique used in single-cell transcriptomics to measure gene expression and epigenetic marks at the single-cell level.",
      "In situ hybridization, used in MIRA-seq, is a method that detects specific RNA molecules within cells using a complementary probe.",
      "RNA sequencing measures the expression levels of genes within a cell and involves converting RNA into cDNA for sequencing.",
      "The process of MIRA-seq includes cell isolation, probe design, in situ hybridization, and cDNA generation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: MIRA-seq stands for \"Methylated RNA immunoprecipitation sequencing.\"\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2108,
    "user_query": "What is the indication of ARCALYST?",
    "llama-2-7b-chat-hf_response": "ARCALYST is a prescription medication used to treat acute pain in adults. It is a combination of the active ingredients meloxicam and bromelain.\nMeloxicam is a nonsteroidal anti-inflammatory drug (NSAID) that works by blocking the production of certain enzymes that cause pain and inflammation in the body. Bromelain is a mixture of enzymes derived from the pineapple plant that helps to break down protein into smaller parts, which can help to reduce inflammation and pain.\nARCALYST is used to treat acute pain caused by a variety of conditions, including:\n* Musculoskeletal conditions such as osteoarthritis, rheumatoid arthritis, and fibromyalgia\n* Post-operative pain\n* Menstrual cramps\n* Headache\n* Migraine\n* Sinus pain\nThe recommended dose of ARCALYST for adults is 1-2 capsules taken every 8-12 hours as needed, up to a maximum of 4 capsules in 24 hours. It is important to follow the dosage instructions provided by your healthcare provider and to not exceed the maximum dose without their permission.\nIt is important to note that ARCALYST may cause side effects, including:\n* Nausea\n* Vomiting\n* Diarrhea\n* Abdominal pain\n* Headache\n* Dizziness\n* Fatigue\n* Skin rash\n* Itching\n* Swelling\nIf you experience any of these side effects or have concerns about taking ARCALYST, it is important to speak with your healthcare provider. They can provide guidance on how to manage side effects and ensure that you are using the medication safely and effectively.\nIn summary, ARCALYST is a prescription medication used to treat acute pain in adults. It is a combination of meloxicam and bromelain, and it is important to follow the dosage instructions provided by your healthcare provider and to be aware of the potential side effects.",
    "llama-2-7b-chat-hf_fact_raw": "1. ARCALYST is a prescription medication used to treat acute pain in adults.\n2. ARCALYST contains the active ingredients meloxicam, a nonsteroidal anti-inflammatory drug, and bromelain, an enzyme mixture derived from pineapple.\n3. ARCALYST can treat pain caused by conditions such as osteoarthritis, rheumatoid arthritis, fibromyalgia, post-operative pain, menstrual cramps, headache, migraine, and sinus pain.\n4. The recommended dose of ARCALYST for adults is 1-2 capsules every 8-12 hours, with a maximum of 4 capsules in 24 hours.\n5. Potential side effects of ARCALYST include nausea, vomiting, diarrhea, abdominal pain, headache, dizziness, fatigue, skin rash, itching, and swelling.",
    "llama-2-7b-chat-hf_fact": [
      "ARCALYST is a prescription medication used to treat acute pain in adults.",
      "ARCALYST contains the active ingredients meloxicam, a nonsteroidal anti-inflammatory drug, and bromelain, an enzyme mixture derived from pineapple.",
      "ARCALYST can treat pain caused by conditions such as osteoarthritis, rheumatoid arthritis, fibromyalgia, post-operative pain, menstrual cramps, headache, migraine, and sinus pain.",
      "The recommended dose of ARCALYST for adults is 1-2 capsules every 8-12 hours, with a maximum of 4 capsules in 24 hours.",
      "Potential side effects of ARCALYST include nausea, vomiting, diarrhea, abdominal pain, headache, dizziness, fatigue, skin rash, itching, and swelling."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: ARCALYST is a prescription medication used to treat Cryopyrin-Associated Periodic Syndromes (CAPS), not acute pain in adults.\n2. FALSE [correction]: ARCALYST does not contain meloxicam or bromelain. It contains the active ingredient rilonacept.\n3. FALSE [correction]: ARCALYST is not indicated to treat the listed conditions. It is used to treat CAPS, including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2170,
    "user_query": "List the human acrocentric chromosomes that are involved in Robertsonian translocation.",
    "llama-2-7b-chat-hf_response": "Certainly! Robertsonian translocations are a type of chromosomal abnormality that involves the transfer of a segment of one chromosome to another chromosome. In humans, there are 23 pairs of autosomal chromosomes, and Robertsonian translocations typically involve one of these pairs.\nThe human acrocentric chromosomes that are involved in Robertsonian translocations are:\n1. Chromosome 1 (1q21-q22)\nRobertsonian translocations involving chromosome 1 are the most common and occur in approximately 1 in 100 births. These translocations typically involve the short arm of chromosome 1 (1q) and can result in a variety of clinical features, including intellectual disability, delayed speech and language development, and a higher risk of certain infections.\n2. Chromosome 13 (13q14)\nRobertsonian translocations involving chromosome 13 are less common than those involving chromosome 1, but they can still have significant clinical consequences. These translocations can result in a higher risk of certain infections, as well as developmental delays and intellectual disability.\n3. Chromosome 15 (15q11-q13)\nRobertsonian translocations involving chromosome 15 are relatively rare, but they can have significant clinical consequences. These translocations can result in a higher risk of certain infections, as well as developmental delays and intellectual disability.\n4. Chromosome 22 (22q11)\nRobertsonian translocations involving chromosome 22 are the least common of the acrocentric chromosomes involved in Robertsonian translocations. These translocations can result in a variety of clinical features, including developmental delays, intellectual disability, and a higher risk of certain infections.\nIt's important to note that the clinical consequences of Robertsonian translocations can vary widely depending on the location and size of the translocation, as well as the individual's overall genetic background. If you or a family member have been diagnosed with a Robertsonian translocation, it's",
    "llama-2-7b-chat-hf_fact_raw": "1. Robertsonian translocations typically involve autosomal chromosomes in humans.\n2. Chromosome 1 is involved in Robertsonian translocations, and such translocations occur in approximately 1 in 100 births.\n3. Chromosome 13 is less commonly involved in Robertsonian translocations than chromosome 1.\n4. Chromosome 15 is relatively rare in Robertsonian translocations but can have significant clinical consequences.\n5. Chromosome 22 is the least common of the acrocentric chromosomes involved in Robertsonian translocations.",
    "llama-2-7b-chat-hf_fact": [
      "Robertsonian translocations typically involve autosomal chromosomes in humans.",
      "Chromosome 1 is involved in Robertsonian translocations, and such translocations occur in approximately 1 in 100 births.",
      "Chromosome 13 is less commonly involved in Robertsonian translocations than chromosome 1.",
      "Chromosome 15 is relatively rare in Robertsonian translocations but can have significant clinical consequences.",
      "Chromosome 22 is the least common of the acrocentric chromosomes involved in Robertsonian translocations."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Robertsonian translocations do not occur in 1 in 100 births; the actual prevalence is approximately 1 in 1000 births.\n3. FALSE [correction]: Chromosome 13 is actually one of the more commonly involved chromosomes in Robertsonian translocations, not less common than chromosome 1.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2237,
    "user_query": "Which R package could be used for the identification of pediatric brain tumors?",
    "llama-2-7b-chat-hf_response": "There are several R packages that can be used for the identification of pediatric brain tumors, depending on the specific task and the type of data you are working with. Here are a few options:\n1. `brainTumor`: This package provides a set of tools for analyzing brain tumor data, including image segmentation, feature extraction, and classification. It can be used to identify pediatric brain tumors based on MRI scans or other imaging modalities.\n2. `pediatricTumor`: This package provides a set of functions for analyzing pediatric tumor data, including brain tumors. It can be used to identify tumor subtypes and predict patient outcomes.\n3. `rstan`: This package provides a Bayesian statistical framework that can be used to model complex data structures, including those used in pediatric brain tumor analysis. It can be used to identify tumor subtypes and predict patient outcomes.\n4. `brat`: This package provides a set of functions for analyzing brain imaging data, including MRI scans. It can be used to identify pediatric brain tumors based on structural and functional imaging features.\n5. `brainTumorSegmentation`: This package provides a set of functions for segmenting brain tumors from MRI scans. It can be used to identify the location and size of pediatric brain tumors.\n6. `pediatricTumorClassification`: This package provides a set of functions for classifying pediatric tumors based on their imaging features. It can be used to identify the type of pediatric brain tumor based on MRI scans.\n7. `brainTumorFeatures`: This package provides a set of functions for extracting features from brain tumor imaging data, including MRI scans. It can be used to identify the characteristics of pediatric brain tumors that are associated with specific outcomes.\n8. `brainTumorClustering`: This package provides a set of functions for clustering brain tumor data based on their imaging features. It can be used to identify groups of pediatric brain tumors that have similar characteristics and outcomes.\n9. `pediatricTumorSurvival`: This package provides a set of functions for analyzing the survival of pediatric tumor",
    "llama-2-7b-chat-hf_fact_raw": "1. The `brainTumor` R package provides tools for analyzing brain tumor data, including image segmentation, feature extraction, and classification.\n2. The `pediatricTumor` R package provides functions for analyzing pediatric tumor data, including brain tumors.\n3. The `rstan` R package provides a Bayesian statistical framework for modeling complex data structures, such as those found in pediatric brain tumor analysis.\n4. The `brat` R package provides functions for analyzing brain imaging data, including MRI scans of pediatric brain tumors.\n5. The `brainTumorSegmentation` R package provides functions for segmenting brain tumors from MRI scans to identify the location and size of pediatric brain tumors.",
    "llama-2-7b-chat-hf_fact": [
      "The `brainTumor` R package provides tools for analyzing brain tumor data, including image segmentation, feature extraction, and classification.",
      "The `pediatricTumor` R package provides functions for analyzing pediatric tumor data, including brain tumors.",
      "The `rstan` R package provides a Bayesian statistical framework for modeling complex data structures, such as those found in pediatric brain tumor analysis.",
      "The `brat` R package provides functions for analyzing brain imaging data, including MRI scans of pediatric brain tumors.",
      "The `brainTumorSegmentation` R package provides functions for segmenting brain tumors from MRI scans to identify the location and size of pediatric brain tumors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2246,
    "user_query": "Is NEMO a zinc finger protein?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! NEMO (Nuclear Envelope-Associated Matrix Organization) is a protein that plays a crucial role in the regulation of various cellular processes, including cell signaling, cytoskeleton organization, and membrane trafficking. While NEMO does contain zinc finger motifs, it is not classified as a zinc finger protein in the classical sense.\nZinc finger proteins are a class of proteins that contain one or more zinc finger domains, which are short sequences of amino acids that bind zinc ions. These proteins are involved in a wide range of cellular processes, including transcriptional regulation, DNA repair, and chromatin remodeling.\nNEMO, on the other hand, is a larger protein that contains multiple zinc finger domains, as well as other structural elements such as an N-terminal transmembrane domain and a C-terminal coiled-coil domain. NEMO plays a key role in the regulation of the cytoskeleton, particularly in the formation of the actin cytoskeleton, and is also involved in the regulation of cell signaling pathways, including the JNK and p38 MAPK pathways.\nWhile NEMO does contain zinc finger motifs, its function is distinct from that of traditional zinc finger proteins. NEMO is not involved in transcriptional regulation, but rather in the regulation of cytoskeleton organization and cell signaling pathways.\nI hope this helps clarify the role of NEMO in cells! Let me know if you have any further questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. NEMO (Nuclear Envelope-Associated Matrix Organization) is a protein that is involved in cell signaling, cytoskeleton organization, and membrane trafficking.\n2. NEMO contains zinc finger motifs but is not classified as a zinc finger protein in the classical sense.\n3. Zinc finger proteins are a class of proteins that contain one or more zinc finger domains.\n4. Zinc finger proteins are involved in cellular processes such as transcriptional regulation, DNA repair, and chromatin remodeling.\n5. NEMO contains multiple zinc finger domains, an N-terminal transmembrane domain, and a C-terminal coiled-coil domain.",
    "llama-2-7b-chat-hf_fact": [
      "NEMO (Nuclear Envelope-Associated Matrix Organization) is a protein that is involved in cell signaling, cytoskeleton organization, and membrane trafficking.",
      "NEMO contains zinc finger motifs but is not classified as a zinc finger protein in the classical sense.",
      "Zinc finger proteins are a class of proteins that contain one or more zinc finger domains.",
      "Zinc finger proteins are involved in cellular processes such as transcriptional regulation, DNA repair, and chromatin remodeling.",
      "NEMO contains multiple zinc finger domains, an N-terminal transmembrane domain, and a C-terminal coiled-coil domain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: NEMO contains a coiled-coil domain and a zinc finger domain, but it does not have an N-terminal transmembrane domain.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2247,
    "user_query": "Does TFIIS affect nucleosome positioning?",
    "llama-2-7b-chat-hf_response": "Yes, TFIIS (Transcription Factor IIS) can affect nucleosome positioning during transcription. Nucleosome positioning refers to the arrangement of nucleosomes along the DNA molecule, which can affect the accessibility of the DNA to the transcription machinery. TFIIS plays a crucial role in regulating nucleosome positioning during transcription.\nTFIIS is a transcriptional elongation factor that is involved in the processivity of RNA polymerase II (RNAPII), the primary transcriptional machinery responsible for transcribing DNA into RNA. TFIIS interacts with the C-terminal domain (CTD) of RNAPII and helps to stabilize the RNAPII-DNA complex, allowing the enzyme to move along the DNA template during transcription.\nStudies have shown that TFIIS can also influence nucleosome positioning by altering the structure of the nucleosome and making it more or less accessible to the transcription machinery. For example, TFIIS can cause the nucleosome to be more compact and less accessible to RNAPII, which can reduce the processivity of transcription. Conversely, TFIIS can also cause the nucleosome to be less compact and more accessible to RNAPII, which can increase the processivity of transcription.\nOne study published in the journal Nature found that TFIIS regulates nucleosome positioning by altering the structure of the nucleosome and making it more or less accessible to RNAPII. The researchers used a combination of biochemical and biophysical techniques to study the interactions between TFIIS and nucleosomes, and found that TFIIS can cause the nucleosome to be more compact and less accessible to RNAPII, which can reduce the processivity of transcription.\nAnother study published in the journal Cell found that TFIIS regulates nucleosome positioning by altering the structure of the nucleosome and making it more or less accessible to RNAPII. The researchers used a combination of genetic and biochemical techniques to study the effects of TFIIS on nucleosome positioning, and found that TFIIS can cause the nucleosome to be less compact and",
    "llama-2-7b-chat-hf_fact_raw": "1. TFIIS (Transcription Factor IIS) can affect nucleosome positioning during transcription.\n2. Nucleosome positioning affects the accessibility of DNA to the transcription machinery.\n3. TFIIS plays a role in regulating nucleosome positioning by interacting with the C-terminal domain (CTD) of RNA polymerase II (RNAPII).\n4. TFIIS can influence the structure of the nucleosome, making it more or less accessible to RNAPII.\n5. A study published in the journal Nature found that TFIIS alters nucleosome structure and accessibility to RNAPII.",
    "llama-2-7b-chat-hf_fact": [
      "TFIIS (Transcription Factor IIS) can affect nucleosome positioning during transcription.",
      "Nucleosome positioning affects the accessibility of DNA to the transcription machinery.",
      "TFIIS plays a role in regulating nucleosome positioning by interacting with the C-terminal domain (CTD) of RNA polymerase II (RNAPII).",
      "TFIIS can influence the structure of the nucleosome, making it more or less accessible to RNAPII.",
      "A study published in the journal Nature found that TFIIS alters nucleosome structure and accessibility to RNAPII."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 2262,
    "user_query": "Do origins of replication close to yeast centromeres fire early or late?",
    "llama-2-7b-chat-hf_response": "The timing of origin firing during the cell cycle can vary depending on the type of organism and the specific chromosomal region being studied. In the case of yeast centromeres, the origins of replication tend to fire later in the cell cycle than other origins.\nIn yeast, there are two main types of origins of replication: the early origin (E), which fires around the G1/S checkpoint, and the late origin (L), which fires around the G2/M checkpoint. The E-origin is located near the centromere of chromosome 1 and fires around 30 minutes after the start of the cell cycle, while the L-origin is located near the centromere of chromosome 6 and fires around 2 hours after the start of the cell cycle.\nStudies have shown that the E-origin tends to fire earlier than the L-origin in yeast. For example, one study found that the E-origin fires around 20-30 minutes after the start of the cell cycle, while the L-origin fires around 1-2 hours after the start of the cell cycle. This means that the E-origin is more likely to fire during the S phase of the cell cycle, while the L-origin is more likely to fire during the G2 phase.\nIt's worth noting that the timing of origin firing can vary depending on the specific conditions of the cell culture or experimental setup. For example, the timing of origin firing can be influenced by the presence of certain proteins or small molecules, or by the cell's energy status or DNA damage.\nOverall, the timing of origin firing in yeast centromeres is an important aspect of the cell cycle and can have significant consequences for the proper progression of the cell cycle and the maintenance of genome stability.",
    "llama-2-7b-chat-hf_fact_raw": "1. In yeast, origins of replication near centromeres tend to fire later in the cell cycle.\n2. Early origin (E) in yeast fires around the G1/S checkpoint, which is about 30 minutes after the start of the cell cycle.\n3. Late origin (L) in yeast fires around the G2/M checkpoint, which is about 2 hours after the start of the cell cycle.\n4. E-origin is located near the centromere of chromosome 1, whereas L-origin is located near the centromere of chromosome 6 in yeast.\n5. Timing of origin firing in yeast can be influenced by factors such as the presence of certain proteins, small molecules, cell energy status, or DNA damage.",
    "llama-2-7b-chat-hf_fact": [
      "In yeast, origins of replication near centromeres tend to fire later in the cell cycle.",
      "Early origin (E) in yeast fires around the G1/S checkpoint, which is about 30 minutes after the start of the cell cycle.",
      "Late origin (L) in yeast fires around the G2/M checkpoint, which is about 2 hours after the start of the cell cycle.",
      "E-origin is located near the centromere of chromosome 1, whereas L-origin is located near the centromere of chromosome 6 in yeast.",
      "Timing of origin firing in yeast can be influenced by factors such as the presence of certain proteins, small molecules, cell energy status, or DNA damage."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Early origin (E) in yeast fires around the G1/S checkpoint, but the specific timing can vary and is not necessarily 30 minutes after the start of the cell cycle.\n3. FALSE [correction]: Late origin (L) in yeast fires later in the cell cycle, but the specific timing can vary and is not necessarily around the G2/M checkpoint or 2 hours after the start of the cell cycle.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2268,
    "user_query": "Which are the properties of mammalian GA-sequences?",
    "llama-2-7b-chat-hf_response": "Mammalian GA-sequences, also known as mammalian microsatellites or mammalian simple sequence repeats (SSRs), are short, repetitive DNA sequences found in the genomes of mammals. These sequences are characterized by a short repeat unit (usually 2-5 nucleotides in length) that is repeated 5-100 times in a row.\nHere are some of the key properties of mammalian GA-sequences:\n1. Short repeat units: Mammalian GA-sequences are characterized by short repeat units, typically ranging from 2-5 nucleotides in length. These repeat units are the building blocks of the longer sequences found in the genome.\n2. High repeat frequency: Mammalian GA-sequences have a high frequency of repeat units, meaning that they are repeated many times throughout the genome. This high repeat frequency is what distinguishes them from other types of repetitive DNA sequences.\n3. Tandem repeats: Mammalian GA-sequences are often found in tandem arrays, meaning that they are arranged in a head-to-tail manner. This arrangement can lead to the formation of larger repeats through the juxtaposition of shorter repeat units.\n4. High mutation rate: Mammalian GA-sequences have a high mutation rate compared to other types of repetitive DNA sequences. This high mutation rate can lead to genetic variation and play a role in evolution.\n5. High variability: Mammalian GA-sequences show high variability between individuals and species, which can be used to infer evolutionary relationships and population history.\n6. Functional implications: Mammalian GA-sequences have been implicated in a variety of biological processes, including gene regulation, chromatin structure, and genome stability. Their functional implications are still being explored and understood.\n7. Higher GC content: Mammalian GA-sequences tend to have a higher GC content compared to other types of repetitive DNA sequences. This higher GC content can affect the stability and function of the sequences.\n8. Association with gene expression: Some studies have found associations between mammalian GA-sequences and gene expression, suggesting that these sequences may play a role in regulating gene function",
    "llama-2-7b-chat-hf_fact_raw": "1. Mammalian GA-sequences, also known as microsatellites or simple sequence repeats (SSRs), are repetitive DNA sequences found in mammalian genomes.\n2. They are characterized by a short repeat unit, usually 2-5 nucleotides in length, that is repeated 5-100 times in a row.\n3. Mammalian GA-sequences have a high frequency of repeat units and are often found in tandem arrays.\n4. They have a high mutation rate compared to other types of repetitive DNA sequences.\n5. Mammalian GA-sequences show high variability between individuals and species.",
    "llama-2-7b-chat-hf_fact": [
      "Mammalian GA-sequences, also known as microsatellites or simple sequence repeats (SSRs), are repetitive DNA sequences found in mammalian genomes.",
      "They are characterized by a short repeat unit, usually 2-5 nucleotides in length, that is repeated 5-100 times in a row.",
      "Mammalian GA-sequences have a high frequency of repeat units and are often found in tandem arrays.",
      "They have a high mutation rate compared to other types of repetitive DNA sequences.",
      "Mammalian GA-sequences show high variability between individuals and species."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2291,
    "user_query": "How many Groucho-related genes (GRG) are contained in the mouse genome?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! I'm happy to help you with that.\nTo answer your question, we need to first understand what Groucho-related genes (GRG) are. Groucho is a transcription factor that plays a crucial role in the regulation of gene expression, particularly in the development and function of the nervous system. The Groucho protein is composed of multiple domains, including an N-terminal Groucho domain, a central PSD-95/Disabled-1 (Dab1) domain, and a C-terminal PDZ domain. These domains allow Groucho to interact with a variety of protein partners and regulate gene expression.\nNow, to answer your question, the mouse genome does contain Groucho-related genes. In fact, the mouse genome contains a total of 15 Groucho-related genes, which are scattered throughout the genome. These genes are referred to as Groucho-related genes 1-15 (GRG1-GRG15).\nGRG1 is the most well-studied of these genes, and it is located on chromosome 17. GRG1 encodes a protein that is highly homologous to the Groucho protein and has been shown to play a role in the regulation of gene expression in the nervous system, particularly in the development of the brain.\nThe other GRG genes are scattered throughout the genome, with the majority located on chromosomes 1, 4, 6, 7, 10, and 19. These genes are highly conserved across species, indicating their importance in the regulation of gene expression.\nWhile the exact function of each GRG gene is not yet fully understood, studies have shown that they play a role in a variety of biological processes, including neural development, synaptic plasticity, and behavioral responses to stress.\nIn summary, the mouse genome contains 15 Groucho-related genes, each with a unique function in the regulation of gene expression. While more research is needed to fully understand the role of these genes, they are an important area of study in the field of molecular biology.",
    "llama-2-7b-chat-hf_fact_raw": "1. Groucho is a transcription factor involved in the regulation of gene expression, particularly in the nervous system's development and function.\n2. The mouse genome contains a total of 15 Groucho-related genes.\n3. Groucho-related genes in the mouse genome are referred to as GRG1-GRG15.\n4. GRG1 is located on chromosome 17 and encodes a protein similar to the Groucho protein.\n5. GRG genes play a role in biological processes such as neural development, synaptic plasticity, and behavioral responses to stress.",
    "llama-2-7b-chat-hf_fact": [
      "Groucho is a transcription factor involved in the regulation of gene expression, particularly in the nervous system's development and function.",
      "The mouse genome contains a total of 15 Groucho-related genes.",
      "Groucho-related genes in the mouse genome are referred to as GRG1-GRG15.",
      "GRG1 is located on chromosome 17 and encodes a protein similar to the Groucho protein.",
      "GRG genes play a role in biological processes such as neural development, synaptic plasticity, and behavioral responses to stress."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The mouse genome does not contain a total of 15 Groucho-related genes; it contains a total of 4 Groucho-related genes known as Tle1, Tle2, Tle3, and Tle4.\n3. FALSE [correction]: In the mouse genome, Groucho-related genes are not referred to as GRG1-GRG15. They are known as Tle1, Tle2, Tle3, and Tle4.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2304,
    "user_query": "Which RNA polymerase II subunit carries RNA cleavage activity?",
    "llama-2-7b-chat-hf_response": "RNA polymerase II (RNAPII) is the primary enzyme responsible for transcribing DNA into RNA in eukaryotic cells. RNAPII is a complex of several subunits, including the catalytic subunits, RNAPII-A and RNAPII-B, and the regulatory subunits, RNAPII-C and RNAPII-D. Among these subunits, it is RNAPII-A that carries the RNA cleavage activity.\nRNAPII-A is the catalytic subunit of RNAPII and is responsible for the polymerization of RNA during transcription. It contains the active site of the enzyme, which is able to add nucleotides to the growing RNA chain. RNAPII-A also has a second function, which is to cleave the RNA transcript after transcription. This cleavage activity is important for the maturation of the RNA transcript and for the regulation of gene expression.\nThe cleavage activity of RNAPII-A is mediated by a specific region of the subunit called the cleavage domain. This domain is located at the C-terminus of the subunit and contains a conserved sequence of amino acids that is responsible for the cleavage of the RNA transcript. The cleavage domain of RNAPII-A is able to recognize specific sequences in the RNA transcript and cleave it at specific sites, leading to the maturation of the RNA transcript.\nIt is worth noting that RNAPII-B, the other catalytic subunit of RNAPII, does not have RNA cleavage activity. Instead, it is involved in the regulation of transcription elongation and the release of the RNA transcript from the DNA template.\nIn summary, RNAPII-A is the subunit of RNAPII that carries the RNA cleavage activity, and it is responsible for the maturation of the RNA transcript during transcription.",
    "llama-2-7b-chat-hf_fact_raw": "1. RNA polymerase II (RNAPII) is responsible for transcribing DNA into RNA in eukaryotic cells.\n2. RNAPII-A is a catalytic subunit of RNAPII that carries RNA cleavage activity.\n3. RNAPII-A contains the active site of the enzyme responsible for the polymerization of RNA during transcription.\n4. The cleavage domain of RNAPII-A, located at its C-terminus, contains a conserved sequence of amino acids responsible for RNA transcript cleavage.\n5. RNAPII-B, the other catalytic subunit of RNAPII, does not have RNA cleavage activity.",
    "llama-2-7b-chat-hf_fact": [
      "RNA polymerase II (RNAPII) is responsible for transcribing DNA into RNA in eukaryotic cells.",
      "RNAPII-A is a catalytic subunit of RNAPII that carries RNA cleavage activity.",
      "RNAPII-A contains the active site of the enzyme responsible for the polymerization of RNA during transcription.",
      "The cleavage domain of RNAPII-A, located at its C-terminus, contains a conserved sequence of amino acids responsible for RNA transcript cleavage.",
      "RNAPII-B, the other catalytic subunit of RNAPII, does not have RNA cleavage activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: RNAPII does not have a subunit specifically labeled as RNAPII-A that carries RNA cleavage activity. The RNA cleavage during transcription is carried out by other proteins or complexes like CPSF.\n3. UNKNOWN\n4. FALSE [correction]: RNAPII does not have a cleavage domain at its C-terminus responsible for RNA transcript cleavage; this activity is typically carried out by separate enzymatic complexes.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2321,
    "user_query": "What is the genetic basis of Ohdo syndrome?",
    "llama-2-7b-chat-hf_response": "Ohdo syndrome, also known as 22q11.2 deletion syndrome or DiGeorge syndrome, is a genetic disorder caused by the deletion of a small portion of chromosome 22. This deletion can occur spontaneously or can be inherited from one or both parents.\nThe genetic basis of Ohdo syndrome is due to the loss of genetic material on chromosome 22, specifically at the q11.2 locus. This region of chromosome 22 contains several genes that are important for the development of various systems in the body, including the brain, heart, and immune system.\nThe most common deletion in Ohdo syndrome is a loss of approximately 30 million base pairs of DNA, which includes the following genes:\n1. TCF4: This gene encodes a transcription factor that plays a critical role in the development of the brain and the immune system.\n2. PTCH1: This gene encodes a protein that inhibits the activity of the Hedgehog signaling pathway, which is important for the development of the brain and the immune system.\n3. DLX5: This gene encodes a transcription factor that is involved in the development of the brain and the immune system.\n4. TDRD3: This gene encodes a protein that is involved in the development of the brain and the immune system.\n5. RP10: This gene encodes a protein that is involved in the development of the brain and the immune system.\n6. GNAQ: This gene encodes a protein that is involved in the development of the brain and the immune system.\n7. GNA11: This gene encodes a protein that is involved in the development of the brain and the immune system.\n8. PDE6A: This gene encodes an enzyme that is involved in the development of the brain and the immune system.\n9. CYP2C8: This gene encodes an enzyme that is involved in the development of the brain and the immune system.\n10. CDH13: This gene encodes a protein that is involved in the development of the brain and the immune system.\nThe loss of these genes can lead to the symptoms associated with Ohdo",
    "llama-2-7b-chat-hf_fact_raw": "1. Ohdo syndrome, also known as 22q11.2 deletion syndrome or DiGeorge syndrome, is caused by the deletion of a portion of chromosome 22.\n2. The deletion occurs specifically at the q11.2 locus of chromosome 22.\n3. The common deletion in Ohdo syndrome involves the loss of approximately 30 million base pairs of DNA.\n4. The TCF4 gene is one that is lost due to this deletion and is important for brain and immune system development.\n5. The PTCH1 gene is another gene lost because of the deletion and inhibits the Hedgehog signaling pathway for brain and immune system development.",
    "llama-2-7b-chat-hf_fact": [
      "Ohdo syndrome, also known as 22q11.2 deletion syndrome or DiGeorge syndrome, is caused by the deletion of a portion of chromosome 22.",
      "The deletion occurs specifically at the q11.2 locus of chromosome 22.",
      "The common deletion in Ohdo syndrome involves the loss of approximately 30 million base pairs of DNA.",
      "The TCF4 gene is one that is lost due to this deletion and is important for brain and immune system development.",
      "The PTCH1 gene is another gene lost because of the deletion and inhibits the Hedgehog signaling pathway for brain and immune system development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ohdo syndrome, also known as SAY/Meyer syndrome or Okamoto syndrome, is not caused by the 22q11.2 deletion. DiGeorge syndrome is the condition caused by the deletion of a portion of chromosome 22.\n2. TRUE (for DiGeorge syndrome)\n3. UNKNOWN (the specific size of the deletion can vary in individuals with DiGeorge syndrome)\n4. FALSE [correction]: The TBX1 gene, not TCF4, is a critical gene lost due to the deletion in DiGeorge syndrome and it plays a role in the development of the heart, thymus, and parathyroid glands.\n5. FALSE [correction]: The PTCH1 gene is not one of the genes commonly lost because of the 22q11.2 deletion in DiGeorge syndrome; instead, the CRKL gene is an important gene lost in the deletion that can disrupt neural crest development, which is important for multiple systems including the brain and immune system.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "false",
      "false"
    ]
  },
  {
    "id": 2331,
    "user_query": "Which R/Bioconductor package has been developed for the analysis of psychiatric disease genes?",
    "llama-2-7b-chat-hf_response": "There are several R/Bioconductor packages that have been developed for the analysis of psychiatric disease genes. Here are some of the most popular ones:\n1. PsychGen: This package provides a comprehensive set of tools for the analysis of genetic data in psychiatric disorders. It includes functions for quality control, genotyping, and imputation, as well as methods for association analysis and gene-set testing.\n2. PsychiatricGenetics: This package provides a range of tools for the analysis of genetic data in psychiatric disorders, including functions for quality control, genotyping, and imputation. It also includes methods for association analysis and gene-set testing, as well as tools for visualizing and interpreting the results.\n3. PsychGWAS: This package provides a set of tools for genome-wide association studies (GWAS) of psychiatric disorders. It includes functions for quality control, genotyping, and imputation, as well as methods for association analysis and gene-set testing.\n4. MentalHealthGenetics: This package provides a comprehensive set of tools for the analysis of genetic data in mental health disorders. It includes functions for quality control, genotyping, and imputation, as well as methods for association analysis and gene-set testing.\n5. PsychiatricGenomics: This package provides a range of tools for the analysis of genetic data in psychiatric disorders, including functions for quality control, genotyping, and imputation. It also includes methods for association analysis and gene-set testing, as well as tools for visualizing and interpreting the results.\n6. PsychiatricGeneticRisk: This package provides a set of tools for identifying genetic risk factors for psychiatric disorders. It includes functions for quality control, genotyping, and imputation, as well as methods for association analysis and gene-set testing.\n7. PsychiatricGeneticAssociation: This package provides a set of tools for identifying genetic associations with psychiatric disorders. It includes functions for quality control, genotyping, and imputation, as well as methods for association analysis and gene-set testing.\n8. PsychiatricGeneticRiskFactors: This package provides a set of tools for identifying genetic risk factors for",
    "llama-2-7b-chat-hf_fact_raw": "1. PsychGen is an R/Bioconductor package developed for the analysis of genetic data in psychiatric disorders.\n2. PsychiatricGenetics is an R/Bioconductor package that provides tools for analyzing genetic data in psychiatric disorders.\n3. PsychGWAS is an R/Bioconductor package designed for genome-wide association studies of psychiatric disorders.\n4. MentalHealthGenetics is an R/Bioconductor package with tools for analyzing genetic data in mental health disorders.\n5. PsychiatricGenomic is an R/Bioconductor package that offers tools for the analysis of genetic data in psychiatric disorders.",
    "llama-2-7b-chat-hf_fact": [
      "PsychGen is an R/Bioconductor package developed for the analysis of genetic data in psychiatric disorders.",
      "PsychiatricGenetics is an R/Bioconductor package that provides tools for analyzing genetic data in psychiatric disorders.",
      "PsychGWAS is an R/Bioconductor package designed for genome-wide association studies of psychiatric disorders.",
      "MentalHealthGenetics is an R/Bioconductor package with tools for analyzing genetic data in mental health disorders.",
      "PsychiatricGenomic is an R/Bioconductor package that offers tools for the analysis of genetic data in psychiatric disorders."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Without access to a reliable source of information about R/Bioconductor packages, it is not possible to verify the accuracy of these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2360,
    "user_query": "Describe swirl sign in intracerebral hemorrhage.",
    "llama-2-7b-chat-hf_response": "Certainly! Swirl sign is a clinical finding that can be observed in patients with intracerebral hemorrhage (ICH), which is a type of stroke caused by bleeding in the brain. The swirl sign is characterized by a spiral or swirling pattern of edema (swelling) in the brain, typically seen on computed tomography (CT) or magnetic resonance imaging (MRI) scans.\nThe swirl sign is thought to be caused by the displacement of the brain's normal structural patterns due to the bleeding in the brain. The bleeding can cause the brain to shift and move in a spiral or swirling motion, leading to the characteristic spiral pattern of edema. The swirl sign can be seen in various locations throughout the brain, including the cerebral hemispheres, cerebellum, and brainstem.\nThe swirl sign can be an important diagnostic indicator of ICH, as it can help doctors identify the location and extent of the bleeding in the brain. For example, a swirl sign seen in the cerebral hemispheres may indicate a bleed in the parenchyma (the outer layer of the brain), while a swirl sign seen in the brainstem may indicate a bleed in the cerebral vasculature.\nIt is important to note that the swirl sign is not specific to ICH and can also be seen in other conditions, such as subarachnoid hemorrhage, cerebral infarction, and neoplastic conditions. Therefore, it is important to combine the swirl sign with other diagnostic findings, such as neurological examination and laboratory tests, to make an accurate diagnosis.\nIn summary, the swirl sign is a clinical finding observed on imaging studies (such as CT or MRI) in patients with intracerebral hemorrhage. It is characterized by a spiral or swirling pattern of edema in the brain, which can help doctors identify the location and extent of the bleeding in the brain.",
    "llama-2-7b-chat-hf_fact_raw": "1. Swirl sign is a clinical finding observed in patients with intracerebral hemorrhage (ICH).\n2. Swirl sign is characterized by a spiral or swirling pattern of edema (swelling) in the brain.\n3. Swirl sign is typically seen on computed tomography (CT) or magnetic resonance imaging (MRI) scans.\n4. Swirl sign can be an important diagnostic indicator of the location and extent of the bleeding in the brain.\n5. Swirl sign is not specific to ICH and can also be seen in other conditions such as subarachnoid hemorrhage, cerebral infarction, and neoplastic conditions.",
    "llama-2-7b-chat-hf_fact": [
      "Swirl sign is a clinical finding observed in patients with intracerebral hemorrhage (ICH).",
      "Swirl sign is characterized by a spiral or swirling pattern of edema (swelling) in the brain.",
      "Swirl sign is typically seen on computed tomography (CT) or magnetic resonance imaging (MRI) scans.",
      "Swirl sign can be an important diagnostic indicator of the location and extent of the bleeding in the brain.",
      "Swirl sign is not specific to ICH and can also be seen in other conditions such as subarachnoid hemorrhage, cerebral infarction, and neoplastic conditions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Swirl sign is characterized by a heterogeneous appearance with areas of low attenuation within a hyperattenuated acute intracerebral hematoma.\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2392,
    "user_query": "What induces Arabidopsis ROF1 expression?",
    "llama-2-7b-chat-hf_response": "Arabidopsis ROF1 (RNA-binding protein 1) is a transcription factor that plays a crucial role in regulating plant growth and development. The expression of ROF1 in Arabidopsis is induced by a variety of environmental and developmental cues. Here are some of the key factors that can induce ROF1 expression in Arabidopsis:\n1. Light: ROF1 expression is light-dependent, meaning that it is induced by exposure to light. The red light component of sunlight is particularly effective at inducing ROF1 expression.\n2. Temperature: ROF1 expression is also temperature-dependent, with higher temperatures inducing higher levels of expression. The optimal temperature range for ROF1 expression is between 15-25°C.\n3. Water availability: ROF1 expression can be induced by changes in water availability. For example, drought conditions can increase ROF1 expression, while high levels of water availability can repress expression.\n4. Hormones: ROF1 expression can be induced by various hormones, including auxin, cytokinin, and ethylene. For example, auxin has been shown to induce ROF1 expression in the roots of Arabidopsis, while cytokinin can induce expression in the shoots.\n5. Developmental cues: ROF1 expression can also be induced by developmental cues, such as the onset of flowering or the formation of seeds. For example, the expression of ROF1 in the floral meristem is critical for proper floral development.\n6. Nutrient availability: ROF1 expression can also be influenced by the availability of nutrients, such as nitrogen and phosphorus. For example, nitrogen deficiency can induce ROF1 expression in Arabidopsis.\n7. Genetic background: The genetic background of the plant can also influence ROF1 expression. For example, certain mutants in Arabidopsis have altered ROF1 expression compared to wild-type plants.\n8. Epigenetic modifications: ROF1 expression can also be influenced by epigenetic modifications, such as DNA methylation and histone modifications. For example, DNA methylation of certain genes can repress ROF1 expression.\n9. Microbial interactions",
    "llama-2-7b-chat-hf_fact_raw": "1. Arabidopsis ROF1 expression is induced by exposure to light, especially the red light component of sunlight.\n2. Higher temperatures, within an optimal range of 15-25°C, induce higher levels of ROF1 expression in Arabidopsis.\n3. Changes in water availability, such as drought conditions, can increase ROF1 expression in Arabidopsis.\n4. Various hormones, including auxin, cytokinin, and ethylene, can induce ROF1 expression in different parts of Arabidopsis.\n5. Developmental cues like the onset of flowering or seed formation can induce ROF1 expression in the floral meristem of Arabidopsis.",
    "llama-2-7b-chat-hf_fact": [
      "Arabidopsis ROF1 expression is induced by exposure to light, especially the red light component of sunlight.",
      "Higher temperatures, within an optimal range of 15-25°C, induce higher levels of ROF1 expression in Arabidopsis.",
      "Changes in water availability, such as drought conditions, can increase ROF1 expression in Arabidopsis.",
      "Various hormones, including auxin, cytokinin, and ethylene, can induce ROF1 expression in different parts of Arabidopsis.",
      "Developmental cues like the onset of flowering or seed formation can induce ROF1 expression in the floral meristem of Arabidopsis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: Without specific scientific research or data provided, it is impossible to determine the accuracy of these statements about Arabidopsis ROF1 expression.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2398,
    "user_query": "What protein is the most common cause of hereditary  renal amyloidosis?",
    "llama-2-7b-chat-hf_response": "Hereditary renal amyloidosis, also known as familial amyloidosis, is a group of rare genetic disorders characterized by the accumulation of abnormal protein aggregates in the kidneys, leading to progressive kidney damage and potentially life-threatening complications. The most common cause of hereditary renal amyloidosis is the accumulation of the protein lysozyme.\nLysozyme is an enzyme that is produced by the liver and secreted into the bloodstream. It is normally present in small amounts in the kidneys, but in hereditary renal amyloidosis, the liver produces too much lysozyme, which can lead to its accumulation in the kidneys. The abnormal lysozyme aggregates and forms insoluble fibrils that deposit in the kidney tissues, leading to inflammation, fibrosis, and eventually kidney failure.\nOther proteins that can cause hereditary renal amyloidosis include:\n1. Apolipoprotein A-I (ApoA-I): ApoA-I is a protein that is involved in lipid metabolism and is produced by the liver. Mutations in the ApoA-I gene can lead to the accumulation of abnormal protein aggregates in the kidneys, which can cause hereditary renal amyloidosis.\n2. Amyloid A (AA): AA is a protein that is produced by the liver in response to inflammation. Mutations in the AA gene can lead to the accumulation of abnormal protein aggregates in the kidneys, which can cause hereditary renal amyloidosis.\n3. Serum amyloid P component (SAP): SAP is a protein that is produced by the liver and is involved in the immune response. Mutations in the SAP gene can lead to the accumulation of abnormal protein aggregates in the kidneys, which can cause hereditary renal amyloidosis.\nIt's important to note that hereditary renal amyloidosis is a rare disorder, and the majority of people with kidney disease do not have this condition. However, if you have a family history of hereditary ren",
    "llama-2-7b-chat-hf_fact_raw": "1. Hereditary renal amyloidosis is caused by the accumulation of abnormal protein aggregates in the kidneys.\n2. The most common cause of hereditary renal amyloidosis is the accumulation of the protein lysozyme.\n3. Lysozyme is an enzyme produced by the liver and secreted into the bloodstream, leading to its accumulation in the kidneys in hereditary renal amyloidosis.\n4. Apolipoprotein A-I (ApoA-I) mutations can lead to hereditary renal amyloidosis.\n5. Accumulation of abnormal protein aggregates due to Amyloid A (AA) gene mutations can cause hereditary renal amyloidosis.",
    "llama-2-7b-chat-hf_fact": [
      "Hereditary renal amyloidosis is caused by the accumulation of abnormal protein aggregates in the kidneys.",
      "The most common cause of hereditary renal amyloidosis is the accumulation of the protein lysozyme.",
      "Lysozyme is an enzyme produced by the liver and secreted into the bloodstream, leading to its accumulation in the kidneys in hereditary renal amyloidosis.",
      "Apolipoprotein A-I (ApoA-I) mutations can lead to hereditary renal amyloidosis.",
      "Accumulation of abnormal protein aggregates due to Amyloid A (AA) gene mutations can cause hereditary renal amyloidosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The most common cause of hereditary renal amyloidosis is the accumulation of the protein transthyretin.\n3. FALSE [correction]: Lysozyme is an enzyme that is part of the innate immune system and is not primarily produced by the liver or associated with hereditary renal amyloidosis.\n4. TRUE\n5. FALSE [correction]: Amyloid A (AA) amyloidosis is a different type of amyloidosis and is not typically classified as hereditary; it is usually associated with chronic inflammatory conditions. Hereditary renal amyloidosis is more commonly associated with mutations in proteins such as transthyretin, fibrinogen A alpha-chain, apolipoprotein A-I, and lysozyme.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2407,
    "user_query": "Has the proteome of mice hippocampus been analysed?",
    "llama-2-7b-chat-hf_response": "Yes, the proteome of the mouse hippocampus has been extensively analyzed through various studies. The hippocampus is a critical structure in the brain involved in memory formation, spatial navigation, and emotional processing. As such, it has been a focus of research in the field of neuroscience and proteomics.\nSeveral studies have used various proteomics techniques, such as two-dimensional gel electrophoresis, mass spectrometry, and protein microarrays, to analyze the proteins present in the hippocampus of mice. These studies have identified a wide range of proteins, including enzymes, transport proteins, signaling molecules, and structural proteins.\nSome of the key proteins found in the hippocampus of mice include:\n1. Synaptotagmin: A protein involved in the release of neurotransmitters from synapses, which are critical for neural communication and learning.\n2. Calcium/calmodulin-dependent protein kinase II (CaMKII): A protein that plays a key role in learning and memory, and is activated by changes in intracellular calcium levels.\n3. N-methyl-D-aspartate (NMDA) receptor subunits: These receptors are involved in the formation of synaptic connections and are critical for learning and memory.\n4. Apoptosis-related proteins: Proteins involved in programmed cell death, which can play a role in the regulation of neural stem cell proliferation and differentiation.\n5. Neurofilaments: Proteins that provide structural support to neurons and are involved in the maintenance of neural integrity.\n6. Tau protein: A protein that is involved in the formation of microtubules, which are essential for maintaining the structure and function of neurons.\n7. GluR1 and GluR2: Glutamate receptors that are involved in the formation of synaptic connections and are critical for learning and memory.\n8. VGluT1 and VGluT2: Vesicular glutamate transporters that are involved in the release of glutamate from synaptic vesicles.\n9. CREB and CBP: Transcription factors that are involved in",
    "llama-2-7b-chat-hf_fact_raw": "1. The proteome of the mouse hippocampus has been analyzed through various proteomics techniques.\n2. Techniques used in the analysis include two-dimensional gel electrophoresis, mass spectrometry, and protein microarrays.\n3. Synaptotagmin, involved in the release of neurotransmitters, is a key protein found in the mouse hippocampus.\n4. Calcium/calmodulin-dependent protein kinase II plays a key role in learning and memory and is present in the mouse hippocampus.\n5. N-methyl-D-aspartate (NMDA) receptor subunits, associated with synaptic connections and learning, are identified in the mouse hippocampus.",
    "llama-2-7b-chat-hf_fact": [
      "The proteome of the mouse hippocampus has been analyzed through various proteomics techniques.",
      "Techniques used in the analysis include two-dimensional gel electrophoresis, mass spectrometry, and protein microarrays.",
      "Synaptotagmin, involved in the release of neurotransmitters, is a key protein found in the mouse hippocampus.",
      "Calcium/calmodulin-dependent protein kinase II plays a key role in learning and memory and is present in the mouse hippocampus.",
      "N-methyl-D-aspartate (NMDA) receptor subunits, associated with synaptic connections and learning, are identified in the mouse hippocampus."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2409,
    "user_query": "Are mouse chromosomes acrocentric?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! I'm here to help you with your query.\nAcrocentric chromosomes are a type of chromosome that has a distinctive shape, with the centromere located near the center of the chromosome. In mice, the chromosomes are actually metacentric, meaning that the centromere is located closer to one end of the chromosome than the other.\nTo explain why mouse chromosomes are not acrocentric, let's take a closer look at the structure of these chromosomes. In mice, each chromosome is made up of two sister chromatids that are identical in DNA sequence. The centromere is the point where the chromosome breaks apart during cell division, and it plays a crucial role in the proper separation of the sister chromatids.\nIn metacentric chromosomes like those of mice, the centromere is located near the center of the chromosome, which means that the sister chromatids are more evenly distributed along the length of the chromosome. This makes it easier for the chromosome to separate properly during cell division, which is important for maintaining the integrity of the genetic material.\nIn contrast, acrocentric chromosomes have a more elongated shape, with the centromere located closer to one end of the chromosome. This can make it more difficult for the chromosome to separate properly during cell division, which can lead to genetic problems.\nSo, while mouse chromosomes are not acrocentric, they do have a unique structure that sets them apart from other types of chromosomes. I hope this helps clarify things for you! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Acrocentric chromosomes have the centromere located near one end of the chromosome.\n2. Mouse chromosomes are metacentric, meaning the centromere is located closer to the center of the chromosome.\n3. Each mouse chromosome is made up of two sister chromatids that are identical in DNA sequence.\n4. The centromere is the point where the chromosome breaks apart during cell division.\n5. In metacentric chromosomes like those of mice, the sister chromatids are more evenly distributed along the length of the chromosome.",
    "llama-2-7b-chat-hf_fact": [
      "Acrocentric chromosomes have the centromere located near one end of the chromosome.",
      "Mouse chromosomes are metacentric, meaning the centromere is located closer to the center of the chromosome.",
      "Each mouse chromosome is made up of two sister chromatids that are identical in DNA sequence.",
      "The centromere is the point where the chromosome breaks apart during cell division.",
      "In metacentric chromosomes like those of mice, the sister chromatids are more evenly distributed along the length of the chromosome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Mouse chromosomes are not metacentric; they are acrocentric, meaning the centromere is located near one end of the chromosome.\n3. TRUE\n4. FALSE [correction]: The centromere is not the point where the chromosome breaks apart during cell division; it is the region of the chromosome where the two sister chromatids are held together.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2417,
    "user_query": "Which siRNA based drug is in clinical trials for the treatment of pancreatic cancer?",
    "llama-2-7b-chat-hf_response": "There are several siRNA-based drugs in clinical trials for the treatment of pancreatic cancer. Here are a few examples:\n1. Patomycin: Patomycin is an siRNA-based drug that is currently in Phase 1 clinical trials for the treatment of pancreatic cancer. It is being developed by the biotech company, Patomac Therapeutics. Patomycin works by selectively targeting and silencing specific cancer-promoting genes in pancreatic cancer cells, leading to cell death and inhibition of tumor growth.\n2. RX-0201: RX-0201 is another siRNA-based drug in clinical trials for the treatment of pancreatic cancer. It is being developed by the biotech company, Rexahn Pharmaceuticals. RX-0201 is designed to target and silence the gene that codes for the protein, mesothelin, which is overexpressed in many pancreatic cancers. By silencing this gene, RX-0201 aims to inhibit the growth and proliferation of pancreatic cancer cells.\n3. BSI-201: BSI-201 is an siRNA-based drug that is in clinical trials for the treatment of pancreatic cancer. It is being developed by the biotech company, BioSpectinum. BSI-201 works by selectively targeting and silencing specific cancer-promoting genes in pancreatic cancer cells, leading to cell death and inhibition of tumor growth.\n4. SIRNA-001: SIRNA-001 is an siRNA-based drug that is in clinical trials for the treatment of pancreatic cancer. It is being developed by the biotech company, Sirna Therapeutics. SIRNA-001 works by selectively targeting and silencing specific cancer-promoting genes in pancreatic cancer cells, leading to cell death and inhibition of tumor growth.\nIt's important to note that these drugs are still in clinical trials and have not yet been approved by regulatory authorities for use in patients. While these drugs show promise in preclinical studies",
    "llama-2-7b-chat-hf_fact_raw": "1. Patomycin is an siRNA-based drug in Phase 1 clinical trials for pancreatic cancer developed by Patomac Therapeutics.\n2. RX-0201 is an siRNA-based drug in clinical trials for pancreatic cancer developed by Rexahn Pharmaceuticals.\n3. BSI-201 is an siRNA-based drug in clinical trials for pancreatic cancer developed by BioSpectinum.\n4. SIRNA-001 is an siRNA-based drug in clinical trials for pancreatic cancer developed by Sirna Therapeutics.",
    "llama-2-7b-chat-hf_fact": [
      "Patomycin is an siRNA-based drug in Phase 1 clinical trials for pancreatic cancer developed by Patomac Therapeutics.",
      "RX-0201 is an siRNA-based drug in clinical trials for pancreatic cancer developed by Rexahn Pharmaceuticals.",
      "BSI-201 is an siRNA-based drug in clinical trials for pancreatic cancer developed by BioSpectinum.",
      "SIRNA-001 is an siRNA-based drug in clinical trials for pancreatic cancer developed by Sirna Therapeutics."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\nNote: The statements provided require specific knowledge about the development of siRNA-based drugs and their respective companies. Without more information or context about the drugs and their developers, it is not possible to determine the truthfulness of these statements.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2419,
    "user_query": "What is the HPG pore?",
    "llama-2-7b-chat-hf_response": "The HPG pore, also known as the hemoglobin-proton pore, is a protein structure found in the membranes of red blood cells. It is a specialized pore that allows ions, such as protons, to pass through the membrane and play a crucial role in maintaining the pH balance within the red blood cell.\nThe HPG pore is composed of a protein called band 3, which is embedded in the red blood cell membrane. This pore is located in the outer leaflet of the membrane, facing the blood plasma. The HPG pore is about 1.5 nanometers in diameter and is capable of passing protons, hydroxyl ions, and other small molecules.\nThe HPG pore serves several important functions in the red blood cell:\n1. pH regulation: The HPG pore allows protons to pass through the membrane, which helps to maintain the pH balance within the red blood cell. The pH of the red blood cell is critical for the proper functioning of the hemoglobin protein, which is responsible for carrying oxygen to the body's tissues.\n2. Oxygen unloading: The HPG pore also plays a role in the unloading of oxygen from hemoglobin to the tissues. When the red blood cell arrives at a tissue, the HPG pore opens, allowing oxygen to diffuse out of the hemoglobin and into the tissue.\n3. ATP synthesis: The HPG pore can also contribute to the production of ATP within the red blood cell. When the pore is open, protons can flow through it, generating a proton motive force that can be used to produce ATP through the electron transport chain.\nDysfunction of the HPG pore has been implicated in several red blood cell disorders, including hereditary elliptocytosis and pyruvate kinase deficiency. These disorders can lead to abnormalities in red blood cell function, including impaired oxygen delivery and increased risk of anemia.\nIn summary, the HPG pore is a specialized protein structure in the red blood cell membrane that plays a critical role in maintaining the pH balance within the red blood cell, regulating oxygen unloading, and contributing to ATP synthesis. Its",
    "llama-2-7b-chat-hf_fact_raw": "1. The HPG pore, also known as the hemoglobin-proton pore, is found in the membranes of red blood cells.\n2. The HPG pore allows ions, such as protons, to pass through the membrane of red blood cells.\n3. The HPG pore is composed of a protein called band 3.\n4. The diameter of the HPG pore is approximately 1.5 nanometers.\n5. Dysfunction of the HPG pore has been implicated in red blood cell disorders like hereditary elliptocytosis and pyruvate kinase deficiency.",
    "llama-2-7b-chat-hf_fact": [
      "The HPG pore, also known as the hemoglobin-proton pore, is found in the membranes of red blood cells.",
      "The HPG pore allows ions, such as protons, to pass through the membrane of red blood cells.",
      "The HPG pore is composed of a protein called band 3.",
      "The diameter of the HPG pore is approximately 1.5 nanometers.",
      "Dysfunction of the HPG pore has been implicated in red blood cell disorders like hereditary elliptocytosis and pyruvate kinase deficiency."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The HPG pore is not known as the hemoglobin-proton pore. It is the Hydrophilic Pore of the red blood cell Glycocalyx.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2472,
    "user_query": "What is the 959 Nematode Genomes initiative?",
    "llama-2-7b-chat-hf_response": "The 959 Nematode Genomes initiative is a research project aimed at sequencing and analyzing the genomes of 959 species of nematodes, which are a group of microscopic worms that are found in a wide range of environments, including soil, plants, and animals. The initiative is a collaborative effort between scientists from around the world and is expected to provide significant insights into the biology and evolution of nematodes, as well as their potential as model organisms for biotechnology and biomedical research.\nNematodes are tiny worms that are found in almost every environment on Earth, from the frozen tundra to the hottest deserts. They are incredibly diverse, with over 30,000 known species, and are important components of many ecosystems. However, despite their ecological and evolutionary significance, nematodes have been relatively understudied compared to other groups of organisms.\nThe 959 Nematode Genomes initiative was launched in 2017 with the goal of sequencing and analyzing the genomes of 959 species of nematodes. The project is being conducted by a consortium of scientists from around the world, including the University of California, Berkeley, the University of Texas at Austin, and the University of Manchester in the UK. The project is using a variety of cutting-edge sequencing technologies, including single-cell genomics and epigenomics, to generate detailed genetic and epigenetic maps of the nematode species.\nOne of the main goals of the 959 Nematode Genomes initiative is to identify and characterize the genes and gene networks that are responsible for the incredible diversity of nematode species. By studying the genomes of these species, scientists hope to gain insights into the evolutionary history of nematodes and how their genomes have adapted to different environments.\nAnother important goal of the project is to identify potential targets for pest control and biotechnology. Many species of nematodes are important pests of agricultural crops, and the genomes of these species will be studied to identify genes that could be targeted for pest control. Additionally, the genomes of nematodes that are beneficial to plants, such as those",
    "llama-2-7b-chat-hf_fact_raw": "1. The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of nematodes.\n2. The initiative began in 2017 and involves scientists from around the world, including from the University of California, Berkeley, the University of Texas at Austin, and the University of Manchester.\n3. The project incorporates single-cell genomics and epigenomics sequencing technologies.\n4. A key goal of the initiative is to study the genes that contribute to the diversity of nematode species and their adaptation to various environments.\n5. The initiative also aims to identify genes in nematodes that can be targeted for pest control in agriculture and used in biotechnology.",
    "llama-2-7b-chat-hf_fact": [
      "The 959 Nematode Genomes initiative aims to sequence and analyze the genomes of 959 species of nematodes.",
      "The initiative began in 2017 and involves scientists from around the world, including from the University of California, Berkeley, the University of Texas at Austin, and the University of Manchester.",
      "The project incorporates single-cell genomics and epigenomics sequencing technologies.",
      "A key goal of the initiative is to study the genes that contribute to the diversity of nematode species and their adaptation to various environments.",
      "The initiative also aims to identify genes in nematodes that can be targeted for pest control in agriculture and used in biotechnology."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2557,
    "user_query": "Which R package has been developed for analyzing Non-invasive prenatal testing (NIPT) data?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed for analyzing Non-invasive prenatal testing (NIPT) data. Here are some of the most popular ones:\n1. `nifti` package: This package provides functions for analyzing NIPT data, including data cleaning, filtering, and visualization. It also includes tools for estimating the risk of fetal aneuploidy based on the NIPT results.\n2. `niphtools` package: This package provides a set of tools for analyzing NIPT data, including functions for data cleaning, filtering, and visualization. It also includes tools for estimating the risk of fetal aneuploidy based on the NIPT results.\n3. `pneu` package: This package provides functions for analyzing NIPT data, including data cleaning, filtering, and visualization. It also includes tools for estimating the risk of fetal aneuploidy based on the NIPT results.\n4. `nipd` package: This package provides functions for analyzing NIPT data, including data cleaning, filtering, and visualization. It also includes tools for estimating the risk of fetal aneuploidy based on the NIPT results.\n5. `aneuploidy` package: This package provides functions for analyzing NIPT data, including data cleaning, filtering, and visualization. It also includes tools for estimating the risk of fetal aneuploidy based on the NIPT results.\n6. `nifti-analysis` package: This package provides functions for analyzing NIPT data, including data cleaning, filtering, and visualization. It also includes tools for estimating the risk of fetal aneuploidy based on the NIPT results.\n7. `nifti-workflow` package: This package provides functions for analyzing NIPT data, including data cleaning, filtering, and visualization. It also includes tools for estimating the risk of fetal aneuploidy based on the NIPT results.\n8. `nifti-tools` package: This package provides functions for analyzing NIPT data, including data cleaning, filtering, and visualization. It also includes tools for estimating the risk of fetal an",
    "llama-2-7b-chat-hf_fact_raw": "1. The `nifti` package is an R package developed for analyzing NIPT data.\n2. The `niphtools` package provides tools for analyzing NIPT data and estimating the risk of fetal aneuploidy.\n3. The `pneu` package is used for analyzing NIPT data and includes data visualization functions.\n4. The `nipd` package is designed for analyzing NIPT data, including tools for data cleaning.\n5. The `aneuploidy` package provides functions for analyzing NIPT data and estimating fetal aneuploidy risk.",
    "llama-2-7b-chat-hf_fact": [
      "The `nifti` package is an R package developed for analyzing NIPT data.",
      "The `niphtools` package provides tools for analyzing NIPT data and estimating the risk of fetal aneuploidy.",
      "The `pneu` package is used for analyzing NIPT data and includes data visualization functions.",
      "The `nipd` package is designed for analyzing NIPT data, including tools for data cleaning.",
      "The `aneuploidy` package provides functions for analyzing NIPT data and estimating fetal aneuploidy risk."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2560,
    "user_query": "Describe Achenbach’s syndrome.",
    "llama-2-7b-chat-hf_response": "Achenbach's syndrome, also known as Achenbach's triad or the triad of Achenbach, is a rare genetic disorder that affects the brain and nervous system. It is characterized by a combination of three main symptoms:\n1. Developmental delay: Children with Achenbach's syndrome typically experience delays in reaching developmental milestones, such as sitting, standing, and walking. These delays can be significant and may persist into early childhood.\n2. Intellectual disability: Achenbach's syndrome is often associated with intellectual disability, which can range from mild to severe. Children with the disorder may have difficulty with cognitive tasks, such as problem-solving, memory, and language skills.\n3. Abnormal facial features: Achenbach's syndrome is sometimes associated with distinctive facial features, including a small head, narrow eyes, and a short nose. These features are not present in all individuals with the disorder, but they are common enough to be a diagnostic marker.\nOther symptoms of Achenbach's syndrome can include:\n* Speech and language difficulties\n* Poor coordination and balance\n* Vision problems\n* Hearing loss\n* Seizures\n* Sleep disturbances\n* Behavioral problems, such as anxiety and aggression\nThe exact cause of Achenbach's syndrome is not fully understood, but it is thought to be related to genetic mutations that affect the development of the brain and nervous system. The disorder is rare, and it is estimated to affect only about 1 in 100,000 people.\nThere is no cure for Achenbach's syndrome, but early intervention and specialized therapies can help manage the symptoms and improve quality of life. Treatment may include physical, occupational, and speech therapy, as well as medication to manage seizures and behavioral problems.\nIt is important to note that Achenbach's syndrome is a complex and multifaceted disorder, and each individual with the disorder may experience a different range of symptoms and severity of the disorder. With appropriate support and treatment, however, many individuals with Achenbach's syndrome are able to lead fulfilling and productive lives",
    "llama-2-7b-chat-hf_fact_raw": "1. Achenbach's syndrome affects the brain and nervous system.\n2. It is characterized by developmental delay, intellectual disability, and abnormal facial features.\n3. The disorder may include symptoms such as speech difficulties, poor coordination, vision problems, hearing loss, seizures, sleep disturbances, and behavioral problems.\n4. Achenbach's syndrome is estimated to affect about 1 in 100,000 people.\n5. Early intervention and specialized therapies can help manage symptoms and improve the quality of life for individuals with Achenbach's syndrome.",
    "llama-2-7b-chat-hf_fact": [
      "Achenbach's syndrome affects the brain and nervous system.",
      "It is characterized by developmental delay, intellectual disability, and abnormal facial features.",
      "The disorder may include symptoms such as speech difficulties, poor coordination, vision problems, hearing loss, seizures, sleep disturbances, and behavioral problems.",
      "Achenbach's syndrome is estimated to affect about 1 in 100,000 people.",
      "Early intervention and specialized therapies can help manage symptoms and improve the quality of life for individuals with Achenbach's syndrome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Achenbach's syndrome affects the fingers and toes causing bruising or bleeding episodes.\n2. FALSE [correction]: Achenbach's syndrome does not typically have developmental delays, intellectual disability, or abnormal facial features as symptoms.\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 2581,
    "user_query": "Which algorithm is used for detection of long repeat expansions?",
    "llama-2-7b-chat-hf_response": "Long repeat expansions are a type of genomic variation that can be challenging to detect using traditional genomic analysis methods. There are several algorithms and techniques that can be used for the detection of long repeat expansions, including:\n1. RepeatMasker: RepeatMasker is a widely used tool for detecting repetitive elements in a genome. It uses a combination of algorithms to identify repeats, including the use of a hidden Markov model (HMM) to predict the presence of repeats based on their sequence context. RepeatMasker can be used to detect long repeat expansions, but it may not be as effective as other methods for detecting very long repeats.\n2. RepeatFinder: RepeatFinder is another popular tool for detecting repetitive elements in a genome. It uses a combination of algorithms, including a HMM and a sliding window approach, to identify repeats. RepeatFinder can be used to detect long repeat expansions, and it is particularly effective for detecting repeats in regions of the genome that are rich in repetitive elements.\n3. LRE-Cutter: LRE-Cutter is a tool specifically designed for the detection of long repeat expansions (LREs). It uses a combination of algorithms, including a HMM and a sliding window approach, to identify LREs in a genome. LRE-Cutter can be used to detect both simple and complex LREs, and it is particularly effective for detecting LREs in regions of the genome that are rich in repetitive elements.\n4. GATA-W: GATA-W is a tool that uses a combination of algorithms, including a HMM and a sliding window approach, to identify repetitive elements in a genome. It can be used to detect long repeat expansions, and it is particularly effective for detecting repeats in regions of the genome that are rich in repetitive elements.\n5. HMMER: HMMER is a tool that uses a HMM to predict the presence of repetitive elements in a genome. It can be used to detect long repeat expansions, and it is particularly effective for detecting repeats in regions of the genome that are rich in repetitive elements.\n6. Prodigal: Prodigal is a tool that uses a combination of algorithms, including a HMM and a",
    "llama-2-7b-chat-hf_fact_raw": "1. RepeatMasker is a tool that uses a hidden Markov model to detect repetitive elements in a genome.\n2. RepeatFinder uses a combination of algorithms, including a hidden Markov model and a sliding window approach, to identify repeats.\n3. LRE-Cutter is specifically designed for the detection of long repeat expansions and can detect both simple and complex LREs.\n4. GATA-W uses a combination of algorithms, including a hidden Markov model and a sliding window approach, to identify repetitive elements.\n5. HMMER uses a hidden Markov model to predict the presence of repetitive elements in a genome.",
    "llama-2-7b-chat-hf_fact": [
      "RepeatMasker is a tool that uses a hidden Markov model to detect repetitive elements in a genome.",
      "RepeatFinder uses a combination of algorithms, including a hidden Markov model and a sliding window approach, to identify repeats.",
      "LRE-Cutter is specifically designed for the detection of long repeat expansions and can detect both simple and complex LREs.",
      "GATA-W uses a combination of algorithms, including a hidden Markov model and a sliding window approach, to identify repetitive elements.",
      "HMMER uses a hidden Markov model to predict the presence of repetitive elements in a genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: RepeatMasker is a tool that uses a curated database of repetitive elements and sequence alignments to detect repeats, not a hidden Markov model.\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. FALSE [correction]: HMMER is a tool that uses hidden Markov models to identify protein domains and does not predict repetitive elements in a genome.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2582,
    "user_query": "Which brain tumors does neuroligin-3 promote?",
    "llama-2-7b-chat-hf_response": "Neuroligin-3 is a protein that has been implicated in the development and progression of various types of brain tumors, including:\n1. Glioblastoma: Glioblastoma, also known as glioblastoma multiforme (GBM), is the most common and aggressive form of primary brain cancer. Neuroligin-3 has been shown to be overexpressed in glioblastoma cells, and high levels of neuroligin-3 have been associated with poor prognosis.\n2. Medulloblastoma: Medulloblastoma is a type of pediatric brain cancer that arises in the cerebellum. Neuroligin-3 has been found to be overexpressed in medulloblastoma cells, and high levels of neuroligin-3 have been associated with poorer outcomes.\n3. Meningioma: Meningioma is a type of benign brain tumor that arises in the meninges, the protective membranes that cover the brain and spinal cord. Neuroligin-3 has been found to be overexpressed in some meningioma tumors, and high levels of neuroligin-3 have been associated with more aggressive tumor behavior.\n4. Oligodendroglioma: Oligodendroglioma is a type of brain tumor that arises in the oligodendrocytes, the cells that produce the myelin sheath that surrounds nerve fibers in the brain. Neuroligin-3 has been found to be overexpressed in some oligodendrogliomas, and high levels of neuroligin-3 have been associated with poorer outcomes.\n5. Pineal gland tumors: The pineal gland is a small endocrine gland located in the brain. Pineal gland tumors are rare, but they can be aggressive and malignant. Neuroligin-3 has been found to be overexpressed in some pineal gland tumors, and high levels of neuroligin-3 have been associated with poorer outcomes.\nIt's important to note that these findings are based on studies of cell cultures and animal models, and more research is needed to confirm these findings in humans. Additionally, the expression of neuroligin-3 in these tumors may",
    "llama-2-7b-chat-hf_fact_raw": "1. Neuroligin-3 has been implicated in the development and progression of glioblastoma multiforme (GBM).\n2. Medulloblastoma, a pediatric brain cancer, has been shown to have overexpression of neuroligin-3.\n3. Meningioma tumors may exhibit overexpression of neuroligin-3, which is associated with aggressive tumor behavior.\n4. Oligodendroglioma tumors can have high levels of neuroligin-3, which is associated with poorer outcomes.\n5. Pineal gland tumors can be aggressive and malignant, with some showing overexpression of neuroligin-3.",
    "llama-2-7b-chat-hf_fact": [
      "Neuroligin-3 has been implicated in the development and progression of glioblastoma multiforme (GBM).",
      "Medulloblastoma, a pediatric brain cancer, has been shown to have overexpression of neuroligin-3.",
      "Meningioma tumors may exhibit overexpression of neuroligin-3, which is associated with aggressive tumor behavior.",
      "Oligodendroglioma tumors can have high levels of neuroligin-3, which is associated with poorer outcomes.",
      "Pineal gland tumors can be aggressive and malignant, with some showing overexpression of neuroligin-3."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2586,
    "user_query": "What is the approximate size of gas vesicles?",
    "llama-2-7b-chat-hf_response": "Gas vesicles are small, hollow structures that are found in some bacteria and archaea. They are typically around 20-100 nanometers (nm) in diameter, which is incredibly small compared to the size of most bacteria, which can be several micrometers (μm) in diameter.\nTo give you an idea of just how small gas vesicles are, consider that the wavelength of light is around 400-700 nm, which means that gas vesicles are only about 1/2 to 1/4 of the wavelength of light. This means that they are incredibly small and can only be observed with a high-powered microscope.\nDespite their small size, gas vesicles play a crucial role in the survival and success of some bacteria and archaea. They are used to store and release gas molecules, such as oxygen, nitrogen, and carbon dioxide, which are essential for the survival of these microorganisms in different environments.\nFor example, some bacteria like Shewanella oneidensi use gas vesicles to store oxygen and release it as needed, which allows them to survive in environments with low oxygen levels. Similarly, some archaea like Methanobacterium thermoautotrophicum use gas vesicles to store and release methane gas, which is used for energy production.\nOverall, gas vesicles are an incredible example of the diversity and complexity of life on Earth, and they continue to be an area of active research in the fields of microbiology and biophysics.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gas vesicles are typically around 20-100 nanometers in diameter.\n2. Most bacteria can be several micrometers in diameter.\n3. The wavelength of light is around 400-700 nanometers.\n4. Gas vesicles are used to store and release gas molecules like oxygen, nitrogen, and carbon dioxide.\n5. Shewanella oneidensi uses gas vesicles to store oxygen for survival in low oxygen environments.",
    "llama-2-7b-chat-hf_fact": [
      "Gas vesicles are typically around 20-100 nanometers in diameter.",
      "Most bacteria can be several micrometers in diameter.",
      "The wavelength of light is around 400-700 nanometers.",
      "Gas vesicles are used to store and release gas molecules like oxygen, nitrogen, and carbon dioxide.",
      "Shewanella oneidensi uses gas vesicles to store oxygen for survival in low oxygen environments."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Gas vesicles are used to regulate buoyancy in aquatic microorganisms, not to store and release gas molecules.\n5. FALSE [correction]: There is no organism called \"Shewanella oneidensi,\" it is likely a misspelling of \"Shewanella oneidensis,\" which does not use gas vesicles for oxygen storage, but has other mechanisms for survival in low oxygen environments.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2589,
    "user_query": "List BET proteins.",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help! BET (bromodomain and extraterminal domain) proteins are a family of proteins that play important roles in various cellular processes, including gene regulation, cell signaling, and immune response. Here are some of the most well-known BET proteins:\n1. BRD2 (Bromodomain-Containing Protein 2): BRD2 is a key regulator of gene expression, and it plays a crucial role in the development and progression of various cancers. It is involved in the regulation of chromatin structure and gene expression, and it has been implicated in the development of cancer through its interactions with oncogenes and tumor suppressors.\n2. BRD3 (Bromodomain-Containing Protein 3): BRD3 is similar to BRD2 in terms of its function and structure, and it is also involved in the regulation of gene expression. It has been shown to play a role in the development of various cancers, including breast, lung, and colon cancer.\n3. BRDT (Bromodomain-Containing Protein 4): BRDT is a BET protein that is primarily involved in the regulation of gene expression during cell differentiation and development. It has been shown to play a role in the development of various cancers, including breast and ovarian cancer.\n4. BATF (Basic Leucine Zipper Transcription Factor): BATF is a transcription factor that is involved in the regulation of gene expression during cell differentiation and development. It has been shown to play a role in the development of various cancers, including breast and lung cancer.\n5. KAT2A (Kinase-Associated Thiol/S-Network 2A): KAT2A is a protein that is involved in the regulation of gene expression through its ability to phosphorylate and activate transcription factors. It has been shown to play a role in the development of various cancers, including breast and ovarian cancer.\n6. TFDP2 (Transcription Factor 7-Like Domain Protein 2): TFDP2 is a transcription factor that is involved in the regulation of gene expression during cell differentiation and development. It has been shown to play a role in the development of",
    "llama-2-7b-chat-hf_fact_raw": "1. BRD2 (Bromodomain-Containing Protein 2) is involved in the regulation of gene expression and the development of various cancers.\n2. BRD3 (Bromodomain-Containing Protein 3) plays a role in cancer development, including breast, lung, and colon cancer.\n3. BRDT (Bromodomain-Containing Protein 4) is a BET protein involved in gene expression regulation during cell differentiation and development.\n4. BATF (Basic Leucine Zipper Transcription Factor) regulates gene expression and is linked to cancer development, such as breast and lung cancer.\n5. KAT2A (Kinase-Associated Thiol/S-Network 2A) is involved in gene expression regulation and has been implicated in the development of breast and ovarian cancer.",
    "llama-2-7b-chat-hf_fact": [
      "BRD2 (Bromodomain-Containing Protein 2) is involved in the regulation of gene expression and the development of various cancers.",
      "BRD3 (Bromodomain-Containing Protein 3) plays a role in cancer development, including breast, lung, and colon cancer.",
      "BRDT (Bromodomain-Containing Protein 4) is a BET protein involved in gene expression regulation during cell differentiation and development.",
      "BATF (Basic Leucine Zipper Transcription Factor) regulates gene expression and is linked to cancer development, such as breast and lung cancer.",
      "KAT2A (Kinase-Associated Thiol/S-Network 2A) is involved in gene expression regulation and has been implicated in the development of breast and ovarian cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: BRDT (Bromodomain-Containing Protein Testis-specific) is a BET protein involved in gene expression regulation during spermatogenesis and development.\n4. TRUE\n5. FALSE [correction]: KAT2A (Lysine Acetyltransferase 2A) is involved in gene expression regulation and has been implicated in the development of various cancers, not limited to breast and ovarian cancer.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 2610,
    "user_query": "Which algorithm has been developed for prediction of protein subcellular localization using deep learning?",
    "llama-2-7b-chat-hf_response": "There are several deep learning algorithms that have been developed for protein subcellular localization prediction. Here are some of the most notable ones:\n1. DeepLocalization: This algorithm was developed by Zhang et al. in 2017 and is considered one of the most popular deep learning models for protein subcellular localization prediction. DeepLocalization uses a combination of sequence-based features and structural-based features to predict the subcellular localization of a protein. The algorithm was trained on a large dataset of protein structures and their corresponding subcellular localization labels.\n2. LocNet: LocNet is another popular deep learning algorithm for protein subcellular localization prediction. Developed by Li et al. in 2018, LocNet uses a lightweight convolutional neural network (CNN) architecture to predict the subcellular localization of a protein. LocNet was trained on a dataset of over 10,000 protein structures and achieved high accuracy on several benchmark datasets.\n3. ConcatENet: ConcatENet is a hierarchical CNN model developed by Li et al. in 2019 for protein subcellular localization prediction. ConcatENet uses a hierarchical architecture to capture both local and global features of protein structures. The model achieved state-of-the-art performance on several benchmark datasets.\n4. GraphConvNet: GraphConvNet is a graph convolutional neural network (CNN) model developed by Gao et al. in 2020 for protein subcellular localization prediction. GraphConvNet uses a graph convolutional layer to capture the structural information of protein structures and achieve high accuracy on several benchmark datasets.\n5. Transformer-based models: In recent years, transformer-based models have also been applied to protein subcellular localization prediction. Models such as TransProt (developed by Zhang et al. in 2020) and TransProt-2 (developed by Li et al. in 2020) use transformer architectures to capture the long-range dependencies between amino acids in a protein sequence. These models have achieved high accuracy on several benchmark datasets.\nIt's worth noting that these algorithms are not mutually exclusive, and many studies have combined different deep learning models to improve the accuracy of protein subcellular localization prediction. For example",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepLocalization was developed by Zhang et al. in 2017 for protein subcellular localization prediction.\n2. LocNet was developed by Li et al. in 2018 and uses a convolutional neural network architecture.\n3. ConcatENet, developed by Li et al. in 2019, is a hierarchical CNN model for protein subcellular localization prediction.\n4. GraphConvNet, developed by Gao et al. in 2020, is a graph convolutional neural network model for protein subcellular localization prediction.\n5. Transformer-based models such as TransProt and TransProt-2 were developed by Zhang et al. and Li et al. in 2020 for protein subcellular localization prediction.",
    "llama-2-7b-chat-hf_fact": [
      "DeepLocalization was developed by Zhang et al. in 2017 for protein subcellular localization prediction.",
      "LocNet was developed by Li et al. in 2018 and uses a convolutional neural network architecture.",
      "ConcatENet, developed by Li et al. in 2019, is a hierarchical CNN model for protein subcellular localization prediction.",
      "GraphConvNet, developed by Gao et al. in 2020, is a graph convolutional neural network model for protein subcellular localization prediction.",
      "Transformer-based models such as TransProt and TransProt-2 were developed by Zhang et al. and Li et al. in 2020 for protein subcellular localization prediction."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note]: Without specific information on the developments and publications of these models in the field of protein subcellular localization prediction, it is impossible to ascertain the truthfulness of the statements. Further research and context would be needed to provide accurate corrections.",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2634,
    "user_query": "What is MULTOVL?",
    "llama-2-7b-chat-hf_response": "Thank you for reaching out with your question! I'm here to help you. However, I must inform you that \"MULTOVL\" is not a valid term or acronym in any field or industry. It's possible that you may have misspelled the term or that it's a made-up word.\nCould you please provide more context or information about where you encountered this term? This will help me better understand your question and provide a more accurate answer.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 2660,
    "user_query": "Can GDF15 be a biomarker for metformin treatment?",
    "llama-2-7b-chat-hf_response": "GDF15 (Growth Differentiation Factor 15) has been identified as a potential biomarker for metformin treatment in recent studies. Metformin is a commonly used medication for type 2 diabetes, and understanding the biomarkers associated with its effectiveness can help improve treatment outcomes. Here's what the scientific literature suggests:\n1. GDF15 is upregulated in response to metformin: Several studies have shown that GDF15 levels increase in response to metformin treatment. For example, a study published in the Journal of Clinical Endocrinology and Metabolism found that GDF15 levels were significantly higher in patients treated with metformin compared to those not treated with the drug.\n2. GDF15 may predict metformin response: Research suggests that GDF15 levels may be able to predict which patients are most likely to respond to metformin treatment. A study published in the journal Diabetes, Obesity and Metabolism found that patients with higher GDF15 levels were more likely to experience improvements in glucose tolerance and insulin sensitivity after metformin treatment.\n3. GDF15 may be related to metformin's mechanism of action: Scientists believe that GDF15 may play a role in the mechanism of action of metformin. Metformin works by increasing insulin sensitivity, and GDF15 has been shown to promote the differentiation of adipocytes (fat cells) and increase insulin sensitivity. Therefore, it is possible that GDF15 is involved in the way metformin improves insulin sensitivity.\n4. Further research is needed: While the current evidence suggests that GDF15 may be a useful biomarker for metformin treatment, more research is needed to confirm these findings. Further studies are needed to investigate the relationship between GDF15 and metformin treatment, as well as to determine the clinical utility of using GDF15 as a biomarker for metformin response.\nIn summary, GDF15 has been identified as a potential biomarker for metformin treatment. While the current evidence is promising, more research is needed to fully understand the relationship between GDF15 and metformin treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. GDF15 (Growth Differentiation Factor 15) has been identified as a potential biomarker for metformin treatment.\n2. Metformin is a commonly used medication for type 2 diabetes.\n3. Studies have shown that GDF15 levels increase in response to metformin treatment.\n4. GDF15 levels may predict which patients are most likely to respond to metformin treatment.\n5. GDF15 may play a role in the mechanism of action of metformin by increasing insulin sensitivity.",
    "llama-2-7b-chat-hf_fact": [
      "GDF15 (Growth Differentiation Factor 15) has been identified as a potential biomarker for metformin treatment.",
      "Metformin is a commonly used medication for type 2 diabetes.",
      "Studies have shown that GDF15 levels increase in response to metformin treatment.",
      "GDF15 levels may predict which patients are most likely to respond to metformin treatment.",
      "GDF15 may play a role in the mechanism of action of metformin by increasing insulin sensitivity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2664,
    "user_query": "Is recursive splicing more common in short introns?",
    "llama-2-7b-chat-hf_response": "Recursive splicing is a type of splicing event in which the same intron is spliced multiple times within a gene. It is a relatively rare occurrence in eukaryotic genes, but it is more common in short introns.\nIntrons are regions of non-coding DNA within a gene that are spliced out during the mRNA processing stage. Short introns are those that are less than 100 nucleotides in length, while long introns are those that are longer than 100 nucleotides.\nRecursive splicing occurs when the same intron is spliced multiple times within a gene, resulting in the creation of multiple mRNA isoforms. This can happen in short introns, where the splicing machinery may get stuck in a loop and keep splicing the same intron over and over again.\nOne reason why recursive splicing is more common in short introns is that these introns are more likely to be located near the 3' splice site of the gene. The 3' splice site is the site where the splicing machinery recognizes the end of the intron and starts the splicing process. When an intron is located near the 3' splice site, there is a higher chance that the splicing machinery will get stuck in a loop and keep splicing the same intron multiple times.\nAnother reason why recursive splicing is more common in short introns is that these introns are more likely to be flanked by strong splice donor and acceptor sites. Strong splice donor and acceptor sites are sequences that are recognized by the splicing machinery and help to initiate and terminate the splicing process. When an intron is flanked by strong splice donor and acceptor sites, it is more likely to be spliced repeatedly, leading to the formation of multiple mRNA isoforms.\nRecursive splicing can have important consequences for gene expression. For example, it can lead to the production of different isoforms of a protein with different functions, or it can result in the production of a protein that is not functional at all. Therefore, understanding the mechanisms of recursive splicing and how it affects gene expression is important for understanding the regulation of gene function.\nIn summary",
    "llama-2-7b-chat-hf_fact_raw": "1. Recursive splicing is a type of splicing event where the same intron is spliced multiple times within a gene.\n2. Recursive splicing is relatively rare in eukaryotic genes.\n3. Short introns, which are less than 100 nucleotides in length, are more likely to experience recursive splicing compared to long introns.\n4. The proximity of short introns to the 3' splice site increases the likelihood of recursive splicing.\n5. Short introns flanked by strong splice donor and acceptor sites are more likely to be spliced repeatedly.",
    "llama-2-7b-chat-hf_fact": [
      "Recursive splicing is a type of splicing event where the same intron is spliced multiple times within a gene.",
      "Recursive splicing is relatively rare in eukaryotic genes.",
      "Short introns, which are less than 100 nucleotides in length, are more likely to experience recursive splicing compared to long introns.",
      "The proximity of short introns to the 3' splice site increases the likelihood of recursive splicing.",
      "Short introns flanked by strong splice donor and acceptor sites are more likely to be spliced repeatedly."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The proximity of short introns to the 5' splice site, not the 3' splice site, increases the likelihood of recursive splicing.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 2679,
    "user_query": "What is the TALE-iD method used for?",
    "llama-2-7b-chat-hf_response": "The TALE-iD method is a gene editing tool used for making targeted changes to the DNA of living organisms. It is a type of gene editing technology that uses a specific type of DNA-binding protein called a transcription activator-like effector (TALE) to recognize and bind to specific DNA sequences. Once the TALE protein has bound to the targeted DNA sequence, it can be used to introduce genetic changes to the organism.\nThe TALE-iD method is used for a variety of purposes, including:\n1. Gene correction: The TALE-iD method can be used to correct genetic mutations that are causing disease. By using the TALE protein to recognize and bind to the mutated DNA sequence, the TALE-iD method can introduce healthy copies of the gene to replace the mutated gene, correcting the disease.\n2. Gene expression: The TALE-iD method can be used to control the expression of specific genes. By using the TALE protein to bind to a specific DNA sequence, the TALE-iD method can either turn on or turn off the expression of the gene, depending on the specific application.\n3. Gene therapy: The TALE-iD method can be used to introduce healthy copies of a gene into cells to replace a faulty or missing gene. This can be used to treat genetic diseases caused by a lack of a specific gene.\n4. Cancer treatment: The TALE-iD method can be used to selectively kill cancer cells by targeting specific genes that are involved in cancer growth and progression.\n5. Gene editing: The TALE-iD method can be used to make targeted changes to the DNA of living organisms, allowing for the precise modification of genes involved in a wide range of biological processes.\n6. Basic research: The TALE-iD method can be used to study the function of specific genes and their role in various biological processes.\nIt's important to note that the TALE-iD method is still a relatively new technology, and more research is needed to fully understand its potential and limitations. However, it has shown great promise in a variety of applications and is an area of ongoing research and development.",
    "llama-2-7b-chat-hf_fact_raw": "1. The TALE-iD method is a gene editing tool that makes targeted changes to DNA.\n2. It employs a transcription activator-like effector (TALE) to recognize and bind to specific DNA sequences.\n3. The TALE-iD method can be used to correct genetic mutations causing diseases.\n4. The method can control gene expression by turning genes on or off.\n5. TALE-iD is used in gene therapy to introduce healthy gene copies to treat genetic diseases.",
    "llama-2-7b-chat-hf_fact": [
      "The TALE-iD method is a gene editing tool that makes targeted changes to DNA.",
      "It employs a transcription activator-like effector (TALE) to recognize and bind to specific DNA sequences.",
      "The TALE-iD method can be used to correct genetic mutations causing diseases.",
      "The method can control gene expression by turning genes on or off.",
      "TALE-iD is used in gene therapy to introduce healthy gene copies to treat genetic diseases."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: TALE-iD is not a gene therapy method to introduce healthy gene copies, it is a gene editing tool that can make targeted changes to existing DNA. Gene therapy typically involves the introduction of new, healthy copies of genes.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2747,
    "user_query": "Which Lisp framework has been developed for image processing?",
    "llama-2-7b-chat-hf_response": "There are several Lisp frameworks that have been developed for image processing, each with their own strengths and weaknesses. Here are some of the most popular ones:\n1. CLISP: CLISP is a Lisp implementation that includes a comprehensive set of libraries for image processing. It provides a wide range of functions for image manipulation, including resizing, cropping, and color correction. CLISP also includes a built-in image display function, which allows you to visualize the images you are working with.\n2. SBCL: SBCL (Steel Bank Common Lisp) is a Lisp implementation that is known for its high performance and reliability. It includes a number of libraries for image processing, including a library for image manipulation and a library for computer vision tasks. SBCL also provides a comprehensive set of tools for debugging and profiling your code.\n3. LispWorks: LispWorks is a Lisp implementation that includes a wide range of libraries for image processing. It provides functions for image manipulation, including resizing, cropping, and color correction, as well as functions for computer vision tasks such as object detection and tracking. LispWorks also includes a built-in image display function, which allows you to visualize the images you are working with.\n4. Allegro CL: Allegro CL is a Lisp implementation that includes a number of libraries for image processing. It provides functions for image manipulation, including resizing, cropping, and color correction, as well as functions for computer vision tasks such as object detection and tracking. Allegro CL also includes a built-in image display function, which allows you to visualize the images you are working with.\n5. Domaine: Domaine is a Lisp implementation that is specifically designed for image processing. It includes a wide range of functions for image manipulation, including resizing, cropping, and color correction, as well as functions for computer vision tasks such as object detection and tracking. Domaine also provides a comprehensive set of tools for debugging and profiling your code.\n6. LispImage: LispImage is a Lisp framework specifically designed for image processing. It provides a wide range of functions for image manipulation, including resizing, cropping, and color correction, as well as functions for computer vision tasks such as object detection and tracking. LispImage also includes a built",
    "llama-2-7b-chat-hf_fact_raw": "1. CLISP is a Lisp implementation with a set of libraries for image processing.\n2. SBCL (Steel Bank Common Lisp) includes libraries for image processing and computer vision tasks.\n3. LispWorks is a Lisp implementation that offers libraries for image manipulation and computer vision tasks.\n4. Allegro CL provides functions for image manipulation as well as computer vision tasks.\n5. Domaine is a Lisp implementation designed specifically for image processing.",
    "llama-2-7b-chat-hf_fact": [
      "CLISP is a Lisp implementation with a set of libraries for image processing.",
      "SBCL (Steel Bank Common Lisp) includes libraries for image processing and computer vision tasks.",
      "LispWorks is a Lisp implementation that offers libraries for image manipulation and computer vision tasks.",
      "Allegro CL provides functions for image manipulation as well as computer vision tasks.",
      "Domaine is a Lisp implementation designed specifically for image processing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: CLISP is a Lisp implementation but does not have a specific set of libraries for image processing.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: There is no Lisp implementation known as Domaine designed specifically for image processing.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 2759,
    "user_query": "How many genes in S. cerevisiae are the result of an ancient whole genome duplication?",
    "llama-2-7b-chat-hf_response": "The question you've been asked is a fascinating one, and I'm happy to help you find the answer!\nWhole genome duplication (WGD) is a process that occurs in some organisms, including yeast, where a large portion of the genome is duplicated. This duplication can occur through various mechanisms, including gene conversion, chromosomal recombination, or even entire chromosomes being duplicated.\nIn the case of Saccharomyces cerevisiae (baker's yeast), there is evidence to suggest that a single ancient WGD event occurred around 100-150 million years ago, during the evolution of the yeast lineage. This event resulted in the duplication of approximately 1,000-2,000 genes, which are now known as the \"yeast gene duplication\" or \"YGD\" genes.\nTo determine the exact number of genes that are the result of this ancient WGD event, we can use a combination of bioinformatic and molecular biology approaches. Here's how:\n1. Bioinformatic analysis: One way to identify genes that are the result of WGD is to look for signature sequences that are associated with gene duplication. These signature sequences, known as \"gene duplication hotspots,\" are regions of the genome where gene duplication is more likely to occur. By analyzing the yeast genome using bioinformatic tools, we can identify regions that are enriched for these hotspots and determine the number of genes that are located within these regions.\nAccording to a study published in the journal Science in 2017, the yeast genome contains around 1,200 gene duplication hotspots. Of these, around 200-300 are located in regions that are likely to have been involved in the ancient WGD event.\n2. Molecular biology analysis: To confirm the number of genes that are the result of the ancient WGD event, we can use molecular biology techniques to study the gene expression patterns in yeast. We can use methods such as RNA sequencing or microarray analysis to measure the expression levels of genes in different parts of the yeast genome.\nBy analyzing the expression patterns of",
    "llama-2-7b-chat-hf_fact_raw": "1. Whole genome duplication (WGD) has occurred in Saccharomyces cerevisiae (baker's yeast).\n2. An ancient WGD event in Saccharomyces cerevisiae is estimated to have happened around 100-150 million years ago.\n3. The ancient WGD event resulted in the duplication of approximately 1,000-2,000 genes.\n4. These duplicated genes are referred to as \"yeast gene duplication\" or \"YGD\" genes.\n5. A study in the journal Science in 2017 stated that the yeast genome contains around 1,200 gene duplication hotspots.",
    "llama-2-7b-chat-hf_fact": [
      "Whole genome duplication (WGD) has occurred in Saccharomyces cerevisiae (baker's yeast).",
      "An ancient WGD event in Saccharomyces cerevisiae is estimated to have happened around 100-150 million years ago.",
      "The ancient WGD event resulted in the duplication of approximately 1,000-2,000 genes.",
      "These duplicated genes are referred to as \"yeast gene duplication\" or \"YGD\" genes.",
      "A study in the journal Science in 2017 stated that the yeast genome contains around 1,200 gene duplication hotspots."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: These duplicated genes are typically referred to as \"ohnologs\" or genes resulting from whole genome duplication, not specifically \"yeast gene duplication\" or \"YGD\" genes.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "unknown"
    ]
  },
  {
    "id": 2763,
    "user_query": "Which complex is bound by estrogen-related receptor β (Esrrb)?",
    "llama-2-7b-chat-hf_response": "Estrogen-related receptor β (Esrrb) is a nuclear receptor that is bound by a variety of complexes, including:\n1. Estrogen: Esrrb is activated by estrogen, and the binding of estrogen to the receptor leads to the regulation of gene expression involved in various cellular processes, including cell growth, differentiation, and survival.\n2. Coactivators: Esrrb is complexed with coactivators, such as p300 and CBP (CREB-binding protein), which enhance the receptor's transcriptional activity by recruiting RNA polymerase and other transcription factors.\n3. Corepressors: Esrrb is also complexed with corepressors, such as N-CoR (nuclear receptor corepressor) and SMRT (SMAD family member-related to Drosophila tumor 1), which can repress the receptor's transcriptional activity by blocking the recruitment of coactivators.\n4. Chromatin-modifying enzymes: Esrrb can also interact with chromatin-modifying enzymes, such as histone acetyltransferases and histone deacetylases, which can alter the chromatin structure and accessibility, leading to changes in gene expression.\n5. Other proteins: Esrrb can also interact with other proteins, such as the tumor suppressor protein, p53, and the oncogene protein, c-Myc, which can modulate the receptor's activity and function.\nExamples of complexes that bind to Esrrb include:\n1. Estrogen-p300 complex: This complex is formed when estrogen binds to Esrrb and recruits p300, leading to the activation of target genes involved in cell growth and differentiation.\n2. Estrogen-CBP complex: This complex is formed when estrogen binds to Esrrb and recruits CBP, leading to the activation of target genes involved in cell growth and differentiation.\n3. Estrogen-N-CoR complex: This complex is formed when estrogen binds to Esrrb and recruits N-CoR, leading to the repression of target genes involved in cell growth",
    "llama-2-7b-chat-hf_fact_raw": "1. Esrrb is activated by the binding of estrogen.\n2. Esrrb complexes with coactivators like p300 and CBP to enhance transcriptional activity.\n3. Esrrb complexes with corepressors like N-CoR and SMRT to repress transcriptional activity.\n4. Esrrb interacts with chromatin-modifying enzymes to alter gene expression.\n5. Esrrb can interact with other proteins such as p53 and c-Myc.",
    "llama-2-7b-chat-hf_fact": [
      "Esrrb is activated by the binding of estrogen.",
      "Esrrb complexes with coactivators like p300 and CBP to enhance transcriptional activity.",
      "Esrrb complexes with corepressors like N-CoR and SMRT to repress transcriptional activity.",
      "Esrrb interacts with chromatin-modifying enzymes to alter gene expression.",
      "Esrrb can interact with other proteins such as p53 and c-Myc."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Esrrb is not activated by the binding of estrogen, it is actually estrogen-related receptor beta, which means it is related to but distinct from estrogen receptors.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 2842,
    "user_query": "What is the role of ZCCHC17?",
    "llama-2-7b-chat-hf_response": "ZCCHC17 is a gene that encodes for a protein called Zinc Finger CCHC-Type 17. This protein is a transcription factor, which means it helps regulate the expression of other genes by binding to specific DNA sequences.\nThe role of ZCCHC17 is primarily involved in the regulation of genes involved in the development and maintenance of the nervous system, particularly in the brain. It is expressed in various regions of the brain, including the cerebral cortex, hippocampus, and cerebellum.\nStudies have shown that ZCCHC17 plays a crucial role in the regulation of neural stem cell proliferation, differentiation, and survival. It is also involved in the regulation of synaptic plasticity and learning and memory processes.\nZCCHC17 has been implicated in several neurological disorders, including:\n1. Autism spectrum disorder: Studies have shown that individuals with autism spectrum disorder (ASD) have altered expression levels of ZCCHC17 in their brains.\n2. Alzheimer's disease: ZCCHC17 has been shown to play a role in the regulation of amyloid-β peptide production, which is a hallmark of Alzheimer's disease.\n3. Parkinson's disease: ZCCHC17 has been implicated in the regulation of dopamine release and synaptic plasticity in the brain, which are affected in Parkinson's disease.\n4. Schizophrenia: ZCCHC17 has been shown to be altered in the brains of individuals with schizophrenia, and may play a role in the regulation of glutamate release and synaptic plasticity.\nOverall, the role of ZCCHC17 is complex and multifaceted, and further research is needed to fully understand its function in the brain and its potential as a therapeutic target for neurological disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZCCHC17 encodes for a protein called Zinc Finger CCHC-Type 17, which is a transcription factor.\n2. ZCCHC17 is involved in regulating genes for nervous system development and maintenance, particularly in the brain.\n3. ZCCHC17 plays a role in neural stem cell proliferation, differentiation, and survival.\n4. Altered expression levels of ZCCHC17 have been observed in individuals with autism spectrum disorder.\n5. ZCCHC17 has been shown to influence amyloid-β peptide production, associated with Alzheimer's disease.",
    "llama-2-7b-chat-hf_fact": [
      "ZCCHC17 encodes for a protein called Zinc Finger CCHC-Type 17, which is a transcription factor.",
      "ZCCHC17 is involved in regulating genes for nervous system development and maintenance, particularly in the brain.",
      "ZCCHC17 plays a role in neural stem cell proliferation, differentiation, and survival.",
      "Altered expression levels of ZCCHC17 have been observed in individuals with autism spectrum disorder.",
      "ZCCHC17 has been shown to influence amyloid-β peptide production, associated with Alzheimer's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: ZCCHC17 has not been definitively shown to influence amyloid-β peptide production, which is associated with Alzheimer's disease.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 2861,
    "user_query": "Which proteins form the nuclear pore basket in human cells?",
    "llama-2-7b-chat-hf_response": "The nuclear pore basket, also known as the nuclear pore complex (NPC), is a large protein structure that spans the nuclear envelope in eukaryotic cells, including human cells. The NPC is responsible for regulating the transport of molecules between the nucleus and the cytoplasm.\nThe proteins that form the nuclear pore basket in human cells are:\n1. Nucleoporins: These are the main proteins that make up the NPC. There are 35 different nucleoporins in humans, which are arranged in a ring-like structure around the central channel of the NPC.\n2. Nuclear lamin: This protein is anchored to the inner nuclear membrane and helps to regulate the transport of molecules across the NPC.\n3. Nuclear lamins: These are a group of proteins that are also anchored to the inner nuclear membrane and help to regulate the transport of molecules across the NPC.\n4. Spectrin: This protein is involved in the formation of the NPC and helps to regulate the transport of molecules across the NPC.\n5. Ankyrin: This protein is involved in the formation of the NPC and helps to regulate the transport of molecules across the NPC.\n6. RanBP9: This protein is involved in the regulation of the NPC and helps to regulate the transport of molecules across the NPC.\n7. Nup107: This protein is involved in the regulation of the NPC and helps to regulate the transport of molecules across the NPC.\n8. Nup133: This protein is involved in the regulation of the NPC and helps to regulate the transport of molecules across the NPC.\n9. Nup206: This protein is involved in the regulation of the NPC and helps to regulate the transport of molecules across the NPC.\n10. Nup358: This protein is involved in the regulation of the NPC and helps to regulate the transport of molecules across the NPC.\nThese proteins work together to form a complex that regulates the transport of molecules across the nuclear envelope. The NPC is a highly selective barrier that allows certain molecules to pass through while keeping others out. This is important for maintain",
    "llama-2-7b-chat-hf_fact_raw": "1. The nuclear pore complex (NPC) spans the nuclear envelope in eukaryotic cells, including human cells.\n2. There are 35 different nucleoporins in humans that make up the NPC.\n3. Nuclear lamin is anchored to the inner nuclear membrane and assists in molecule transport regulation across the NPC.\n4. Nuclear lamins are a group of proteins anchored to the inner nuclear membrane, contributing to molecule transport regulation across the NPC.\n5. The NPC acts as a selective barrier that allows certain molecules to pass through while keeping others out.",
    "llama-2-7b-chat-hf_fact": [
      "The nuclear pore complex (NPC) spans the nuclear envelope in eukaryotic cells, including human cells.",
      "There are 35 different nucleoporins in humans that make up the NPC.",
      "Nuclear lamin is anchored to the inner nuclear membrane and assists in molecule transport regulation across the NPC.",
      "Nuclear lamins are a group of proteins anchored to the inner nuclear membrane, contributing to molecule transport regulation across the NPC.",
      "The NPC acts as a selective barrier that allows certain molecules to pass through while keeping others out."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: There are around 30 different nucleoporins in humans that make up the NPC.\n3. FALSE [correction]: Nuclear lamin provides structural support to the nuclear envelope and is not directly involved in molecule transport regulation across the NPC.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 2919,
    "user_query": "What type of topoisomerase inhibitor is gepotidacin?",
    "llama-2-7b-chat-hf_response": "Gepotidacin is a specific type of topoisomerase inhibitor called a quinolone-based topoisomerase inhibitor. Topoisomerase inhibitors are a class of drugs that work by binding to and blocking the activity of topoisomerase enzymes, which are involved in the regulation of DNA replication and repair.\nGepotidacin is a member of the quinolone class of topoisomerase inhibitors, which are characterized by their ability to bind to and inhibit the activity of topoisomerase II (TOP2). TOP2 is an enzyme that plays a critical role in the repair of DNA double-strand breaks, and is overexpressed in many types of cancer.\nGepotidacin works by binding to the active site of TOP2 and forming a covalent complex, which prevents the enzyme from cutting and rejoining DNA strands. This leads to a buildup of DNA strands in the cell, which can ultimately lead to cell death.\nGepotidacin has shown promise as a potential cancer treatment, particularly in the context of BRCA-mutated breast and ovarian cancer. It has been shown to be effective in preclinical studies, and is currently being evaluated in clinical trials for the treatment of various types of cancer.\nIt is worth noting that topoisomerase inhibitors can have off-target effects, such as disrupting the repair of non-cancerous DNA damage, which can lead to genetic instability and potentially increase the risk of cancer. Therefore, the development of topoisomerase inhibitors as cancer therapies is ongoing, and more research is needed to fully understand their mechanisms of action and potential side effects.",
    "llama-2-7b-chat-hf_fact_raw": "1. Gepotidacin is a quinolone-based topoisomerase inhibitor.\n2. Topoisomerase inhibitors work by binding to and blocking the activity of topoisomerase enzymes.\n3. Gepotidacin binds to the active site of topoisomerase II (TOP2) and forms a covalent complex.\n4. Gepotidacin has shown promise as a potential treatment for BRCA-mutated breast and ovarian cancer.\n5. Gepotidacin is currently being evaluated in clinical trials for the treatment of various types of cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Gepotidacin is a quinolone-based topoisomerase inhibitor.",
      "Topoisomerase inhibitors work by binding to and blocking the activity of topoisomerase enzymes.",
      "Gepotidacin binds to the active site of topoisomerase II (TOP2) and forms a covalent complex.",
      "Gepotidacin has shown promise as a potential treatment for BRCA-mutated breast and ovarian cancer.",
      "Gepotidacin is currently being evaluated in clinical trials for the treatment of various types of cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Gepotidacin is not a quinolone-based inhibitor; it is a novel triazaacenaphthylene antibacterial agent that targets bacterial type II topoisomerases.\n2. TRUE\n3. FALSE [correction]: Gepotidacin targets bacterial type II topoisomerases, specifically DNA gyrase and topoisomerase IV, not human topoisomerase II (TOP2).\n4. FALSE [correction]: Gepotidacin has been studied primarily for its potential use in treating bacterial infections, not for BRCA-mutated breast and ovarian cancer.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 2943,
    "user_query": "Describe Canvas SPW",
    "llama-2-7b-chat-hf_response": "Canvas SPW (Secure Payment Workflow) is a payment solution provided by Canva, a popular graphic design platform. Canvas SPW is designed to help businesses and individuals simplify their payment processes and reduce the risk of fraudulent transactions. Here are some key features and benefits of Canvas SPW:\n1. Secure Payment Processing: Canvas SPW uses a secure payment processing system that is compliant with industry standards, such as Payment Card Industry Data Security Standard (PCI DSS). This ensures that sensitive payment information is protected and secure.\n2. Customizable Payment Forms: Canvas SPW allows you to create custom payment forms that match your branding and design. You can add your logo, colors, and other design elements to create a seamless payment experience for your customers.\n3. Multiple Payment Gateways: Canvas SPW supports multiple payment gateways, including Stripe, PayPal, and Square. This allows you to offer your customers a range of payment options and increase the chances of successful transactions.\n4. Real-Time Payment Notifications: Canvas SPW provides real-time payment notifications, which means you can track the status of each payment in real-time. This helps you to manage your finances more effectively and reduce the risk of missed payments.\n5. Automated Payment Reminders: Canvas SPW allows you to send automated payment reminders to your customers. This helps to ensure that payments are made on time and reduces the risk of missed payments.\n6. Integration with Canva's Design Tools: Canvas SPW integrates seamlessly with Canva's design tools, allowing you to create custom payment forms that match your branding and design. This helps to create a consistent and professional payment experience for your customers.\n7. Easy to Use: Canvas SPW is designed to be easy to use, even for those without technical expertise. The platform provides a user-friendly interface that makes it simple to set up and manage payment forms.\n8. Scalable: Canvas SPW is designed to be scalable, which means it can handle a high volume of payments without compromising performance. This makes it ideal for businesses that experience a high volume of transactions.\n9. Customizable: Canvas SPW allows you to customize the payment process to suit",
    "llama-2-7b-chat-hf_fact_raw": "1. Canvas SPW (Secure Payment Workflow) is a payment solution provided by Canva.\n2. Canvas SPW uses a secure payment processing system compliant with the Payment Card Industry Data Security Standard (PCI DSS).\n3. Canvas SPW supports multiple payment gateways, including Stripe, PayPal, and Square.\n4. Canvas SPW provides real-time payment notifications.\n5. Canvas SPW allows for the creation of customizable payment forms that match branding and design.",
    "llama-2-7b-chat-hf_fact": [
      "Canvas SPW (Secure Payment Workflow) is a payment solution provided by Canva.",
      "Canvas SPW uses a secure payment processing system compliant with the Payment Card Industry Data Security Standard (PCI DSS).",
      "Canvas SPW supports multiple payment gateways, including Stripe, PayPal, and Square.",
      "Canvas SPW provides real-time payment notifications.",
      "Canvas SPW allows for the creation of customizable payment forms that match branding and design."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Canva does not have a payment solution called Canvas SPW.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2960,
    "user_query": "List STING agonists.",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'd be happy to provide you with a list of STING agonists. STING (Stimulator of Interferon Genes) is a protein found on the surface of immune cells, including T cells and B cells, that plays a crucial role in the immune response. STING agonists are molecules that activate STING and trigger an immune response. Here are some examples of STING agonists:\n1. Poly (I:C): Poly (I:C) is a synthetic analog of viral double-stranded RNA that activates STING and triggers an antiviral response. It is commonly used as a STING agonist in research studies.\n2. DNA: DNA can activate STING and induce an immune response, particularly during viral infections.\n3. R8P: R8P is a small molecule that activates STING and induces an antiviral response. It has been shown to be effective in reducing inflammation and improving lung function in mouse models of acute respiratory distress syndrome.\n4. Toll-like receptor (TLR) agonists: TLRs are a family of receptors that recognize pathogen-associated molecular patterns (PAMPs) and activate STING. Examples of TLR agonists include lipopolysaccharide (LPS), flagellin, and viral RNA.\n5. Interferons: Interferons are a family of cytokines that can activate STING and induce an antiviral response. Examples of interferons include interferon-alpha (IFN-α), interferon-beta (IFN-β), and interferon-omega (IFN-ω).\n6. Resveratrol: Resveratrol is a polyphenol found in grapes, berries, and other plant-based foods. It has been shown to activate STING and induce an antiviral response in vitro and in vivo.\n7. Quercetin: Quercetin is a flavonoid found in fruits, vegetables, and herbs. It has been shown to activate STING and induce an antiviral response in vitro and in vivo.\n8.",
    "llama-2-7b-chat-hf_fact_raw": "1. STING (Stimulator of Interferon Genes) is a protein found on the surface of immune cells, including T cells and B cells.\n2. Poly (I:C) is a synthetic analog of viral double-stranded RNA that activates STING.\n3. DNA can activate STING and induce an immune response during viral infections.\n4. Toll-like receptor (TLR) agonists, such as lipopolysaccharide (LPS), flagellin, and viral RNA, can activate STING.\n5. Interferons, including interferon-alpha (IFN-α), interferon-beta (IFN-β), and interferon-omega (IFN-ω), can activate STING and induce an antiviral response.",
    "llama-2-7b-chat-hf_fact": [
      "STING (Stimulator of Interferon Genes) is a protein found on the surface of immune cells, including T cells and B cells.",
      "Poly (I:C) is a synthetic analog of viral double-stranded RNA that activates STING.",
      "DNA can activate STING and induce an immune response during viral infections.",
      "Toll-like receptor (TLR) agonists, such as lipopolysaccharide (LPS), flagellin, and viral RNA, can activate STING.",
      "Interferons, including interferon-alpha (IFN-α), interferon-beta (IFN-β), and interferon-omega (IFN-ω), can activate STING and induce an antiviral response."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: STING (Stimulator of Interferon Genes) is not a protein found on the surface of immune cells, but rather an intracellular protein located in the endoplasmic reticulum.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: TLR agonists do not activate STING directly; they activate other pathways that can lead to STING activation.\n5. FALSE [correction]: Interferons do not activate STING; rather, STING activation can lead to the production of interferons.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 2964,
    "user_query": "Describe SLIC-CAGE",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help!\nSLIC-CAGE is a method used in bioinformatics and computational biology to identify functional modules in protein complexes. The acronym SLIC-CAGE stands for \"Spectral Log-Inhibition of CAGE,\" which refers to the two main steps involved in the method:\n1. Spectral Log-Inhibition: In this step, the protein complex is first separated into its component proteins using a technique called two-dimensional gel electrophoresis. The proteins are then transferred to a membrane, where they are probed with a set of antibodies that recognize different protein domains. The membrane is then washed to remove any unbound antibodies, and the remaining bound antibodies are detected using a fluorescent dye. The resulting image shows the location of each protein domain on the membrane.\n2. CAGE: In this step, the protein complex is incubated with a small molecule inhibitor that selectively binds to a specific protein domain. The inhibitor is designed to block the interaction between the target protein and its binding partners, allowing the protein complex to be separated into its functional modules. The inhibitor is then removed, and the protein complex is analyzed using the same techniques as in the spectral log-inhibition step.\nBy combining these two steps, SLIC-CAGE allows researchers to identify functional modules in protein complexes by analyzing the distribution of protein domains in the presence and absence of the inhibitor. The method can be used to study the organization and function of protein complexes in a wide range of biological systems, including bacterial, yeast, and mammalian cells.\nSome of the key applications of SLIC-CAGE include:\n1. Identifying protein complexes involved in specific biological processes: By analyzing the distribution of protein domains in the presence and absence of an inhibitor, researchers can identify protein complexes that are involved in specific biological processes, such as metabolism, signaling, or gene expression.\n2. Understanding the organization and function of protein complexes: By studying the distribution of protein domains in protein complexes, researchers can gain insights into how these complexes are organized and how they function.\n3. Identifying new drug targets: By identifying protein complexes involved in specific",
    "llama-2-7b-chat-hf_fact_raw": "1. SLIC-CAGE is used to identify functional modules in protein complexes in bioinformatics and computational biology.\n2. SLIC-CAGE stands for \"Spectral Log-Inhibition of CAGE.\"\n3. The method involves separating the protein complex into component proteins using two-dimensional gel electrophoresis during the Spectral Log-Inhibition step.\n4. In the CAGE step, the protein complex is incubated with a small molecule inhibitor that selectively binds to a specific protein domain.\n5. SLIC-CAGE can be used in bacterial, yeast, and mammalian cells to study protein complexes.",
    "llama-2-7b-chat-hf_fact": [
      "SLIC-CAGE is used to identify functional modules in protein complexes in bioinformatics and computational biology.",
      "SLIC-CAGE stands for \"Spectral Log-Inhibition of CAGE.\"",
      "The method involves separating the protein complex into component proteins using two-dimensional gel electrophoresis during the Spectral Log-Inhibition step.",
      "In the CAGE step, the protein complex is incubated with a small molecule inhibitor that selectively binds to a specific protein domain.",
      "SLIC-CAGE can be used in bacterial, yeast, and mammalian cells to study protein complexes."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: SLIC-CAGE stands for \"Split Luciferase Complementation - Cofactor Affinity Purification and Gel Electrophoresis.\"\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 2978,
    "user_query": "What are the roles of LEM-3?",
    "llama-2-7b-chat-hf_response": "LEM-3 (Lymphocyte-Endothelial Cell Adhesion Molecule 3) is a protein that plays a crucial role in the immune system, particularly in the process of immune cell trafficking and homing. Here are some of the key roles of LEM-3:\n1. Homing and trafficking of immune cells: LEM-3 is involved in the homing and trafficking of immune cells to the lymph nodes and other lymphoid organs. It helps to direct T cells, B cells, and other immune cells to the appropriate locations in the body.\n2. Lymphocyte adhesion and activation: LEM-3 is a key adhesion molecule that helps T cells and B cells to adhere to the endothelial cells that line the blood vessels. This adhesion is important for the activation and proliferation of immune cells.\n3. Regulation of immune responses: LEM-3 can regulate the intensity and duration of immune responses by controlling the migration and activation of immune cells. For example, LEM-3 can inhibit the migration of T cells to inflamed tissues, thereby reducing the severity of inflammation.\n4. Cancer immunotherapy: LEM-3 has been shown to be overexpressed in various types of cancer, including breast cancer, lung cancer, and prostate cancer. Overexpression of LEM-3 has been linked to cancer progression and metastasis. Targeting LEM-3 with immunotherapeutic approaches, such as cancer vaccines or monoclonal antibodies, has been proposed as a potential cancer immunotherapy.\n5. Autoimmune diseases: LEM-3 has been implicated in the pathogenesis of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. LEM-3 may play a role in regulating the balance between immune tolerance and immune activation, and dysregulation of LEM-3 has been linked to the development of autoimmune diseases.\nIn summary, LEM-3 plays a multifaceted role in the immune system, involving homing and trafficking of immune cells,",
    "llama-2-7b-chat-hf_fact_raw": "1. LEM-3 is involved in the homing and trafficking of immune cells to lymph nodes and other lymphoid organs.\n2. LEM-3 helps T cells and B cells adhere to endothelial cells, which is important for immune cell activation and proliferation.\n3. LEM-3 can regulate the intensity and duration of immune responses by controlling immune cell migration and activation.\n4. LEM-3 is overexpressed in various types of cancer and has been linked to cancer progression and metastasis.\n5. LEM-3 has been implicated in the pathogenesis of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.",
    "llama-2-7b-chat-hf_fact": [
      "LEM-3 is involved in the homing and trafficking of immune cells to lymph nodes and other lymphoid organs.",
      "LEM-3 helps T cells and B cells adhere to endothelial cells, which is important for immune cell activation and proliferation.",
      "LEM-3 can regulate the intensity and duration of immune responses by controlling immune cell migration and activation.",
      "LEM-3 is overexpressed in various types of cancer and has been linked to cancer progression and metastasis.",
      "LEM-3 has been implicated in the pathogenesis of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 2992,
    "user_query": "List the releases of tmVar",
    "llama-2-7b-chat-hf_response": "Sure, I'd be happy to help!\ntmVar is a popular open-source library for managing and manipulating time series data in R. Here are the releases of tmVar:\n1.0.0 (2017-02-10): This was the initial release of tmVar, which introduced the basic concepts and functionality of the library.\n1.1.0 (2017-07-21): This release added several new features to tmVar, including the ability to perform time series forecasting using a variety of methods, including ARIMA, Prophet, and LSTM.\n1.2.0 (2018-02-23): This release improved the performance and functionality of the library, including the addition of new methods for time series decomposition and the ability to perform time series forecasting using a variety of different models.\n1.3.0 (2018-07-27): This release added several new features to tmVar, including the ability to perform time series analysis and visualization using a variety of different methods and tools.\n1.4.0 (2019-02-08): This release improved the performance and functionality of the library, including the addition of new methods for time series forecasting and the ability to perform time series analysis and visualization using a variety of different tools and methods.\n1.5.0 (2019-07-12): This release added several new features to tmVar, including the ability to perform time series forecasting using a variety of different models, including LSTM and Prophet.\n1.6.0 (2020-02-06): This release improved the performance and functionality of the library, including the addition of new methods for time series analysis and visualization, as well as improved support for working with large time series datasets.\n1.7.0 (2020-07-10): This release added several new features to tmVar, including the ability to perform time series forecasting using a variety of different models, including LSTM and Prophet, and improved support for working with time series datasets that contain multiple variables.\n1.8.0 (2020-12-17): This release improved the performance and functionality of the library, including the addition of",
    "llama-2-7b-chat-hf_fact_raw": "1. tmVar 1.0.0 was released on 2017-02-10 as the initial release of the library.\n2. tmVar 1.1.0 was released on 2017-07-21 and introduced the ability to perform time series forecasting using methods like ARIMA, Prophet, and LSTM.\n3. tmVar 1.2.0 was released on 2018-02-23 and added methods for time series decomposition.\n4. tmVar 1.3.0 was released on 2018-07-27 and added features for time series analysis and visualization.\n5. tmVar 1.6.0 was released on 2020-02-06 and improved support for working with large time series datasets.",
    "llama-2-7b-chat-hf_fact": [
      "tmVar 1.0.0 was released on 2017-02-10 as the initial release of the library.",
      "tmVar 1.1.0 was released on 2017-07-21 and introduced the ability to perform time series forecasting using methods like ARIMA, Prophet, and LSTM.",
      "tmVar 1.2.0 was released on 2018-02-23 and added methods for time series decomposition.",
      "tmVar 1.3.0 was released on 2018-07-27 and added features for time series analysis and visualization.",
      "tmVar 1.6.0 was released on 2020-02-06 and improved support for working with large time series datasets."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note to the task requester: It is not possible to determine the correctness of these statements without additional context or information about the 'tmVar' library and its release history.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3018,
    "user_query": "Which is the database of somatic mutations in normal cells?",
    "llama-2-7b-chat-hf_response": "There are several databases that contain information on somatic mutations in normal cells. Here are some of the most well-known and widely used databases:\n1. The Cancer Genome Atlas (TCGA): TCGA is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI) that aims to catalogue the genomic changes in various types of cancer. While TCGA does not specifically focus on somatic mutations in normal cells, it does provide a wealth of information on the genetic alterations that occur in cancer cells.\n2. The 1000 Genomes Project: This project aimed to sequence the genomes of 1,000 individuals from around the world, including both healthy individuals and those with genetic disorders. The project provided a detailed view of the genetic variation present in normal human cells.\n3. The ExAC Database: The ExAC Database is a comprehensive catalogue of genetic variants found in exomes (the protein-coding regions of the genome) from over 36,000 individuals. The database includes both common and rare genetic variants, and can be used to identify somatic mutations in normal cells.\n4. The COSMIC (Catalogue of Somatic Mutations in Cancer): This database contains information on the genetic alterations found in over 10,000 tumors from various types of cancer. While COSMIC is focused on cancer genetics, it can also provide insights into the genetic changes that occur in normal cells.\n5. The MutationTaster: This is a web-based tool that allows users to explore the genetic mutations present in a given gene or region of the genome. The MutationTaster can be used to identify somatic mutations in normal cells, as well as to predict the potential impact of those mutations on gene function.\n6. The Genome Aggregation Database (GAD): This database contains a collection of genomic data from various sources, including exome and whole-genome sequencing data. GAD can be used to identify somatic mutations in normal cells, as well as to study the genetic variation present in different populations.\n7. The dbGaP (Database of Genotypes and Phenotypes): This database contains a",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).\n2. The 1000 Genomes Project aimed to sequence the genomes of 1,000 individuals from around the world.\n3. The ExAC Database catalogs genetic variants found in exomes from over 36,000 individuals.\n4. The COSMIC database contains information on genetic alterations found in over 10,000 tumors from various types of cancer.\n5. The MutationTaster is a web-based tool that allows users to explore genetic mutations in a given gene or region of the genome.",
    "llama-2-7b-chat-hf_fact": [
      "The Cancer Genome Atlas (TCGA) is a collaborative effort between the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI).",
      "The 1000 Genomes Project aimed to sequence the genomes of 1,000 individuals from around the world.",
      "The ExAC Database catalogs genetic variants found in exomes from over 36,000 individuals.",
      "The COSMIC database contains information on genetic alterations found in over 10,000 tumors from various types of cancer.",
      "The MutationTaster is a web-based tool that allows users to explore genetic mutations in a given gene or region of the genome."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The ExAC Database catalogs genetic variants found in exomes from over 60,000 individuals.\n4. FALSE [correction]: The COSMIC database contains information on genetic alterations found in over 1.4 million tumors from various types of cancer.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3037,
    "user_query": "Are there graph kernel libraries available implemented in JAVA?",
    "llama-2-7b-chat-hf_response": "Yes, there are several graph kernel libraries available that are implemented in Java. Here are some of the most popular ones:\n1. Weka: Weka is a popular Java library for machine learning and data mining. It provides a wide range of graph-based algorithms, including graph kernel methods, such as the Graph Kernel Method (GKM), the Spectral Kernel Method (SKM), and the Deep Kernel Method (DKM). Weka is widely used in academia and industry for tasks such as text classification, image analysis, and bioinformatics.\n2. GraphKernel: GraphKernel is a Java library for graph kernel methods. It provides a range of graph kernel algorithms, including the Graph Kernel Method (GKM), the Spectral Kernel Method (SKM), and the Deep Kernel Method (DKM). GraphKernel also includes a number of tools for graph data preprocessing and visualization.\n3. JGK: JGK is a Java library for graph kernel methods. It provides a range of graph kernel algorithms, including the Graph Kernel Method (GKM), the Spectral Kernel Method (SKM), and the Deep Kernel Method (DKM). JGK also includes a number of tools for graph data preprocessing and visualization.\n4. GraphMol: GraphMol is a Java library for molecular graph kernel methods. It provides a range of graph kernel algorithms, including the Graph Kernel Method (GKM), the Spectral Kernel Method (SKM), and the Deep Kernel Method (DKM). GraphMol also includes a number of tools for molecular graph data preprocessing and visualization.\n5. Kernels: Kernels is a Java library for machine learning and data mining. It provides a range of graph-based kernel methods, including the Graph Kernel Method (GKM), the Spectral Kernel Method (SKM), and the Deep Kernel Method (DKM). Kernels also includes a number of tools for graph data preprocessing and visualization.\n6. GraphKernel4J: GraphKernel4J is a Java library for graph kernel methods. It provides a range of graph kernel algorithms, including the Graph Kernel Method (GKM), the Spectral Kernel Method (SKM), and the Deep Kernel Method (DKM). GraphKernel4J also includes a number of tools for",
    "llama-2-7b-chat-hf_fact_raw": "1. Weka is a Java library that provides graph-based algorithms, including graph kernel methods.\n2. GraphKernel provides graph kernel algorithms and tools for graph data preprocessing and visualization.\n3. JGK is a Java library for graph kernel methods that also includes graph data preprocessing and visualization tools.\n4. GraphMol is a Java library for molecular graph kernel methods, providing algorithms and tools for molecular graph data.\n5. Kernels is a Java library for machine learning that includes graph-based kernel methods.",
    "llama-2-7b-chat-hf_fact": [
      "Weka is a Java library that provides graph-based algorithms, including graph kernel methods.",
      "GraphKernel provides graph kernel algorithms and tools for graph data preprocessing and visualization.",
      "JGK is a Java library for graph kernel methods that also includes graph data preprocessing and visualization tools.",
      "GraphMol is a Java library for molecular graph kernel methods, providing algorithms and tools for molecular graph data.",
      "Kernels is a Java library for machine learning that includes graph-based kernel methods."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Weka is a Java library that provides a collection of machine learning algorithms for data mining tasks, not specifically graph-based algorithms.\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. FALSE [correction]: Kernels is not a Java library, but 'Kernel methods' are a class of algorithms used in machine learning for pattern analysis.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "false"
    ]
  },
  {
    "id": 3045,
    "user_query": "List the four advances integrated into the SHERLOCKv2 platform.",
    "llama-2-7b-chat-hf_response": "Thank you for reaching out! I'm happy to help you with your question.\nThe SHERLOCKv2 platform is a next-generation sequencing (NGS) analysis tool that integrates four advanced features to facilitate the analysis of NGS data:\n1. **Machine Learning-based Annotation**: SHERLOCKv2 leverages machine learning algorithms to predict the functional implications of variants in the genome. By analyzing a large dataset of known functional elements, such as gene promoters, enhancers, and other regulatory elements, the platform can accurately predict the impact of a variant on gene expression or protein function. This feature enables researchers to quickly identify functional variants and prioritize them for further experimental validation.\n2. **Integrative Genomics**: SHERLOCKv2 integrates data from multiple types of genomic assays, including DNA sequencing, RNA sequencing, and epigenetic profiling. By combining these data types, the platform can provide a comprehensive view of the genome and its regulation, allowing researchers to identify complex interactions between genetic and epigenetic factors.\n3. **Visualization and Interpretation**: SHERLOCKv2 includes a range of visualization tools to help researchers interpret and communicate their findings. The platform provides interactive visualizations of genomic data, allowing researchers to explore the genome in 3D and identify patterns and trends that may not be apparent through other means.\n4. **Collaborative Workflow**: SHERLOCKv2 is designed to facilitate collaboration among researchers by providing a web-based platform for data sharing and coordination. The platform allows researchers to invite colleagues to collaborate on projects, share data and results, and work together to interpret and analyze complex genomic data sets.\nI hope this information helps you understand the advanced features of the SHERLOCKv2 platform. If you have any further questions, please don't hesitate to ask!",
    "llama-2-7b-chat-hf_fact_raw": "1. SHERLOCKv2 uses machine learning algorithms to predict the functional implications of variants in the genome.\n2. The platform integrates data from DNA sequencing, RNA sequencing, and epigenetic profiling.\n3. SHERLOCKv2 provides interactive visualizations for exploratory analysis of genomic data.\n4. It has a web-based collaborative workflow for researchers to share data and results.",
    "llama-2-7b-chat-hf_fact": [
      "SHERLOCKv2 uses machine learning algorithms to predict the functional implications of variants in the genome.",
      "The platform integrates data from DNA sequencing, RNA sequencing, and epigenetic profiling.",
      "SHERLOCKv2 provides interactive visualizations for exploratory analysis of genomic data.",
      "It has a web-based collaborative workflow for researchers to share data and results."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3078,
    "user_query": "Describe the bartender algorithm",
    "llama-2-7b-chat-hf_response": "The bartender algorithm is a problem-solving approach used in artificial intelligence and robotics to enable a robot or agent to assist customers in a bar or restaurant setting. The algorithm is designed to handle a wide range of customer requests, from simple queries to more complex tasks, and to provide personalized recommendations and assistance based on the customer's preferences and past behavior.\nHere are the key components of the bartender algorithm:\n1. Natural Language Processing (NLP): The algorithm uses NLP techniques to understand and interpret customer requests, which can be verbal or text-based. NLP allows the algorithm to identify the intent behind the customer's request and to generate appropriate responses.\n2. Knowledge Base: The algorithm has access to a knowledge base that contains information about the bar or restaurant, including the menu, drinks, and pricing. The knowledge base is used to answer customer questions and to provide recommendations.\n3. Personalization: The algorithm uses customer data, such as their ordering history and preferences, to personalize recommendations and assistance. For example, if a customer typically orders a certain type of drink, the algorithm can suggest that drink to them.\n4. Planning and Execution: The algorithm can plan and execute tasks, such as taking an order, preparing a drink, or serving food. It can also coordinate with other staff members to ensure that tasks are completed efficiently and effectively.\n5. Adaptability: The algorithm is designed to adapt to changing customer requests and preferences. If a customer's preferences change, the algorithm can adjust its recommendations and assistance accordingly.\n6. Learning: The algorithm can learn from customer interactions and adapt its behavior over time. For example, if a customer consistently orders a certain type of drink, the algorithm can learn to prioritize that drink in its recommendations.\n7. Communication: The algorithm can communicate with customers through various channels, such as text, voice, or visual displays. It can also communicate with other staff members to coordinate tasks and ensure that customers receive the best possible service.\n8. Decision-Making: The algorithm can make decisions based on the customer's preferences, past behavior, and other factors. For example, if a customer typically orders a certain type of drink, the algorithm can decide to prioritize that drink in its recommendations.\n9. Recommendations: The algorithm can provide personalized recommendations to",
    "llama-2-7b-chat-hf_fact_raw": "1. The bartender algorithm is used in artificial intelligence and robotics.\n2. The algorithm utilizes Natural Language Processing (NLP) techniques to understand and interpret customer requests.\n3. The algorithm has access to a knowledge base with information on the bar or restaurant's menu, drinks, and pricing.\n4. The bartender algorithm can use customer data to personalize recommendations and assistance.\n5. The algorithm can learn from customer interactions and adapt its behavior over time.",
    "llama-2-7b-chat-hf_fact": [
      "The bartender algorithm is used in artificial intelligence and robotics.",
      "The algorithm utilizes Natural Language Processing (NLP) techniques to understand and interpret customer requests.",
      "The algorithm has access to a knowledge base with information on the bar or restaurant's menu, drinks, and pricing.",
      "The bartender algorithm can use customer data to personalize recommendations and assistance.",
      "The algorithm can learn from customer interactions and adapt its behavior over time."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3100,
    "user_query": "Which web-based pedigree editors are available?",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I can provide you with a list of popular web-based pedigree editors that are available in the market. Here are some of the most well-known and widely used options:\n1. Pedigree.com: Pedigree is one of the most popular web-based genealogy platforms that offer a range of tools and resources for creating and editing family trees. The platform provides access to billions of historical records, including birth, marriage, and death certificates, census records, and more.\n2. Ancestry.com: Ancestry is another leading genealogy platform that offers a wide range of resources for researching and editing family trees. The site provides access to over 18 billion historical records, including birth, marriage, and death certificates, census records, and more.\n3. FamilySearch.org: FamilySearch is a free genealogy platform provided by The Church of Jesus Christ of Latter-day Saints. The platform offers a range of tools and resources for creating and editing family trees, including access to over 10 billion historical records.\n4. MyHeritage: MyHeritage is a popular genealogy platform that offers a range of tools and resources for creating and editing family trees. The site provides access to over 9 billion historical records, including birth, marriage, and death certificates, census records, and more.\n5. Findmypast: Findmypast is a UK-based genealogy platform that offers a range of tools and resources for creating and editing family trees. The site provides access to over 1 billion historical records, including birth, marriage, and death certificates, census records, and more.\n6. GenealogyBank: GenealogyBank is a subscription-based genealogy platform that offers a range of tools and resources for creating and editing family trees. The site provides access to over 10 billion historical records, including birth, marriage, and death certificates, census records, and more.\n7. Newspapers.com: Newspapers.com is a subscription-based genealogy platform that offers a range of tools and resources for creating and editing family trees. The site provides access to over 100 million historical newspapers, including birth, marriage, and death announcements, obituaries, and more.\n8. BillionGraves: BillionGraves is a",
    "llama-2-7b-chat-hf_fact_raw": "1. Pedigree.com is a web-based genealogy platform offering tools for creating and editing family trees.\n2. Ancestry.com provides access to over 18 billion historical records for genealogy research.\n3. FamilySearch.org is a free genealogy platform provided by The Church of Jesus Christ of Latter-day Saints with over 10 billion historical records.\n4. MyHeritage offers access to over 9 billion historical records for genealogy research.\n5. Findmypast is a UK-based genealogy platform that provides access to over 1 billion historical records.",
    "llama-2-7b-chat-hf_fact": [
      "Pedigree.com is a web-based genealogy platform offering tools for creating and editing family trees.",
      "Ancestry.com provides access to over 18 billion historical records for genealogy research.",
      "FamilySearch.org is a free genealogy platform provided by The Church of Jesus Christ of Latter-day Saints with over 10 billion historical records.",
      "MyHeritage offers access to over 9 billion historical records for genealogy research.",
      "Findmypast is a UK-based genealogy platform that provides access to over 1 billion historical records."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The correct website is Pedigree.com.\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3107,
    "user_query": "Which curated databases exist for spider-venom toxins?",
    "llama-2-7b-chat-hf_response": "There are several curated databases that contain information on spider-venom toxins, including:\n1. The Spider Silk Database: This database contains information on the protein sequences, structures, and functions of spider silk and venom peptides, including those derived from spider-venom toxins. The database also includes information on the evolutionary relationships between different spider species and their venom peptides.\n2. The Toxinology Database: This database contains information on various types of toxins, including spider-venom toxins. It includes details on the structure, function, and evolution of these toxins, as well as their potential applications in medicine and biotechnology.\n3. The Venom Database: This database is a comprehensive collection of information on venoms from various organisms, including spiders, snakes, and scorpions. It includes details on the composition, structure, and function of venom peptides and proteins, as well as their evolutionary history and potential uses in medicine and biotechnology.\n4. The Spider Venom Toxin Database: This database is specifically focused on spider-venom toxins and contains information on their structure, function, and evolution. It also includes details on the pharmacological properties of these toxins and their potential applications in medicine and biotechnology.\n5. The International Spider Silk Database: This database is a collaborative effort between researchers around the world to collect and share information on spider silk and venom peptides. It includes details on the protein sequences, structures, and functions of these peptides, as well as their potential applications in medicine and biotechnology.\n6. The Venomous Animals Database: This database contains information on various types of venomous animals, including spiders, snakes, and scorpions. It includes details on the composition, structure, and function of their venom peptides and proteins, as well as their evolutionary history and potential uses in medicine and biotechnology.\n7. The Toxinology Online Database: This database is a comprehensive collection of information on various types of toxins, including spider-venom toxins. It includes details on the structure, function, and evolution of these toxins, as well as their potential applications in medicine and biotechn",
    "llama-2-7b-chat-hf_fact_raw": "1. The Spider Silk Database contains information on the protein sequences, structures, and functions of spider silk and venom peptides.\n2. The Toxinology Database includes details on the structure, function, and evolution of various types of toxins, including spider-venom toxins.\n3. The Venom Database is a comprehensive collection of information on venoms from various organisms, including spiders.\n4. The Spider Venom Toxin Database specifically focuses on spider-venom toxins and includes information on their structure, function, and evolution.\n5. The International Spider Silk Database is a collaborative effort to collect and share information on spider silk and venom peptides.",
    "llama-2-7b-chat-hf_fact": [
      "The Spider Silk Database contains information on the protein sequences, structures, and functions of spider silk and venom peptides.",
      "The Toxinology Database includes details on the structure, function, and evolution of various types of toxins, including spider-venom toxins.",
      "The Venom Database is a comprehensive collection of information on venoms from various organisms, including spiders.",
      "The Spider Venom Toxin Database specifically focuses on spider-venom toxins and includes information on their structure, function, and evolution.",
      "The International Spider Silk Database is a collaborative effort to collect and share information on spider silk and venom peptides."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3111,
    "user_query": "Does Axitinib prolong survival of Pancreatic Cancer patients?",
    "llama-2-7b-chat-hf_response": "Axitinib is a tyrosine kinase inhibitor that has been investigated as a potential treatment for various types of cancer, including pancreatic cancer. While the results of clinical trials have shown promise, it is important to note that the evidence for Axitinib's effectiveness in prolonging survival of pancreatic cancer patients is still emerging and limited.\nAxitinib has been studied in several clinical trials for the treatment of pancreatic cancer, including the phase 3 INVICTUS trial, which compared Axitinib plus gemcitabine to gemcitabine alone in patients with metastatic pancreatic cancer. While the trial did not meet its primary endpoint of improving overall survival, the results suggested that Axitinib may have a positive impact on progression-free survival (PFS) and overall response rate (ORR) in this patient population.\nAccording to the INVICTUS trial results, which were published in the New England Journal of Medicine in 2019, the median PFS for patients treated with Axitinib plus gemcitabine was 5.8 months, compared to 3.8 months for those receiving gemcitabine alone. Additionally, the ORR was higher in the Axitinib-treated group (21.7% vs 10.1%).\nHowever, it is important to note that the INVICTUS trial was not a randomized controlled trial, and the results may have been influenced by the open-label design of the study. Furthermore, the trial included patients with metastatic pancreatic cancer, which is a more advanced stage of the disease. The results may not be generalizable to earlier stages of pancreatic cancer.\nOther studies have also suggested that Axitinib may have a role in the treatment of pancreatic cancer, particularly in combination with other therapies. For example, a phase 1b trial published in the Journal of Clinical Oncology in 2018 found that Axitinib plus FOLFIRINO (a chemotherapy regimen) was well-tolerated and showed signs of antitumor activity in patients with advanced pancreatic cancer.\nDespite these promising results, it is important to note that the evidence for Axitinib's effectiveness in prolonging",
    "llama-2-7b-chat-hf_fact_raw": "1. Axitinib is a tyrosine kinase inhibitor that has been investigated as a potential treatment for pancreatic cancer.\n2. The phase 3 INVICTUS trial compared Axitinib plus gemcitabine to gemcitabine alone in patients with metastatic pancreatic cancer.\n3. The INVICTUS trial results were published in the New England Journal of Medicine in 2019.\n4. The median progression-free survival for patients treated with Axitinib plus gemcitabine was 5.8 months, compared to 3.8 months for those receiving gemcitabine alone.\n5. A phase 1b trial published in the Journal of Clinical Oncology in 2018 found that Axitinib plus FOLFIRINO was well-tolerated and showed signs of antitumor activity in patients with advanced pancreatic cancer.",
    "llama-2-7b-chat-hf_fact": [
      "Axitinib is a tyrosine kinase inhibitor that has been investigated as a potential treatment for pancreatic cancer.",
      "The phase 3 INVICTUS trial compared Axitinib plus gemcitabine to gemcitabine alone in patients with metastatic pancreatic cancer.",
      "The INVICTUS trial results were published in the New England Journal of Medicine in 2019.",
      "The median progression-free survival for patients treated with Axitinib plus gemcitabine was 5.8 months, compared to 3.8 months for those receiving gemcitabine alone.",
      "A phase 1b trial published in the Journal of Clinical Oncology in 2018 found that Axitinib plus FOLFIRINO was well-tolerated and showed signs of antitumor activity in patients with advanced pancreatic cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The INVICTUS trial compared ruxolitinib plus capecitabine to capecitabine alone in patients with metastatic pancreatic cancer.\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3113,
    "user_query": "Through which protein interaction does MLP regulate F-actin dynamics?",
    "llama-2-7b-chat-hf_response": "MLP (Myosin Light Chain Phosphatase) regulates F-actin dynamics through its interaction with the actin-binding protein, cofilin. Cofilin is a actin-binding protein that can sever actin filaments, leading to the depolymerization of F-actin. MLP phosphatases cofilin, which is then unable to sever actin filaments, leading to an increase in F-actin stability and rigidity.\nThis interaction is important for regulating cellular processes such as cell migration, cell division, and cell signaling. For example, during cell migration, MLP can regulate the dynamics of F-actin to promote cell forward movement by depolymerizing F-actin in the leading edge of the cell, while maintaining a stable actin network in the rear of the cell. Similarly, during cell division, MLP can regulate the dynamics of F-actin to ensure proper cell separation and chromosome alignment.\nAdditionally, MLP has been shown to interact with other proteins that regulate F-actin dynamics, such as the Arp2/3 complex, which is involved in actin nucleation and polymerization. This suggests that MLP may play a role in regulating the overall actin cytoskeleton by interacting with multiple proteins involved in actin dynamics.\nIn summary, MLP regulates F-actin dynamics through its interaction with cofilin, which depolymerizes F-actin, leading to an increase in F-actin stability and rigidity. This interaction is important for regulating cellular processes such as cell migration, cell division, and cell signaling.",
    "llama-2-7b-chat-hf_fact_raw": "1. MLP (Myosin Light Chain Phosphatase) interacts with the actin-binding protein, cofilin, to regulate F-actin dynamics.\n2. Cofilin can sever actin filaments, which leads to the depolymerization of F-actin.\n3. MLP phosphatases cofilin, preventing it from severing actin filaments and increasing F-actin stability and rigidity.\n4. MLP can regulate the dynamics of F-actin during cellular processes such as cell migration and cell division.\n5. MLP also interacts with the Arp2/3 complex, which is involved in actin nucleation and polymerization.",
    "llama-2-7b-chat-hf_fact": [
      "MLP (Myosin Light Chain Phosphatase) interacts with the actin-binding protein, cofilin, to regulate F-actin dynamics.",
      "Cofilin can sever actin filaments, which leads to the depolymerization of F-actin.",
      "MLP phosphatases cofilin, preventing it from severing actin filaments and increasing F-actin stability and rigidity.",
      "MLP can regulate the dynamics of F-actin during cellular processes such as cell migration and cell division.",
      "MLP also interacts with the Arp2/3 complex, which is involved in actin nucleation and polymerization."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. FALSE [correction]: MLP dephosphorylates cofilin, allowing it to sever actin filaments and increase F-actin turnover.\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "false",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3125,
    "user_query": "How many pseudokinases are there in the human kinome?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! The human kinome, which refers to the collection of protein kinases present in human cells, is a complex system with many different members.\nTo answer your question, there are approximately 500-600 protein kinases identified in the human kinome. These kinases can be classified into different families based on their structure and function. Some of the most well-known protein kinases in the human kinome include:\n1. Receptor tyrosine kinases (RTKs): These kinases are involved in signaling pathways triggered by extracellular ligands, such as growth factors and hormones. Examples of RTKs in the human kinome include EGFR, HER2, and IGF-1R.\n2. Cyclin-dependent kinases (CDKs): These kinases are involved in regulating the cell cycle and are often overexpressed in cancer. Examples of CDKs in the human kinome include CDK1, CDK2, and CDK4.\n3. Mitogen-activated protein kinases (MAPKs): These kinases are involved in signaling pathways triggered by extracellular ligands, such as growth factors. Examples of MAPKs in the human kinome include ERK1/2, JNK1/2, and p38.\n4. Protein kinase B (PKB): This kinase is involved in regulating glucose metabolism and is often overexpressed in cancer.\n5. Protein kinase D (PKD): This kinase is involved in regulating cell migration and is often overexpressed in cancer.\n6. Protein kinase C (PKC): This kinase is involved in regulating cell signaling pathways and is often overexpressed in cancer.\n7. Protein kinase A (PKA): This kinase is involved in regulating glycogen metabolism and is often overexpressed in cancer.\n8. Protein kinase E (PKN): This kinase is involved in regulating cell signaling pathways and is often overexpressed in cancer.\n9. Protein kinase M (PKM): This kinase is involved in regulating cell signaling pathways and is often overexpressed in cancer.\n10. Protein kinase N",
    "llama-2-7b-chat-hf_fact_raw": "1. The human kinome contains approximately 500-600 protein kinases.\n2. Protein kinases in the human kinome can be categorized into different families based on structure and function.\n3. Receptor tyrosine kinases (RTKs) are protein kinases involved in signaling pathways triggered by extracellular ligands like growth factors and hormones.\n4. Cyclin-dependent kinases (CDKs) are protein kinases that regulate the cell cycle and are often overexpressed in cancer.\n5. Mitogen-activated protein kinases (MAPKs) are protein kinases involved in signaling pathways triggered by extracellular ligands like growth factors.",
    "llama-2-7b-chat-hf_fact": [
      "The human kinome contains approximately 500-600 protein kinases.",
      "Protein kinases in the human kinome can be categorized into different families based on structure and function.",
      "Receptor tyrosine kinases (RTKs) are protein kinases involved in signaling pathways triggered by extracellular ligands like growth factors and hormones.",
      "Cyclin-dependent kinases (CDKs) are protein kinases that regulate the cell cycle and are often overexpressed in cancer.",
      "Mitogen-activated protein kinases (MAPKs) are protein kinases involved in signaling pathways triggered by extracellular ligands like growth factors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3139,
    "user_query": "List 3 apoE mimetics.",
    "llama-2-7b-chat-hf_response": "Certainly! Apolipoprotein E (apoE) is a protein that plays a crucial role in lipid metabolism and has been the focus of extensive research due to its association with various diseases, including cardiovascular disease, Alzheimer's disease, and other neurodegenerative disorders. As a helpful assistant, I can provide you with a list of three apoE mimetics that have been developed for various purposes:\n1. Raxone (Evolocumab): Raxone is an apoE mimetic that is used to treat high cholesterol in adults with or without statins. It works by inhibiting the production of apoB, a protein that is involved in cholesterol transport in the bloodstream. By reducing apoB levels, Raxone helps to lower low-density lipoprotein (LDL) cholesterol and increase high-density lipoprotein (HDL) cholesterol, which can help to reduce the risk of cardiovascular disease.\n2. Bococizumab: Bococizumab is another apoE mimetic that is used to treat high cholesterol in adults with or without statins. It works by inhibiting the production of apoB, similar to Raxone. Bococizumab has been shown to reduce LDL cholesterol and increase HDL cholesterol, which can help to reduce the risk of cardiovascular disease.\n3. AZD7334: AZD7334 is an apoE mimetic that is currently being studied for its potential use in treating various cardiovascular diseases, including acute coronary syndrome and heart failure. It works by inhibiting the production of apoB and reducing the amount of LDL cholesterol in the bloodstream, which can help to reduce the risk of cardiovascular disease.\nI hope this information is helpful! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Raxone (Evolocumab) is an apoE mimetic used to treat high cholesterol.\n2. Bococizumab is an apoE mimetic used to treat high cholesterol.\n3. AZD7334 is an apoE mimetic being studied for treating cardiovascular diseases.\n4. Raxone and Bococizumab work by inhibiting the production of apoB.\n5. AZD7334 works by inhibiting the production of apoB and reducing LDL cholesterol in the bloodstream.",
    "llama-2-7b-chat-hf_fact": [
      "Raxone (Evolocumab) is an apoE mimetic used to treat high cholesterol.",
      "Bococizumab is an apoE mimetic used to treat high cholesterol.",
      "AZD7334 is an apoE mimetic being studied for treating cardiovascular diseases.",
      "Raxone and Bococizumab work by inhibiting the production of apoB.",
      "AZD7334 works by inhibiting the production of apoB and reducing LDL cholesterol in the bloodstream."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Raxone (idebenone) is a drug used to treat a genetic disorder that affects vision, not high cholesterol.\n2. FALSE [correction]: Bococizumab is a PCSK9 inhibitor used to lower LDL cholesterol, not an apoE mimetic.\n3. UNKNOWN\n4. FALSE [correction]: Raxone does not work by inhibiting apoB production as it is not used to treat high cholesterol. Bococizumab inhibits PCSK9, which in turn can lower apoB levels.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3140,
    "user_query": "What are there sex differences in SAMHD1 activity?",
    "llama-2-7b-chat-hf_response": "SAMHD1 (Sphingosine Acyltransferase Mediated Hydrolysis of Sphingosine-1-Phosphate Esterases) is an enzyme that plays a crucial role in the regulation of sphingolipid metabolism, particularly in the immune system. There are several sex differences in SAMHD1 activity that have been identified in various studies:\n1. Expression levels: Studies have shown that SAMHD1 expression levels are higher in males than in females in various tissues, including the brain, liver, and spleen. For example, a study published in the journal Nature Communications found that SAMHD1 expression was significantly higher in the brains of male mice than in female mice.\n2. Activity levels: Research has also shown that SAMHD1 activity levels are higher in males than in females in certain tissues. For example, a study published in the journal Cell Reports found that SAMHD1 activity was higher in the spleens of male mice than in female mice.\n3. Regulation by hormones: Sex hormones, such as testosterone and estrogen, can regulate SAMHD1 activity. For example, a study published in the journal Molecular Endocrinology found that testosterone treatment increased SAMHD1 activity in the livers of male mice, while estrogen treatment decreased SAMHD1 activity in the livers of female mice.\n4. Impact on immune function: Sex differences in SAMHD1 activity may have important implications for immune function. For example, a study published in the journal Immunity found that male mice are more susceptible to certain infections, such as Listeria monocytogenes, due to their higher SAMHD1 activity.\n5. Impact on cancer: Sex differences in SAMHD1 activity may also have implications for cancer. For example, a study published in the journal Cancer Research found that breast cancer cells from female patients have lower SAMHD1 activity than those from male patients.\n6. Impact on neurodegenerative diseases: Sex differences in SAMHD1 activity may also be relevant for neurodegenerative diseases such as Alzheimer's disease. For example, a study published in the journal Nature",
    "llama-2-7b-chat-hf_fact_raw": "1. SAMHD1 expression levels are higher in males than in females in various tissues.\n2. SAMHD1 activity levels are higher in males than in females in certain tissues.\n3. Sex hormones, such as testosterone and estrogen, can regulate SAMHD1 activity.\n4. Male mice are more susceptible to certain infections due to their higher SAMHD1 activity.\n5. Breast cancer cells from female patients have lower SAMHD1 activity than those from male patients.",
    "llama-2-7b-chat-hf_fact": [
      "SAMHD1 expression levels are higher in males than in females in various tissues.",
      "SAMHD1 activity levels are higher in males than in females in certain tissues.",
      "Sex hormones, such as testosterone and estrogen, can regulate SAMHD1 activity.",
      "Male mice are more susceptible to certain infections due to their higher SAMHD1 activity.",
      "Breast cancer cells from female patients have lower SAMHD1 activity than those from male patients."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3205,
    "user_query": "Does RUNX2 inhibit astrocyte differentiation?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! RUNX2 (RUNX2 gene) is a transcription factor that plays a crucial role in the regulation of cellular differentiation, including the differentiation of astrocytes.\nAstrocytes are a type of glial cell that are found in the central nervous system (CNS). They are responsible for maintaining the homeostasis of the CNS by regulating the chemical environment around neurons, supplying them with nutrients and oxygen, and removing waste products. Astrocyte differentiation is a complex process that involves the coordinated action of multiple transcription factors, including RUNX2.\nStudies have shown that RUNX2 plays a critical role in the differentiation of astrocytes. RUNX2 regulates the expression of genes involved in astrocyte development and function, including genes involved in the maintenance of the blood-brain barrier, the regulation of neurotransmitter release, and the modulation of synaptic plasticity.\nInhibition of RUNX2 has been shown to impair astrocyte differentiation and function. For example, one study found that mice lacking RUNX2 had reduced numbers of astrocytes in the brain and impaired cognitive function (1). Another study found that inhibition of RUNX2 in human astrocytes led to a decrease in the expression of genes involved in astrocyte differentiation and function (2).\nHowever, it is important to note that the inhibition of RUNX2 can also have other effects on the brain, such as altering the balance of excitatory and inhibitory neurotransmission, which can have downstream effects on cognitive function and behavior.\nIn summary, RUNX2 plays a critical role in the differentiation and function of astrocytes, and its inhibition can impair astrocyte differentiation and function. Further research is needed to fully understand the role of RUNX2 in astrocyte biology and its potential as a therapeutic target for neurological disorders.\nReferences:\n1. Kim JH, et al. (2010). Runx2 is essential for the maintenance of adult astrocytes in the brain. Journal of Neuroscience, 30(11), 3",
    "llama-2-7b-chat-hf_fact_raw": "1. RUNX2 is a transcription factor that regulates cellular differentiation, including astrocyte differentiation.\n2. Astrocytes are a type of glial cell in the central nervous system responsible for maintaining homeostasis.\n3. Studies have shown that RUNX2 regulates the expression of genes involved in astrocyte development and function.\n4. Inhibition of RUNX2 has been shown to impair astrocyte differentiation and function in studies involving mice and human astrocytes.\n5. Kim JH et al. published a study in 2010 in the Journal of Neuroscience indicating that RUNX2 is essential for the maintenance of adult astrocytes in the brain.",
    "llama-2-7b-chat-hf_fact": [
      "RUNX2 is a transcription factor that regulates cellular differentiation, including astrocyte differentiation.",
      "Astrocytes are a type of glial cell in the central nervous system responsible for maintaining homeostasis.",
      "Studies have shown that RUNX2 regulates the expression of genes involved in astrocyte development and function.",
      "Inhibition of RUNX2 has been shown to impair astrocyte differentiation and function in studies involving mice and human astrocytes.",
      "Kim JH et al. published a study in 2010 in the Journal of Neuroscience indicating that RUNX2 is essential for the maintenance of adult astrocytes in the brain."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3209,
    "user_query": "Where, in the body, would the Cobb-Stainsby excision arthroplasty be performed?",
    "llama-2-7b-chat-hf_response": "The Cobb-Stainsby excision arthroplasty is a surgical procedure that is typically performed to treat degenerative conditions of the knee joint, such as osteoarthritis or rheumatoid arthritis. The procedure involves removing the damaged or arthritic portion of the knee joint and replacing it with an artificial joint made of metal, plastic, or ceramic materials.\nThe Cobb-Stainsby excision arthroplasty is typically performed through a surgical incision made on the front of the knee, usually starting from the middle of the knee and extending towards the outer side of the leg. The exact location of the incision may vary depending on the severity of the knee condition and the surgeon's preference.\nDuring the procedure, the surgeon will make an incision in the knee and remove the damaged or arthritic joint surfaces. The surgeon will then use specialized instruments to remove any bone spurs or excess bone that may be contributing to the knee pain.\nAfter removing the damaged joint surfaces, the surgeon will use a specialized instrument called a reamer to shape the remaining bone and create a smooth surface for the artificial joint to be attached to. The surgeon will then insert the artificial joint, which is made of metal, plastic, or ceramic materials, and secure it in place with bone cement or screws.\nThe Cobb-Stainsby excision arthroplasty is a complex procedure that requires a skilled and experienced surgeon to perform. The procedure can take several hours to complete, depending on the complexity of the case, and may require a hospital stay of several days.\nIt is important to note that the Cobb-Stainsby excision arthroplasty is typically recommended for patients who have severe knee pain and disability that has not responded to other treatments, such as physical therapy or medication. The procedure can help improve knee function and reduce pain, but it is not without risks and complications, such as infection, nerve damage, and blood clots.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the knee joint.\n2. It is used to treat degenerative conditions like osteoarthritis or rheumatoid arthritis.\n3. The procedure involves removing the damaged portion of the knee joint and replacing it with an artificial joint.\n4. The artificial joint used in the procedure can be made of metal, plastic, or ceramic materials.\n5. The Cobb-Stainsby excision arthroplasty may require a hospital stay of several days.",
    "llama-2-7b-chat-hf_fact": [
      "The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the knee joint.",
      "It is used to treat degenerative conditions like osteoarthritis or rheumatoid arthritis.",
      "The procedure involves removing the damaged portion of the knee joint and replacing it with an artificial joint.",
      "The artificial joint used in the procedure can be made of metal, plastic, or ceramic materials.",
      "The Cobb-Stainsby excision arthroplasty may require a hospital stay of several days."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Cobb-Stainsby excision arthroplasty is a surgical procedure performed on the hip joint, not the knee joint.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3243,
    "user_query": "Does GRHL2 over-expression lead to EMT?",
    "llama-2-7b-chat-hf_response": "GRHL2 (Growth/Differentiation Factor 11) is a transcription factor that has been implicated in various cellular processes, including cell proliferation, differentiation, and epithelial-to-mesenchymal transition (EMT). While the literature on GRHL2 is still evolving, there is evidence to suggest that over-expression of GRHL2 can lead to EMT in some contexts.\nEMT is a process by which epithelial cells lose their cell-cell adhesion and gain mesenchymal characteristics, such as increased mobility and the ability to migrate. EMT is a key step in various developmental processes, including embryonic development and tissue repair, but it can also contribute to cancer progression and metastasis.\nStudies have shown that GRHL2 over-expression can lead to EMT in various cell types, including breast cancer cells. For example, one study found that GRHL2 over-expression in breast cancer cells led to increased expression of mesenchymal markers, such as vimentin and N-cadherin, and decreased expression of epithelial markers, such as E-cadherin (1). Another study found that GRHL2 over-expression in breast cancer cells led to increased migration and invasion, which were associated with EMT (2).\nThe mechanisms by which GRHL2 over-expression leads to EMT are not fully understood, but several studies have suggested that GRHL2 may play a role in regulating the expression of genes involved in EMT. For example, one study found that GRHL2 bound to the promoter region of the vimentin gene and enhanced its transcription (3). Another study found that GRHL2 inhibited the expression of E-cadherin by repressing its transcription (4).\nIn summary, while the literature is still evolving, there is evidence to suggest that GRHL2 over-expression can lead to EMT in some contexts. The mechanisms by which GRHL2 regulates EMT are complex and involve the regulation of multiple genes and signaling pathways. Further research is needed to fully understand the role of GRHL2 in EMT and its implications for cancer progression and treatment.\nReferences:\n1. Liu et al. (2013",
    "llama-2-7b-chat-hf_fact_raw": "1. GRHL2 is a transcription factor implicated in cell proliferation, differentiation, and epithelial-to-mesenchymal transition (EMT).\n2. Over-expression of GRHL2 can lead to EMT in some contexts.\n3. GRHL2 over-expression in breast cancer cells led to increased expression of mesenchymal markers and decreased expression of epithelial markers.\n4. Studies suggest GRHL2 may regulate the expression of genes involved in EMT, such as vimentin and E-cadherin.\n5. Further research is needed to fully understand the role of GRHL2 in EMT and its implications for cancer progression and treatment.",
    "llama-2-7b-chat-hf_fact": [
      "GRHL2 is a transcription factor implicated in cell proliferation, differentiation, and epithelial-to-mesenchymal transition (EMT).",
      "Over-expression of GRHL2 can lead to EMT in some contexts.",
      "GRHL2 over-expression in breast cancer cells led to increased expression of mesenchymal markers and decreased expression of epithelial markers.",
      "Studies suggest GRHL2 may regulate the expression of genes involved in EMT, such as vimentin and E-cadherin.",
      "Further research is needed to fully understand the role of GRHL2 in EMT and its implications for cancer progression and treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3254,
    "user_query": "Which T-UCRs have been implicated in lung cancer?",
    "llama-2-7b-chat-hf_response": "Lung cancer is a complex disease that is caused by a combination of genetic and environmental factors. The tumor microenvironment, including the extracellular matrix (ECM), immune cells, and growth factors, plays a crucial role in the development and progression of lung cancer.\nSeveral T-UCRs have been implicated in lung cancer, including:\n1. TGF-β: Transforming growth factor beta (TGF-β) is a potent cytokine that regulates cell growth, differentiation, and migration. TGF-β has been shown to promote the growth and invasion of lung cancer cells, and high levels of TGF-β have been detected in the blood and tumor tissues of lung cancer patients.\n2. HIF-1α: Hypoxia-inducible factor 1-alpha (HIF-1α) is a transcription factor that plays a critical role in response to hypoxia. HIF-1α has been shown to promote the survival and proliferation of lung cancer cells, and high levels of HIF-1α have been detected in lung cancer tissues.\n3. VEGF: Vascular endothelial growth factor (VEGF) is a potent angiogenic factor that regulates blood vessel growth and maintenance. VEGF has been shown to promote the growth and invasion of lung cancer cells, and high levels of VEGF have been detected in the blood and tumor tissues of lung cancer patients.\n4. EGFR: Epidermal growth factor receptor (EGFR) is a transmembrane receptor that plays a critical role in cell growth and differentiation. Mutations in the EGFR gene are common in non-small cell lung cancer (NSCLC), and these mutations can lead to uncontrolled cell growth and tumor formation.\n5. PDGFRA: Platelet-derived growth factor receptor alpha (PDGFRA) is a transmembrane receptor that regulates cell growth and differentiation. Mutations in the PDGFRA gene have been associated with the development of lung cancer, particularly in adenocarcinoma.\n6. KRAS: Kirsten rat sarcoma viral oncogene homolog (KRAS) is a GTPase that regulates",
    "llama-2-7b-chat-hf_fact_raw": "1. TGF-β has been implicated in lung cancer and high levels have been detected in the blood and tumor tissues of lung cancer patients.\n2. HIF-1α has been implicated in lung cancer and high levels have been detected in lung cancer tissues.\n3. VEGF has been implicated in lung cancer and high levels have been detected in the blood and tumor tissues of lung cancer patients.\n4. Mutations in the EGFR gene are common in non-small cell lung cancer.\n5. Mutations in the PDGFRA gene have been associated with the development of lung cancer.",
    "llama-2-7b-chat-hf_fact": [
      "TGF-β has been implicated in lung cancer and high levels have been detected in the blood and tumor tissues of lung cancer patients.",
      "HIF-1α has been implicated in lung cancer and high levels have been detected in lung cancer tissues.",
      "VEGF has been implicated in lung cancer and high levels have been detected in the blood and tumor tissues of lung cancer patients.",
      "Mutations in the EGFR gene are common in non-small cell lung cancer.",
      "Mutations in the PDGFRA gene have been associated with the development of lung cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: Mutations in the PDGFRA gene have not been commonly associated with the development of lung cancer; instead, they are more commonly associated with gastrointestinal stromal tumors.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3268,
    "user_query": "What is known about the orphan receptor GPR151?",
    "llama-2-7b-chat-hf_response": "GPR151, also known as orphan receptor GPR151, is a G protein-coupled receptor (GPCR) that has been identified as a potential therapeutic target for various diseases, including inflammatory disorders, metabolic disorders, and neurological disorders. Here is what is currently known about GPR151:\n1. Structure: GPR151 is a seven-transmembrane receptor that is composed of an N-terminus and a C-terminus, with a transmembrane domain in between. It has a unique structure that is different from other GPCRs, with a longer N-terminus and a shorter C-terminus.\n2. Distribution: GPR151 is expressed in various tissues, including the brain, heart, liver, and immune cells. It is particularly abundant in the brain, where it is found in high levels in areas such as the hippocampus and cerebral cortex.\n3. Function: GPR151 has been shown to play a role in regulating various physiological processes, including inflammation, immune response, and neurotransmission. It is activated by a variety of ligands, including fatty acids, eicosanoids, and neurotransmitters.\n4. Ligands: GPR151 has been shown to be activated by a variety of ligands, including arachidonic acid, docosahexaenoic acid, and the neurotransmitter glutamate. These ligands bind to the receptor and trigger a cascade of intracellular signaling events that lead to changes in gene expression and cellular behavior.\n5. Signaling pathways: GPR151 activates a variety of signaling pathways, including the PI3K/Akt pathway, the MAPK/ERK pathway, and the JNK pathway. These pathways lead to changes in gene expression, cellular proliferation, and differentiation.\n6. Disease associations: GPR151 has been implicated in various diseases, including inflammatory disorders such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel",
    "llama-2-7b-chat-hf_fact_raw": "1. GPR151 is a G protein-coupled receptor (GPCR).\n2. GPR151 is expressed in various tissues, including the brain, heart, liver, and immune cells.\n3. GPR151 has been shown to play a role in regulating various physiological processes, including inflammation, immune response, and neurotransmission.\n4. GPR151 is activated by ligands like arachidonic acid, docosahexaenoic acid, and the neurotransmitter glutamate.\n5. GPR151 activates signaling pathways such as the PI3K/Akt pathway, the MAPK/ERK pathway, and the JNK pathway.",
    "llama-2-7b-chat-hf_fact": [
      "GPR151 is a G protein-coupled receptor (GPCR).",
      "GPR151 is expressed in various tissues, including the brain, heart, liver, and immune cells.",
      "GPR151 has been shown to play a role in regulating various physiological processes, including inflammation, immune response, and neurotransmission.",
      "GPR151 is activated by ligands like arachidonic acid, docosahexaenoic acid, and the neurotransmitter glutamate.",
      "GPR151 activates signaling pathways such as the PI3K/Akt pathway, the MAPK/ERK pathway, and the JNK pathway."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: GPR151 has not been definitively shown to be activated by arachidonic acid, docosahexaenoic acid, or the neurotransmitter glutamate.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3285,
    "user_query": "List the attenuated live viruses contained in the Fluzone intradermal quadrivalent vaccine.",
    "llama-2-7b-chat-hf_response": "Thank you for reaching out! The Fluzone intradermal quadrivalent vaccine contains four attenuated live viruses:\n1. A/New York/17/2009 (H1N1): This is a strain of the H1N1 subtype of the influenza A virus. It was isolated from a patient in New York in 2009 and has been shown to cause mild to severe illness in humans.\n2. B/Brisbane/60/2008 (B/Victoria/2007): This is a strain of the B/Victoria subtype of the influenza B virus. It was isolated from a patient in Brisbane, Australia in 2008 and has been shown to cause mild to severe illness in humans.\n3. A/Perth/16/2009 (H1N1): This is a strain of the H1N1 subtype of the influenza A virus. It was isolated from a patient in Perth, Australia in 2009 and has been shown to cause mild to severe illness in humans.\n4. B/Phuket/309/2008 (B/Yangtze): This is a strain of the B/Yangtze subtype of the influenza B virus. It was isolated from a patient in Phuket, Thailand in 2008 and has been shown to cause mild to severe illness in humans.\nIt's important to note that the Fluzone intradermal quadrivalent vaccine is designed to provide protection against four different strains of the influenza virus, including two strains of the H1N1 subtype and two strains of the B/Victoria subtype. The vaccine is given as an intradermal injection, which means it is injected into the skin rather than into a muscle. This type of injection is designed to provide a stronger immune response than a traditional muscle injection.\nI hope this information helps! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Fluzone intradermal quadrivalent vaccine contains the A/New York/17/2009 (H1N1) strain of the influenza A virus.\n2. The Fluzone intradermal quadrivalent vaccine contains the B/Brisbane/60/2008 (B/Victoria/2007) strain of the influenza B virus.\n3. The Fluzone intradermal quadrivalent vaccine contains the A/Perth/16/2009 (H1N1) strain of the influenza A virus.\n4. The Fluzone intradermal quadrivalent vaccine contains the B/Phuket/309/2008 (B/Yangtze) strain of the influenza B virus.\n5. The Fluzone intradermal quadrivalent vaccine is administered via an intradermal injection.",
    "llama-2-7b-chat-hf_fact": [
      "The Fluzone intradermal quadrivalent vaccine contains the A/New York/17/2009 (H1N1) strain of the influenza A virus.",
      "The Fluzone intradermal quadrivalent vaccine contains the B/Brisbane/60/2008 (B/Victoria/2007) strain of the influenza B virus.",
      "The Fluzone intradermal quadrivalent vaccine contains the A/Perth/16/2009 (H1N1) strain of the influenza A virus.",
      "The Fluzone intradermal quadrivalent vaccine contains the B/Phuket/309/2008 (B/Yangtze) strain of the influenza B virus.",
      "The Fluzone intradermal quadrivalent vaccine is administered via an intradermal injection."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine does not contain the B/Brisbane/60/2008 (B/Victoria/2007) strain of the influenza B virus.\n3. FALSE [correction]: The Fluzone intradermal quadrivalent vaccine contains the A/California/7/2009 (H1N1) strain of the influenza A virus, not A/Perth/16/2009.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3345,
    "user_query": "Which part of the TNFR2 gene is genetically associated with Systemic Lupus Erythematosus?",
    "llama-2-7b-chat-hf_response": "Systemic Lupus Erythematosus (SLE) is a complex and multifactorial autoimmune disease that affects various tissues and organs throughout the body. While the exact cause of SLE is still not fully understood, research has identified several genetic variants that are associated with an increased risk of developing the disease.\nOne of the genes that have been implicated in SLE is the Tumor Necrosis Factor Receptor Superfamily Member 2 (TNFR2), also known as CD26. TNFR2 is a cell surface receptor that plays a crucial role in the regulation of immune responses, including the activation of immune cells and the production of cytokines.\nSeveral studies have identified genetic variants in the TNFR2 gene that are associated with an increased risk of developing SLE. These variants are found in the promoter region of the TNFR2 gene, which regulates the expression of the gene. Specifically, the -173G>C polymorphism in the promoter region of the TNFR2 gene has been found to be associated with an increased risk of SLE in multiple studies.\nThis polymorphism results in a change in the DNA sequence of the promoter region of the TNFR2 gene, which can affect the transcriptional activity of the gene. Studies have shown that individuals with the -173G>C polymorphism have a higher risk of developing SLE compared to those without the polymorphism. However, it's important to note that the relationship between the TNFR2 gene and SLE is complex, and other genetic and environmental factors are also likely to be involved.\nAdditionally, several studies have found that the TNFR2 gene is overexpressed in the peripheral blood mononuclear cells of SLE patients compared to healthy controls. Overexpression of TNFR2 has been linked to an increased risk of SLE flares and disease activity.\nIn summary, the -173G>C polymorphism in the promoter region of the TNFR2 gene is genetically associated with an increased risk of developing Systemic Lupus Erythematosus. The overexpression of TNFR2 in peripheral blood mononuclear cells of SLE patients is also a key player in the development and progression of the disease. However, it",
    "llama-2-7b-chat-hf_fact_raw": "1. The -173G>C polymorphism in the promoter region of the TNFR2 gene is associated with an increased risk of developing Systemic Lupus Erythematosus.\n2. TNFR2 is a cell surface receptor that is involved in the regulation of immune responses.\n3. Genetic variants in the TNFR2 gene have been identified as a risk factor for Systemic Lupus Erythematosus.\n4. The TNFR2 gene is overexpressed in the peripheral blood mononuclear cells of SLE patients compared to healthy controls.\n5. Overexpression of TNFR2 is linked to an increased risk of SLE flares and disease activity.",
    "llama-2-7b-chat-hf_fact": [
      "The -173G>C polymorphism in the promoter region of the TNFR2 gene is associated with an increased risk of developing Systemic Lupus Erythematosus.",
      "TNFR2 is a cell surface receptor that is involved in the regulation of immune responses.",
      "Genetic variants in the TNFR2 gene have been identified as a risk factor for Systemic Lupus Erythematosus.",
      "The TNFR2 gene is overexpressed in the peripheral blood mononuclear cells of SLE patients compared to healthy controls.",
      "Overexpression of TNFR2 is linked to an increased risk of SLE flares and disease activity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3353,
    "user_query": "Is there a vaccine for peanut allergy?",
    "llama-2-7b-chat-hf_response": "Thank you for reaching out with your question! I'm glad you're interested in learning more about peanut allergy and its potential treatments.\nUnfortunately, there is currently no widely available vaccine for peanut allergy. Peanut allergy is an immune-mediated reaction, meaning that the body's immune system mistakenly identifies peanuts as a threat and tries to fight them off. This can lead to a range of symptoms, including hives, itching, swelling, stomach cramps, and difficulty breathing.\nWhile researchers have been working on developing a vaccine for peanut allergy, the progress has been slow and the current treatments are limited. The most common approach is to use oral immunotherapy (OIT), which involves gradually increasing the amount of peanut protein consumed over time to build up tolerance to the allergen. However, OIT can be time-consuming and may not be effective for everyone.\nOther potential treatments for peanut allergy include sublingual immunotherapy (SLIT), which involves placing a small amount of peanut protein under the tongue to stimulate the immune system, and epicutaneous immunotherapy (EIT), which involves wearing a patch containing peanut protein on the skin for a period of time. These treatments are still in the experimental stage and have not yet been widely tested or approved.\nIn summary, while there is currently no widely available vaccine for peanut allergy, researchers are actively working on developing new treatments to help manage this condition. If you or someone you know has a peanut allergy, it's important to consult with a healthcare professional to discuss the best course of treatment.",
    "llama-2-7b-chat-hf_fact_raw": "1. There is currently no widely available vaccine for peanut allergy.\n2. Peanut allergy is an immune-mediated reaction.\n3. Oral immunotherapy is a common approach to building tolerance to peanut allergens.\n4. Sublingual immunotherapy and epicutaneous immunotherapy are potential treatments for peanut allergy that are still in the experimental stage.\n5. Researchers are working on developing new treatments for peanut allergy.",
    "llama-2-7b-chat-hf_fact": [
      "There is currently no widely available vaccine for peanut allergy.",
      "Peanut allergy is an immune-mediated reaction.",
      "Oral immunotherapy is a common approach to building tolerance to peanut allergens.",
      "Sublingual immunotherapy and epicutaneous immunotherapy are potential treatments for peanut allergy that are still in the experimental stage.",
      "Researchers are working on developing new treatments for peanut allergy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3365,
    "user_query": "What is particular about the mouse Fxy gene's chromosomal position?",
    "llama-2-7b-chat-hf_response": "The mouse Fxy gene, also known as the fibroblast growth factor X (FGF-X) gene, is located on chromosome 12 in mice. Specifically, it is located on the distal part of chromosome 12, near the telomere end of the chromosome.\nThe Fxy gene is composed of 12 exons, which are the regions of the gene that contain the instructions for making proteins. These exons are arranged in a specific order, and the gene is transcribed from 5' to 3', meaning that the RNA transcript is synthesized from the 5' end of the gene to the 3' end.\nThe Fxy gene is located on the long arm of chromosome 12 (chromosome 12q), which is one of the larger chromosomes in mammals. Chromosome 12 contains many genes that are involved in a variety of biological processes, including cell growth and differentiation, immune function, and neural development.\nThe Fxy gene is particularly interesting because it plays a critical role in the development and maintenance of the mouse embryo. Mice that are homozygous for a mutation in the Fxy gene (i.e., they have two copies of the mutated gene) do not survive beyond embryonic development, indicating that the gene is essential for embryonic viability.\nIn addition, the Fxy gene has been implicated in a number of human diseases, including cancer and cardiovascular disease. For example, studies have shown that the Fxy gene is overexpressed in certain types of cancer, and that inhibition of the gene can reduce tumor growth in these cancers.\nOverall, the mouse Fxy gene is a critical gene that plays a central role in embryonic development and has important implications for human health and disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. The mouse Fxy gene, also known as the fibroblast growth factor X (FGF-X) gene, is located on chromosome 12 in mice.\n2. The Fxy gene is situated on the distal part of chromosome 12, near the telomere end of the chromosome.\n3. The Fxy gene is composed of 12 exons and is transcribed from 5' to 3'.\n4. The gene is located on the long arm of chromosome 12 (chromosome 12q).\n5. Mice that are homozygous for a mutation in the Fxy gene do not survive beyond embryonic development.",
    "llama-2-7b-chat-hf_fact": [
      "The mouse Fxy gene, also known as the fibroblast growth factor X (FGF-X) gene, is located on chromosome 12 in mice.",
      "The Fxy gene is situated on the distal part of chromosome 12, near the telomere end of the chromosome.",
      "The Fxy gene is composed of 12 exons and is transcribed from 5' to 3'.",
      "The gene is located on the long arm of chromosome 12 (chromosome 12q).",
      "Mice that are homozygous for a mutation in the Fxy gene do not survive beyond embryonic development."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: Without specific scientific knowledge or reference to the relevant research, it is not possible to accurately confirm or correct these statements about the mouse Fxy gene.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3397,
    "user_query": "What is the basis of the methidiumpropyl-EDTA sequencing (MPE-seq) method?",
    "llama-2-7b-chat-hf_response": "MPE-seq, or methylation-specific PCR-based sequencing, is a method used to detect and quantify DNA methylation at specific regions of the genome. The method is based on the following steps:\n1. Sample Preparation: The starting material for MPE-seq is typically 50-100 ng of DNA. The DNA is first fragmented to create shorter fragments, typically in the range of 100-500 base pairs (bp). This is done to increase the efficiency of the PCR reaction and to reduce the risk of primer-dimer formation.\n2. Primer Design: Next, primers are designed to specifically target the regions of interest, typically CpG islands or other methylation-sensitive regions. These primers are usually 18-24 nucleotides in length and are complementary to the target region.\n3. PCR Amplification: The fragmented DNA is then amplified using PCR with the primers designed in the previous step. This step amplifies the target region of interest, allowing for the detection of methylation levels.\n4. Sequencing: The amplified DNA is then sequenced using Next-Generation Sequencing (NGS) technologies, such as Illumina or PacBio. The sequencing reads are then mapped back to the reference genome to determine the methylation status of the target regions.\n5. Data Analysis: The sequencing data is then analyzed using bioinformatic tools to quantify the methylation levels at the target regions. The analysis typically includes base quality score recalibration, adapter removal, and demethylation correction. The methylation levels are then visualized using a heatmap or a scatter plot to identify regions of high and low methylation.\nThe basis of MPE-seq is the use of PCR primers that are specific to the target regions of interest. These primers are designed to be complementary to the target region, allowing for the amplification of only the targeted region. By using PCR primers that are specific to the target regions, MPE-seq can detect methylation levels with high sensitivity and specificity. Additionally, the use of NGS technologies allows for the analysis of millions of DNA sequences in a single run, making MPE-seq a powerful",
    "llama-2-7b-chat-hf_fact_raw": "1. Methylation-specific PCR-based sequencing (MPE-seq) is used to detect and quantify DNA methylation at specific regions of the genome.\n2. The starting material for MPE-seq is typically 50-100 ng of DNA.\n3. Primers used in MPE-seq are usually 18-24 nucleotides in length.\n4. MPE-seq involves amplifying target regions of interest using PCR.\n5. Next-Generation Sequencing (NGS) technologies, such as Illumina or PacBio, are used for sequencing in MPE-seq.",
    "llama-2-7b-chat-hf_fact": [
      "Methylation-specific PCR-based sequencing (MPE-seq) is used to detect and quantify DNA methylation at specific regions of the genome.",
      "The starting material for MPE-seq is typically 50-100 ng of DNA.",
      "Primers used in MPE-seq are usually 18-24 nucleotides in length.",
      "MPE-seq involves amplifying target regions of interest using PCR.",
      "Next-Generation Sequencing (NGS) technologies, such as Illumina or PacBio, are used for sequencing in MPE-seq."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Methylation-specific PCR (MSP) is used to detect and quantify DNA methylation at specific regions of the genome, not MPE-seq.\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3400,
    "user_query": "Which programming language has been used for implementing GWAR?",
    "llama-2-7b-chat-hf_response": "GWAR is a fictional race of aliens from the comic book series of the same name, created by artist and writer Bob Camp. As such, there is no real-world programming language that has been used to implement GWAR. GWAR is a fictional entity, and as such, it does not have a physical existence that could be replicated using any programming language.\nHowever, if you're interested in creating a digital representation of GWAR using a programming language, you could consider using a 3D modeling and animation software such as Blender or Maya. These programs allow you to create and manipulate 3D models, including characters and creatures like GWAR.\nAlternatively, you could use a programming language like Python or JavaScript to create a virtual GWAR that can be interacted with through a web application or game. This would allow you to simulate the behavior and interactions of GWAR in a virtual environment, without having to create a physical representation of the character.\nIn summary, there is no real-world programming language that has been used to implement GWAR, as GWAR is a fictional entity. However, you could use various programming languages and tools to create a virtual representation of GWAR for use in digital media and entertainment.",
    "llama-2-7b-chat-hf_fact_raw": "1. GWAR is a fictional race of aliens from a comic book series.\n2. The GWAR comic book series was created by Bob Camp.\n3. GWAR does not have a real-world physical existence.\n4. Blender and Maya are 3D modeling and animation software that can create digital representations of characters like GWAR.\n5. Python and JavaScript are programming languages that could be used to create a virtual GWAR in a web application or game.",
    "llama-2-7b-chat-hf_fact": [
      "GWAR is a fictional race of aliens from a comic book series.",
      "The GWAR comic book series was created by Bob Camp.",
      "GWAR does not have a real-world physical existence.",
      "Blender and Maya are 3D modeling and animation software that can create digital representations of characters like GWAR.",
      "Python and JavaScript are programming languages that could be used to create a virtual GWAR in a web application or game."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: GWAR is not a race of aliens from a comic book series; they are a real-world heavy metal band known for their elaborate costumes and stage presence, which often portrays them as intergalactic warriors.\n2. UNKNOWN\n3. FALSE [correction]: GWAR has a real-world physical existence as a band with members who perform on stage.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3406,
    "user_query": "Does xaliproden improve prognosis of amyotrophic lateral sclerosis?",
    "llama-2-7b-chat-hf_response": "Xaliproden, also known as fampridine, is a medication that has been studied for its potential to improve the prognosis of amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease. While the results of these studies have been mixed, there is some evidence to suggest that xaliproden may have a positive impact on the progression of ALS.\nALS is a progressive neurological disorder that affects the nerve cells responsible for controlling voluntary muscle movement. As the disease progresses, muscle weakness, atrophy, and paralysis can occur, leading to significant disability and mortality. Currently, there is no cure for ALS, and treatment is limited to managing symptoms and improving quality of life.\nXaliproden is a small molecule that acts as a sodium channel blocker, specifically targeting the Nav1.6 sodium channel. This channel is overactive in ALS patients, leading to an abnormal increase in the excitability of motor neurons. By blocking the Nav1.6 channel, xaliproden can help reduce the excitability of these neurons and potentially slow down the progression of ALS.\nSeveral studies have investigated the efficacy and safety of xaliproden in ALS patients. A phase II clinical trial published in the New England Journal of Medicine in 2017 found that treatment with xaliproden resulted in a 30% slowing of the progression of ALS over a 12-month period, compared to a 10% slowing in the placebo group. However, the study also found that xaliproden was associated with an increased risk of adverse events, including dysgeusia (taste disturbances), dyspepsia (indigestion), and fatigue.\nA more recent phase III clinical trial, published in the Lancet in 2020, found that xaliproden did not meet its primary endpoint of slowing the progression of ALS over a 24-month period. However, the study did find that xaliproden was associated with a significant improvement in muscle strength and function compared to the placebo group.\nWhile the results of these",
    "llama-2-7b-chat-hf_fact_raw": "1. Xaliproden, also known as fampridine, has been studied for its potential to improve the prognosis of amyotrophic lateral sclerosis (ALS).\n2. ALS is a progressive neurological disorder that affects nerve cells responsible for controlling voluntary muscle movement.\n3. Xaliproden acts as a sodium channel blocker, specifically targeting the Nav1.6 sodium channel.\n4. A phase II clinical trial published in the New England Journal of Medicine in 2017 found that xaliproden resulted in a 30% slowing of the progression of ALS over a 12-month period.\n5. A phase III clinical trial published in the Lancet in 2020 found that xaliproden was associated with an improvement in muscle strength and function compared to the placebo group.",
    "llama-2-7b-chat-hf_fact": [
      "Xaliproden, also known as fampridine, has been studied for its potential to improve the prognosis of amyotrophic lateral sclerosis (ALS).",
      "ALS is a progressive neurological disorder that affects nerve cells responsible for controlling voluntary muscle movement.",
      "Xaliproden acts as a sodium channel blocker, specifically targeting the Nav1.6 sodium channel.",
      "A phase II clinical trial published in the New England Journal of Medicine in 2017 found that xaliproden resulted in a 30% slowing of the progression of ALS over a 12-month period.",
      "A phase III clinical trial published in the Lancet in 2020 found that xaliproden was associated with an improvement in muscle strength and function compared to the placebo group."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Xaliproden, also known as SR57746A, has been studied for its potential to improve the prognosis of amyotrophic lateral sclerosis (ALS), not fampridine which is another compound.\n2. TRUE\n3. FALSE [correction]: Xaliproden is known to act as a neurotrophic agent, not specifically as a sodium channel blocker targeting the Nav1.6 sodium channel.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3410,
    "user_query": "In which chromosome are transgenes inserted in the case of the LiPS-A3S line?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! The LiPS-A3S line is a transgenic line of mice that have been genetically modified to express a humanized version of the ApoA-III gene, which is involved in lipid metabolism.\nWhen transgenes are inserted into a mouse genome, they are typically inserted into the chromosome using a process called homologous recombination. This involves finding a region of DNA that is similar in sequence to the gene you want to insert, and then using that region as a template to repair the target site in the genome.\nIn the case of the LiPS-A3S line, the ApoA-III gene was inserted into chromosome 17. Specifically, the gene was inserted into the region designated as chromosome 17p13.3, which is located on the p arm of chromosome 17. This region is also known as the 17p13.3 region.\nIt's worth noting that the LiPS-A3S line is a complex genetic construct, and the ApoA-III gene is just one of several genes that have been inserted into the mouse genome. The line has been engineered to express a number of human genes in addition to ApoA-III, including genes involved in lipid metabolism, inflammation, and immune response.\nI hope this information helps! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. The LiPS-A3S line is a transgenic line of mice.\n2. In the LiPS-A3S line, the humanized version of the ApoA-III gene is inserted into chromosome 17.\n3. The ApoA-III gene in the LiPS-A3S line is located in the region designated as chromosome 17p13.3.\n4. The chromosome region 17p13.3 is located on the p arm of chromosome 17.\n5. The LiPS-A3S line has been engineered to express several human genes in addition to ApoA-III.",
    "llama-2-7b-chat-hf_fact": [
      "The LiPS-A3S line is a transgenic line of mice.",
      "In the LiPS-A3S line, the humanized version of the ApoA-III gene is inserted into chromosome 17.",
      "The ApoA-III gene in the LiPS-A3S line is located in the region designated as chromosome 17p13.3.",
      "The chromosome region 17p13.3 is located on the p arm of chromosome 17.",
      "The LiPS-A3S line has been engineered to express several human genes in addition to ApoA-III."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3430,
    "user_query": "Which tool exist for predicting drug synergy with deep learning?",
    "llama-2-7b-chat-hf_response": "There are several deep learning tools and models that have been developed for predicting drug synergy. Here are some of the most notable ones:\n1. DeepDrugSynergy: This is a deep learning-based tool developed by the University of California, San Diego. It uses a combination of convolutional neural networks (CNNs) and recurrent neural networks (RNNs) to predict drug synergy. The tool takes as input a set of molecular structures and outputs a prediction of drug synergy.\n2. DrugSynth: This is another deep learning-based tool developed by the University of California, San Francisco. It uses a combination of CNNs and long short-term memory (LSTM) networks to predict drug synergy. The tool takes as input a set of molecular structures and outputs a prediction of drug synergy.\n3. RDKit: This is an open-source toolkit for drug discovery and development. It includes a number of deep learning models for predicting drug synergy, including a CNN-based model and an LSTM-based model. The tool takes as input a set of molecular structures and outputs a prediction of drug synergy.\n4. DeepMolecular: This is a deep learning-based tool developed by the University of California, Berkeley. It uses a combination of CNNs and RNNs to predict drug synergy. The tool takes as input a set of molecular structures and outputs a prediction of drug synergy.\n5. DrugDiscovery: This is a deep learning-based tool developed by the University of California, Los Angeles. It uses a combination of CNNs and LSTMs to predict drug synergy. The tool takes as input a set of molecular structures and outputs a prediction of drug synergy.\n6. SynergyNet: This is a deep learning-based tool developed by the University of California, San Diego. It uses a combination of CNNs and RNNs to predict drug synergy. The tool takes as input a set of molecular structures and outputs a prediction of drug synergy.\n7. DrugCombinator: This is a deep learning-based tool developed by the University of California, Berkeley. It uses a combination of CNNs and LSTMs to predict drug synergy. The tool takes as input a set of molecular structures and outputs",
    "llama-2-7b-chat-hf_fact_raw": "1. DeepDrugSynergy is developed by the University of California, San Diego and uses CNNs and RNNs for predicting drug synergy.\n2. DrugSynth is developed by the University of California, San Francisco and uses CNNs and LSTM networks for predicting drug synergy.\n3. RDKit is an open-source toolkit that includes deep learning models for predicting drug synergy.\n4. DeepMolecular is developed by the University of California, Berkeley and uses CNNs and RNNs for predicting drug synergy.\n5. DrugDiscovery is developed by the University of California, Los Angeles and uses CNNs and LSTMs for predicting drug synergy.",
    "llama-2-7b-chat-hf_fact": [
      "DeepDrugSynergy is developed by the University of California, San Diego and uses CNNs and RNNs for predicting drug synergy.",
      "DrugSynth is developed by the University of California, San Francisco and uses CNNs and LSTM networks for predicting drug synergy.",
      "RDKit is an open-source toolkit that includes deep learning models for predicting drug synergy.",
      "DeepMolecular is developed by the University of California, Berkeley and uses CNNs and RNNs for predicting drug synergy.",
      "DrugDiscovery is developed by the University of California, Los Angeles and uses CNNs and LSTMs for predicting drug synergy."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. FALSE [correction]: RDKit is an open-source toolkit for cheminformatics that does not specifically focus on deep learning models for predicting drug synergy.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3433,
    "user_query": "Which cloud-based platform has been developed for comparing GWAS?",
    "llama-2-7b-chat-hf_response": "There are several cloud-based platforms that have been developed for comparing Genome-Wide Association Studies (GWAS). Here are some of the most popular ones:\n1. CloudGWAS: CloudGWAS is a cloud-based platform developed by the University of California, San Diego. It allows researchers to store, analyze, and share GWAS data in a secure and scalable manner. CloudGWAS provides a user-friendly interface for uploading and analyzing GWAS data, as well as tools for quality control, imputation, and association testing.\n2. AWS GWAS: Amazon Web Services (AWS) offers a GWAS service that allows researchers to store and analyze large-scale GWAS data in the cloud. The service provides a scalable infrastructure for processing and analyzing GWAS data, as well as tools for quality control and association testing.\n3. Google Genomics: Google Genomics is a cloud-based platform that provides tools for storing, analyzing, and sharing GWAS data. The platform offers a user-friendly interface for uploading and analyzing GWAS data, as well as tools for quality control, imputation, and association testing.\n4. 23andMe Research: 23andMe is a cloud-based platform that provides tools for storing, analyzing, and sharing GWAS data. The platform offers a user-friendly interface for uploading and analyzing GWAS data, as well as tools for quality control, imputation, and association testing.\n5. eMERGE: eMERGE is a cloud-based platform developed by the University of California, San Francisco. It allows researchers to store, analyze, and share GWAS data in a secure and scalable manner. eMERGE provides tools for quality control, imputation, and association testing, as well as a user-friendly interface for uploading and analyzing GWAS data.\n6. GWAS Cloud: GWAS Cloud is a cloud-based platform developed by the University of California, Los Angeles. It allows researchers to store, analyze, and share GWAS data in a secure and scalable manner. GWAS Cloud provides tools for quality control, imputation, and association testing, as well as a user-friendly interface for uploading and analyzing GWAS data.\n7.",
    "llama-2-7b-chat-hf_fact_raw": "1. CloudGWAS is a cloud-based platform developed by the University of California, San Diego.\n2. Amazon Web Services offers a GWAS service for storing and analyzing large-scale GWAS data in the cloud.\n3. Google Genomics provides tools for storing, analyzing, and sharing GWAS data on a cloud-based platform.\n4. 23andMe Research is a cloud-based platform that provides tools for GWAS data analysis.\n5. eMERGE is a cloud-based platform developed by the University of California, San Francisco for GWAS data storage, analysis, and sharing.",
    "llama-2-7b-chat-hf_fact": [
      "CloudGWAS is a cloud-based platform developed by the University of California, San Diego.",
      "Amazon Web Services offers a GWAS service for storing and analyzing large-scale GWAS data in the cloud.",
      "Google Genomics provides tools for storing, analyzing, and sharing GWAS data on a cloud-based platform.",
      "23andMe Research is a cloud-based platform that provides tools for GWAS data analysis.",
      "eMERGE is a cloud-based platform developed by the University of California, San Francisco for GWAS data storage, analysis, and sharing."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3434,
    "user_query": "Can CMB305 be used against sarcomas?",
    "llama-2-7b-chat-hf_response": "CMB305 is a small molecule that has been shown to have potential as a cancer treatment, particularly against certain types of cancer, including sarcomas.\nSarcomas are a type of cancer that develops in the connective tissue of the body, including bone, cartilage, and fat. They can arise in various parts of the body, including the limbs, trunk, and internal organs. Sarcomas are often aggressive and can be difficult to treat, particularly once they have spread to other parts of the body.\nCMB305 is a first-in-class, orally available small molecule that selectively targets and inhibits the activity of the enzyme histone methyltransferase (HMT) enzyme, which is overexpressed in many types of cancer, including sarcomas. By inhibiting the activity of HMT, CMB305 can disrupt the epigenetic changes that contribute to the development and progression of cancer.\nStudies have shown that CMB305 can inhibit the growth and proliferation of sarcoma cells both in vitro and in vivo. For example, a study published in the journal Cancer Research in 2018 found that CMB305 significantly inhibited the growth of human osteosarcoma cells both in vitro and in a mouse model of the disease.\nAdditionally, CMB305 has been shown to have synergistic effects when combined with other cancer therapies, such as chemotherapy and targeted therapies. For example, a study published in the journal Oncogene in 2020 found that CMB305 enhanced the efficacy of chemotherapy in treating osteosarcoma by inhibiting the expression of the P-glycoprotein (P-gp) drug efflux pump, which can limit the delivery of chemotherapy drugs to cancer cells.\nWhile the current evidence suggests that CMB305 may be a promising treatment option for sarcomas, further research is needed to fully understand its efficacy and safety in humans. Clinical trials are currently underway to evaluate the safety and efficacy of CMB305 in patients with various types of cancer, including sarcomas.",
    "llama-2-7b-chat-hf_fact_raw": "1. CMB305 is a small molecule that has potential as a cancer treatment against sarcomas.\n2. Sarcomas are a type of cancer that develops in connective tissue, including bone, cartilage, and fat.\n3. CMB305 targets and inhibits the activity of the histone methyltransferase (HMT) enzyme.\n4. Studies have shown that CMB305 can inhibit the growth of sarcoma cells both in vitro and in vivo.\n5. CMB305 has been shown to have synergistic effects when combined with other cancer therapies.",
    "llama-2-7b-chat-hf_fact": [
      "CMB305 is a small molecule that has potential as a cancer treatment against sarcomas.",
      "Sarcomas are a type of cancer that develops in connective tissue, including bone, cartilage, and fat.",
      "CMB305 targets and inhibits the activity of the histone methyltransferase (HMT) enzyme.",
      "Studies have shown that CMB305 can inhibit the growth of sarcoma cells both in vitro and in vivo.",
      "CMB305 has been shown to have synergistic effects when combined with other cancer therapies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3461,
    "user_query": "What are manifestations of the Saint's Triad?",
    "llama-2-7b-chat-hf_response": "The Saint's Triad, also known as the Three Principles or the Three Pillars of the Saint's Teachings, are the fundamental principles that underlie the spiritual philosophy of the Saint. These manifestations are:\n1. The Principle of Divine Love: This principle is the foundation of the Saint's teachings and is the cornerstone of his spiritual philosophy. It is the belief that God is love, and that the ultimate goal of human existence is to attain divine love and to express it in all aspects of life. The Saint taught that divine love is the highest form of love and that it is the key to spiritual growth and enlightenment.\n2. The Principle of the Unity of Existence: This principle is the belief that everything in the universe is interconnected and interdependent. The Saint taught that all things are part of a larger whole and that each individual is connected to every other individual and to the universe as a whole. This principle is based on the idea that everything in the universe is part of a single, unified whole, and that each individual has a unique role to play in the grand scheme of things.\n3. The Principle of the Immutable Self: This principle is the belief that the individual self is immutable and unchanging. The Saint taught that the individual self is a fixed and unchanging entity, and that it is the source of all spiritual growth and enlightenment. He believed that the individual self is the foundation of all spiritual practices and that it is the key to understanding the nature of the universe and the divine.\nThese three principles are the core of the Saint's teachings and are the foundation of his spiritual philosophy. They are interconnected and interdependent, and they are meant to be understood and practiced together in order to achieve spiritual growth and enlightenment. By understanding and embracing these principles, individuals can gain a deeper understanding of the nature of the universe and the divine, and can live a more fulfilling and meaningful life.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Saint's Triad consists of the Principle of Divine Love, the Principle of the Unity of Existence, and the Principle of the Immutable Self.\n2. The Principle of Divine Love is the belief that God is love and the ultimate goal is to attain and express divine love in all aspects of life.\n3. The Principle of the Unity of Existence is the belief that everything in the universe is interconnected and interdependent.\n4. The Principle of the Immutable Self is the belief that the individual self is immutable and unchanging.\n5. The Saint's Triad principles are meant to be understood and practiced together for spiritual growth and enlightenment.",
    "llama-2-7b-chat-hf_fact": [
      "The Saint's Triad consists of the Principle of Divine Love, the Principle of the Unity of Existence, and the Principle of the Immutable Self.",
      "The Principle of Divine Love is the belief that God is love and the ultimate goal is to attain and express divine love in all aspects of life.",
      "The Principle of the Unity of Existence is the belief that everything in the universe is interconnected and interdependent.",
      "The Principle of the Immutable Self is the belief that the individual self is immutable and unchanging.",
      "The Saint's Triad principles are meant to be understood and practiced together for spiritual growth and enlightenment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3470,
    "user_query": "Is overexpression of LY6K associated with better prognosis for non-small cell lung cancer patients?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! I'm here to help you understand the association between LY6K overexpression and prognosis in non-small cell lung cancer (NSCLC) patients.\nLY6K is a protein that has been found to be overexpressed in various types of cancer, including NSCLC. Overexpression of LY6K has been associated with several favorable outcomes, including improved prognosis and response to chemotherapy.\nStudies have shown that high levels of LY6K expression are associated with better overall survival and disease-free survival in NSCLC patients. For example, a study published in the journal \"Clinical Cancer Research\" in 2018 found that high LY6K expression was associated with improved overall survival and disease-free survival in NSCLC patients.\nAnother study published in the journal \"Oncogene\" in 2019 found that LY6K overexpression was associated with better response to chemotherapy in NSCLC patients. The study found that patients with high levels of LY6K expression had a higher response rate to chemotherapy compared to those with low levels of expression.\nThe mechanisms by which LY6K overexpression may improve prognosis in NSCLC patients are not fully understood, but several studies have suggested that LY6K may play a role in immune modulation and cancer cell death. For example, LY6K has been shown to inhibit the activity of cancer-associated fibroblasts, which are cells that promote the growth and spread of cancer cells. LY6K has also been shown to induce apoptosis (cell death) in cancer cells, which may contribute to its prognostic value.\nIt's important to note that while high levels of LY6K expression have been associated with better prognosis in NSCLC patients, it's not a guarantee of a good prognosis. Other factors, such as the stage and location of the cancer, the patient's overall health, and the effectiveness of treatment, also play a role in determining prognosis.\nIn summary, overexpression of LY6K has been associated with better prognosis in non-small cell lung cancer patients. However, it's important to consider other factors and to consult with a healthcare professional for an accurate assessment of prognosis.\nI",
    "llama-2-7b-chat-hf_fact_raw": "1. LY6K overexpression has been associated with improved prognosis and response to chemotherapy in non-small cell lung cancer (NSCLC) patients.\n2. A study published in \"Clinical Cancer Research\" in 2018 found high LY6K expression was linked to better overall survival and disease-free survival in NSCLC patients.\n3. Another study published in \"Oncogene\" in 2019 found that LY6K overexpression was associated with a better response to chemotherapy in NSCLC patients.\n4. LY6K has been shown to inhibit the activity of cancer-associated fibroblasts and induce apoptosis in cancer cells.\n5. High levels of LY6K expression are not a guarantee of a good prognosis and other factors also play a role in determining prognosis.",
    "llama-2-7b-chat-hf_fact": [
      "LY6K overexpression has been associated with improved prognosis and response to chemotherapy in non-small cell lung cancer (NSCLC) patients.",
      "A study published in \"Clinical Cancer Research\" in 2018 found high LY6K expression was linked to better overall survival and disease-free survival in NSCLC patients.",
      "Another study published in \"Oncogene\" in 2019 found that LY6K overexpression was associated with a better response to chemotherapy in NSCLC patients.",
      "LY6K has been shown to inhibit the activity of cancer-associated fibroblasts and induce apoptosis in cancer cells.",
      "High levels of LY6K expression are not a guarantee of a good prognosis and other factors also play a role in determining prognosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: LY6K overexpression has been associated with poor prognosis and response to chemotherapy in non-small cell lung cancer (NSCLC) patients.\n2. FALSE [correction]: A study published in \"Clinical Cancer Research\" in 2018 found high LY6K expression was linked to worse overall survival and disease-free survival in NSCLC patients.\n3. FALSE [correction]: Another study published in \"Oncogene\" in 2019 found that LY6K overexpression was associated with a worse response to chemotherapy in NSCLC patients.\n4. FALSE [correction]: LY6K has been shown to promote the activity of cancer-associated fibroblasts and inhibit apoptosis in cancer cells.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3473,
    "user_query": "List Cdk targets that are dephosphorylated during cytokinesis",
    "llama-2-7b-chat-hf_response": "Certainly! Cytokinesis is the process by which a cell divides into two daughter cells, and it involves the dephosphorylation of specific protein targets. CDKs (cyclin-dependent kinases) are key regulators of the cell cycle, and they are dephosphorylated during cytokinesis. Here are some of the CDK targets that are dephosphorylated during cytokinesis:\n1. CDK1 (also known as CDC2): CDK1 is one of the most well-studied CDKs, and it is a key regulator of the G1/S checkpoint. During cytokinesis, CDK1 is dephosphorylated by the protein phosphatase PTPN11, leading to the activation of the RhoA GTPase and the formation of the cytokinetic ring.\n2. CDK2: CDK2 is another well-studied CDK that is involved in the G1/S checkpoint and the progression of the cell cycle. During cytokinesis, CDK2 is dephosphorylated by the protein phosphatase PTPN11, leading to the activation of the RhoA GTPase and the formation of the cytokinetic ring.\n3. CDK5: CDK5 is a CDK that is involved in the regulation of the G1/S checkpoint and the progression of the cell cycle. During cytokinesis, CDK5 is dephosphorylated by the protein phosphatase PTPN11, leading to the activation of the RhoA GTPase and the formation of the cytokinetic ring.\n4. CDK6: CDK6 is a CDK that is involved in the regulation of the G1/S checkpoint and the progression of the cell cycle. During cytokinesis, CDK6 is dephosphorylated by the protein phosphatase PTPN11, leading to the activation of the RhoA GTPase and the formation of the cytokinetic ring.\n5. CDK7: CDK7 is a CDK that is involved in the regulation of the G1/S checkpoint and the progression of the cell cycle. During cytokinesis, CDK7 is de",
    "llama-2-7b-chat-hf_fact_raw": "1. CDK1 is dephosphorylated by the protein phosphatase PTPN11 during cytokinesis.\n2. CDK2 is dephosphorylated by the protein phosphatase PTPN11 during cytokinesis.\n3. CDK5 is dephosphorylated by the protein phosphatase PTPN11 during cytokinesis.\n4. CDK6 is dephosphorylated by the protein phosphatase PTPN11 during cytokinesis.\n5. CDK7 is involved in the regulation of the G1/S checkpoint and the progression of the cell cycle.",
    "llama-2-7b-chat-hf_fact": [
      "CDK1 is dephosphorylated by the protein phosphatase PTPN11 during cytokinesis.",
      "CDK2 is dephosphorylated by the protein phosphatase PTPN11 during cytokinesis.",
      "CDK5 is dephosphorylated by the protein phosphatase PTPN11 during cytokinesis.",
      "CDK6 is dephosphorylated by the protein phosphatase PTPN11 during cytokinesis.",
      "CDK7 is involved in the regulation of the G1/S checkpoint and the progression of the cell cycle."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3508,
    "user_query": "What is Xanamem?",
    "llama-2-7b-chat-hf_response": "Xanamem is a fictional drug that appears in the popular manga and anime series \"Death Note.\" It is a powerful psychotropic substance that is capable of inducing a state of euphoria and increased creativity in those who consume it.\nIn the Death Note universe, Xanamem is a highly addictive drug that is illegal in many countries. It is often used by characters in the series to enhance their cognitive abilities and to experience a heightened sense of awareness and creativity. However, it is also known to have serious side effects, including hallucinations, paranoia, and even psychotic episodes.\nThe origins of Xanamem are unclear, but it is believed to have been created by a mysterious organization known as the \"Death Note Corporation.\" The corporation is rumored to have developed Xanamem as a means of controlling the population through the use of mind-altering drugs.\nIn the series, Xanamem is often used by characters to gain an advantage over their opponents. For example, the main character, Light Yagami, uses Xanamem to enhance his cognitive abilities and to gain an edge over his enemies. However, the drug can also be dangerous, as it can lead to addiction and can have unpredictable side effects.\nOverall, Xanamem is a complex and intriguing element of the Death Note universe, with a rich history and a significant impact on the series' plot.",
    "llama-2-7b-chat-hf_fact_raw": "NO FACTS",
    "llama-2-7b-chat-hf_fact": [],
    "llama-2-7b-chat-hf_judge": []
  },
  {
    "id": 3520,
    "user_query": "What is the role of the Hof1-Cyk3 interaction in yeast?",
    "llama-2-7b-chat-hf_response": "The Hof1-Cyk3 interaction plays a crucial role in the regulation of the yeast cell cycle, particularly during the G1/S checkpoint. Here's a detailed explanation of the role of this interaction:\nHof1 is a protein that functions as a molecular switch, controlling the progression of the cell cycle by interacting with different partners at different stages of the cell cycle. Cyk3 is a protein that is involved in the regulation of the G1/S checkpoint, which is a critical control point in the cell cycle that ensures that cells are ready to enter the S phase of the cell cycle.\nThe Hof1-Cyk3 interaction is essential for the proper regulation of the G1/S checkpoint in yeast. When the cell is ready to enter the S phase, Hof1 binds to the Cyk3 protein, which triggers a conformational change in Hof1 that allows it to interact with other proteins and activate the G1/S checkpoint. This checkpoint ensures that the cell is ready to enter the S phase by verifying that the necessary conditions for DNA replication are met.\nThe Hof1-Cyk3 interaction also plays a role in the regulation of the cell cycle by controlling the activity of the protein kinase A (PKA). PKA is an enzyme that plays a central role in the regulation of the cell cycle by phosphorylating and activating various proteins involved in the cell cycle. The Hof1-Cyk3 interaction inhibits the activity of PKA, which helps to ensure that the cell cycle progresses in an orderly manner.\nIn addition to its role in the G1/S checkpoint, the Hof1-Cyk3 interaction has been implicated in other cellular processes, including the regulation of gene expression and the response to stress. For example, Hof1 has been shown to regulate the expression of genes involved in the cell cycle and DNA replication, and the Hof1-Cyk3 interaction has been shown to be involved in the response of yeast to oxidative stress.\nIn summary, the Hof1-Cyk3 interaction plays a crucial role in the regulation of the G1/S checkpoint in yeast, and is involved in the regulation of other cellular processes as well. This interaction is essential for ensuring that the cell cycle progresses in an",
    "llama-2-7b-chat-hf_fact_raw": "1. The Hof1-Cyk3 interaction regulates the yeast cell cycle, specifically during the G1/S checkpoint.\n2. Hof1 functions as a molecular switch, controlling cell cycle progression by interacting with different partners.\n3. Cyk3 is involved in the regulation of the G1/S checkpoint, a critical control point ensuring cells are ready for the S phase.\n4. The Hof1-Cyk3 interaction inhibits the activity of the protein kinase A (PKA), which regulates the cell cycle.\n5. The Hof1-Cyk3 interaction has been implicated in the regulation of gene expression and the response to oxidative stress in yeast.",
    "llama-2-7b-chat-hf_fact": [
      "The Hof1-Cyk3 interaction regulates the yeast cell cycle, specifically during the G1/S checkpoint.",
      "Hof1 functions as a molecular switch, controlling cell cycle progression by interacting with different partners.",
      "Cyk3 is involved in the regulation of the G1/S checkpoint, a critical control point ensuring cells are ready for the S phase.",
      "The Hof1-Cyk3 interaction inhibits the activity of the protein kinase A (PKA), which regulates the cell cycle.",
      "The Hof1-Cyk3 interaction has been implicated in the regulation of gene expression and the response to oxidative stress in yeast."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: There is no direct evidence showing that the Hof1-Cyk3 interaction inhibits the activity of protein kinase A (PKA). PKA is regulated by cyclic AMP levels and other factors.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 3598,
    "user_query": "Which T-UCRs have been implicated in gastric cancer?",
    "llama-2-7b-chat-hf_response": "Gastric cancer is a common type of cancer worldwide, and there are several T-cell-related genetic alterations (T-UCRs) that have been implicated in its development and progression. Here are some of the T-UCRs that have been linked to gastric cancer:\n1. TP53: TP53 is a tumor suppressor gene that is mutated in over 50% of gastric cancers. The TP53 protein plays a crucial role in regulating cell growth and division, and mutations in this gene can lead to uncontrolled cell growth and the development of cancer.\n2. CDKN2A: CDKN2A is a gene that encodes a protein called p16, which is involved in the regulation of the cell cycle. Mutations in this gene are common in gastric cancer and are associated with poor prognosis.\n3. CDH1: CDH1 is a gene that encodes a protein called E-cadherin, which is involved in the adhesion of epithelial cells and the maintenance of tissue structure. Mutations in this gene are associated with the development of gastric cancer.\n4. MSH2: MSH2 is a gene that encodes a protein called mutS, which is involved in the repair of DNA mutations. Mutations in this gene are associated with the development of gastric cancer.\n5. MLH1: MLH1 is a gene that encodes a protein called mutL, which is involved in the repair of DNA mutations. Mutations in this gene are associated with the development of gastric cancer.\n6. MSH6: MSH6 is a gene that encodes a protein called mutS, which is involved in the repair of DNA mutations. Mutations in this gene are associated with the development of gastric cancer.\n7. PTEN: PTEN is a gene that encodes a protein called phosphatase and tensin homolog, which is involved in the regulation of cell growth and division. Mutations in this gene are associated with the development of gastric cancer.\n8. APC: APC is a gene that encodes a protein called adenomatous polyps coli, which is involved in the regulation of cell growth and division. Mutations",
    "llama-2-7b-chat-hf_fact_raw": "1. TP53 is a tumor suppressor gene that is mutated in over 50% of gastric cancers.\n2. CDKN2A is a gene that encodes a protein called p16 and mutations in this gene are common in gastric cancer.\n3. CDH1 is a gene that encodes a protein called E-cadherin and mutations in this gene are associated with the development of gastric cancer.\n4. MSH2 is a gene that encodes a protein called mutS and mutations in this gene are associated with the development of gastric cancer.\n5. MLH1 is a gene that encodes a protein called mutL and mutations in this gene are associated with the development of gastric cancer.",
    "llama-2-7b-chat-hf_fact": [
      "TP53 is a tumor suppressor gene that is mutated in over 50% of gastric cancers.",
      "CDKN2A is a gene that encodes a protein called p16 and mutations in this gene are common in gastric cancer.",
      "CDH1 is a gene that encodes a protein called E-cadherin and mutations in this gene are associated with the development of gastric cancer.",
      "MSH2 is a gene that encodes a protein called mutS and mutations in this gene are associated with the development of gastric cancer.",
      "MLH1 is a gene that encodes a protein called mutL and mutations in this gene are associated with the development of gastric cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3607,
    "user_query": "What is the Lupus Severity Index (LSI)?",
    "llama-2-7b-chat-hf_response": "The Lupus Severity Index (LSI) is a clinical tool used to assess the severity of systemic lupus erythematosus (SLE), a chronic autoimmune disease that affects various parts of the body, including the skin, joints, and organs. The LSI was developed by a team of researchers led by Dr. Gordon D. Schroeder in the 1980s and has been widely used in clinical practice and research studies since then.\nThe LSI is a 10-point scale that evaluates the severity of SLE based on the following organ systems:\n1. Skin: The severity of skin involvement is assessed using a 5-point scale, with higher scores indicating more severe skin disease.\n2. Joints: The severity of joint involvement is assessed using a 5-point scale, with higher scores indicating more severe joint disease.\n3. Serosal involvement: The severity of serosal involvement (pleuritis, pericarditis, or peritonitis) is assessed using a 5-point scale, with higher scores indicating more severe serosal disease.\n4. Renal involvement: The severity of renal involvement is assessed using a 5-point scale, with higher scores indicating more severe renal disease.\n5. Haemato-lymphoid involvement: The severity of haemato-lymphoid involvement (spleen enlargement, lymphadenopathy, or pancytopenia) is assessed using a 5-point scale, with higher scores indicating more severe haemato-lymphoid disease.\n6. Neuropsychiatric involvement: The severity of neuropsychiatric involvement (cognitive impairment, psychosis, or depression) is assessed using a 5-point scale, with higher scores indicating more severe neuropsychiatric disease.\n7. Immunological involvement: The severity of immunological involvement (antinuclear antibodies, anti-double-stranded DNA antibodies, or anti-Smith antibodies) is assessed using a 5-point scale, with higher scores indicating more severe immunological disease.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).\n2. The LSI was developed by a team of researchers led by Dr. Gordon D. Schroeder in the 1980s.\n3. It is a 10-point scale that evaluates severity based on organ systems including skin, joints, serosal, renal, haemato-lymphoid, neuropsychiatric, and immunological involvement.\n4. Higher scores on the LSI indicate more severe involvement of the assessed organ system.\n5. The severity of each organ involvement is assessed using a 5-point scale on the LSI.",
    "llama-2-7b-chat-hf_fact": [
      "The Lupus Severity Index (LSI) is used to assess the severity of systemic lupus erythematosus (SLE).",
      "The LSI was developed by a team of researchers led by Dr. Gordon D. Schroeder in the 1980s.",
      "It is a 10-point scale that evaluates severity based on organ systems including skin, joints, serosal, renal, haemato-lymphoid, neuropsychiatric, and immunological involvement.",
      "Higher scores on the LSI indicate more severe involvement of the assessed organ system.",
      "The severity of each organ involvement is assessed using a 5-point scale on the LSI."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. TRUE\n5. FALSE [correction]: The severity of each organ involvement is assessed using a specific number of points, not necessarily a 5-point scale, on the LSI.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3615,
    "user_query": "Which disorders are caused by de novo mutations in ZSWIM6?",
    "llama-2-7b-chat-hf_response": "ZSWIM6 is a gene that has recently been identified as a causative gene for several neurodevelopmental disorders, including intellectual disability, autism spectrum disorder, and ADHD. De novo mutations in ZSWIM6 have been found to be associated with these disorders, meaning that the mutations occur spontaneously and are not inherited from the parents.\nSeveral studies have identified de novo mutations in ZSWIM6 in individuals with neurodevelopmental disorders. For example, a study published in the journal Nature in 2019 found that de novo mutations in ZSWIM6 were present in 17% of individuals with intellectual disability, and in 23% of individuals with autism spectrum disorder. Another study published in the journal American Journal of Human Genetics in 2020 found that de novo mutations in ZSWIM6 were present in 10% of individuals with ADHD.\nThe specific disorders that have been linked to de novo mutations in ZSWIM6 include:\n1. Intellectual disability: De novo mutations in ZSWIM6 have been found to be associated with intellectual disability, which is characterized by below-average intelligence and cognitive abilities, as well as difficulties with communication, social interactions, and daily living skills.\n2. Autism spectrum disorder: De novo mutations in ZSWIM6 have been found to be associated with autism spectrum disorder, which is characterized by difficulties with social interactions, communication, and repetitive behaviors.\n3. ADHD: De novo mutations in ZSWIM6 have been found to be associated with attention deficit hyperactivity disorder (ADHD), which is characterized by difficulties with attention, hyperactivity, and impulsivity.\nIt is important to note that the relationship between de novo mutations in ZSWIM6 and these disorders is complex and not fully understood. More research is needed to determine the exact mechanisms by which these mutations contribute to the development of these disorders.\nIn summary, de novo mutations in ZSWIM6 have been found to be associated with several neurodevelopmental disorders, including intellectual disability, autism spectrum disorder, and ADHD. Further research is needed to fully understand the relationship between these mutations and these disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. ZSWIM6 has been identified as a causative gene for several neurodevelopmental disorders.\n2. De novo mutations in ZSWIM6 have been associated with intellectual disability, autism spectrum disorder, and ADHD.\n3. A study published in Nature in 2019 found de novo mutations in ZSWIM6 in 17% of individuals with intellectual disability and 23% of individuals with autism spectrum disorder.\n4. A study published in the American Journal of Human Genetics in 2020 found de novo mutations in ZSWIM6 in 10% of individuals with ADHD.\n5. De novo mutations in ZSWIM6 are not inherited from parents but occur spontaneously.",
    "llama-2-7b-chat-hf_fact": [
      "ZSWIM6 has been identified as a causative gene for several neurodevelopmental disorders.",
      "De novo mutations in ZSWIM6 have been associated with intellectual disability, autism spectrum disorder, and ADHD.",
      "A study published in Nature in 2019 found de novo mutations in ZSWIM6 in 17% of individuals with intellectual disability and 23% of individuals with autism spectrum disorder.",
      "A study published in the American Journal of Human Genetics in 2020 found de novo mutations in ZSWIM6 in 10% of individuals with ADHD.",
      "De novo mutations in ZSWIM6 are not inherited from parents but occur spontaneously."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3626,
    "user_query": "Which disease can be classified using the Koos Classification?",
    "llama-2-7b-chat-hf_response": "The Koos Classification is a system used to classify and categorize diseases based on their underlying pathophysiological mechanisms. The classification system was developed by Dr. H.P. Koos, a Dutch physician and pathologist, and it is widely used in clinical medicine and research.\nAccording to the Koos Classification, diseases can be classified into one of the following categories:\n1. Inflammatory diseases: These are diseases that are caused by an abnormal immune response, resulting in inflammation and tissue damage. Examples of inflammatory diseases include rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis.\n2. Autoimmune diseases: These are diseases that occur when the immune system mistakenly attacks the body's own tissues and organs. Examples of autoimmune diseases include lupus, type 1 diabetes, and rheumatoid arthritis.\n3. Neoplastic diseases: These are diseases that are caused by the growth and spread of abnormal cells in the body. Examples of neoplastic diseases include cancer, benign tumors, and sarcomas.\n4. Metabolic diseases: These are diseases that are caused by abnormalities in the body's metabolism, such as diabetes, thyroid disorders, and metabolic bone disease.\n5. Genetic diseases: These are diseases that are caused by inherited genetic mutations or variations. Examples of genetic diseases include sickle cell anemia, cystic fibrosis, and Huntington's disease.\n6. Infectious diseases: These are diseases that are caused by the presence of a pathogen, such as a virus, bacterium, or parasite. Examples of infectious diseases include tuberculosis, malaria, and influenza.\n7. Cardiovascular diseases: These are diseases that affect the heart and blood vessels, such as heart failure, coronary artery disease, and atherosclerosis.\n8. Neurological diseases: These are diseases that affect the nervous system, such as stroke, epilepsy, and multiple sclerosis",
    "llama-2-7b-chat-hf_fact_raw": "1. The Koos Classification system was developed by Dr. H.P. Koos, a Dutch physician and pathologist.\n2. Inflammatory diseases are categorized in the Koos Classification as caused by abnormal immune response resulting in inflammation and tissue damage.\n3. Autoimmune diseases in the Koos Classification occur when the immune system attacks the body's own tissues and organs.\n4. Neoplastic diseases in the Koos Classification are caused by the growth and spread of abnormal cells in the body.\n5. Infectious diseases in the Koos Classification are caused by the presence of a pathogen, such as a virus, bacterium, or parasite.",
    "llama-2-7b-chat-hf_fact": [
      "The Koos Classification system was developed by Dr. H.P. Koos, a Dutch physician and pathologist.",
      "Inflammatory diseases are categorized in the Koos Classification as caused by abnormal immune response resulting in inflammation and tissue damage.",
      "Autoimmune diseases in the Koos Classification occur when the immune system attacks the body's own tissues and organs.",
      "Neoplastic diseases in the Koos Classification are caused by the growth and spread of abnormal cells in the body.",
      "Infectious diseases in the Koos Classification are caused by the presence of a pathogen, such as a virus, bacterium, or parasite."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3628,
    "user_query": "What are the in vivo effects of AZD8601?",
    "llama-2-7b-chat-hf_response": "AZD8601 is a small molecule inhibitor of the enzyme Bruton's tyrosine kinase (BTK), which is a key player in the B-cell receptor signaling pathway. In vivo, AZD8601 has been shown to have a range of effects on B cells and the immune system. Here are some of the in vivo effects of AZD8601:\n1. Reduction of B cells: AZD8601 has been shown to reduce the number of B cells in the peripheral blood and lymphoid organs, such as the spleen and lymph nodes. This reduction is thought to be due to the inhibition of BTK, which is essential for the survival and activation of B cells.\n2. Increased apoptosis of B cells: AZD8601 has been shown to induce increased apoptosis (cell death) of B cells, particularly in the context of B-cell malignancies. This suggests that AZD8601 may be effective in reducing the number of cancerous B cells in the body.\n3. Inhibition of B-cell receptor signaling: AZD8601 has been shown to inhibit the activation and signaling of B cells through their receptors, including the B-cell receptor (BCR) and the T-cell receptor (TCR). This inhibition can lead to a reduction in the production of antibodies and immune complexes, which can contribute to the treatment of autoimmune diseases.\n4. Modulation of T-cell responses: AZD8601 has been shown to modulate T-cell responses, including the activation and proliferation of T cells, as well as the production of cytokines and chemokines. This suggests that AZD8601 may be effective in regulating the immune response and reducing inflammation.\n5. Increased immune response: AZD8601 has been shown to increase the immune response in some contexts, such as in the treatment of cancer. This may be due to the inhibition of BTK, which can reduce the number of cancerous B cells and increase the immune response",
    "llama-2-7b-chat-hf_fact_raw": "1. AZD8601 is an inhibitor of the enzyme Bruton's tyrosine kinase (BTK).\n2. AZD8601 has been shown to reduce the number of B cells in the peripheral blood and lymphoid organs.\n3. AZD8601 can induce increased apoptosis of B cells, particularly in B-cell malignancies.\n4. AZD8601 inhibits the activation and signaling of B cells through their receptors, such as BCR and TCR.\n5. AZD8601 can modulate T-cell responses, including activation, proliferation, and production of cytokines and chemokines.",
    "llama-2-7b-chat-hf_fact": [
      "AZD8601 is an inhibitor of the enzyme Bruton's tyrosine kinase (BTK).",
      "AZD8601 has been shown to reduce the number of B cells in the peripheral blood and lymphoid organs.",
      "AZD8601 can induce increased apoptosis of B cells, particularly in B-cell malignancies.",
      "AZD8601 inhibits the activation and signaling of B cells through their receptors, such as BCR and TCR.",
      "AZD8601 can modulate T-cell responses, including activation, proliferation, and production of cytokines and chemokines."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: AZD8601 is not an inhibitor of Bruton's tyrosine kinase (BTK); it is an mRNA therapy that encodes for a protein called VEGF-A, which is involved in the growth of blood vessels.\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: Since AZD8601 is not a BTK inhibitor, it does not inhibit the activation and signaling of B cells through their receptors such as BCR and TCR. This statement might be true for a BTK inhibitor, but not for AZD8601.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3640,
    "user_query": "How are SAHFS created?",
    "llama-2-7b-chat-hf_response": "SAHFS, or Superfund Amendments of 1986, were created through a series of legislative actions and policy decisions in the United States. Here is a detailed explanation of how SAHFS were created:\n1. The Superfund Act of 1980: The Superfund Act of 1980, also known as the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), was passed in response to growing public concern about the release of toxic chemicals into the environment. The Act established a system for identifying, investigating, and cleaning up hazardous waste sites across the country.\n2. The 1981 Budget Act: In 1981, Congress passed the Budget Act, which included a provision that authorized the President to transfer funds from the Superfund Trust Fund to the General Fund of the Treasury. This provision allowed the President to use Superfund funds for other purposes, such as paying for other environmental programs or reducing the national debt.\n3. The 1986 Superfund Amendments: In 1986, Congress passed the Superfund Amendments of 1986, which made significant changes to the Superfund program. These amendments included:\na. Creation of the SAHFS: The SAHFS were created as a new funding source for the Superfund program. The SAHFS were funded by a tax on certain types of chemicals, including pesticides, herbicides, and other toxic substances.\nb. Increased Funding for Superfund: The 1986 Amendments increased funding for the Superfund program by $100 million per year for five years. This increased funding was used to accelerate the cleanup of hazardous waste sites and to provide additional resources for state and tribal governments to use in their cleanup efforts.\nc. New Priorities for Superfund: The 1986 Amendments established new priorities for the Superfund program, including:\ni. Priority for Sites with the Greatest Risk to Human Health: The Amendments required EPA to give higher priority to sites that posed the greatest risk to human health, such as sites contaminated with highly toxic chemicals or sites located",
    "llama-2-7b-chat-hf_fact_raw": "1. The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), also known as the Superfund Act of 1980, was passed in response to public concern about toxic chemicals in the environment.\n2. The 1981 Budget Act included a provision allowing the President to transfer funds from the Superfund Trust Fund to the General Fund of the Treasury.\n3. The Superfund Amendments of 1986 created the SAHFS as a new funding source for the Superfund program.\n4. The 1986 Superfund Amendments increased funding for the Superfund program by $100 million per year for five years.\n5. The 1986 Amendments established new priorities for the Superfund program, including giving higher priority to sites with the greatest risk to human health.",
    "llama-2-7b-chat-hf_fact": [
      "The Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), also known as the Superfund Act of 1980, was passed in response to public concern about toxic chemicals in the environment.",
      "The 1981 Budget Act included a provision allowing the President to transfer funds from the Superfund Trust Fund to the General Fund of the Treasury.",
      "The Superfund Amendments of 1986 created the SAHFS as a new funding source for the Superfund program.",
      "The 1986 Superfund Amendments increased funding for the Superfund program by $100 million per year for five years.",
      "The 1986 Amendments established new priorities for the Superfund program, including giving higher priority to sites with the greatest risk to human health."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The 1981 Budget Act did not include a provision allowing the President to transfer funds from the Superfund Trust Fund to the General Fund of the Treasury.\n3. FALSE [correction]: The Superfund Amendments of 1986 did not create the SAHFS as a new funding source for the Superfund program. SAHFS stands for the Superfund Accelerated Cleanup Model.\n4. FALSE [correction]: The 1986 Superfund Amendments increased funding for the Superfund program by $1.6 billion over five years.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3672,
    "user_query": "What is the function of the PDZ domain in SATB1?",
    "llama-2-7b-chat-hf_response": "The PDZ domain is a structural motif found in various proteins, including SATB1. The PDZ domain is a short sequence of about 100 amino acids that is typically located at the carboxy-terminal end of a protein. It is involved in protein-protein interactions and plays a crucial role in regulating various cellular processes, including cell signaling, adhesion, and trafficking.\nIn SATB1, the PDZ domain is located at the C-terminal end of the protein and is involved in the regulation of SATB1's functions. The PDZ domain of SATB1 can bind to specific phosphorylated serine/threonine residues on target proteins, which leads to the modulation of SATB1's activity. The PDZ domain of SATB1 can also interact with other proteins, such as the actin cytoskeleton, and play a role in regulating cell migration and invasion.\nStudies have shown that the PDZ domain of SATB1 is involved in the regulation of several cellular processes, including:\n1. Cell adhesion and migration: The PDZ domain of SATB1 can interact with the actin cytoskeleton and regulate cell adhesion and migration.\n2. Cell signaling: The PDZ domain of SATB1 can interact with phosphorylated serine/threonine residues on target proteins, which leads to the modulation of cell signaling pathways.\n3. Protein degradation: The PDZ domain of SATB1 can interact with the ubiquitin-proteasome system and regulate protein degradation.\n4. Nuclear localization: The PDZ domain of SATB1 can interact with nuclear localization sequences and regulate the nuclear localization of SATB1.\n5. Transcriptional regulation: The PDZ domain of SATB1 can interact with transcription factors and regulate the activity of specific genes.\nOverall, the PDZ domain of SATB1 plays a crucial role in regulating various cellular processes, including cell adhesion, migration, signaling, protein degradation, and transcriptional",
    "llama-2-7b-chat-hf_fact_raw": "1. The PDZ domain is a structural motif consisting of about 100 amino acids typically found at the carboxy-terminal end of proteins.\n2. In SATB1, the PDZ domain is involved in protein-protein interactions and regulates various cellular processes.\n3. The PDZ domain of SATB1 can bind to phosphorylated serine/threonine residues on target proteins.\n4. The PDZ domain of SATB1 interacts with the actin cytoskeleton to regulate cell migration and invasion.\n5. Studies have shown that the PDZ domain of SATB1 is involved in regulating cell adhesion, migration, signaling, protein degradation, nuclear localization, and transcriptional regulation.",
    "llama-2-7b-chat-hf_fact": [
      "The PDZ domain is a structural motif consisting of about 100 amino acids typically found at the carboxy-terminal end of proteins.",
      "In SATB1, the PDZ domain is involved in protein-protein interactions and regulates various cellular processes.",
      "The PDZ domain of SATB1 can bind to phosphorylated serine/threonine residues on target proteins.",
      "The PDZ domain of SATB1 interacts with the actin cytoskeleton to regulate cell migration and invasion.",
      "Studies have shown that the PDZ domain of SATB1 is involved in regulating cell adhesion, migration, signaling, protein degradation, nuclear localization, and transcriptional regulation."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The PDZ domain typically binds to specific sequences at the C-termini of target proteins, but not to phosphorylated serine/threonine residues.\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3678,
    "user_query": "What is the basis of the BLISS technique?",
    "llama-2-7b-chat-hf_response": "The BLISS technique is a systematic method for evaluating and selecting the most appropriate psychedelic substance for an individual's specific needs and goals. The acronym BLISS stands for:\nB - Behavioral: Assessing the individual's current behavior and how it relates to their desired outcomes. This includes evaluating their level of motivation, self-discipline, and ability to follow through on commitments.\nL - Life Situation: Examining the individual's current life situation, including their relationships, living situation, work environment, and overall level of stress.\nI - Intention: Identifying the individual's specific intentions and goals for using psychedelics, such as personal growth, creativity enhancement, or therapeutic healing.\nS - Substance: Considering the specific psychedelic substance being considered, including its effects, dosage, and potential risks and side effects.\nS - Setting: Evaluating the setting in which the psychedelic experience will take place, including the physical environment, the presence of supportive individuals, and the level of safety and privacy.\nBy considering each of these factors, the BLISS technique aims to provide a comprehensive and personalized approach to selecting the most appropriate psychedelic substance for an individual's specific needs and goals.\nIt's important to note that the BLISS technique is not a substitute for medical or therapeutic advice. If you are considering using psychedelics for therapeutic purposes, it is important to consult with a qualified healthcare professional before proceeding.",
    "llama-2-7b-chat-hf_fact_raw": "1. The BLISS technique is used for evaluating and selecting the most appropriate psychedelic substance for an individual.\n2. The acronym BLISS stands for Behavioral, Life Situation, Intention, Substance, and Setting.\n3. The BLISS technique considers factors such as an individual's behavior, life situation, and intentions.\n4. The technique also assesses the specific psychedelic substance and the setting in which the experience will take place.\n5. The BLISS technique is not a substitute for medical or therapeutic advice.",
    "llama-2-7b-chat-hf_fact": [
      "The BLISS technique is used for evaluating and selecting the most appropriate psychedelic substance for an individual.",
      "The acronym BLISS stands for Behavioral, Life Situation, Intention, Substance, and Setting.",
      "The BLISS technique considers factors such as an individual's behavior, life situation, and intentions.",
      "The technique also assesses the specific psychedelic substance and the setting in which the experience will take place.",
      "The BLISS technique is not a substitute for medical or therapeutic advice."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3679,
    "user_query": "List 3 NK3R antagonists.",
    "llama-2-7b-chat-hf_response": "As a helpful assistant, I'm glad to provide you with information on NK3R antagonists. NK3R (N-methyl-D-aspartate receptor) is a receptor that plays a crucial role in the regulation of various physiological processes, including pain, mood, and cognitive function. Here are three NK3R antagonists:\n1. Tirasemet: Tirasemet is a selective NK3R antagonist that has been shown to have analgesic effects in various animal models of pain. It has been investigated as a potential treatment for chronic pain, including fibromyalgia and osteoarthritis.\n2. SNC-083: SNC-083 is a potent and selective NK3R antagonist that has been shown to have anti-inflammatory effects in various animal models. It has been investigated as a potential treatment for conditions such as rheumatoid arthritis and inflammatory bowel disease.\n3. BL-1020: BL-1020 is a highly selective NK3R antagonist that has been shown to have cognitive-enhancing effects in various animal models. It has been investigated as a potential treatment for conditions such as Alzheimer's disease and Parkinson's disease.\nIt's important to note that these are just a few examples of NK3R antagonists, and there are many other compounds that have been identified as potential NK3R antagonists. Additionally, while these compounds have shown promise in preclinical studies, further research is needed to determine their safety and efficacy in humans.",
    "llama-2-7b-chat-hf_fact_raw": "1. Tirasemet is a selective NK3R antagonist investigated for chronic pain treatment.\n2. SNC-083 is a potent and selective NK3R antagonist investigated for conditions like rheumatoid arthritis.\n3. BL-1020 is a highly selective NK3R antagonist investigated for cognitive enhancement in conditions like Alzheimer's disease.",
    "llama-2-7b-chat-hf_fact": [
      "Tirasemet is a selective NK3R antagonist investigated for chronic pain treatment.",
      "SNC-083 is a potent and selective NK3R antagonist investigated for conditions like rheumatoid arthritis.",
      "BL-1020 is a highly selective NK3R antagonist investigated for cognitive enhancement in conditions like Alzheimer's disease."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3691,
    "user_query": "Which drug is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects?",
    "llama-2-7b-chat-hf_response": "The first oral ghrelin receptor inverse agonist to be profiled in healthy subjects is a drug called BIBP-631.\nGhrelin is a hormone produced by the stomach that stimulates appetite and food intake. The ghrelin receptor is a G protein-coupled receptor that is activated by ghrelin and other related hormones. Inverse agonists of the ghrelin receptor are drugs that bind to the receptor but do not activate it, instead blocking the activity of endogenous ghrelin.\nBIBP-631 is a potent and selective oral inverse agonist of the ghrelin receptor. It was first identified in the early 2000s and has been extensively studied in animal models of obesity and metabolic disorders.\nStudies in healthy human subjects have shown that BIBP-631 reduces food intake and body weight in a dose-dependent manner. In a randomized, double-blind, placebo-controlled study published in The Lancet in 2009, healthy male subjects were given either BIBP-631 or a placebo and were then fed a standardized meal. The results showed that BIBP-631 significantly reduced food intake and increased the feeling of fullness compared to the placebo.\nIn addition to reducing food intake, BIBP-631 has also been shown to improve glucose tolerance and insulin sensitivity in animal models of obesity and type 2 diabetes.\nWhile BIBP-631 has shown promise as a potential treatment for obesity and related metabolic disorders, it is important to note that it is still a relatively new drug and more research is needed to fully understand its safety and efficacy in humans. Additionally, ghrelin receptor inverse agonists may have potential side effects, such as nausea and vomiting, and may interact with other medications.\nIn summary, BIBP-631 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects, and it has shown promise as a potential treatment for obesity and related metabolic disorders. However, more research",
    "llama-2-7b-chat-hf_fact_raw": "1. The drug BIBP-631 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.\n2. BIBP-631 is a potent and selective oral inverse agonist of the ghrelin receptor.\n3. BIBP-631 was first identified in the early 2000s.\n4. BIBP-631 reduced food intake and body weight in a dose-dependent manner in studies with healthy human subjects.\n5. A randomized, double-blind, placebo-controlled study published in The Lancet in 2009 showed that BIBP-631 significantly reduced food intake compared to a placebo.",
    "llama-2-7b-chat-hf_fact": [
      "The drug BIBP-631 is the first oral ghrelin receptor inverse agonist to be profiled in healthy subjects.",
      "BIBP-631 is a potent and selective oral inverse agonist of the ghrelin receptor.",
      "BIBP-631 was first identified in the early 2000s.",
      "BIBP-631 reduced food intake and body weight in a dose-dependent manner in studies with healthy human subjects.",
      "A randomized, double-blind, placebo-controlled study published in The Lancet in 2009 showed that BIBP-631 significantly reduced food intake compared to a placebo."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: The veracity of these statements cannot be determined without additional context or access to specific scientific literature regarding BIBP-631.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3693,
    "user_query": "What is the protective efficacy of vaxchora against moderate to severe cholera?",
    "llama-2-7b-chat-hf_response": "Vaxchora is an investigational cholera vaccine that has shown promising results in clinical trials for its protective efficacy against moderate to severe cholera. Here is a detailed answer to your question based on the available scientific evidence:\nProtective Efficacy Against Moderate Cholera:\nVaxchora has been shown to provide protection against moderate cholera in several clinical trials. In a phase 2b clinical trial conducted in Bangladesh, Vaxchora was found to be 67% effective in preventing moderate cholera in vaccinated individuals compared to placebo recipients. The trial included 4,000 participants, of whom 2,000 received the vaccine and 2,000 received a placebo. The results were published in The Lancet in 2018.\nIn another phase 3 clinical trial conducted in Africa, Vaxchora was found to be 77% effective in preventing moderate cholera in vaccinated individuals compared to placebo recipients. The trial included 15,000 participants, of whom 10,000 received the vaccine and 5,000 received a placebo. The results were published in The New England Journal of Medicine in 2020.\nProtective Efficacy Against Severe Cholera:\nWhile there are limited data on the protective efficacy of Vaxchora against severe cholera, the available evidence suggests that it may provide some protection against this more severe form of the disease. In the phase 2b clinical trial conducted in Bangladesh, Vaxchora was found to be 44% effective in preventing severe cholera in vaccinated individuals compared to placebo recipients. However, it is important to note that the trial was not powered to detect a difference in severe cholera cases, and the results may not be generalizable to all populations.\nIn the phase 3 clinical trial conducted in Africa, Vaxchora was found to be 60% effective in preventing severe cholera in vaccinated individuals compared to placebo recipients. However, the trial was conducted during a cholera outbreak, and the results may not be generalizable",
    "llama-2-7b-chat-hf_fact_raw": "1. Vaxchora is an investigational cholera vaccine.\n2. In a phase 2b clinical trial in Bangladesh, Vaxchora was 67% effective in preventing moderate cholera.\n3. The phase 2b trial in Bangladesh included 4,000 participants, with half receiving Vaxchora and half receiving a placebo.\n4. In a phase 3 clinical trial in Africa, Vaxchora was 77% effective in preventing moderate cholera.\n5. The phase 3 trial in Africa included 15,000 participants, with 10,000 receiving Vaxchora and 5,000 receiving a placebo.",
    "llama-2-7b-chat-hf_fact": [
      "Vaxchora is an investigational cholera vaccine.",
      "In a phase 2b clinical trial in Bangladesh, Vaxchora was 67% effective in preventing moderate cholera.",
      "The phase 2b trial in Bangladesh included 4,000 participants, with half receiving Vaxchora and half receiving a placebo.",
      "In a phase 3 clinical trial in Africa, Vaxchora was 77% effective in preventing moderate cholera.",
      "The phase 3 trial in Africa included 15,000 participants, with 10,000 receiving Vaxchora and 5,000 receiving a placebo."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Vaxchora is not an investigational vaccine, it is an FDA-approved vaccine for the prevention of cholera. \n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3716,
    "user_query": "Which was the first cholera vaccine approved in the US?",
    "llama-2-7b-chat-hf_response": "The first cholera vaccine approved in the US was the Cholera Vaccine A (CVA) developed by the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and approved by the Food and Drug Administration (FDA) in 1985.\nThe CVA vaccine was developed using a killed (inactivated) form of the cholera bacterium, Vibrio cholerae, and was shown to be highly effective in preventing cholera in clinical trials. The vaccine was initially approved for use in adults aged 18-64 years old, and later expanded to include children and adolescents.\nThe CVA vaccine has undergone several updates and improvements since its initial approval, including the development of a new formulation called the Cholera Vaccine, Injectable (CVD), which was approved in 2016. This new vaccine is given as a single dose and provides longer-lasting protection against cholera than the earlier CVA vaccine.\nIt's worth noting that while cholera vaccines are effective in preventing cholera, they are not 100% effective, and it's still important to take precautions to avoid getting cholera, such as drinking safe water and practicing good hygiene.",
    "llama-2-7b-chat-hf_fact_raw": "1. The first cholera vaccine approved in the US was the Cholera Vaccine A (CVA).\n2. The Cholera Vaccine A was developed by the US Army Medical Research Institute of Infectious Diseases (USAMRIID).\n3. The Food and Drug Administration (FDA) approved the CVA vaccine in 1985.\n4. The CVA vaccine was initially approved for use in adults aged 18-64 years old.\n5. A new cholera vaccine formulation called the Cholera Vaccine, Injectable (CVD) was approved in 2016.",
    "llama-2-7b-chat-hf_fact": [
      "The first cholera vaccine approved in the US was the Cholera Vaccine A (CVA).",
      "The Cholera Vaccine A was developed by the US Army Medical Research Institute of Infectious Diseases (USAMRIID).",
      "The Food and Drug Administration (FDA) approved the CVA vaccine in 1985.",
      "The CVA vaccine was initially approved for use in adults aged 18-64 years old.",
      "A new cholera vaccine formulation called the Cholera Vaccine, Injectable (CVD) was approved in 2016."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The first cholera vaccine approved in the US was the Vaxchora.\n2. UNKNOWN\n3. FALSE [correction]: The Food and Drug Administration (FDA) approved the Vaxchora vaccine in 2016.\n4. TRUE\n5. FALSE [correction]: The new cholera vaccine formulation approved in 2016 is called Vaxchora, not Cholera Vaccine, Injectable (CVD).",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3737,
    "user_query": "Which is the most common monogenic cause of common variable immunodeficiency (CVID) in Europeans?",
    "llama-2-7b-chat-hf_response": "Common variable immunodeficiency (CVID) is a rare genetic disorder that affects the immune system, specifically the B cells, which are responsible for producing antibodies to fight infections. Monogenic disorders are caused by a single genetic mutation, and CVID is one such disorder.\nThe most common monogenic cause of CVID in Europeans is mutations in the IL7R gene. The IL7R gene provides instructions for making a protein called interleukin 7 receptor, which is important for the development and survival of B cells. Mutations in the IL7R gene can lead to a decrease in the production of B cells, which can result in recurrent infections and other immune-related problems.\nAccording to the European CVID Consortium, which is a group of researchers who have studied CVID in Europe, the IL7R mutations are found in approximately 70% of CVID patients in Europe. The most common mutations are found in the exons 4-6 region of the IL7R gene.\nOther genetic causes of CVID include mutations in the genes encoding the proteins CD40L (CD40 ligand), CD40 (CD40 receptor), and XBP1 (X-box binding protein 1). However, these mutations are less common than IL7R mutations in European CVID patients.\nIt's important to note that CVID is a rare disorder, and the exact cause is not always known. In some cases, CVID may be caused by a combination of genetic and environmental factors.\nI hope this information helps! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. Common variable immunodeficiency (CVID) is a rare genetic disorder that affects the immune system, specifically the B cells.\n2. The most common monogenic cause of CVID in Europeans is mutations in the IL7R gene.\n3. The IL7R gene provides instructions for making a protein called interleukin 7 receptor.\n4. According to the European CVID Consortium, IL7R mutations are found in approximately 70% of CVID patients in Europe.\n5. Other genetic causes of CVID include mutations in the genes CD40L, CD40, and XBP1.",
    "llama-2-7b-chat-hf_fact": [
      "Common variable immunodeficiency (CVID) is a rare genetic disorder that affects the immune system, specifically the B cells.",
      "The most common monogenic cause of CVID in Europeans is mutations in the IL7R gene.",
      "The IL7R gene provides instructions for making a protein called interleukin 7 receptor.",
      "According to the European CVID Consortium, IL7R mutations are found in approximately 70% of CVID patients in Europe.",
      "Other genetic causes of CVID include mutations in the genes CD40L, CD40, and XBP1."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The most common monogenic cause of CVID in Europeans is mutations in the TNFRSF13B gene.\n3. TRUE \n4. FALSE [correction]: IL7R mutations are not the most common cause of CVID in Europe, and the specific percentage of 70% is not accurate according to the European CVID Consortium.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3743,
    "user_query": "Which is the role of the IFIT1 gene in Systemic Lupus Erythematosus (SLE)?",
    "llama-2-7b-chat-hf_response": "The IFIT1 gene has been implicated in the development and progression of Systemic Lupus Erythematosus (SLE), an autoimmune disease that affects various tissues and organs throughout the body. Here are some key points to understand the role of the IFIT1 gene in SLE:\n1. Structure and Function: The IFIT1 gene encodes a protein called Interferon-induced protein with tetratonic activity 1 (IFIT1). This protein is a member of the interferon-induced protein family, which plays a crucial role in the antiviral and antibacterial immune response.\n2. Genetic Variation: Studies have shown that genetic variations in the IFIT1 gene are associated with an increased risk of developing SLE. Specifically, certain single nucleotide polymorphisms (SNPs) in the IFIT1 gene have been linked to SLE susceptibility.\n3. Expression in SLE: IFIT1 is expressed at higher levels in SLE patients compared to healthy individuals. This increased expression may contribute to the overactive immune response that characterizes SLE.\n4. Role in Autoantibody Production: IFIT1 has been shown to play a role in the production of autoantibodies, which are antibodies that target the body's own tissues. SLE patients often produce autoantibodies against their own tissues, which can contribute to the development of organ damage and other SLE manifestations.\n5. Regulation of Immune Cells: IFIT1 has been shown to regulate the activity of immune cells, such as T cells and macrophages, which are involved in the immune response. Dysregulation of these cells may contribute to the development of SLE.\n6. Impact on Disease Severity: Studies have suggested that higher levels of IFIT1 expression are associated with more severe SLE manifestations, such as kidney damage and neurological problems.\n7. Potential as a Biomarker: IFIT1 expression levels have been proposed as a potential biomarker for SLE diagnosis and disease severity. This could help clinicians identify patients at high risk of developing severe SLE manifestations and tailor treatment accordingly.\n8. Therapeutic Target: Given the role of IF",
    "llama-2-7b-chat-hf_fact_raw": "1. The IFIT1 gene encodes a protein called Interferon-induced protein with tetratonic activity 1 (IFIT1).\n2. Genetic variations in the IFIT1 gene are associated with an increased risk of developing SLE.\n3. IFIT1 is expressed at higher levels in SLE patients compared to healthy individuals.\n4. IFIT1 plays a role in the production of autoantibodies in SLE patients.\n5. IFIT1 expression levels have been proposed as a potential biomarker for SLE diagnosis and disease severity.",
    "llama-2-7b-chat-hf_fact": [
      "The IFIT1 gene encodes a protein called Interferon-induced protein with tetratonic activity 1 (IFIT1).",
      "Genetic variations in the IFIT1 gene are associated with an increased risk of developing SLE.",
      "IFIT1 is expressed at higher levels in SLE patients compared to healthy individuals.",
      "IFIT1 plays a role in the production of autoantibodies in SLE patients.",
      "IFIT1 expression levels have been proposed as a potential biomarker for SLE diagnosis and disease severity."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "unknown",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3752,
    "user_query": "What is the use of the Liverpool Elbow Score?",
    "llama-2-7b-chat-hf_response": "The Liverpool Elbow Score (LES) is a clinical assessment tool used to evaluate the severity of elbow pain and disability in patients with elbow injuries or conditions. It was developed by a team of orthopedic surgeons at the Royal Liverpool University Hospital in the UK and was first published in 1992.\nThe LES is a self-report questionnaire that assesses six domains of elbow function:\n1. Pain: The patient is asked to rate the severity of their elbow pain on a scale of 0-10.\n2. Function: The patient is asked to rate their ability to perform various elbow functions, such as gripping, pinching, and twisting, on a scale of 0-3.\n3. Stability: The patient is asked to rate the stability of their elbow on a scale of 0-3.\n4. Mobility: The patient is asked to rate the mobility of their elbow on a scale of 0-3.\n5. Grip strength: The patient is asked to perform a grip strength test, and the result is recorded on a scale of 0-10.\n6. Functional ability: The patient is asked to rate their ability to perform various daily activities, such as dressing, grooming, and feeding oneself, on a scale of 0-3.\nThe scores from each of these domains are then added up to give a total LES score, which can range from 0 to 18. A higher score indicates greater severity of elbow pain and disability.\nThe LES has been found to be a reliable and valid measure of elbow function and disability in various studies. It is commonly used in clinical practice and research to evaluate the effectiveness of treatments for elbow injuries and conditions, such as tennis elbow, golfer's elbow, and osteoarthritis.\nIn summary, the Liverpool Elbow Score is a clinical assessment tool used to evaluate the severity of elbow pain and disability in patients with elbow injuries or conditions. It assesses six domains of elbow function and provides a total score that can be used to monitor progress and evaluate the effectiveness of treatments.",
    "llama-2-7b-chat-hf_fact_raw": "1. The Liverpool Elbow Score (LES) was developed by orthopedic surgeons at the Royal Liverpool University Hospital in the UK.\n2. The LES was first published in 1992.\n3. The LES is a self-report questionnaire that assesses six domains of elbow function.\n4. The total LES score can range from 0 to 18, with a higher score indicating greater severity of elbow pain and disability.\n5. The LES has been found to be a reliable and valid measure of elbow function and disability in various studies.",
    "llama-2-7b-chat-hf_fact": [
      "The Liverpool Elbow Score (LES) was developed by orthopedic surgeons at the Royal Liverpool University Hospital in the UK.",
      "The LES was first published in 1992.",
      "The LES is a self-report questionnaire that assesses six domains of elbow function.",
      "The total LES score can range from 0 to 18, with a higher score indicating greater severity of elbow pain and disability.",
      "The LES has been found to be a reliable and valid measure of elbow function and disability in various studies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: The LES was first published in 1999.\n3. FALSE [correction]: The LES is not a self-report questionnaire, it is a clinician-based scoring system that assesses six domains of elbow function.\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "true",
      "true"
    ]
  },
  {
    "id": 3763,
    "user_query": "Describe efforts on Sarcoma from the 100,000 Genomes Project",
    "llama-2-7b-chat-hf_response": "The 100,000 Genomes Project was a large-scale genomics project launched in 2012 with the goal of analyzing the genomes of 100,000 individuals from the UK to better understand the genetic basis of disease and improve healthcare. The project included a significant focus on sarcoma, a rare and complex cancer that affects connective tissue. Here are some key efforts made by the 100,000 Genomes Project in the area of sarcoma research:\n1. Whole-genome sequencing: The project aimed to sequence the entire genome of 100,000 individuals, including those with sarcoma. This involved analyzing the DNA sequence of the genome and identifying genetic variations associated with the disease.\n2. Identification of new sarcoma-related genetic variants: The project identified several new genetic variants associated with sarcoma, including mutations in genes such as KRAS, PIK3CA, and ATRX. These findings helped researchers better understand the genetic basis of sarcoma and could lead to the development of new diagnostic tests and treatments.\n3. Development of a sarcoma genomic classification system: The project developed a system for classifying sarcomas based on their genomic characteristics. This system could help clinicians better understand the underlying genetic causes of sarcoma and develop more targeted and effective treatment strategies.\n4. Analysis of genomic heterogeneity in sarcoma: The project investigated the genomic diversity of sarcoma, including the identification of different subclones within individual tumors. This research could lead to a better understanding of the mechanisms driving sarcoma growth and progression.\n5. Investigation of the role of somatic mutations in sarcoma: The project analyzed the frequency and distribution of somatic mutations in sarcoma, including those in genes such as TP53, BRCA1, and BRCA2. These findings could help researchers understand the genetic alterations that contribute to sarcoma development and progression.\n6. Identification of potential therapeutic targets: The project identified several potential therapeutic targets for sarcoma, including genes involved in cell signaling pathways and DNA repair. These find",
    "llama-2-7b-chat-hf_fact_raw": "1. The 100,000 Genomes Project was launched in 2012 in the UK.\n2. The project aimed to sequence the entire genome of 100,000 individuals.\n3. The project included a significant focus on sarcoma research.\n4. The project identified new genetic variants associated with sarcoma, including mutations in genes such as KRAS, PIK3CA, and ATRX.\n5. The project developed a sarcoma genomic classification system based on genomic characteristics.",
    "llama-2-7b-chat-hf_fact": [
      "The 100,000 Genomes Project was launched in 2012 in the UK.",
      "The project aimed to sequence the entire genome of 100,000 individuals.",
      "The project included a significant focus on sarcoma research.",
      "The project identified new genetic variants associated with sarcoma, including mutations in genes such as KRAS, PIK3CA, and ATRX.",
      "The project developed a sarcoma genomic classification system based on genomic characteristics."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The 100,000 Genomes Project was launched in 2013 in the UK.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3777,
    "user_query": "Does protein ALEX1 contain armadillo repeats?",
    "llama-2-7b-chat-hf_response": "Thank you for your question! I'm happy to help you.\nProtein ALEX1 is a fascinating protein that has been the subject of much research in the scientific community. To answer your question, protein ALEX1 does indeed contain armadillo repeats.\nArmadillo repeats are a type of structural motif that are found in many proteins, including ALEX1. These repeats are characterized by a specific pattern of amino acids that are repeated in a specific sequence. In the case of ALEX1, the protein contains several armadillo repeats, which are located in the N-terminal region of the protein.\nThe presence of armadillo repeats in ALEX1 is important because these repeats play a crucial role in the protein's function. Armadillo repeats are involved in the formation of protein complexes and are thought to be involved in the regulation of gene expression.\nStudies have shown that the armadillo repeats in ALEX1 are important for the protein's ability to bind to specific DNA sequences and to regulate the expression of target genes. For example, one study found that the armadillo repeats in ALEX1 are required for the protein's ability to bind to the promoter region of the human epidermal growth factor receptor gene.\nOverall, the presence of armadillo repeats in ALEX1 is an important aspect of the protein's structure and function, and further research is needed to fully understand the role of these repeats in the protein's mechanisms of action.\nI hope this information helps to answer your question! Let me know if you have any further queries.",
    "llama-2-7b-chat-hf_fact_raw": "1. Protein ALEX1 contains armadillo repeats.\n2. Armadillo repeats are a structural motif characterized by a specific pattern of amino acids.\n3. The armadillo repeats in ALEX1 are located in the N-terminal region of the protein.\n4. Armadillo repeats in ALEX1 play a role in the formation of protein complexes and regulation of gene expression.\n5. The armadillo repeats in ALEX1 are required for the protein's ability to bind to the promoter region of the human epidermal growth factor receptor gene.",
    "llama-2-7b-chat-hf_fact": [
      "Protein ALEX1 contains armadillo repeats.",
      "Armadillo repeats are a structural motif characterized by a specific pattern of amino acids.",
      "The armadillo repeats in ALEX1 are located in the N-terminal region of the protein.",
      "Armadillo repeats in ALEX1 play a role in the formation of protein complexes and regulation of gene expression.",
      "The armadillo repeats in ALEX1 are required for the protein's ability to bind to the promoter region of the human epidermal growth factor receptor gene."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3789,
    "user_query": "List enzymes that removes histone modifications.",
    "llama-2-7b-chat-hf_response": "There are several enzymes that can remove histone modifications, including:\n1. Histone demethylases: These enzymes specifically remove methyl groups from histones, leading to demethylation of the histone tail. Examples of histone demethylases include KDM4B (also known as LSD1), KDM5A, and KDM6A.\n2. Histone acetyltransferases: These enzymes add acetyl groups to the histone tail, leading to acetylation of the histone. Examples of histone acetyltransferases include p300 and CBP (CREB-binding protein).\n3. Histone deacetylases: These enzymes remove acetyl groups from the histone tail, leading to deacetylation of the histone. Examples of histone deacetylases include HDAC1, HDAC2, and HDAC3.\n4. Histone phosphatases: These enzymes remove phosphate groups from the histone tail, leading to dephosphorylation of the histone. Examples of histone phosphatases include PP1 and PP2A.\n5. Histone ubiquitin ligases: These enzymes attach ubiquitin tags to histones, leading to ubiquitination of the histone. Examples of histone ubiquitin ligases include RNF2 and RNF43.\n6. Histone-specific proteases: These enzymes specifically cleave histones, leading to degradation of the histone. Examples of histone-specific proteases include histone-specific proteases from the proteasome, such as the proteasome subunit PSMD4.\n7. Histone-modifying enzymes: These enzymes can modify histones by adding or removing other modifications, such as ADP-ribosylation, glycosylation, or methylation of the histone tail. Examples of histone-modifying enzymes include ADP-ribosyltransferases and glycosyltransferases.\nIt's worth noting that these enzymes can have different functions in different cellular compartments and under different cellular conditions, and some of them can also have non",
    "llama-2-7b-chat-hf_fact_raw": "1. Histone demethylases, such as KDM4B (LSD1), KDM5A, and KDM6A, remove methyl groups from histones.\n2. Histone acetyltransferases, such as p300 and CBP, add acetyl groups to the histone tail.\n3. Histone deacetylases, such as HDAC1, HDAC2, and HDAC3, remove acetyl groups from the histone tail.\n4. Histone phosphatases, such as PP1 and PP2A, remove phosphate groups from the histone tail.\n5. Histone ubiquitin ligases, such as RNF2 and RNF43, attach ubiquitin tags to histones.",
    "llama-2-7b-chat-hf_fact": [
      "Histone demethylases, such as KDM4B (LSD1), KDM5A, and KDM6A, remove methyl groups from histones.",
      "Histone acetyltransferases, such as p300 and CBP, add acetyl groups to the histone tail.",
      "Histone deacetylases, such as HDAC1, HDAC2, and HDAC3, remove acetyl groups from the histone tail.",
      "Histone phosphatases, such as PP1 and PP2A, remove phosphate groups from the histone tail.",
      "Histone ubiquitin ligases, such as RNF2 and RNF43, attach ubiquitin tags to histones."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: KDM4B (LSD1) is not a histone demethylase, LSD1 is the common name for KDM1A, not KDM4B.\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3806,
    "user_query": "Does head ct increase brain tumor risk?",
    "llama-2-7b-chat-hf_response": "Thank you for reaching out with your question! I'm here to help you understand the potential risks associated with head CT scans and brain tumors.\nFirstly, it's important to understand that head CT scans are a diagnostic tool used to detect and diagnose various medical conditions, including brain tumors. A head CT scan uses X-rays to produce detailed images of the brain and its blood vessels. While CT scans are generally safe, there is some evidence to suggest that repeated exposure to X-rays during CT scans may increase the risk of developing a brain tumor.\nThe International Agency for Research on Cancer (IARC) has classified CT scans as \"possibly carcinogenic to humans,\" which means that there is limited evidence in humans that CT scans may increase the risk of developing cancer. However, it's important to note that the evidence is still limited, and the overall risk is considered to be low.\nStudies have shown that the risk of developing a brain tumor from a single CT scan is relatively low, around 1 in 10,000 to 1 in 100,000. However, the risk may be slightly higher for people who have had multiple CT scans, particularly in children and young adults.\nIt's important to keep in mind that the benefits of a CT scan in diagnosing and treating a medical condition can far outweigh the potential risks. If you have concerns about the risks of a head CT scan, you should discuss them with your healthcare provider. They can help you understand the potential risks and benefits of the scan and make an informed decision about whether it's necessary for your care.\nIn summary, while there is some evidence to suggest that repeated exposure to X-rays during CT scans may increase the risk of developing a brain tumor, the overall risk is considered to be low. If you have concerns about the risks of a head CT scan, be sure to discuss them with your healthcare provider.",
    "llama-2-7b-chat-hf_fact_raw": "1. Head CT scans are a diagnostic tool used to detect and diagnose various medical conditions, including brain tumors.\n2. A head CT scan uses X-rays to produce detailed images of the brain and its blood vessels.\n3. The International Agency for Research on Cancer has classified CT scans as \"possibly carcinogenic to humans.\"\n4. The risk of developing a brain tumor from a single CT scan is estimated to be between 1 in 10,000 to 1 in 100,000.\n5. The risk of developing a brain tumor may be higher for people who have had multiple CT scans, particularly in children and young adults.",
    "llama-2-7b-chat-hf_fact": [
      "Head CT scans are a diagnostic tool used to detect and diagnose various medical conditions, including brain tumors.",
      "A head CT scan uses X-rays to produce detailed images of the brain and its blood vessels.",
      "The International Agency for Research on Cancer has classified CT scans as \"possibly carcinogenic to humans.\"",
      "The risk of developing a brain tumor from a single CT scan is estimated to be between 1 in 10,000 to 1 in 100,000.",
      "The risk of developing a brain tumor may be higher for people who have had multiple CT scans, particularly in children and young adults."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "true"
    ]
  },
  {
    "id": 3809,
    "user_query": "Which type of pluripotency is Otx2 associated with?",
    "llama-2-7b-chat-hf_response": "Otx2 is a transcription factor that is associated with neural pluripotency. Neural pluripotency refers to the ability of neural stem cells to differentiate into different types of neurons and glia in the developing nervous system. Otx2 is expressed in neural stem cells and is important for their maintenance of pluripotency and their ability to differentiate into specific neural cell types.\nStudies have shown that Otx2 is required for the proper formation of the nervous system, particularly the cerebral cortex, and that mice lacking Otx2 have defects in neural patterning and differentiation. Otx2 is also involved in the regulation of cell fate decisions in the developing nervous system, and it has been shown to interact with other transcription factors, such as Pax6 and Nkx2.2, to regulate the expression of genes involved in neural differentiation.\nIn addition to its role in neural development, Otx2 has also been implicated in the regulation of adult neurogenesis, the process by which new neurons are generated in the adult brain. Studies have shown that Otx2 is expressed in adult neural stem cells and is involved in the maintenance of their pluripotency and their ability to differentiate into specific neural cell types.\nOverall, Otx2 is an important transcription factor that plays a critical role in the regulation of neural pluripotency and differentiation, both during development and in the adult brain.",
    "llama-2-7b-chat-hf_fact_raw": "1. Otx2 is associated with neural pluripotency.\n2. Otx2 is expressed in neural stem cells and is important for maintaining pluripotency and differentiation into specific neural cell types.\n3. Otx2 is required for the proper formation of the nervous system, particularly the cerebral cortex.\n4. Mice lacking Otx2 exhibit defects in neural patterning and differentiation.\n5. Otx2 is involved in the regulation of adult neurogenesis.",
    "llama-2-7b-chat-hf_fact": [
      "Otx2 is associated with neural pluripotency.",
      "Otx2 is expressed in neural stem cells and is important for maintaining pluripotency and differentiation into specific neural cell types.",
      "Otx2 is required for the proper formation of the nervous system, particularly the cerebral cortex.",
      "Mice lacking Otx2 exhibit defects in neural patterning and differentiation.",
      "Otx2 is involved in the regulation of adult neurogenesis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "true"
    ]
  },
  {
    "id": 3815,
    "user_query": "How many DNaseI hypersensitive sites (DHS) mark the murine beta globin locus region?",
    "llama-2-7b-chat-hf_response": "The number of DNaseI hypersensitive sites (DHS) marking the murine beta globin locus region is a matter of scientific interest and research. The beta globin locus is a well-studied region in mice that is involved in the regulation of red blood cell production and is known to be highly active in terms of chromatin accessibility.\nSeveral studies have used techniques such as DNaseI footprinting, ChIP-seq, and ATAC-seq to map the DHS in the beta globin locus region. These studies have reported a range of values for the number of DHS in this region, which I will summarize below:\n1. A study published in the journal Nature in 2015 used DNaseI footprinting to identify 147 DHS in the beta globin locus region. The authors found that these DHS were distributed across the region and were enriched in certain genomic features, such as gene bodies and regulatory elements.\n2. A subsequent study published in the journal Cell in 2017 used ChIP-seq to identify 207 DHS in the beta globin locus region. The authors found that these DHS were enriched in regions with high levels of histone H3 lysine 4 trimethylation (H3K4me3), which is a mark of active gene expression.\n3. A more recent study published in the journal Nature Communications in 2020 used ATAC-seq to identify 317 DHS in the beta globin locus region. The authors found that these DHS were enriched in regions with high levels of histone H3 lysine 27 trimethylation (H3K27me3), which is a mark of gene silencing.\nTaking these studies together, it is estimated that there are around 200-300 DHS marking the murine beta globin locus region. However, it is important to note that the exact number of DHS in this region may vary depending on the specific technique used to identify them and the specific genomic context in which they are found.",
    "llama-2-7b-chat-hf_fact_raw": "1. A study published in Nature in 2015 identified 147 DNaseI hypersensitive sites in the murine beta globin locus region.\n2. A study published in Cell in 2017 identified 207 DNaseI hypersensitive sites in the murine beta globin locus region.\n3. A study published in Nature Communications in 2020 identified 317 DNaseI hypersensitive sites in the murine beta globin locus region.\n4. DNaseI hypersensitive sites are associated with chromatin accessibility in the beta globin locus region of mice.\n5. The estimated range of DNaseI hypersensitive sites marking the murine beta globin locus region is around 200-300.",
    "llama-2-7b-chat-hf_fact": [
      "A study published in Nature in 2015 identified 147 DNaseI hypersensitive sites in the murine beta globin locus region.",
      "A study published in Cell in 2017 identified 207 DNaseI hypersensitive sites in the murine beta globin locus region.",
      "A study published in Nature Communications in 2020 identified 317 DNaseI hypersensitive sites in the murine beta globin locus region.",
      "DNaseI hypersensitive sites are associated with chromatin accessibility in the beta globin locus region of mice.",
      "The estimated range of DNaseI hypersensitive sites marking the murine beta globin locus region is around 200-300."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 3822,
    "user_query": "List as many European influenza vaccines as possible.",
    "llama-2-7b-chat-hf_response": "Certainly! There are several European influenza vaccines available in the market. Here are some of the most popular ones:\n1. Fluad: This is a quadrivalent influenza vaccine, which means it protects against four strains of the virus: two A strains and two B strains. It is approved for use in people aged 65 years and older.\n2. Fluarix: This is also a quadrivalent influenza vaccine, similar to Fluad. It is approved for use in people aged 18 years and older.\n3. Fluvirin: This is a trivalent influenza vaccine, which means it protects against three strains of the virus: two A strains and one B strain. It is approved for use in people aged 12 years and older.\n4. Aggripal: This is a quadrivalent influenza vaccine, similar to Fluad and Fluarix. It is approved for use in people aged 18 years and older.\n5. Nasovac: This is a trivalent influenza vaccine, which means it protects against three strains of the virus: two A strains and one B strain. It is approved for use in people aged 12 years and older.\n6. Flumad: This is a quadrivalent influenza vaccine, similar to Fluad and Fluarix. It is approved for use in people aged 18 years and older.\n7. Flublok: This is a trivalent influenza vaccine, which means it protects against three strains of the virus: two A strains and one B strain. It is approved for use in people aged 18 years and older.\n8. Fluad Pediatric: This is a quadrivalent influenza vaccine, similar to Fluad. It is approved for use in children and adolescents aged 6 months to 17 years.\n9. Fluarix Quadra: This is a quadrivalent influenza vaccine, similar to Fluarix. It is approved for use in people aged 18 years and older.\n10. Fluvirin Quadra: This is a quadrivalent influenza vaccine, similar to",
    "llama-2-7b-chat-hf_fact_raw": "1. Fluad is a quadrivalent influenza vaccine approved for use in people aged 65 years and older.\n2. Fluarix is a quadrivalent influenza vaccine approved for use in people aged 18 years and older.\n3. Fluvirin is a trivalent influenza vaccine approved for use in people aged 12 years and older.\n4. Aggripal is a quadrivalent influenza vaccine approved for use in people aged 18 years and older.\n5. Fluad Pediatric is a quadrivalent influenza vaccine approved for use in children and adolescents aged 6 months to 17 years.",
    "llama-2-7b-chat-hf_fact": [
      "Fluad is a quadrivalent influenza vaccine approved for use in people aged 65 years and older.",
      "Fluarix is a quadrivalent influenza vaccine approved for use in people aged 18 years and older.",
      "Fluvirin is a trivalent influenza vaccine approved for use in people aged 12 years and older.",
      "Aggripal is a quadrivalent influenza vaccine approved for use in people aged 18 years and older.",
      "Fluad Pediatric is a quadrivalent influenza vaccine approved for use in children and adolescents aged 6 months to 17 years."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Fluvirin is a trivalent influenza vaccine approved for use in people aged 4 years and older.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3832,
    "user_query": "Is the Paramyxovirus geneome segmented, negative-sense RNA?",
    "llama-2-7b-chat-hf_response": "Yes, the Paramyxovirus genome is segmented, negative-sense RNA.\nThe Paramyxovirus family of viruses, which includes viruses such as parainfluenza, mumps, and Nipah virus, have a unique genome organization compared to other RNA viruses. The Paramyxovirus genome is composed of several segments of RNA, each with a distinct function in the virus life cycle.\nThe Paramyxovirus genome is segmented into seven segments:\n1. L (large) segment: This segment codes for the viral RNA-dependent RNA polymerase (RdRp), which is responsible for transcribing the viral genome into messenger RNA (mRNA).\n2. S (small) segment: This segment codes for the viral phosphoprotein (P) and is involved in the regulation of viral transcription and replication.\n3. M (medium) segment: This segment codes for the viral matrix protein (M) and is involved in the assembly and release of the virus from infected cells.\n4. C (small cytoplasmic) segment: This segment codes for the viral cytoplasmic protein (C) and is involved in the regulation of viral transcription and replication.\n5. V (small nuclear) segment: This segment codes for the viral nuclear protein (V) and is involved in the regulation of viral transcription and replication.\n6. W (small nuclear) segment: This segment codes for the viral nuclear protein (W) and is involved in the regulation of viral transcription and replication.\n7. U (small cytoplasmic) segment: This segment codes for the viral cytoplasmic protein (U) and is involved in the regulation of viral transcription and replication.\nThe Paramyxovirus genome is negative-sense RNA, meaning that the genome is transcribed in the opposite direction to the direction of the viral mRNA. This means that the genome is transcribed from the 3' end of the genome to the 5' end, rather than from the 5' end to the 3' end like positive-sense RNA viruses.\nThe negative-sense RNA genome of Paramyxov",
    "llama-2-7b-chat-hf_fact_raw": "1. The Paramyxovirus genome is composed of segmented, negative-sense RNA.\n2. The Paramyxovirus family includes viruses such as parainfluenza, mumps, and Nipah virus.\n3. The L segment of the Paramyxovirus genome codes for the viral RNA-dependent RNA polymerase.\n4. The M segment of the Paramyxovirus genome codes for the viral matrix protein.\n5. The Paramyxovirus genome is transcribed from the 3' end to the 5' end.",
    "llama-2-7b-chat-hf_fact": [
      "The Paramyxovirus genome is composed of segmented, negative-sense RNA.",
      "The Paramyxovirus family includes viruses such as parainfluenza, mumps, and Nipah virus.",
      "The L segment of the Paramyxovirus genome codes for the viral RNA-dependent RNA polymerase.",
      "The M segment of the Paramyxovirus genome codes for the viral matrix protein.",
      "The Paramyxovirus genome is transcribed from the 3' end to the 5' end."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: The Paramyxovirus genome is composed of non-segmented, negative-sense RNA.\n2. TRUE\n3. TRUE\n4. FALSE [correction]: The Paramyxovirus genome does not have segments labeled as L or M, as it is non-segmented; the matrix protein is encoded within the single RNA strand.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 3869,
    "user_query": "Roflumilast Cream is effective for which disease?",
    "llama-2-7b-chat-hf_response": "Roflumilast cream is a topical medication that is used to treat a specific type of skin condition called psoriasis. Specifically, it is approved for the treatment of plaque psoriasis, which is a chronic autoimmune disease that causes red, scaly patches on the skin.\nRoflumilast cream works by blocking the action of a chemical called cytokine in the skin, which is involved in the inflammation and immune response that occurs in psoriasis. By blocking the action of cytokine, roflumilast cream can help reduce the inflammation and scaliness associated with psoriasis, leading to improved skin appearance and reduced symptoms.\nIt is important to note that roflumilast cream is not effective for other skin conditions, such as acne, eczema, or rosacea. It is also not effective for systemic psoriasis, which affects the entire body, as it is only applied topically to the affected skin area.\nIf you have psoriasis and are considering using roflumilast cream, it is important to consult with a healthcare professional to determine if it is safe and effective for you. They can help you determine the best treatment plan for your specific needs and condition.",
    "llama-2-7b-chat-hf_fact_raw": "1. Roflumilast cream is used to treat psoriasis.\n2. It is specifically approved for the treatment of plaque psoriasis.\n3. Roflumilast cream works by blocking the action of cytokine in the skin.\n4. Roflumilast cream is not effective for other skin conditions such as acne, eczema, or rosacea.\n5. Roflumilast cream is not effective for systemic psoriasis, as it is only applied topically.",
    "llama-2-7b-chat-hf_fact": [
      "Roflumilast cream is used to treat psoriasis.",
      "It is specifically approved for the treatment of plaque psoriasis.",
      "Roflumilast cream works by blocking the action of cytokine in the skin.",
      "Roflumilast cream is not effective for other skin conditions such as acne, eczema, or rosacea.",
      "Roflumilast cream is not effective for systemic psoriasis, as it is only applied topically."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Roflumilast cream works by blocking the action of phosphodiesterase 4 (PDE4) in the skin.\n4. FALSE [correction]: The effectiveness of Roflumilast cream for other skin conditions such as acne, eczema, or rosacea has not been established.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 3885,
    "user_query": "Which tools have been developed for identifying and visualising ncRNA promoters?",
    "llama-2-7b-chat-hf_response": "There are several tools that have been developed for identifying and visualizing non-coding RNA (ncRNA) promoters. Here are some of the most popular tools:\n1. PROMoterFinder: This tool was developed by the University of California, Santa Cruz and can be used to identify putative promoters for ncRNAs in any organism. PROMoterFinder uses a combination of computational methods, including sequence analysis and machine learning algorithms, to predict the location of ncRNA promoters.\n2. RNApromoter: This tool was developed by the University of California, San Diego and can be used to identify promoters for ncRNAs in any organism. RNApromoter uses a combination of sequence analysis and machine learning algorithms to predict the location of ncRNA promoters.\n3. NCmRNA-PROM: This tool was developed by the University of California, Los Angeles and can be used to identify promoters for ncRNAs in any organism. NCmRNA-PROM uses a combination of sequence analysis and machine learning algorithms to predict the location of ncRNA promoters.\n4. PromoterFinder: This tool was developed by the University of California, Berkeley and can be used to identify promoters for ncRNAs in any organism. PromoterFinder uses a combination of sequence analysis and machine learning algorithms to predict the location of ncRNA promoters.\n5. RNA-PROM: This tool was developed by the University of California, San Francisco and can be used to identify promoters for ncRNAs in any organism. RNA-PROM uses a combination of sequence analysis and machine learning algorithms to predict the location of ncRNA promoters.\n6. ncRNA-Promoter: This tool was developed by the University of Texas, Austin and can be used to identify promoters for ncRNAs in any organism. ncRNA-Promoter uses a combination of sequence analysis and machine learning algorithms to predict the location of ncRNA promoters.\n7. Promoter-Finder: This tool was developed by the University of Michigan and can be used to identify promoters for ncRNAs in any organism. Promoter-Finder uses a combination of sequence analysis",
    "llama-2-7b-chat-hf_fact_raw": "1. PROMoterFinder was developed by the University of California, Santa Cruz for identifying ncRNA promoters.\n2. RNApromoter was developed by the University of California, San Diego for identifying ncRNA promoters.\n3. NCmRNA-PROM was developed by the University of California, Los Angeles for identifying ncRNA promoters.\n4. PromoterFinder was developed by the University of California, Berkeley for identifying ncRNA promoters.\n5. RNA-PROM was developed by the University of California, San Francisco for identifying ncRNA promoters.",
    "llama-2-7b-chat-hf_fact": [
      "PROMoterFinder was developed by the University of California, Santa Cruz for identifying ncRNA promoters.",
      "RNApromoter was developed by the University of California, San Diego for identifying ncRNA promoters.",
      "NCmRNA-PROM was developed by the University of California, Los Angeles for identifying ncRNA promoters.",
      "PromoterFinder was developed by the University of California, Berkeley for identifying ncRNA promoters.",
      "RNA-PROM was developed by the University of California, San Francisco for identifying ncRNA promoters."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3918,
    "user_query": "List example genes that SWIM tool has identified and which are down-regulated in glioblastoma",
    "llama-2-7b-chat-hf_response": "The SWIM tool is a computational method that uses RNA sequencing data to identify differentially expressed genes between different tissues or tumor types. To answer your question, I must first clarify that the SWIM tool is specifically designed to identify genes that are down-regulated in glioblastoma, which is a type of aggressive brain cancer.\nUsing the SWIM tool, here are some example genes that have been identified as down-regulated in glioblastoma:\n1. PTEN: The phosphatase and tensin homolog (PTEN) gene is a tumor suppressor that is frequently mutated or lost in glioblastoma. PTEN is involved in the regulation of cell growth and survival, and its down-regulation can contribute to the development and progression of glioblastoma.\n2. TP53: The tumor protein p53 (TP53) is a transcription factor that plays a crucial role in maintaining genomic stability and preventing cancer. TP53 is frequently mutated in glioblastoma, leading to its down-regulation.\n3. CDKN2A: The cyclin-dependent kinase inhibitor 2A (CDKN2A) gene is a tumor suppressor that is frequently lost in glioblastoma. CDKN2A regulates the cell cycle and can inhibit the growth of cancer cells.\n4. APC: The adenomatous polyps coli (APC) gene is a tumor suppressor that is involved in the regulation of cell growth and differentiation. APC is frequently mutated in glioblastoma, leading to its down-regulation.\n5. PIK3CA: The phosphatidylinositol 4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA) gene is involved in the PI3K/AKT signaling pathway, which is commonly altered in glioblastoma. PIK3CA mutations can lead to the down-regulation of the PI3K/AKT pathway, which can promote the growth and proliferation of glioblastoma cells.\n6. MTHFR: The methylenetetrahydrofolate reductase (M",
    "llama-2-7b-chat-hf_fact_raw": "1. The SWIM tool identifies differentially expressed genes in different tissues or tumor types.\n2. PTEN, a tumor suppressor gene, is down-regulated in glioblastoma.\n3. TP53, a gene that plays a role in genomic stability and cancer prevention, is frequently mutated and down-regulated in glioblastoma.\n4. CDKN2A, a gene that regulates the cell cycle, is frequently lost and down-regulated in glioblastoma.\n5. APC, a tumor suppressor gene involved in cell growth regulation, is frequently mutated in glioblastoma.",
    "llama-2-7b-chat-hf_fact": [
      "The SWIM tool identifies differentially expressed genes in different tissues or tumor types.",
      "PTEN, a tumor suppressor gene, is down-regulated in glioblastoma.",
      "TP53, a gene that plays a role in genomic stability and cancer prevention, is frequently mutated and down-regulated in glioblastoma.",
      "CDKN2A, a gene that regulates the cell cycle, is frequently lost and down-regulated in glioblastoma.",
      "APC, a tumor suppressor gene involved in cell growth regulation, is frequently mutated in glioblastoma."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. TRUE\n5. FALSE [correction]: APC, a tumor suppressor gene involved in cell growth regulation, is frequently mutated in colorectal cancer, not specifically glioblastoma.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "true",
      "false"
    ]
  },
  {
    "id": 3926,
    "user_query": "Which R packages have been developed for studying TADs?",
    "llama-2-7b-chat-hf_response": "There are several R packages that have been developed specifically for studying Transcriptional Activation Domains (TADs). Here are some of the most popular ones:\n1. TADA: TADA is a package designed to identify and characterize TADs in genomic data. It uses a Bayesian approach to infer the boundaries of TADs and to predict the regulatory functions of their associated genetic elements.\n2. Tissue-specific TADs (TiTADs): TiTADs is a package that focuses on identifying TADs in specific tissues or cell types. It uses a combination of genomic and transcriptomic data to identify tissue-specific TADs and to understand their regulatory functions.\n3. TAD-seq: TAD-seq is a package designed to analyze sequencing data from TADs. It uses a probabilistic approach to identify the boundaries of TADs and to determine the regulatory functions of their associated genetic elements.\n4. ChromHMM: ChromHMM is a package that uses a hidden Markov model to identify TADs and to predict their regulatory functions. It can be used to analyze both genomic and transcriptomic data.\n5. TARBase: TARBase is a package that provides a comprehensive database of TADs and their associated regulatory elements. It includes information on the genomic location, chromatin structure, and regulatory functions of TADs.\n6. TADR: TADR is a package that uses a machine learning approach to identify TADs and to predict their regulatory functions. It can be used to analyze both genomic and transcriptomic data.\n7. TAD-detect: TAD-detect is a package that uses a probabilistic approach to identify TADs and to determine their regulatory functions. It can be used to analyze both genomic and transcriptomic data.\n8. TAD-predict: TAD-predict is a package that uses a machine learning approach to predict the regulatory functions of TADs. It can be used to analyze both genomic and transcriptomic data.\n9. TAD-region: TAD-region is a package that uses a probabilistic approach to identify the regulatory regions within TADs. It can be used to analyze both genomic and transcriptomic data.\n10. T",
    "llama-2-7b-chat-hf_fact_raw": "1. TADA is an R package designed to identify and characterize Transcriptional Activation Domains in genomic data.\n2. TiTADs is an R package that focuses on identifying TADs in specific tissues or cell types.\n3. TAD-seq is an R package designed to analyze sequencing data from TADs.\n4. ChromHMM is an R package that uses a hidden Markov model to identify TADs.\n5. TARBase is an R package that provides a database of TADs and their associated regulatory elements.",
    "llama-2-7b-chat-hf_fact": [
      "TADA is an R package designed to identify and characterize Transcriptional Activation Domains in genomic data.",
      "TiTADs is an R package that focuses on identifying TADs in specific tissues or cell types.",
      "TAD-seq is an R package designed to analyze sequencing data from TADs.",
      "ChromHMM is an R package that uses a hidden Markov model to identify TADs.",
      "TARBase is an R package that provides a database of TADs and their associated regulatory elements."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: TiTADs is not an R package, it refers to tissue-specific TADs which are regions in the genome.\n3. FALSE [correction]: TAD-seq is not an R package, it is a method to map TADs using sequencing data.\n4. FALSE [correction]: ChromHMM is an R package but it is used for characterizing chromatin states, not specifically for identifying TADs.\n5. FALSE [correction]: TARBase is not an R package, it is a database that contains information on experimentally supported microRNA targets.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "false",
      "false"
    ]
  },
  {
    "id": 3927,
    "user_query": "Which bioconductor tool has been developed for accessing bacterial regulatory networks?",
    "llama-2-7b-chat-hf_response": "There are several bioconductor tools that have been developed for accessing bacterial regulatory networks. Here are some of the most popular ones:\n1. CRISPR-Chip: CRISPR-Chip is a bioconductor tool that uses CRISPR-Cas9 technology to interrogate bacterial regulatory networks. It allows researchers to knockout or knockdown specific genes in a bacterial strain and measure the resulting changes in gene expression and regulatory interactions.\n2. Bacterial Network Analyzer (BNA): BNA is a bioconductor tool that uses a combination of machine learning and statistical methods to reconstruct bacterial regulatory networks from high-throughput data. It can predict the behavior of bacterial strains under different conditions and identify potential drug targets.\n3. RegulonDB: RegulonDB is a bioconductor tool that provides a comprehensive database of bacterial regulatory networks. It contains information on the regulatory interactions between genes, as well as the transcriptional responses to different environmental cues.\n4. BactoSignal: BactoSignal is a bioconductor tool that uses a combination of machine learning and signal processing methods to identify and interpret bacterial signaling pathways. It can predict the activity of signaling pathways and identify potential drug targets.\n5. Bacterial Gene Regulation (BGR): BGR is a bioconductor tool that uses a combination of machine learning and statistical methods to predict the regulatory interactions between genes in bacteria. It can identify potential regulatory networks and predict the behavior of bacterial strains under different conditions.\n6. Bacterial Network Inference (BNI): BNI is a bioconductor tool that uses a combination of machine learning and statistical methods to reconstruct bacterial regulatory networks from high-throughput data. It can predict the behavior of bacterial strains under different conditions and identify potential drug targets.\n7. Bacterial Gene Regulation (BGR): BGR is a bioconductor tool that uses a combination of machine learning and statistical methods to predict the regulatory interactions between genes in bacteria. It can identify potential regulatory networks and predict the behavior of bacterial strains under different conditions.\n8. Bacterial Signaling Network (BSN): B",
    "llama-2-7b-chat-hf_fact_raw": "1. CRISPR-Chip is a bioconductor tool that employs CRISPR-Cas9 technology for studying bacterial regulatory networks.\n2. Bacterial Network Analyzer (BNA) reconstructs bacterial regulatory networks using machine learning and statistical methods.\n3. RegulonDB provides a comprehensive database of bacterial regulatory networks and their responses to environmental cues.\n4. BactoSignal uses machine learning and signal processing methods to interpret bacterial signaling pathways.\n5. Bacterial Network Inference (BNI) reconstructs bacterial regulatory networks from high-throughput data to predict behavior under various conditions.",
    "llama-2-7b-chat-hf_fact": [
      "CRISPR-Chip is a bioconductor tool that employs CRISPR-Cas9 technology for studying bacterial regulatory networks.",
      "Bacterial Network Analyzer (BNA) reconstructs bacterial regulatory networks using machine learning and statistical methods.",
      "RegulonDB provides a comprehensive database of bacterial regulatory networks and their responses to environmental cues.",
      "BactoSignal uses machine learning and signal processing methods to interpret bacterial signaling pathways.",
      "Bacterial Network Inference (BNI) reconstructs bacterial regulatory networks from high-throughput data to predict behavior under various conditions."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: CRISPR-Chip is a technology that combines CRISPR-Cas9 and electronic transistors for detecting specific DNA sequences, not studying bacterial regulatory networks.\n2. UNKNOWN\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "unknown",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3933,
    "user_query": "What are the end products of the shikimate pathway?",
    "llama-2-7b-chat-hf_response": "The shikimate pathway is a metabolic pathway found in many organisms, including bacteria, fungi, and plants. It is involved in the production of aromatic amino acids, which are important building blocks of proteins. The end products of the shikimate pathway are a variety of compounds, including:\n1. Aromatic amino acids: The shikimate pathway produces several aromatic amino acids, including phenylalanine, tyrosine, and tryptophan. These amino acids are important for the structure and function of proteins.\n2. Quinates: The shikimate pathway produces quinates, which are compounds that contain a quinoid ring. Quinates are involved in the synthesis of various compounds, including antibiotics and anticancer agents.\n3. Tannins: The shikimate pathway produces tannins, which are compounds that are found in plant cell walls and are involved in plant defense mechanisms. Tannins can also act as antioxidants and have been shown to have anti-inflammatory properties.\n4. Flavonoids: The shikimate pathway produces flavonoids, which are a class of compounds that are found in plants and are involved in plant defense mechanisms. Flavonoids have been shown to have antioxidant and anti-inflammatory properties, and may also play a role in protecting against cancer and cardiovascular disease.\n5. Anthracyclines: The shikimate pathway produces anthracyclines, which are a class of compounds that are used in cancer chemotherapy. Anthracyclines are known for their ability to kill cancer cells and are often used in combination with other chemotherapy drugs.\n6. Chlorophyll: The shikimate pathway produces chlorophyll, which is the green pigment found in plants and is involved in photosynthesis. Chlorophyll is important for plant growth and development, and has been shown to have antioxidant and anti-inflammatory properties.\n7. Indole: The shikimate pathway produces indole, which is a compound that is found in many organisms and is involved in the synthesis of various compounds, including antibiot",
    "llama-2-7b-chat-hf_fact_raw": "1. The shikimate pathway produces aromatic amino acids, including phenylalanine, tyrosine, and tryptophan.\n2. Quinates are produced by the shikimate pathway and are involved in the synthesis of antibiotics and anticancer agents.\n3. Tannins, produced by the shikimate pathway, are found in plant cell walls and have anti-inflammatory properties.\n4. Flavonoids, another product of the shikimate pathway, have antioxidant and anti-inflammatory properties and may protect against cancer and cardiovascular disease.\n5. The shikimate pathway is involved in the production of chlorophyll, which is essential for photosynthesis in plants.",
    "llama-2-7b-chat-hf_fact": [
      "The shikimate pathway produces aromatic amino acids, including phenylalanine, tyrosine, and tryptophan.",
      "Quinates are produced by the shikimate pathway and are involved in the synthesis of antibiotics and anticancer agents.",
      "Tannins, produced by the shikimate pathway, are found in plant cell walls and have anti-inflammatory properties.",
      "Flavonoids, another product of the shikimate pathway, have antioxidant and anti-inflammatory properties and may protect against cancer and cardiovascular disease.",
      "The shikimate pathway is involved in the production of chlorophyll, which is essential for photosynthesis in plants."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: Tannins are polyphenolic compounds that can be found in plant cell walls, but they are not produced by the shikimate pathway.\n4. TRUE\n5. FALSE [correction]: The shikimate pathway is not directly involved in the production of chlorophyll. Chlorophyll biosynthesis is part of a different pathway called the porphyrin and chlorophyll metabolism pathway.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "true",
      "false"
    ]
  },
  {
    "id": 3936,
    "user_query": "Is cabergoline used for treatment of the Nelson's syndrome ?",
    "llama-2-7b-chat-hf_response": "Yes, cabergoline is sometimes used to treat Nelson's syndrome, which is a condition characterized by the rapid growth of a pituitary tumor, leading to excessive production of growth hormone and other hormones. Cabergoline is a dopamine receptor agonist that can help reduce the size of the tumor and normalize hormone levels.\nNelson's syndrome is a rare condition that typically affects adults in their 40s or 50s. It is caused by the growth of a pituitary tumor, which can produce excessive amounts of growth hormone, prolactin, and adrenocorticotropic hormone (ACTH). This can lead to a range of symptoms, including:\n* Growth of facial features, such as a prominent forehead, nose, and jawline\n* Enlargement of the hands and feet\n* Abnormal fat distribution, leading to a \"doughy\" appearance of the face and body\n* Muscle weakness and wasting\n* Bone pain and fractures\n* Headaches\n* Vision problems, including blurred vision and double vision\n* Hormonal imbalances, leading to changes in menstruation, fertility, and sexual function\nCabergoline works by binding to dopamine receptors in the pituitary gland, which helps to reduce the size of the tumor and normalize hormone production. It is usually taken orally, once a week, and can be effective in reducing the size of the tumor and normalizing hormone levels in people with Nelson's syndrome.\nHowever, it's important to note that cabergoline is not a cure for Nelson's syndrome, and it may not completely eliminate all symptoms. Additionally, cabergoline can have side effects, including:\n* Fatigue\n* Headache\n* Dizziness and lightheadedness\n* Nausea and vomiting\n* Muscle weakness\n* Joint pain\n* Changes in mood and cognitive function\nIt's important to work closely with a healthcare provider to determine the best course of treatment for Nelson's syndrome. While cabergoline can be effective in reducing symptoms, it may not be the only treatment option.",
    "llama-2-7b-chat-hf_fact_raw": "1. Cabergoline is used to treat Nelson's syndrome.\n2. Nelson's syndrome is characterized by the rapid growth of a pituitary tumor and excessive production of growth hormone and other hormones.\n3. Nelson's syndrome typically affects adults in their 40s or 50s.\n4. Cabergoline is a dopamine receptor agonist that helps reduce the size of pituitary tumors and normalize hormone levels.\n5. Cabergoline is usually taken orally, once a week.",
    "llama-2-7b-chat-hf_fact": [
      "Cabergoline is used to treat Nelson's syndrome.",
      "Nelson's syndrome is characterized by the rapid growth of a pituitary tumor and excessive production of growth hormone and other hormones.",
      "Nelson's syndrome typically affects adults in their 40s or 50s.",
      "Cabergoline is a dopamine receptor agonist that helps reduce the size of pituitary tumors and normalize hormone levels.",
      "Cabergoline is usually taken orally, once a week."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Cabergoline is used to treat prolactinomas, not Nelson's syndrome.\n2. FALSE [correction]: Nelson's syndrome is characterized by the growth of a pituitary tumor and excessive production of ACTH, not growth hormone.\n3. UNKNOWN\n4. TRUE\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "unknown",
      "true",
      "true"
    ]
  },
  {
    "id": 3939,
    "user_query": "What is the main manifestation of Liebenberg syndrome?",
    "llama-2-7b-chat-hf_response": "Liebenberg syndrome, also known as Liebenberg-Koller syndrome or progressive encephalopathy with rigidity and myoclonus, is a rare and poorly understood neurodegenerative disorder that primarily affects the brain and spinal cord. The main manifestations of Liebenberg syndrome include:\n1. Progressive rigidity: Patients with Liebenberg syndrome experience progressive rigidity of the muscles, which can lead to difficulty with movement and balance.\n2. Myoclonus: The syndrome is characterized by sudden, involuntary muscle jerks or twitches, which can occur throughout the body. These myoclonic movements can be triggered by various stimuli, including noise, light, or movement.\n3. Cognitive decline: Patients may experience cognitive decline, including difficulties with memory, attention, and language.\n4. Ataxia: Liebenberg syndrome can cause progressive ataxia, or loss of coordination and balance, which can lead to difficulty with walking, balance, and other motor functions.\n5. Seizures: Some patients with Liebenberg syndrome may experience seizures, which can be caused by the abnormal brain activity associated with the disorder.\n6. Visual disturbances: Patients may experience visual disturbances, including blurred vision, double vision, or loss of peripheral vision.\n7. Hearing loss: Some patients with Liebenberg syndrome may experience hearing loss or tinnitus (ringing in the ears).\n8. Difficulty with speech: Patients may experience difficulty with speech, including slurred speech or difficulty articulating words.\n9. Emotional changes: Liebenberg syndrome can also cause emotional changes, including depression, anxiety, or mood swings.\n10. Autonomic dysfunction: Patients may experience autonomic dysfunction, including problems with blood pressure regulation, heart rate regulation, or digestive problems.\nIt is important to note that the symptoms of Liebenberg syndrome can vary in severity and frequency, and may progress over time. The disorder is often diagnosed through a combination of clinical evaluation, imaging studies (such as MRI or CT scans), and laboratory tests (",
    "llama-2-7b-chat-hf_fact_raw": "1. Liebenberg syndrome affects the brain and spinal cord.\n2. Progressive rigidity is a symptom of Liebenberg syndrome.\n3. Myoclonus, or involuntary muscle jerks, is characteristic of Liebenberg syndrome.\n4. Cognitive decline, including memory and attention difficulties, can occur in Liebenberg syndrome patients.\n5. Some patients with Liebenberg syndrome may experience seizures.",
    "llama-2-7b-chat-hf_fact": [
      "Liebenberg syndrome affects the brain and spinal cord.",
      "Progressive rigidity is a symptom of Liebenberg syndrome.",
      "Myoclonus, or involuntary muscle jerks, is characteristic of Liebenberg syndrome.",
      "Cognitive decline, including memory and attention difficulties, can occur in Liebenberg syndrome patients.",
      "Some patients with Liebenberg syndrome may experience seizures."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN\n\n[Note: Liebenberg syndrome is not a recognized medical condition, hence the veracity of these statements cannot be determined.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 3977,
    "user_query": "List orally bioavailable MPS1 kinase inhibitors",
    "llama-2-7b-chat-hf_response": "Certainly! There are several orally bioavailable MPS1 kinase inhibitors that have been developed and are being investigated for various therapeutic applications. Here are some examples:\n1. Ruxolitinib: This is a selective MPS1 kinase inhibitor that has been approved for the treatment of myelofibrosis, a rare blood cancer. Ruxolitinib works by inhibiting the activity of MPS1, which is overexpressed in myelofibrosis cells.\n2. Dasatinib: This is a pan-Src family kinase (SFK) inhibitor that has been shown to inhibit MPS1 activity in vitro and in vivo. Dasatinib has been investigated as a potential treatment for various cancers, including breast, ovarian, and lung cancers.\n3. Sotrastaurin: This is a highly selective MPS1 kinase inhibitor that has been shown to have antitumor activity in various cancer models, including breast, lung, and ovarian cancers. Sotrastaurin has also been shown to inhibit the activity of other kinases, including IKK-epsilon and IRAK-4, which are involved in inflammation and immune response.\n4. BAY 80-6946: This is a potent and selective MPS1 kinase inhibitor that has been shown to have antitumor activity in various cancer models, including breast, lung, and ovarian cancers. BAY 80-6946 has also been shown to inhibit the activity of other kinases, including IKK-epsilon and IRAK-4.\n5. PP2-101: This is a potent and selective MPS1 kinase inhibitor that has been shown to have antitumor activity in various cancer models, including breast, lung, and ovarian cancers. PP2-101 has also been shown to inhibit the activity of other kinases, including IKK-epsilon and IRAK-4.\n6. ML-099: This is a potent and selective MPS1 kinase inhibitor that has been shown to have antitumor activity in various cancer models",
    "llama-2-7b-chat-hf_fact_raw": "1. Ruxolitinib is an orally bioavailable MPS1 kinase inhibitor approved for the treatment of myelofibrosis.\n2. Dasatinib is a pan-Src family kinase inhibitor that has been shown to inhibit MPS1 activity.\n3. Sotrastaurin is a highly selective MPS1 kinase inhibitor with antitumor activity in various cancer models.\n4. BAY 80-6946 is a selective MPS1 kinase inhibitor with demonstrated antitumor activity in cancer models.\n5. PP2-101 is a selective MPS1 kinase inhibitor that inhibits the activity of other kinases, including IKK-epsilon and IRAK-4.",
    "llama-2-7b-chat-hf_fact": [
      "Ruxolitinib is an orally bioavailable MPS1 kinase inhibitor approved for the treatment of myelofibrosis.",
      "Dasatinib is a pan-Src family kinase inhibitor that has been shown to inhibit MPS1 activity.",
      "Sotrastaurin is a highly selective MPS1 kinase inhibitor with antitumor activity in various cancer models.",
      "BAY 80-6946 is a selective MPS1 kinase inhibitor with demonstrated antitumor activity in cancer models.",
      "PP2-101 is a selective MPS1 kinase inhibitor that inhibits the activity of other kinases, including IKK-epsilon and IRAK-4."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Ruxolitinib is a JAK1 and JAK2 inhibitor approved for the treatment of myelofibrosis, not an MPS1 kinase inhibitor.\n2. TRUE\n3. UNKNOWN\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4031,
    "user_query": "Was golimumab tested for diabetes?",
    "llama-2-7b-chat-hf_response": "Thank you for reaching out with your question! I'm here to help you.\nGolimumab is a medication that is used to treat certain autoimmune diseases, such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is not specifically approved for the treatment of diabetes.\nDiabetes is a metabolic disorder characterized by high blood sugar levels, and it is typically treated with insulin therapy or oral hypoglycemic medications. While there are some medications that can help manage diabetes-related symptoms, such as cholesterol-lowering drugs or blood pressure-lowering drugs, there is no medication that has been specifically tested and approved for the treatment of diabetes.\nThat being said, there are some ongoing clinical trials that are investigating the potential benefits of golimumab in treating diabetes-related complications, such as nerve damage (neuropathy) and vision problems (retinopathy). These trials are still in the early stages, and more research is needed to determine the safety and efficacy of golimumab in treating diabetes.\nIf you have diabetes and are interested in learning more about these clinical trials or exploring other treatment options, I recommend speaking with your healthcare provider or a diabetes specialist. They can provide you with more information and help you determine the best course of action for your individual situation.\nI hope this information is helpful. Please let me know if you have any other questions!",
    "llama-2-7b-chat-hf_fact_raw": "1. Golimumab is a medication used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.\n2. Golimumab is not specifically approved for the treatment of diabetes.\n3. Diabetes is treated with insulin therapy or oral hypoglycemic medications.\n4. There are ongoing clinical trials investigating the potential benefits of golimumab in treating diabetes-related complications.\n5. These trials are still in the early stages and are researching the safety and efficacy of golimumab for diabetes treatment.",
    "llama-2-7b-chat-hf_fact": [
      "Golimumab is a medication used to treat autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.",
      "Golimumab is not specifically approved for the treatment of diabetes.",
      "Diabetes is treated with insulin therapy or oral hypoglycemic medications.",
      "There are ongoing clinical trials investigating the potential benefits of golimumab in treating diabetes-related complications.",
      "These trials are still in the early stages and are researching the safety and efficacy of golimumab for diabetes treatment."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4055,
    "user_query": "Is progeria caused by an autosomal recessive gene?",
    "llama-2-7b-chat-hf_response": "Progeria, also known as Hutchinson-Gilford progeria syndrome (HGPS), is a rare genetic disorder that causes accelerated aging in children. While the exact cause of progeria is still not fully understood, research has shown that it is caused by a mutation in the LMNA gene, which codes for the lamin A/C protein. This protein is involved in the structure and function of the nuclear lamina, a network of filaments that provides mechanical support to the nucleus and regulates various cellular processes.\nThe mutation that causes progeria is an autosomal recessive mutation, meaning that a child must inherit two copies of the mutated gene, one from each parent, to develop the disorder. This means that if both parents are carriers of the mutated gene, there is a 25% chance with each pregnancy that their child will inherit the mutated gene and develop progeria.\nThe LMNA gene mutation that causes progeria leads to a deficiency of the lamin A/C protein, which disrupts the normal functioning of the nuclear lamina. This disruption can lead to a range of symptoms, including:\n1. Accelerated aging: Children with progeria typically appear older than their age due to their rapidly progressing age-related changes. They may have a small face, thin arms and legs, and a thin, wrinkled skin.\n2. Cardiovascular problems: Children with progeria are at increased risk of developing cardiovascular problems, such as hypertension, heart failure, and atherosclerosis.\n3. Respiratory problems: Progeria can also lead to respiratory problems, including shortness of breath, wheezing, and recurrent lung infections.\n4. Joint and muscle problems: Children with progeria may experience joint and muscle pain, stiffness, and limited mobility.\n5. Cognitive impairment: Some children with progeria may experience cognitive impairment, including difficulty with concentration, memory loss, and language difficulties.\n6. Eye problems: Progeria can also lead to eye problems, including cataracts, glaucoma, and detached retinas.\n7. Hearing loss",
    "llama-2-7b-chat-hf_fact_raw": "1. Progeria is also known as Hutchinson-Gilford progeria syndrome (HGPS).\n2. Progeria is caused by a mutation in the LMNA gene, which codes for the lamin A/C protein.\n3. The mutation that causes progeria is an autosomal recessive mutation, meaning a child must inherit two copies of the mutated gene to develop the disorder.\n4. The LMNA gene mutation that causes progeria leads to a deficiency of the lamin A/C protein.\n5. Children with progeria are at increased risk of developing cardiovascular problems, such as hypertension, heart failure, and atherosclerosis.",
    "llama-2-7b-chat-hf_fact": [
      "Progeria is also known as Hutchinson-Gilford progeria syndrome (HGPS).",
      "Progeria is caused by a mutation in the LMNA gene, which codes for the lamin A/C protein.",
      "The mutation that causes progeria is an autosomal recessive mutation, meaning a child must inherit two copies of the mutated gene to develop the disorder.",
      "The LMNA gene mutation that causes progeria leads to a deficiency of the lamin A/C protein.",
      "Children with progeria are at increased risk of developing cardiovascular problems, such as hypertension, heart failure, and atherosclerosis."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. FALSE [correction]: The mutation that causes progeria is a de novo (sporadic) autosomal dominant mutation, meaning only one copy of the mutated gene is necessary for a child to develop the disorder.\n4. FALSE [correction]: The LMNA gene mutation that causes progeria leads to the production of an abnormal form of the lamin A protein, called progerin, which disrupts the structure of the cell nucleus.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "false",
      "false",
      "true"
    ]
  },
  {
    "id": 4082,
    "user_query": "What are common variants at 12q14 and 12q24 associated with?",
    "llama-2-7b-chat-hf_response": "The 12q14 and 12q24 regions on chromosome 12 are associated with several genetic variants that have been linked to various diseases and conditions. Here are some of the most common variants found in these regions:\n12q14:\n* HLA-B*57: This variant is associated with an increased risk of developing certain autoimmune diseases, including rheumatoid arthritis, psoriasis, and multiple sclerosis.\n* HLA-A*31: This variant is associated with an increased risk of developing certain infections, including tuberculosis and histoplasmosis.\n* HLA-C*07: This variant is associated with an increased risk of developing certain cancers, including melanoma and lymphoma.\n12q24:\n* HLA-B*51: This variant is associated with an increased risk of developing certain autoimmune diseases, including type 1 diabetes, thyroiditis, and autoimmune hepatitis.\n* HLA-A*02: This variant is associated with an increased risk of developing certain infections, including tuberculosis and bacterial infections.\n* HLA-C*04: This variant is associated with an increased risk of developing certain cancers, including breast cancer and ovarian cancer.\nIt's important to note that the presence of these variants does not guarantee the development of these diseases, and many other factors can also contribute to an individual's risk. Additionally, the frequency and distribution of these variants can vary depending on the population being studied.\nIt's worth mentioning that these variants are not the only ones associated with these regions, and there are many other genetic variants in these areas that have been linked to different diseases and conditions.\nIt's also important to note that genetic testing for these variants is not typically performed as a routine screening test, but may be ordered by a healthcare provider in certain situations, such as:\n* In individuals with a strong family history of a particular disease.\n* In individuals with a rare genetic disorder.\n* In individuals undergoing organ transplantation.\n* In individuals with a history of autoimmune disorders.\nIt's important to consult with a healthcare provider or a",
    "llama-2-7b-chat-hf_fact_raw": "1. HLA-B*57 variant at 12q14 is associated with an increased risk of developing certain autoimmune diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis.\n2. HLA-A*31 variant at 12q14 is associated with an increased risk of developing certain infections such as tuberculosis and histoplasmosis.\n3. HLA-C*07 variant at 12q14 is associated with an increased risk of developing certain cancers such as melanoma and lymphoma.\n4. HLA-B*51 variant at 12q24 is associated with an increased risk of developing certain autoimmune diseases such as type 1 diabetes, thyroiditis, and autoimmune hepatitis.\n5. HLA-C*04 variant at 12q24 is associated with an increased risk of developing certain cancers such as breast cancer and ovarian cancer.",
    "llama-2-7b-chat-hf_fact": [
      "HLA-B*57 variant at 12q14 is associated with an increased risk of developing certain autoimmune diseases such as rheumatoid arthritis, psoriasis, and multiple sclerosis.",
      "HLA-A*31 variant at 12q14 is associated with an increased risk of developing certain infections such as tuberculosis and histoplasmosis.",
      "HLA-C*07 variant at 12q14 is associated with an increased risk of developing certain cancers such as melanoma and lymphoma.",
      "HLA-B*51 variant at 12q24 is associated with an increased risk of developing certain autoimmune diseases such as type 1 diabetes, thyroiditis, and autoimmune hepatitis.",
      "HLA-C*04 variant at 12q24 is associated with an increased risk of developing certain cancers such as breast cancer and ovarian cancer."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. FALSE [correction]: HLA-B*51 variant is located at 6p21, not 12q24, and is associated with an increased risk of developing Behçet's disease, not the autoimmune diseases listed.\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "false",
      "unknown"
    ]
  },
  {
    "id": 4096,
    "user_query": "Which are the ligands of the Roundabout (Robo) receptors?",
    "llama-2-7b-chat-hf_response": "The Roundabout (Robo) receptors are a family of five-transmembrane receptors that play a crucial role in regulating cellular behavior, including cell migration, differentiation, and survival. The ligands that bind to Robo receptors are diverse and include:\n1. Slit: Slit is a secreted protein that functions as a Robo ligand. Slit proteins are expressed in the nervous system and play a role in the regulation of cell migration and differentiation.\n2. Robo: Robo is the prototypic ligand for the Robo receptors. Robo proteins are expressed in the nervous system and play a role in the regulation of cell migration and differentiation.\n3. Rho: Rho is a secreted protein that functions as a Robo ligand. Rho proteins are expressed in the nervous system and play a role in the regulation of cell migration and differentiation.\n4. Netrin: Netrin is a secreted protein that functions as a Robo ligand. Netrin proteins are expressed in the nervous system and play a role in the regulation of cell migration and differentiation.\n5. Ephrin: Ephrin is a secreted protein that functions as a Robo ligand. Ephrin proteins are expressed in the nervous system and play a role in the regulation of cell migration and differentiation.\n6. Hedgehog: Hedgehog is a secreted protein that functions as a Robo ligand. Hedgehog proteins are expressed in the nervous system and play a role in the regulation of cell migration and differentiation.\n7. Wnt: Wnt is a secreted protein that functions as a Robo ligand. Wnt proteins are expressed in the nervous system and play a role in the regulation of cell migration and differentiation.\n8. Bone morphogenetic protein (BMP): BMP is a secreted protein that functions as a Robo ligand. BMP proteins are expressed in the nervous system and play a role in the regulation of cell migration and differentiation.\n9. Fibroblast growth factor (FGF): FGF is a secreted protein that functions as a Robo ligand. FGF proteins are expressed in the nervous system and play a",
    "llama-2-7b-chat-hf_fact_raw": "1. Slit is a secreted protein that functions as a ligand for Robo receptors.\n2. Robo proteins themselves can act as ligands for Robo receptors.\n3. Netrin is a secreted protein that functions as a ligand for Robo receptors.\n4. Ephrin is a secreted protein that functions as a ligand for Robo receptors.\n5. Bone morphogenetic protein (BMP) is a secreted protein that functions as a ligand for Robo receptors.",
    "llama-2-7b-chat-hf_fact": [
      "Slit is a secreted protein that functions as a ligand for Robo receptors.",
      "Robo proteins themselves can act as ligands for Robo receptors.",
      "Netrin is a secreted protein that functions as a ligand for Robo receptors.",
      "Ephrin is a secreted protein that functions as a ligand for Robo receptors.",
      "Bone morphogenetic protein (BMP) is a secreted protein that functions as a ligand for Robo receptors."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. FALSE [correction]: Robo proteins are receptors and do not act as ligands for themselves.\n3. FALSE [correction]: Netrin is a secreted protein that functions as a ligand for DCC receptors, not Robo receptors.\n4. UNKNOWN\n5. FALSE [correction]: Bone morphogenetic protein (BMP) is a secreted protein that functions as a ligand for BMP receptors, not Robo receptors.",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "false",
      "false",
      "unknown",
      "false"
    ]
  },
  {
    "id": 4112,
    "user_query": "Is there a role for TFII-I in megakaryopoiesis?",
    "llama-2-7b-chat-hf_response": "Yes, TFII-I plays a crucial role in megakaryopoiesis, which is the process of blood cell formation in the bone marrow. TFII-I (Transcription Factor II-I) is a transcription factor that regulates the expression of genes involved in the development and function of platelets.\nPlatelets are small, anucleate blood cells that play a critical role in blood clotting. Megakaryopoiesis is the process by which platelets are produced in the bone marrow from precursor cells. During this process, TFII-I regulates the expression of genes involved in the development and function of platelets.\nStudies have shown that TFII-I is required for the proper formation of platelets in the bone marrow. Mice lacking TFII-I have impaired platelet production and exhibit bleeding symptoms, such as bruising and petechiae (small red spots on the skin). Conversely, overexpression of TFII-I has been shown to promote platelet production and increase bleeding risk.\nTFII-I regulates the expression of genes involved in platelet function, including those involved in platelet activation, aggregation, and secretion. It also regulates the expression of genes involved in the maintenance of platelet membrane structure and function.\nIn addition to its role in megakaryopoiesis, TFII-I has been implicated in the development and progression of certain blood disorders, including platelet disorders and myeloproliferative neoplasms.\nIn summary, TFII-I plays a crucial role in megakaryopoiesis by regulating the expression of genes involved in the development and function of platelets. Its dysregulation can lead to impaired platelet production and bleeding symptoms, and it has been implicated in the development and progression of certain blood disorders.",
    "llama-2-7b-chat-hf_fact_raw": "1. TFII-I (Transcription Factor II-I) is a transcription factor that regulates gene expression in platelet development and function.\n2. Megakaryopoiesis is the process of blood cell formation in the bone marrow which produces platelets from precursor cells.\n3. Mice lacking TFII-I exhibit impaired platelet production and bleeding symptoms such as bruising and petechiae.\n4. Overexpression of TFII-I in mice can promote platelet production and increase bleeding risk.\n5. TFII-I is implicated in the development and progression of certain blood disorders, including platelet disorders and myeloproliferative neoplasms.",
    "llama-2-7b-chat-hf_fact": [
      "TFII-I (Transcription Factor II-I) is a transcription factor that regulates gene expression in platelet development and function.",
      "Megakaryopoiesis is the process of blood cell formation in the bone marrow which produces platelets from precursor cells.",
      "Mice lacking TFII-I exhibit impaired platelet production and bleeding symptoms such as bruising and petechiae.",
      "Overexpression of TFII-I in mice can promote platelet production and increase bleeding risk.",
      "TFII-I is implicated in the development and progression of certain blood disorders, including platelet disorders and myeloproliferative neoplasms."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. TRUE\n2. TRUE\n3. TRUE\n4. FALSE [correction]: Overexpression of TFII-I in mice can promote platelet production but does not increase bleeding risk; it may actually improve platelet function.\n5. TRUE",
    "llama-2-7b-chat-hf_judge": [
      "true",
      "true",
      "true",
      "false",
      "true"
    ]
  },
  {
    "id": 4145,
    "user_query": "Is atenolol metabolized by CYP2D6?",
    "llama-2-7b-chat-hf_response": "Yes, atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.\nAtenolol, a beta-blocker medication, is metabolized by several cytochrome P450 enzymes, including CYP2D6, CYP3A4, and CYP2C9. CYP2D6 is one of the main enzymes responsible for the metabolism of atenolol.\nCYP2D6 is an important enzyme in the metabolism of many drugs, including beta-blockers like atenolol. Approximately 2-8% of the population has a reduced activity of the CYP2D6 enzyme, which can lead to reduced metabolism of drugs that are metabolized by this enzyme.\nStudies have shown that individuals with reduced CYP2D6 activity may have lower levels of the active metabolite of atenolol, which can result in lower drug efficacy or increased side effects. For example, one study found that individuals with reduced CYP2D6 activity had lower levels of the active metabolite of atenolol and experienced more frequent side effects compared to those with normal CYP2D6 activity.\nTherefore, it is important to consider the metabolism of atenolol by CYP2D6 when prescribing this medication. If a patient has reduced CYP2D6 activity, alternative medications or dosing strategies may be necessary to ensure adequate drug efficacy and minimize side effects.\nIn summary, atenolol is metabolized by CYP2D6, and the activity of this enzyme can affect the metabolism and efficacy of the drug.",
    "llama-2-7b-chat-hf_fact_raw": "1. Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.\n2. CYP2D6 is one of the main enzymes responsible for the metabolism of atenolol, along with CYP3A4 and CYP2C9.\n3. Approximately 2-8% of the population has a reduced activity of the CYP2D6 enzyme.\n4. Individuals with reduced CYP2D6 activity may have lower levels of the active metabolite of atenolol and experience more frequent side effects.\n5. It is important to consider CYP2D6 metabolism when prescribing atenolol, as reduced enzyme activity may require alternative medications or dosing strategies.",
    "llama-2-7b-chat-hf_fact": [
      "Atenolol is metabolized by the cytochrome P450 enzyme CYP2D6.",
      "CYP2D6 is one of the main enzymes responsible for the metabolism of atenolol, along with CYP3A4 and CYP2C9.",
      "Approximately 2-8% of the population has a reduced activity of the CYP2D6 enzyme.",
      "Individuals with reduced CYP2D6 activity may have lower levels of the active metabolite of atenolol and experience more frequent side effects.",
      "It is important to consider CYP2D6 metabolism when prescribing atenolol, as reduced enzyme activity may require alternative medications or dosing strategies."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Atenolol is not significantly metabolized by the cytochrome P450 enzyme system, including CYP2D6.\n2. FALSE [correction]: Since atenolol is not significantly metabolized by the cytochrome P450 system, CYP2D6, CYP3A4, and CYP2C9 are not the main enzymes responsible for its metabolism.\n3. TRUE\n4. FALSE [correction]: Since atenolol is not metabolized by CYP2D6, individuals with reduced CYP2D6 activity would not necessarily have lower levels of the active metabolite of atenolol or experience more frequent side effects due to this enzyme's activity.\n5. FALSE [correction]: Considering CYP2D6 metabolism when prescribing atenolol is not as crucial since atenolol is not significantly metabolized by this enzyme. However, individual patient factors and enzyme activity may still be relevant for alternative medications or dosing strategies.",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "false",
      "true",
      "false",
      "false"
    ]
  },
  {
    "id": 4158,
    "user_query": "List versions of ExpansionHunter",
    "llama-2-7b-chat-hf_response": "Certainly! ExpansionHunter is a powerful tool for managing and optimizing your Steam library. Here are some of the versions of ExpansionHunter that you might be interested in:\n1. ExpansionHunter 1.0 - This is the original version of ExpansionHunter, released in 2017. It provides a simple and easy-to-use interface for managing your Steam library, including the ability to sort games by various criteria, view detailed information about each game, and create custom collections.\n2. ExpansionHunter 2.0 - Released in 2018, this version of ExpansionHunter adds several new features, including the ability to search for games by keyword, filter games by genre or platform, and view detailed information about each game's developers and publishers.\n3. ExpansionHunter 3.0 - This version, released in 2019, includes a number of significant updates and improvements. These include the ability to sort games by release date, view detailed information about each game's DLC and add-ons, and create custom lists of games based on various criteria.\n4. ExpansionHunter 4.0 - The latest version of ExpansionHunter, released in 2020, includes a number of exciting new features. These include the ability to view detailed information about each game's achievements and trophies, sort games by their Metacritic scores, and create custom lists of games based on their Steam curator ratings.\nIn addition to these versions, there may be other, older versions of ExpansionHunter available for download. These versions may offer different features and functionality than the more recent versions, but they can still be useful for managing and optimizing your Steam library.\nI hope this information is helpful! Let me know if you have any other questions.",
    "llama-2-7b-chat-hf_fact_raw": "1. ExpansionHunter 1.0 was released in 2017.\n2. ExpansionHunter 2.0 was released in 2018.\n3. ExpansionHunter 3.0 was released in 2019.\n4. ExpansionHunter 4.0 was released in 2020.",
    "llama-2-7b-chat-hf_fact": [
      "ExpansionHunter 1.0 was released in 2017.",
      "ExpansionHunter 2.0 was released in 2018.",
      "ExpansionHunter 3.0 was released in 2019.",
      "ExpansionHunter 4.0 was released in 2020."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. UNKNOWN\n2. UNKNOWN\n3. UNKNOWN\n4. UNKNOWN\n\n[Note: Without additional context on the software \"ExpansionHunter\" and its release history, it is impossible to verify the accuracy of these statements.]",
    "llama-2-7b-chat-hf_judge": [
      "unknown",
      "unknown",
      "unknown",
      "unknown"
    ]
  },
  {
    "id": 4164,
    "user_query": "What is the role of Adamts18 in hormone receptor signaling?",
    "llama-2-7b-chat-hf_response": "Adamts18 is a protein that plays a crucial role in hormone receptor signaling, specifically in the regulation of estrogen receptor alpha (ERα) signaling. Here's a detailed explanation of the role of Adamts18 in hormone receptor signaling:\n1. Modulation of ERα activity: Adamts18 is an extracellular matrix (ECM) protein that is predominantly expressed in the basal lamina of various tissues, including the uterus, breast, and bone. It has been shown to modulate ERα activity by interacting with the ERα protein and altering its activity.\n2. Enhancement of ERα signaling: Adamts18 has been shown to enhance ERα signaling by increasing the activity of the ERα protein. This is achieved through the formation of a complex between Adamts18 and ERα, which leads to increased phosphorylation and activation of ERα.\n3. Regulation of gene expression: Adamts18 has been shown to regulate the expression of genes involved in various cellular processes, including cell proliferation, differentiation, and survival. It does this by interacting with transcription factors and altering their ability to bind to specific DNA sequences.\n4. Involvement in cancer: Adamts18 has been implicated in various types of cancer, including breast, ovarian, and endometrial cancer. It is thought to play a role in the development and progression of these cancers by modulating ERα signaling and promoting cell proliferation.\n5. Interaction with other proteins: Adamts18 has been shown to interact with other proteins involved in hormone receptor signaling, including the ERα protein, the progesterone receptor (PR), and the androgen receptor (AR). These interactions may play a role in the regulation of hormone receptor signaling and the development of hormone-sensitive cancers.\n6. Tissue-specific expression: Adamts18 is expressed in a tissue-specific manner, with higher levels of expression observed in tissues that are sensitive to estrogens, such as the uterus and breast. This tissue-specific expression may play a role in the regulation of hormone receptor signaling in these",
    "llama-2-7b-chat-hf_fact_raw": "1. Adamts18 is a protein that plays a role in the regulation of estrogen receptor alpha (ERα) signaling.\n2. Adamts18 is an extracellular matrix (ECM) protein predominantly expressed in the basal lamina of tissues including the uterus, breast, and bone.\n3. Adamts18 modulates ERα activity by interacting with the ERα protein and altering its activity.\n4. Adamts18 has been implicated in various types of cancer, including breast, ovarian, and endometrial cancer.\n5. Adamts18 interacts with other proteins involved in hormone receptor signaling, including the ERα protein, the progesterone receptor (PR), and the androgen receptor (AR).",
    "llama-2-7b-chat-hf_fact": [
      "Adamts18 is a protein that plays a role in the regulation of estrogen receptor alpha (ERα) signaling.",
      "Adamts18 is an extracellular matrix (ECM) protein predominantly expressed in the basal lamina of tissues including the uterus, breast, and bone.",
      "Adamts18 modulates ERα activity by interacting with the ERα protein and altering its activity.",
      "Adamts18 has been implicated in various types of cancer, including breast, ovarian, and endometrial cancer.",
      "Adamts18 interacts with other proteins involved in hormone receptor signaling, including the ERα protein, the progesterone receptor (PR), and the androgen receptor (AR)."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Adamts18 is a metalloproteinase involved in the processing of extracellular matrix components, not directly in the regulation of ERα signaling.\n2. TRUE\n3. UNKNOWN\n4. TRUE\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "unknown",
      "true",
      "unknown"
    ]
  },
  {
    "id": 4208,
    "user_query": "What is the mode of action of Thiazovivin?",
    "llama-2-7b-chat-hf_response": "Thiazovivin is a small molecule inhibitor of the enzyme histone deacetylase (HDAC). HDACs are a family of enzymes that play a crucial role in regulating gene expression by modifying chromatin structure. Thiazovivin works by binding to the active site of HDACs and preventing them from deacetylating histones, which are the main proteins that make up chromatin.\nWhen histones are deacetylated, they become more compact and less accessible to the transcriptional machinery, leading to the repression of gene expression. By blocking the activity of HDACs, thiazovivin can increase the accessibility of histones to the transcriptional machinery, leading to the activation of gene expression.\nThiazovivin has been shown to have a variety of biological effects, including:\n1. Cell cycle arrest: Thiazovivin can cause cells to arrest in the G1 phase of the cell cycle, which can be beneficial for cancer treatment.\n2. Apoptosis: Thiazovivin can induce programmed cell death (apoptosis) in cancer cells, which can help to eliminate cancer cells.\n3. Differentiation: Thiazovivin can promote the differentiation of cancer cells into more mature and less aggressive cell types.\n4. Anti-inflammatory effects: Thiazovivin has been shown to have anti-inflammatory effects in various models of inflammation.\n5. Neuroprotection: Thiazovivin has been shown to have neuroprotective effects in models of neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease.\n6. Immune system modulation: Thiazovivin can modulate the immune system by inhibiting the activity of immune suppressive cells, such as regulatory T cells, and promoting the activity of immune stimulatory cells, such as natural killer cells.\n7. Cardiovascular protection: Thiazovivin has been shown to have cardiovascular protective effects in models of cardiovascular disease.\nOverall, the mode of action of thiazovivin",
    "llama-2-7b-chat-hf_fact_raw": "1. Thiazovivin is a small molecule inhibitor of the enzyme histone deacetylase (HDAC).\n2. HDACs modify chromatin structure and regulate gene expression.\n3. Thiazovivin prevents HDACs from deacetylating histones by binding to their active site.\n4. Thiazovivin can cause cell cycle arrest in the G1 phase.\n5. Thiazovivin can induce programmed cell death (apoptosis) in cancer cells.",
    "llama-2-7b-chat-hf_fact": [
      "Thiazovivin is a small molecule inhibitor of the enzyme histone deacetylase (HDAC).",
      "HDACs modify chromatin structure and regulate gene expression.",
      "Thiazovivin prevents HDACs from deacetylating histones by binding to their active site.",
      "Thiazovivin can cause cell cycle arrest in the G1 phase.",
      "Thiazovivin can induce programmed cell death (apoptosis) in cancer cells."
    ],
    "llama-2-7b-chat-hf_judge_raw": "1. FALSE [correction]: Thiazovivin is a small molecule inhibitor of Rho-associated protein kinase (ROCK), not histone deacetylase (HDAC).\n2. TRUE\n3. FALSE [correction]: Thiazovivin does not prevent HDACs from deacetylating histones as it does not target HDACs but rather targets ROCK.\n4. UNKNOWN\n5. UNKNOWN",
    "llama-2-7b-chat-hf_judge": [
      "false",
      "true",
      "false",
      "unknown",
      "unknown"
    ]
  }
]